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ABSTRACT
Influence of Epstein-Barr Virus on Systemic Lupus Erythematosus Disease Development and the
Role of Depression on Disease Progression
Caleb Cornaby
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy

Systemic Lupus Erythematosus (SLE) is an autoimmune disease affecting 20 to 250
individuals per 100,000 worldwide. Symptomology includes dermatological manifestations such
as discoid lesions, acute cutaneous rashes, and oral and nasal ulcers, along with musculoskeletal,
pulmonary, and renal complications. Abnormal T and B lymphocyte function and apoptosis,
immune complex clearance, complement function, and nucleosome processing are typical of
disease pathophysiology. SLE is the result of both environmental and genetic factors, which
together create the conditions leading to disease onset and progression. Of these environmental
factors, Epstein-Barr virus (EBV) infection is known to cause the genesis of cross-reactive
antibodies in SLE prone individuals that can initiate disease activity. Viral infection and
modulation of cellular genes is important in understanding the microenvironment that could lead
to immune mis-regulation and the inception of lupus in those individuals at risk. During disease
development, a variety of variables assist and detract from disease progression and the quality of
life experienced by SLE patients. Research into EBV-infected naïve B lymphocytes revealed that
EBV modulates the chemotactic receptor EBI2 during viral infection via the BRRF1 viral gene
product Na. This likely changes B lymphocyte chemotaxis in secondary tissue in virally infected
B cells. Current literature suggests this results in sequestration of cells to peripheral areas of the
tissue and mis-regulation of the immune response.
It is not uncommon for SLE patients to have neuropsychiatric disorders due to lupus
disease activity. With SLE patients being up to 6 times more at risk for depression, recognition
and treatment of depression and anxiety have been shown to improve quality of life, pain, and
treatment outcomes. Two studies investigate both clinical laboratory and psychosocial
assessment variables that we suspect to be correlated with depression in patients with SLE.
Univariate and multivariate analysis from our first study identified an array of variables that
show strong associations with depression, including: Body Mass Index, Pain, Total Complement,
fatigue assessments, and SF-36 scores. The second study found similar associations, but further
found that serum IL-10 levels demonstrated a strong correlation with depression in SLE patients.
In this final study SLE patients are compared alongside healthy, clinically depressed, and
rheumatoid arthritis patients to provide evidence that increased depression in SLE patients is due
more to disease pathology than a result of chronic inflammation.
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Preface
To help the reader better understand the order and organization of this document, I will
provide a brief explanation on that count. Due to the amount and variety of content contained in
chapter 1, it has been organized slightly differently than chapters 2 through 5. This chapter has
been dissected into three sections, each providing background information, as well as a review of
the current literature pertinent to the research that will be explained in chapters 2 through 4.
These three sections have further been organized into subsections labeled as such. For example,
chapter 1, section 2, subsection 2 would be labeled 1.2.2 and so on. Section 3, which contains
subsections of subsections would be labeled as 1.3.3.1, 1.3.3.2, and so on.
Chapters 2 through 4 have been organized like a scientific article, as that is how they
were intended to be read. In these chapters a summary is provided followed by the introduction,
methods, results, and discussion sections. Like in chapter 1, the chapter number is provided first
and then the section number. For example, the summary for chapter 2 would be denoted 2.1.
Chapter 5 is the concluding chapter and contains merely two parts addressing future potential
experiments and providing final discussions of the research outlined in chapters 2 through 4.
It is also important to note that the content contained in chapter 1 sections 1 and 3 were
published in peer reviewed journals (Cornaby, Gibbons, et al., 2015; Cornaby, Tanner, Stutz,
Poole, & Berges, 2016). Chapter 2 was also published (Cornaby et al., 2017). Chapters 3 and 4
are currently under review in different peer-reviewed journals.

xviii

Chapter I. Introduction and Review of the Literature

Section 1: Introduction to Systemic Lupus Erythematosus and B Lymphocyte
Involvement in Autoimmune Disease Pathophysiology1
Systemic Lupus Erythematosus
When healthy tissue is damaged due to an immune response against cellular markers or
proteins that are mistaken as foreign antigens, this is termed autoimmunity. It is suspected that
autoimmune diseases afflict 7.6 – 9.4 % of the world population and, in most cases, are more
prevalent in females than in males of a given human population (Cooper, Bynum, & Somers,
2009; Gutierrez-Arcelus, Rich, & Raychaudhuri, 2016). About 140 – 150 in 100,000 people in
the United States of America have Systemic Lupus Erythematosus (SLE) (Feldman et al., 2013).
The incidence and prevalence of SLE differs greatly among populations due to sex, race,
ethnicity, and socioeconomic status (Alarcon et al., 2004; Fessel, 1974; McCarty et al., 1995).
Nearly 90% of SLE patients in the US are women, and the prevalence of SLE is twice as high in
African Americans compared to the Caucasian population (Feldman et al., 2013). The highest
prevalence of SLE observed in the continental United States was in the southern United States
(Feldman et al., 2013).
SLE is a chronic autoimmune disease that affects multiple body systems often
influencing the skin, joints, central nervous system, lungs, kidney, digestive tract, and

1

Most of the material comprising this section was published in the journal Immunology Letters, see Cornaby,
Gibbons, et al., 2015.

1

hemopoietic system (Tiffin, Adeyemo, & Okpechi, 2013). This results in a diverse display of
clinical signs and symptoms. Commonly exhibited symptoms include cutaneous manifestations
such as malar rash, photosensitivity, discoid lesions, and oral ulcers, joint pain and swelling,
serositis, renal disorders, hemolytic anemia, leukopenia, neuropsychiatric disorders and poor
vascularization (C. Yu, Gershwin, & Chang, 2014). While the exact pathological mechanisms
responsible for all the symptoms displayed by SLE patients is not yet well defined, the basic
etiology of disease cause and progression has advanced quite rapidly in the last several decades.
This being the case, there is still much that is not understood that if better defined could assist in
the development of better patient care and treatment options.

B cell Involvement and Epitope Spreading in Autoimmune Disease
1.1.1 Introduction
Epitope spreading is the process by which T and B lymphocytes expand their receptor
repertoire for one initial antigen (Ag) epitope to various other epitopes. This process is an
important contributor to the efficiency and breadth of the immune system. However, epitope
spreading is implicated in multiple autoimmune diseases (McCluskey et al., 1998; C. L.
Vanderlugt & Miller, 2002). Epitope spreading is known to be a major component of systemic
lupus erythematosus and bullous pemphigous, and is implicated in multiple other autoimmune
diseases ranging from multiple sclerosis to diabetes (Table 1). In B cell epitope spreading, the
antibody (Ab) specificity develops from the initial Ag that triggered the response to include other
epitopes of these Ags, or other Ags altogether.
The contribution of epitope spreading in the progression of autoimmune disease was first
recognized in print during the study of experimental autoimmune encephalomyelitis (EAE) in
2

able 1. Compiled evidence implicating B cell epitope spreading in autoimmune
diseases.
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Table 1. Compiled evidence implicating B cell epitope spreading in various autoimmune
diseases. The autoimmune diseases are listed with the completed cumulative research that
provided provocative evidence for B cell epitope spreading. It is specified for each evidenced
example of epitope spreading a sentence summary of the example, what type of experiment was
performed to obtain the data, the type of epitope spreading involved, and the reference for that
example.

Lewis rat and mouse models (Bernard et al., 1997; Steinman, 1995). In these studies, it was
found that rats and mice injected with Myelin oligodendrocyte glycoprotein (MOG) induced a T
cell encephalitogenic and B cell Ab immune response resulting in demyelination. During this
study it was demonstrated that the Antigenic targets of the Abs changed and diversified during
the course of EAE. It was later shown that epitope spreading was the cause of the Ab
diversification. We now understand that B cell epitope spreading assists in the progression of
many autoimmune diseases, acting as a two-edged sword for many that are affected by
autoimmune diseases (McCluskey et al., 1998; C. L. Vanderlugt & Miller, 2002). Epitope
spreading is essential for an effective adaptive immune response, at the same time contributing to
the progression of self-targeting disorders. It is important to better understand epitope spreading
due to its influence in autoimmune progression and the potential to develop more advanced
strategies to assist in the treatment and prevention of autoimmune diseases.
While much research has been done to determine the significance of T cell epitope
spreading in disease, far less is known about B cell epitope spreading. This review will address B
cell epitope spreading and its involvement in the progression of various autoimmune diseases.
The current understanding about factors contributing to B cell epitope spreading and intracellular
mechanisms involved in this process will be discussed. Areas for future research and gaps in our
understanding of B cell epitope spreading will also be commented upon. The purpose of this
review is to provide a summary of our current understanding about B cell epitope spreading
4

mechanisms, involvement in autoimmune disease, and the importance of epitope spreading in
treatment options.
1.1.2 Potential Mechanisms of B Lymphocyte Epitope Spreading
Types of Epitope Spreading
There are two different types of epitope spreading, intermolecular and intramolecular (C.
J. Vanderlugt & Miller, 1996). The latter describes a type of spreading where the immune
response is directed against different epitopes of the same molecule, while the former is a
diversification of the immune response against two or more different molecules (Thrasyvoulides
& Lymberi, 2003). By expanding the antigenic epitopes that our immune system recognizes,
responses to these foreign Ags becomes optimized, allowing for neutralization via Abs,
recognition by various immune cells, and clearance of the pathogen (Figure 1). Intermolecular
epitope spreading is not dependent on intramolecular epitope spreading (Deshmukh, Bagavant,
Sim, Pidiyar, & Fu, 2007); rather these different types of epitope spreading are independent of
each other. Diversification takes place only after Ag recognition by cells of the immune system.
B cell activation by CD 4+ T cells or by surface clustering immunoglobin bound to the specific
Ag epitope initiate the beginning of this process. Through clonal expansion and affinity
maturation, the spreading of epitopes for a given Ag expand and continue to broaden the longer
the immune response continues. It has been shown that there are two ways to initiate B cell
epitope spreading in autoimmune diseases. McCluskey et al. describe the first to be independent
of a physical association with immune cells presenting the Ag, while the second is dependent
(McCluskey et al., 1998). In an Ag presenting cell (APC) independent scenario, the
inflammation and activation cytokines are sufficient enough to allow T cells to recognize cryptic
epitopes and activate complementary B cells. This is observed in non-obese diabetic (NOD) and
5

EAE animal models (Kurien & Scofield, 2008). On the other hand, a dependent response
happens typically when there is no tissue destruction, or it is delayed, relying on processing and
presentation to achieve activated T cells that, through intrastructural T cell help, activate
reciprocal B cells. In fine, the independent scenario exists when there are environmental
conditions, such that T cells can recognize cryptic, or novel, epitopes without the processing and
presentation by APCS, such as B cells and dendritic cells. The dependent circumstance relies
upon APC processing and presentation to T cells in order for the immune system to recognize
cryptic epitopes.
Intermolecular Epitope Spreading
Many of the Ags recognized in autoimmune diseases are part of multi-Antigenic
complexes. For example, the spliceosome is a common target for auto-Abs in lupus, and consists
of multiple proteins and nucleic acids that are associated with each other. T cells specific for one
epitope of a multi-Antigenic complex can activate B cells that are specific for other Ags of the
complex (Deshmukh, Bagavant, Lewis, Gaskin, & Fu, 2005). T cell help allows B cells to target
a range of Ags to proliferate, differentiate, and produce Abs, even against Ags that were not
originally involved in either the B cell or the T cell response (Fatenejad, Mamula, & Craft, 1993;
Singh, 2004).
An experimental example of this concept was illustrated by Deshmukh et al. during their study of
systemic lupus erythematosus (Deshmukh et al., 2007). To induce lupus-like symptoms in a
mouse model, female A/J mice were immunized with various SmD peptides. This stimulates an
immune response against the small nuclear ribonucleoprotein (snRNP) complex that is
characteristic of systemic lupus erythematosus. Immunoprecipitation assays were used to
determine Ab reactivity to SmD, SmB, and associated ribonucleoprotein (A-RNP molecules). It
6

was found that immunization with the SmD52-66 lead to the development of Abs against not only
regions of the SmD protein, but also to the U1 A-RNP. The Ab diversification from the SmD
protein to the A-RNP is a demonstration of intermolecular epitope spreading. During their study
of viral triggers leading to SLE, Poole et al. observed a similar example of intermolecular
epitope spreading (B. D. Poole, Gross, Maier, Harley, & James, 2008). Immunization of rabbits
with the protein peptide PPPGMRPP from Epstein-Barr virus (EBV) protein EBNA-1, lead to
the development of antibodies to SmB, SmD, nRNPs and La/SSB.
Clinical studies and reports continue to provide evidence for this process. Maeda et al.
described a case where a 64-year-old Brazilian male developed bullous pemphigoid twelve years
after being diagnosed with pemphigus foliaceus (Maeda et al., 2006). He was diagnosed with
bullous pemphigoid when subepidermal blistering was observed and immunoblotting assays
revealed Ab activity against BP180. A congruous event was recorded by Peterson et al. where
they observed similar results from a 86 year old African American male (Peterson, Chang, &
Chan, 2007). This development of bullous pemphigoid after pemphigus foliaceus is a clinical
manifestation of intermolecular spreading. Autoimmune targets resulting in pemphigus foliaceus
are typically desmoglein proteins, particularly desmoglein 1. The cause of bullous pemphigoid is
an autoimmune reaction against several bullous pemphigoid proteins (BP180 and BP230) of the
hemidesmosome. In fine, the incidences reported above indicate an intermolecular epitope
spreading event from the desmoglein proteins to the bullous pemphigoid proteins.
It does not take a large variety of T cells to drive a diverse B cell response leading to
intermolecular epitope spreading. An example of this was shown by Milich et al. in using mouse
T cells primed for the Hepatitis B nucleocapsid to invoke an immune response against the
Hepatitis B virus. The result was Ab production against Hepatitis B surface Ags (Milich,
7

McLachlan, Thornton, & Hughes, 1987). This demonstrates CD 4+ T cells specific for priming
recognition of just one region, leading to an immune response that diversified to include the
surface Ag and nucleocapsid Ag of Hepatitis B. Intrastructural T cell help is necessary for B cell
epitope spreading to elicit an immune response against pathogens and contributes during
development of immune diseases(Craft & Fatenejad, 1997; Datta, Kaliyaperumal, & DesaiMehta, 1997).
Intramolecular Epitope Spreading
After B cells are activated in response to Ag and T cell stimulation, they respond by
progressing through clonal expansion and affinity maturation. Upon processing of the Ag, these
cells can in turn present novel cryptic epitopes to CD 4+ T cells in the context of MHC class II
molecules. Cryptic epitopes are understood to be epitopes that were previously un-recognized by
the immune system. These cryptic epitopes allow for the priming of reciprocal T cells and the
activation of complementary B cells. This process allows the immune response to recognize
various epitopes from the same molecule, or associated molecules, and thus contributes to
epitope spreading. Affinity maturation allows for selection of the clonally expanded B cell
population for those cells that have a higher affinity for the Ag. Because of this selection,
intramolecular epitope spreading can occur as B cells with higher affinity for a different epitope
of the Ag are selected (Deshmukh et al., 2005). Endocytic processing and the subsequent MHC
class II presentation is a further mechanism that can promote intramolecular epitope spreading.
During endocytic antigen processing the antigen is endocytosed, selectively cleaved and loaded
into a compatible MHC class II complex that is then displayed on the cell surface. This process
allows for presentation of previously unrecognized epitopes and the broadening of the immune
response to various epitopes on the endocytosed molecule.
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A clinical study of pemphigus foliaceus in Brazil provided evidence that intramolecular
epitope spreading contributes to autoimmune disease development (N. Li, Aoki, Hans-Filho,
Rivitti, & Diaz, 2003). Sera from patients were collected pre-disease onset and while the patients
were exhibiting clinical symptoms of skin lesions. Using immunoprecipitation assays to analyze
the sera from the patients, several interesting observations came to light. Patients still in the

Figure 1. Intramolecular B cell epitope spreading.
(A) Once activated through T cell intrastructural help or (B) clustering of the BCRs attached to a
specific epitope on the Ag, B cells endocytose the Ag, selectively cleave it, load selected peptides
in MHC II molecules and display it in this context to T cells. Once a T cell is activated by the B
cell for a new epitope presented via MHC II, it can then activate a reciprocal B cell which will then
express Abs specific for that epitope. This process is known as intramolecular B cell epitope
spreading.
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pre-clinical phase of the disease developed Abs for the COOH-terminus region of the
desmoglein 1 protein. During the study several patients progressed from the pre-clinical phase to
the clinical phase of the disease. Testing of the serum during clinical onset of pemphigus
foliaceus revealed Abs against the EC1 and EC2 domains of the NH2 terminal region of the
desmoglein 1 protein. Another example is presented by Poole et al. in a serum analysis study of
SLE diagnosed patients collected at the Oklahoma Clinical Immunology Serum Repository, it
was found that intramolecular epitope spreading contributed to the progression of SLE (B. D.
Poole et al., 2009). Using autoantibody analysis of the extensive serum samples, it was observed
that antibody diversification happened over time during disease progression to various epitopes
on the nRNP-A and nRNP-C proteins. Anti-nRNP-A antibodies were found to bind to the Nterminus of the protein more frequently in later samples when compared to the initial samples.
This diversification of Abs from one region of the protein to the other region demonstrates
intramolecular epitope spreading and provides evidence of the role it plays in the progression of
autoimmune disease.
Molecular Mimicry and Cross-Reactivity
B cell epitope spreading after molecular mimicry is a mechanism by which the body
likely begins to break self-tolerance, leading to the development of autoimmune disease.
Molecular mimicry has been indicated as a contributing factor in autoimmune diseases such as
type I diabetes (Leech, 1998), rheumatoid arthritis, multiple sclerosis, glomerulonephritis
(Cusick, Libbey, & Fujinami, 2012), and systemic lupus erythematosus.
Molecular mimicry exists when an auto-Ag is similar enough to an antigen from a
pathogen or other environmental source that Abs generated against the pathogen will also bind to
the autoantigen (Cusick et al., 2012). Cross-reactivity is a phenomenon that occurs in the
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immune system when a single Ab reacts with multiple Ags varying in structure and composition.
The immunochemical evidence in recent literature suggests that conformation as well as
structure is essential for an effective Antigenic mimic (Ohtaki, Kieber-Emmons, & Murali,
2013). This was demonstrated by Marluzza et al. at the University of Maryland when they
showed that the anti-idiotopic Ab E5.2 was a mimic for lysozyme in the way that it bound to
D1.3 (Fields, Goldbaum, Ysern, Poljak, & Mariuzza, 1995). Marluzza’s group further showed
that it was a binding group mimic and shared no homologous sequence between the Ag and Ab
E5.2 (Braden et al., 1996). These findings verified that the binding of Abs is not determined by
amino acid sequence alone, but by the conformation of the epitope to which it binds. While
certain amino acid sequences tend to display select conformations and structures, there is
variability due to protein folding, molecular interaction, and binding. These findings indicate that
an Ag, or auto-Ag, does not need to share homologous amino acid sequences in order to be an
effective mimic.
The mechanisms of molecular mimicry and cross-reactivity are thought to be key
contributors in B cell epitope spreading. One example of molecular mimicry was explored by
Poole at al. in experiments tying Epstein-Barr Virus (EBV) infection to the development of the
autoimmune disease systemic lupus erythematosus (SLE). The EBV nuclear Ag-1 (EBNA-1)
contains a peptide sequence, PPPGRRP, that closely resembles the PPPGMRPP region on the
Smith Ag (Sm) targeted by auto-Abs in SLE patients. Immunization with the PPPGRRP
sequence from EBNA-1 led to development of cross-reactive antibodies that recognized both
epitopes, as well as further epitope spreading leading to autoimmunity against Sm and nRNP
complexes. Also, 5 out of the 6 rabbits immunized developed SLE like symptoms over the
course of the experiment indicating that the mechanism of molecular mimicry involving EBNA11

1 can lead to development of systemic lupus erythematosus-like disease (B. D. Poole, Scofield,
Harley, & James, 2006). Clinical evidence shows similar results with respect to the spreading of
epitopes in SLE. After an individual loses tolerance for 60 kDa Ro/SSA and beings to produce
Abs that specifically target Ro/SSA, later blood samples reveal Abs against Sm B’, SmD1,
nRNP A and C, and eventually La/SSB (B. D. Poole et al., 2009).
1.1.3 Intracellular Mechanisms of B Lymphocyte Epitope Spreading
Endocytic processing and Ag presentation
B cell endocytosis and Ag presentation to T cells contribute to epitope spreading.
Endocytosis takes place after Ag binding to B cell receptors (Amigorena & Bonnerot, 1999a).
During this process of B cell endocytosis, Ag processing and presentation determines what
peptides will be loaded into MHC class II molecules and displayed on the cell surface. This
determines what epitopes will be presented to T cells, ultimately identifying what epitopes
should be targeted by the immune system. There are various circumstances that affect this
processing (Figure 2).
The first part of endocytosis to affect processing is the BCR to which the Ag is bound
(Amigorena & Bonnerot, 1999b; Binder et al., 2011). Binding to the BCR can affect the
selection of epitopes presented to T cells (Watts, 1997), however, it is not known exactly how it
impacts processing of Ags and the loading of class II MHC complexes (Lankar et al., 2002;
McGovern, Moquin, Caballero, & Drake, 2004). Thanks to McGovern and Moquin et al. we now
understand that the difference in Ag processing and presentation is due to BCR signaling and not
due to the signaling induced changes in the biology of the cell (McGovern et al., 2004). It has
been suggested that stability between the Ag and the surface immunoglobin (sIg) to which it is
bound influences processing (Aluvihare, Khamlichi, Williams, Adorini, & Neuberger, 1997).
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Figure 2. The endocytic pathway is a primary mechanism in B cell epitope spreading.
(A) The binding of the sIg to the Ag can affect the epitope that is selected for and loaded into
MHC II. (B) The endosome fuses with the lysome, containing GILT, cathepsins, and other
proteases. These enzymes selectively digest the Ag into peptide segments. This provides another
point for selection of epitopes and the exclusion of others based on the cleavage sites. (C) With the
disassociation of CLIP, peptides are selectively loaded into the MHC II molecule based on amino
acid motifs, pH, HLA-DM association, among other enodsomal environmental factors (D) Once
these various selective processes are accomplished the resulting epitope chosen is displayed via the
MHC II on the surface of the cell. Because of the many factors involved, various peptides could be
displayed.

A second point of processing selection is due to the selective cleavage of proteases
contained in the lysosome. This selective processing of Ag into smaller peptide fragments
depends on the proteases present in the lysosome, including their relative concentration and
activity which is regulated by various endogenous cytokines and competitive inhibitors (LennonDumenil, Bakker, Wolf-Bryant, Ploegh, & Lagaudriere-Gesbert, 2002). These competitive
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Another proposed reason for the difference in the processing of Ags might be related to targeting
as a consequence of the sIg cytoplasmic tail, the Igα/Igβ associated chains, or both (Amigorena
& Bonnerot, 1998). These various components of the BCR play a role in internalization and
processing, however, it is unknown how they affect this process in detail. It has been
demonstrated that Igα and Igβ selectively target Ags to be loaded into MHC II (Bonnerot et al.,
1995). inhibitors vie with protein that is being digested, regulating what proteases are more
active in the cleaving of the endocytosed Ag. Cytokines can affect endocytic proteases by
adjusting their activity, synthesis, or stability. Various cytokines have been shown to affect the
endosomal pH, increasing or decreasing the ability of protease activity (Drakesmith et al., 1998;
Fiebiger et al., 2001). In this way, cytokines can stimulate or inhibit enzymes involved in Ag
cleavage and degradation, affecting what peptide segments are available to be loaded into MHC
II complexes.
A final mechanism affecting the presentation of epitopes proposed is the loading of MHC
II molecules. HLA-DM and the MHC II complex load only peptides that have an appropriate
length and affinity. Peptides need to display specific amino acid motifs to be loaded
(Rammensee, 1995). Several other factors affecting this loading include endosomal environment,
including pH, and the HLA-DM (Escola, Grivel, Chavrier, & Gorvel, 1995; Griffin, Chu, &
Harding, 1997). Age of the individual is also a factor that affects cellular efficiency. It is known
that Ag presentation is better in younger individuals and declines with age (H. L. Clark et al.,
2012). Recycled and newly synthesized MHC II molecules also play a role in selection. They are
known to associate with different peptides (Lindner & Unanue, 1996), thus levels of recycled
and newly synthesized MHC class II molecules could affect the peptides selectively loaded.
Many questions remain unanswered about peptide selection for MHC class II loading and Ag
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processing. Future investigation includes determining regulatory factors responsible for
endocytic compartment targeting to lysosomes in the endocytic pathway and regulation of
proteases in the cell, endogenous competitive inhibitors, and cytokines are other areas for
research into selective processing of Ag.
It has also been demonstrated that through endocytosis, molecules that are associated
together, non-covalently, can be presented in the context of MHC class II molecules as well
(McCluskey et al., 1998). The event where an Ag and the associated molecule are processed and
part of the Ag associated molecule is presented via MHC II to T cells has been termed
intermolecular/intrastructural help (Lake & Mitchison, 1977). Such processing leads to
intermolecular epitope spreading. Understanding of these events in concert with B cell
processing and selection is essential for adequate comprehension of how and to what extent
epitope spreading contributes to the human immune response, disorders, and diseases.
Somatic Hypermutation
During affinity maturation, B lymphocytes undergo somatic hypermutation (SHM) which can
contribute to the spreading of epitopes (Deshmukh et al., 2005). This process takes place in
germinal centers to improve B cell Ab affinity for an Ag. At this period of time SHM of the IgV
gene region experiences single nucleotide substitutions. These happen at a frequency of about
103 per base pair in each B lymphocyte generation (Di Noia & Neuberger, 2007). The
consequence of SHM results in Abs with a higher affinity for the Ag presented by dendritic cells
in secondary lymphoid tissue during affinity maturation (Figure 3). It has been suggested that
SHM also leading to B cell epitope spreading, contributes in the progression of autoimmune
diseases. Auto reactive Abs can be generated against dsDNA through SHM in the development
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Figure 3. Somatic Hypermutation (SHM) as a mechanism of B cell epitope spreading.
Figure 3. Somatic Hypermutation (SHM) as a mechanism of B cell epitope spreading.
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of systemic lupus erythematosus (Ray, Putterman, & Diamond, 1996). It is uncertain to what
extent SHM contributes to B cell epitope spreading. Investigating this question and determining
if SHM contributes to other autoimmune diseases remains an area for future research that is
lacking at this time.
1.1.4 B cell Epitope Spreading in Autoimmune disease
Rheumatoid Arthritis
The most common inflammatory arthritis worldwide, rheumatoid arthritis (RA) affects
nearly 1% of the global population and can cause severe debilitation and joint deformity within
the first few years of clinical symptoms due to joint inflammation and tissue degradation
(McInnes & Schett, 2011; Schellekens, de Jong, van den Hoogen, van de Putte, & van Venrooij,
1998; Sokolove et al., 2012). While joint damage is the most characteristic and common
symptom, the inflammation produced can also affect organs such as the cardiovascular and
pulmonary systems (McInnes & Schett, 2011). Although the specific causes that lead to RA are
unclear, it is thought to be the result of interplaying genetic factors, environmental agents, and
chance, similarly observed among other autoimmune diseases. Certain Abs, including
rheumatoid factor and Anti-Citrullinated Protein Abs (ACPA) are important contributors to RA
(Schellekens et al., 1998). Rheumatoid factor is a high-affinity auto-Ab against the FC region of
immunoglobulins (McInnes & Schett, 2011). These Abs often develop years before clinical
disease, preceding the development of rheumatoid arthritis, with the number of targeted proteins
gradually increasing until the time of diagnosis (Nielen et al., 2004; Rantapaa-Dahlqvist et al.,
2003; Sokolove et al., 2012). Interestingly, increasing Ab targets correlate with increased
inflammatory cytokine levels (Sokolove et al., 2012) and the disease course of RA. ACPAs can
be directed against a multitude of targets (Snir et al., 2009). This wide range of targets arises
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because citrullinated proteins result when arginine residues in proteins are converted to citrulline
residues due to a post-translational modification by peptidylarginine deiminase, a process that is
not specific to a single protein (Kidd et al., 2008).
Epitope spreading is seen in the development of the ACPA repertoire. It is hypothesized
that the neo-Ags that result from citrullination could evoke an initial immune response, which
then develops into a polyclonal Ab response against the entire protein or protein-complex due to
epitope spreading (Schellekens et al., 1998). This process is restricted mainly to genetically
susceptible individuals, and the mechanism that triggers the initial citrullination is still unclear
(Schellekens et al., 1998). Additionally, the reason why a systemic loss of self-tolerance leads to
localized joint inflammation is also unclear (McInnes & Schett, 2011).
An investigation into United States Armed Services personnel clinically diagnosed with
Rheumatoid Arthritis revealed unique information about Ab development and epitope spreading
during the development of RA (Sokolove et al., 2012). Using clinical Ab assays and a novel
multiplex auto-Ab assay, it was possible to process serum samples obtained from the Department
of Defense Serum Repository and screen for various Abs unique to RA patients. The samples
used predated and preceded clinical symptoms and diagnosis of RA. Upon analysis, it was noted
that the Ab diversification increases with the progression of RA and occurs before the onset of
clinical symptoms. ACPAs were observed prior to the development of anti-cyclic citrullinated
peptides (anti-CCP). These findings indicate both intramolecular and intermolecular B cell
epitope spreading during the progression of rheumatoid arthritis. It is hypothesized that this
epitope spreading was initiated by B cells stimulated by citrullinated fibrinogen complexes
(Sokolove et al., 2012). These examples indicate that B cell epitope spreading takes place during
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disease progression in rheumatoid arthritis and that citrullination of peptides contributes to these
epitope spreading events.
Type 1 Diabetes
Type I diabetes (T1D) results when an autoimmune reaction attacks and destroys the
insulin producing beta cells of the pancreas. T cells specific for a number of diabetogenic autoAgs are responsible for the destruction of the pancreatic islet cells. T1D is the most prevalent
chronic disorder among children, and the loss of glucose level homeostasis that results can cause
polydipsia, polyuria, weight loss, and potential complications of hypoglycemia such as
hypoglycemic shock (Prasad, Kohm, McMahon, Luo, & Miller, 2012).
Autoimmunity may first be triggered against the B9-23 region of insulin (Prasad et al.,
2012) and progression to overt disease is mediated by epitope spreading to an array of beta cell
Ags. It was shown that non-obese diabetic (NOD) mice that lacked mature B cells could not
develop this autoimmunity, suggesting a crucial role of B cells in the mechanism of epitope
spreading. In this experiment, two to three-week old NOD mice were transfused with naive T
and B cells, or only naïve T cells, and the T cell response to various beta cell Ags was measured
at four and ten weeks after transfusion. The TB NOD mice demonstrated progressive
autoimmunity development to glutamic acid decarboxylase (GAD), heat shock protein 277
(HSP277) and insulin B-chain while the T NOD mice showed no T cell response to any of the
beta cell Ags tested. Researchers showed that NOD mice B cells have deficient tolerance to autoAgs, and are relatively resistant to activation-induced cell death, which could explain why
autoimmunity was able to develop (Tian, Zekzer, Lu, Dang, & Kaufman, 2006). In C57BL/KsJ
db/db mice, it was found that the retroviral p73 protein, a group-specific Ag, acts as a molecular
mimic of insulin (Serreze, Leiter, Kuff, Jardieu, & Ishizaka, 1988). It is speculated that
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presentation of this retroviral Ag to T-helper cells may stimulate B-lymphocytes producing the
cross-reactive anti-p73 Ab, which also bind insulin (Serreze et al., 1988). Once the initial selftolerance to insulin is broken, epitope spreading can contribute to the development of
autoimmunity. The currently proposed model is that an initial wave of activated T cells causes B
cell activation through T-B cell interaction and cytokine release. This enhances the Ag
presenting functions of the B cells, causing them to capture and present beta cell Ags to T cells,
causing the expansion of T cell autoimmunity (Tian et al., 2006).
A clinical study further demonstrated epitope spreading as a mechanism leading to
disease progression and clinical diagnosis (Brooks-Worrell, Gersuk, Greenbaum, & Palmer,
2001). During an average of 30 months, 25 volunteers at risk for type 1 diabetes donated blood
for analysis. These individuals were classified as ‘at risk’ due to the detection of islet cell Abs
(ICA), Glutamic acid decarboxylase Abs (GADA), islet cell Ab-2 (IA-2), or insulin auto-Abs
(IAA). Serum samples obtained were tested for the four Abs using specific Ab assays for ICA,
GADA, IA-2, and IAA. Out of the 25 at risk volunteers under observation, seven developed
clinical type 1 diabetes. All seven of these volunteers displayed serological evidence of
intermolecular B cell epitope spreading. One patient, during pre-clinical T1D only displayed ICA
in the serum. By the end of the study the B cell repertoire had diversified to include all four Abs.
Other at-risk volunteers not diagnosed with clinical type 1 diabetes also displayed evidence of
intermolecular B cell epitope spreading (Brooks-Worrell et al., 2001).
Multiple Sclerosis
An autoimmune disease of the central nervous system, multiple sclerosis results from the
degradation of myelin proteins that sheath the neurons. The demyelization is caused by the
attacking immune cells, particularly T and B cells, causing inflammation and a subsequent
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autoimmune response. With the destruction of the myelin sheath, biochemical electrical
impulses from the brain are not transmitted efficiently. A variety of symptoms result including:
fatigue, pain, movement, coordination, cognitive, and visual problems (Hemmer, Nessler, Zhou,
Kieseier, & Hartung, 2006). Citrullination, via peptidylargenine deiminase, is thought to be
caused by inflammation of target tissues and occurs in many circumstances normally. Myelin
basic protein (MBP) is partially citrullinated in healthy brain tissue, but in those with MS there is
an increase of citrullination. It is hypothesized that citrullination contributes to the progression of
multiple sclerosis (Cao, Sun, & Whitaker, 1998). Auto-Abs derived during mouse model studies
were between two and 20-fold more reactive against citrullinated MBP compared to noncitrullinated MBP (Kidd et al., 2008). In addition, these auto-Abs were found to be reactive
against epitopes derived from αB-crystallin, the most abundant early gene transcript. Recent
studies have shown that development of B cells into tertiary lymphoid tissue near CNS regions
further contribute to the progression of MS (Kuerten et al., 2012).
The essential role of B cell epitope spreading in MS was demonstrated clearly in SJL/J
mice with remitting-relapsing experimental autoimmune encephalomyelitis (RR-EAE) (Pollinger
et al., 2009). These transgenic mice spontaneously develop RR-EAE affecting various central
nervous system tissues and have a TCR specific for mouse myelin oligodendrocyte glycoprotein
(MOG) peptide 92-106. The study showed that with the SJL/J mice, the endogenous B cells
secreted Abs for new epitopes besides the peptide sequence the T cells targeted. Their findings
also showed that there was no spontaneous EAE development in B cell deficient mice and that B
cells enhanced the pathogenesis of EAE in the RR-EAE mouse model. The spreading of the B
cell repertoire to other MOG epitopes besides the targeted amino acid sequence suggests that in
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EAE, the mouse model equivalent of multiple sclerosis, B cells are essential for the development
of the disease, with a likely role for epitope spreading (Pollinger et al., 2009).
A different study conducted using EAE mice models contributed further to our
understanding by showing that epitope spreading was found to directly correlate with disease
progression (Kidd et al., 2008). In a mouse model, proteolipid proteins (PLP) where used to
induce EAE. Various regions of these PLPs became targets for Abs, along with the targeting of
additional epitopes on other myelin proteins, both citrullinated and non-citrullinated. This is
indicative of both intramolecular and intermolecular B cell epitope spreading. These results add
credence to previous research demonstrating the development of cryptic epitopes during disease
development and provides an explanation for why this occurs (Lehmann, Forsthuber, Miller, &
Sercarz, 1992). Epitope spreading has been shown to lead to the development of multiple
sclerosis in mice during infection by Theiler’s virus (Miller et al., 1997), indicating viruses as a
potential trigger for the development of CNS autoimmune diseases.
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disease caused by immune
reacting with targets at diverse locations in the human body leading to a variety of clinical
manifestations. SLE affects approximately 1 in every 2000 individuals with a 9:1 ratio for
female vs. male diagnosis respectively (Klippel, Weyand, & Wortmann, 1997). Auto-Abs in
SLE are often raised against double-stranded DNA as well as ribonuclear-proteins (RNPs) of the
Sm complex found in spliceosomes (Klippel et al., 1997; B. D. Poole et al., 2006; C. J.
Vanderlugt & Miller, 1996). This autoimmune response causes an accumulation of immune
complexes and immune-mediated attack of various organs. Symptoms of SLE include: butterfly
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rash, chest pain, sensitivity to light, joint pain, and kidney damage (Deshmukh et al., 2005; K. E.
Taylor et al., 2011).
Arbuckle et al. explored the clinical evidences of B cell epitope spreading by comparing
the presence of auto-Abs from the serum of pre-diagnosed and post diagnosed SLE patients
(Arbuckle et al., 2003). This was made possible through The Department of Defense Serum
Repository, containing over 30 million serum samples from members of the U.S. Armed Forces.
Serum is collected at the time of enlistment and on average every year thereafter. This allowed
Arbuckle et al. to identify SLE patients and then go back and observe the development of autoAbs prior to SLE diagnosis. 130 SLE patients were selected and then tested for the presence of
the major SLE autoantibodies including: anti-double-stranded DNA, anti-Ro, anti-La, anti-Sm,
anti-nuclear ribonucleoprotein, and antiphospholipid. The presence of auto-Abs was confirmed
via indirect immunofluorescence with HEp-2000 cells and ELISA assays. Arbuckle at el.
observed that pre-diagnosis of SLE patients auto-Ab detection recognized on average 1.5 of 7
auto-Ags associated with SLE. At the time of clinical SLE diagnosis typically 3 of 7 auto-Ags
were recognized, on average, by the Abs showing a spread of auto-Ab specificity over time
(Arbuckle et al., 2003). These results indicate the occurrence of intermolecular B cell epitope
spreading during the progression of preclinical to clinical autoimmune manifestation as well as
during the progression of the pathogenesis of SLE.
Another investigation demonstrated the role of epitope spreading in SLE by studying
auto-Ab diversification in response to small nuclear ribonuclear proteins (snRNP’s) Ags
(Deshmukh, Kannapell, & Fu, 2002). SLE patients often show diverse auto-Ab reactivity to
snRNP’s. To demonstrate this phenomenon, A/J mice were vaccinated with recombinant Smith
D (SmD), Smith B (SmB), and A ribonuclear protein (A-RNP) and the specificity of the Abs that
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developed were observed. Using western blots and immunoprecipitation assays to identify Ab
specificity, it was observed that mice immunized with SmD also developed Abs specific against
SmB and A-RNP. Likewise, mice immunized with SmB showed a development of Ab
specificity against A-RNP and A-RNP immunized mice developed Abs against SmB as well as
the 70-kDa protein A of the U1-snRNP. These results demonstrated that auto-Ab reactivity can
spread from a single Antigenic site in a multi protein complex to associated complex proteins
(Deshmukh et al., 2002).
Studies by Bavel et al. have investigated new antigenic epitopes presented after cell
apoptosis that have been linked with SLE (van Bavel, Dieker, Tamboer, van der Vlag, & Berden,
2010). They found that acetylated epitopes of chromatin could allow for increased pathogenesis
and epitope spreading. Scofield and associates studied a related line of research that indicate
modification of Ro/SSA with lipid oxidation products, 4-hydroxy-2-alkenals in particular,
increases the antigenicity and opportunity for B cell epitope spreading (Scofield, Kurien, et al.,
2005). Research using A/J mice has also lead to the understanding that in some cases it is
possible that intermolecular epitope spreading is more likely to occur than intramolecular epitope
spreading (Deshmukh et al., 2007). As has been mentioned previously, environmental factors
have been implicated leading to the breaking of tolerance and subsequent initiation of epitope
spreading via molecular mimicry (B. D. Poole et al., 2006). Thanks to recent and past research, it
is apparent that B cell epitope spreading plays a crucial role in the pathogenesis of SLE once
self-tolerance is broken.
Sjogren’s Syndrome
Sjogren’s syndrome (SS) is an autoimmune disease that is associated with lymphocytic
infiltration of the salivary and lacrimal glands resulting in dry mouth and eyes (Kurien et al.,
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2013). The immune response can result in the damage and destruction of the glands. When only
exocrine glands are involved in the autoimmune response it is considered primary Sjogren’s
syndrome, after other connective tissue becomes involved it is considered secondary Sjogren’s
syndrome. In SS, auto-Abs commonly develop against the Ro/SSA and La/SSB
ribonucleoprotein particle linking SS to SLE through a common auto Antigenic site. SS is the
second most common rheumatic disease but frequently goes without diagnosis due to its
common symptoms. While a portion of the disease can be attributed to genetic risk factors, other
stimuli are hypothesized to play a role in the development of SS, such as hormone imbalance and
stress. Several environmental factors are thought to be triggers for SS including Epstein-Barr
virus, Hepatitis C, tuberculosis, and malaria among others (Kivity et al., 2014).
Scofield et al. explored the role of epitope spreading in SS by vaccinating BALB/c mice with
different amino acid sequences from 60-kDa Ro/SSA and observed whether auto-Abs against the
entire 60-kDa Ro/SSA protein would develop (Scofield, Asfa, Obeso, Jonsson, & Kurien, 2005).
In the experiment ten mice were vaccinated with Ro/SSA 480 and 10 separate mice were
vaccinated with Ro/SSA 274. The results showed that mice developed Abs against their
respective peptide sequence in 2-3 weeks and then over the course of several months developed
auto-Abs that were reactive against the entire Ro/SSA and La/SSB complex. They further
observed that mice vaccinated with 60-kDa Ro peptides not only developed SS associated autoAbs but that the vaccinated mice developed salivary gland lymphocyte infiltrates and salivary
gland dysfunction that resembled symptoms seen in human SS (Scofield, Asfa, et al., 2005).
It is important to continue research investigating risk factors related to the development
of SS. Recent studies have reported HLA class II specific genetic markers as risk factor for SS
and leading to B cell epitope spreading (Gottenberg et al., 2003; Kurien et al., 2013;
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Paisansinsup et al., 2002). Routsias et al. recently suggested that intermolecular B cell epitope
spreading in SS may begin via molecular mimicry in the RRM region of La/SSB (Routsias,
Kyriakidis, Latreille, & Tzioufas, 2010). Further studies on possible risk factors and
mechanisms of epitope spreading are needed to better understand the initiation and advancement
of SS. Increased understanding in these areas would allow for the potential development of
therapeutic treatments.
Graves’ Disease
Also known as Basedow disease, Graves’ disease is a condition where Abs develop that
bind thyrotrophin receptors of the thyroid causing their activation and a subsequent up regulation
of cyclic adenosine monophosphate and thyroid hormone synthesis (B. M. Genovese,
Noureldine, Gleeson, Tufano, & Kandil, 2013; Prabhakar, Bahn, & Smith, 2003). This
stimulation leads to hyperthyroidism and hyperplasia of the thyroid. Pathological symptoms
include goiter development, insomnia, pretibial myxedema, muscle weakness, itching and
Graves’ ophthalmopathy (B. M. Genovese et al., 2013; Lazarus, 2012).
B cell epitope spreading has been related to thyroid diseases in clinical settings. Kim et
al. found that in the serum analyzed during their study, Ab targets changed during disease
progression. Since that time various experimental animal models have provided evidence of B
cell epitope spreading in Graves’ disease. Using New Zealand White rabbits in a study to
determine if B cell epitope spreading plays a role in the pathogenesis of Graves’ disease,
Thrasvoulides et al. immunized their rabbits with three different peptides from thyroglobulin
(Thrasyvoulides & Lymberi, 2003). Using affinity chromatography and ELISA assays, they
confirmed that when they immunized the rabbits with peptide AA2471-2490, after a period of
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several weeks there was intramolecular epitope spreading resulting in Abs binding to other
epitopes on the thyroglobulin protein other than the initial peptide used during immunization.
Using Balb/c mice, evidence was found indicating intramolecular B cell epitope
spreading (Vlase et al., 1995). In later mouse model studies, similar results were noted. When
Balb/c and C57BL/6 mice where immunized with TSH receptor protein (TSHR), the Ab
diversified from recognizing only the N-terminus domain to additional epitopes including the
TSHR ectodomain (Schwarz-Lauer et al., 2003). Using more specific methods, Inaba et al.
immunized breeding stock mice transgenic for HLA-DR3 and HLADR2 with 41 different TSHR
peptides (Inaba et al., 2009). When mice where immunized with peptides AA70-88, AA83-102,
or AA105-118 there was an Ab diversification outside of the original peptide epitope presented.
More recently, it has been demonstrated that B cell epitope spreading occurs more rapidly than T
cell epitope spreading (Inaba et al., 2013). The variety of research using animal and clinical
means establishes B cell epitope spreading as a participant process in the development of
Graves’ disease.
Scleroderma
Scleroderma, or systemic sclerosis, is an autoimmune disease that involves connective
tissue damage, most notably endothelial cells and fibroblasts of the extracellular matrix (Chung
& Utz, 2004). Scleroderma is characterized by fibrosis of various organs throughout the body.
The hardening of the organs is thought to be caused by an overproduction of collagen. An early
symptom indicative of scleroderma, termed Raynaud’s phenomenon, is when extremities such as
fingers or toes, experience an exaggerated response to temperatures and distress. These areas will
often feel numb or pained and may change color. B cells have often been shown to over express
CD19, an activating receptor, during autoimmune progression. Auto-Abs for various targets are
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seen in patients with scleroderma including anti-endothelial cell, anti-fibroblast, anti-MMP, and
anti-fibrillin-1 among others, which involve targeting many DNA binding proteins including
DNA topoisomerase (Chung & Utz, 2004; Henry et al., 2000). These autoimmune responses
results in inflammation and tissue damage in the affected regions (Asano, Ihn, Yamane, Kubo, &
Tamaki, 2003).
In scleroderma, B cell epitope spreading is initiated for a variety of reasons such as
molecular mimicry or displays of previously cryptic domains which are displayed by enzymatic
degradation, in which portions of the protein are degraded and novel domains are available for
recognition. Furthermore, modification of target Ags may occur, such as the modification of U170 kd Ag modified by reactive oxygen species (Chung & Utz, 2004; Kurien & Scofield, 2008).
Cryptic domains may also be exposed after vascular spasms, and the release of reactive oxygen
(Gavanescu, Vazquez-Abad, McCauley, Senecal, & Doxsey, 1999). Few studies in recent years
have investigated into epitope spreading and the development of scleroderma. In two studies,
auto-Abs to differing centrosome domains were present in the same sera, suggesting
intermolecular spreading (Gavanescu et al., 1999).
B cell epitope spreading has been observed as novel Ags are identified in patients with
scleroderma. Of particular note is anti-PM/Scl Abs, antinucleolar Abs. Though further studies
are necessary, it is thought that novel auto-Ags are targeted during disease progression. In a
study conducted by Henry et al, auto-Abs were shown to have higher incidences to certain autoAgs than to other target auto-Ags (Henry et al., 2000). For example, reactivity towards Scl-70
was much higher than topoisomerase I epitopes. These differences were concluded to occur
because of the greater number of conformational determinants, which are larger than linear
domains. This could explain the development of auto-Ags later in disease development resulting
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from the protein preference and subsequent epitope spreading events. The continued
identification of novel auto-Ags and how B cell epitope spreading contributes to the
pathogenesis of scleroderma remain areas for substantial future research.
Cardiomyopathy
A disease resulting in the weakening and enlarging of the myocardium, dilated
cardiomyopathy (DCM) is a fatal disorder causing various cardiovascular problems and a
frequent culprit of heart failure. Dilated cardiomyopathy generated as an autoimmune response is
a consequence of Abs reactive to heart associated protein (Rose, 2009). Anti-myosin IgG Abs are
commonly observed in patients with autoimmune cardiomyopathy along with other auto Abs
including anti-C protein Abs (Caforio et al., 2013; Neumann, Burek, Baughman, Rose, &
Herskowitz, 1990; Nishimura et al., 2001). A clinical familial study conducted by Catorio et al.
found that the production of cardiac specific Abs usually precludes disease development (Caforio
et al., 2007). The occurrence of dilated cardiomyopathy is due to several factors both genetic
and environmental. Potential triggers for dilated cardiomyopathy include enteroviruses and other
myopathic diseases (Caforio et al., 2013; Miller et al., 1997).
One of the few examples showing the involvement of B cell epitope spreading in
cardiomyopathy, Matsumoto et al., observed this event in Lewis rats immunized with C protein
fragment 2 (CC2) (Matsumoto, Park, & Kohyama, 2007). During their study they immunized
Lewis rats with various peptides derived from CC2, peptide segments P1 through P12. All CC2
peptide mixes induced experimental autoimmune carditis (EAC) and lead to DCM, with the
exception of P12, which only lead to the development of EAC. Mixes of P1 to P3, P4 to P6, P7
to P9, P10 to P12, and several individual peptide segments were used to inoculate the Lewis rats.
After immunization, it was observed that the Ab response diversified to include not only the Abs
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against the mix of segments used to immunize the rats, but also against various other peptide
segments on CC2. All of the Lewis rats immunized P1 through P11 demonstrated this
diversification and eventually progressed from EAC to DCM. While those Lewis rats immunized
with CC2P12 only developed Abs against that region and did not develop DCM, but remained
expressing EAC symptoms(Matsumoto et al., 2007). The study evidences the influence that B
cell epitope spreading plays in the progression of dilated cardiomyopathy.
Heymann Nephritis
Heymann Nephritis (HN) disease models using Lewis rats are one of the most valuable
tools for researchers to use in understanding the immunopathology of glomerular subepithelial
immune deposit formation and mechanisms by which such deposits injure glomeruli. The Lewis
rat model of induced active Heymann Nephritis first described in 1959 closely resembles that of
glomerular injury and nephropathy in humans. Mechanisms of renal sodium retention, edema
formation, and metabolic abnormalities have been observed as a guide to treating primary and
secondary human glomerulonephritis diseases (Raychowdhury, Niles, McCluskey, & Smith,
1989; Salant, Quigg, & Cybulsky, 1989). Inducing active HN in rats is conducted by immunizing
susceptible strains of rats with certain fractions of homologous or heterologous proximal tubular
brush border. Granular glomerular capillary wall deposits of rat IgG and subepithelial electrondense deposits characterize the disease after three to four weeks. Primary manifestations of HN
include proteinuria (developing in 30-80% of induced rats), changes in glomerular
hemodynamics, tubular function, and alterations in renal hormone production. These disease
manifestations are closely related to human nephropathy disease manifestations, and demonstrate
that active HN is indeed an autoimmune-induced disease (Raychowdhury et al., 1989; Salant et
al., 1989; Shah, Tramontano, & Makker, 2007).
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Megalin, or more specifically termed gp330, was found in 1982 and determined to be the
glycoprotein and target Ag within the pits of glomerular and proximal tubular epithelia. The
pathogenesis of HN includes the binding of circulating Abs to glomerular components. Megalin
and RAP (receptor associated protein – 44kd) are the target Ags for nephritic activity and it was
determined that RAP binds to Megalin (Farquhar, Saito, Kerjaschki, & Orlando, 1995; Shah et
al., 2007).
Megalin is a complex Ag with four discrete ligand-binding domains (LBDs) that may
contain epitopes to which pathogenic auto-Abs are directed. In a recent study a 236-residue Nterminal fragment (termed “L6”) that spans the first LBD was shown to induce auto-Abs and
severe disease in Megalin-immunized HN rats (Shah et al., 2007). Sera obtained from test
results of rats that had received an L6 fragment showed reactivity only with the first LBD after a
4-week period. However, after 8 weeks the same L6 fragment showed reactivity with all four
recombinant LBDs. The study demonstrated that the L6 immunogen did not contain the
epitopes responsible for reactivity with the LBD fragments and therefore suggest intramolecular
epitope spreading as the key variant to the increased severity and reactivity of HN rats. Further
correlation of epitope spreading to the pathogenesis of HN disease indicated by the study was the
onset of proteinuria. Proteinuria in rats immunized with L6 was seen at 6 to 8 weeks. ELISA of
antisera indicated peak titers against L6 at weeks 4 through 6, however reactivity of LBDs arose
after week 6 and had maximal values at week 9. Thus induction of proteinuria with serum
reactivity was indicative of epitope spreading (Farquhar et al., 1995; Shah et al., 2007).
Treatment in HN Lewis rats with DNA vaccinations resulted in lowered proteinuria and promise
for future treatment (Y. Wang et al., 2013; H. Wu, Walters, Knight, & Alexander, 2003).
Pemphigus
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Pemphigus is classified as a rare form of skin blistering caused by an autoimmune
response against desmosomal adhesion proteins. These proteins are responsible for the
homeostasis and attachment of epidermal cell layers (Galichet, Borradori, & Muller, 2014).
There are four distinct forms and each is classified according to clinical signs and symptoms.
Pemphigus vulgarius is the most common and is diagnosed by the presence of anti-Desmoglein 3
protein IgG Abs, with the initiation of sores in the oral mucosa and spreading to blisters on the
face, limbs, and trunk of the body (Groves, 2009). Pemphigus foliaceus is characterized by
Desmoglein 1 auto-Abs and superficial blister formation on the extremities. P. foliaceus tends to
be one of the least severe forms of Pemphigus. Immunoglobulin A pemphigus is identified by the
characteristic IgA Abs directed against desmoglein, and in some cases, desmocollin, proteins.
The final and most severe form, Paraneoplastic pemphigus, is often associated with a secondary
malignancy. The product is a wide spread autoimmune response causing severe cutaneous
blistering in potentially any epidermal or mucosal tissue of the body. The cause of the
autoimmune response in this case is unknown, although it is suspect that disease initiation may
be related to insect bites (Groves, 2009).
To demonstrate that intermolecular and intramolecular epitope spreading occurs in
Pemphigus, Valerie K. Salato, Mong-Shang Lin, and their associates at the Medical College of
Wisconsin collected and analyzed sera from Pemphigus Vulgaris (PV) positive volunteers
(Salato, Hacker-Foegen, Lazarova, Fairley, & Lin, 2005). These samples were taken at various
times during the course of disease progression. In their study 14% of their volunteers transitioned
from mucosal PV to mucocutaneous PV. They evaluated their Ab profiles during the progression
of PV by immunoprecipitation and competition indirect immunofluorescence assays. Giving an
example of one of these patients, early assays and detailed epitope mapping showed that they had
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Abs autoreactive for region AA405-566 of Desmoglein 3. Several years later that same patient
transitioned to produce auto-Abs that reacted with regions AA1-88 and AA87-566 of
Desmoglein 3, demonstrating the spread of the B cell repertoire and offering evidence of
intramolecular spreading. This same patient also showed evidence of intermolecular epitope
spreading when they developed Abs that were auto-reactive with human skin cells. Samples
collected earlier in the study showed no human skin auto-Abs while six years later, after the
patient had transitioned to mucocutaneous PV, samples taken exhibited these auto-Abs. This
hypothesis of intermolecular spreading was further supported when they confirmed the Abs autoreactive for desmoglein 1in later samples (Salato et al., 2005). Their study demonstrates how B
cell epitope spreading contributes to the progression of Pemphigus Vulgarius from displaying
strictly mucosal legions to cutaneous legions.
Further observations give credence to the phenomenon of epitope spreading and its role
in the development of Pemphigus when Bowen et al. described the development of
Paraneoplastic Pemphigus from patients displaying Lichenoid Dermatitis (Bowen et al., 2000).
They speculate that the intramolecular spreading could be due to lichenoid sores and the
subsequential inflammation predisposing patients via a heightened immune response. This theory
was further compared to other leading ideas as to the cause for disease progression in
Paraneoplastic pemphigus and was suggested as a possible area for future research (Chan, 2000).
In a study done in a Brazilian community it was proposed that epitope spreading was the cause
for the development of Pemphigus Foliaceus in patients diagnosed with Fogo Selvagem, loosely
translated as “wild fire” disease (N. Li et al., 2003). In their study, Li et al. proposed that a
genetic predisposition may contribute along with epitope spreading leading to Pemphigus
Foliaceus. In a unique case, clinical evidence suggests that B cell epitope spreading can
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contribute to the progression of Pemphigus to Bullous Pemphigoid (Peterson et al., 2007). B cell
epitope spreading has been observed to play a role in the progression of Pemphigus and
contribute in the development to more severe symptoms.
Bullous Pemphigoid
Similar to Pemphigus, Bullous Pemphigoid is a cutaneous blistering autoimmune disease.
Patients suffering from Bullous Pemphigoid do not typically experience mucosal lesions and the
disease is often marked by pruritic blisters on the trunk of the body, epithelial areas of the joints,
and the extremities. The autoimmune response in this case is characterized by the development
of Abs against Bullous Pemphigoid Ag 1 and 2 (BP230 and BP180 respectively), also known as
BPAG 1 and BPAG2, which compose part of the hemidesmosome and assist with cell to matrix
adhesion in the epithelium (Chan et al., 1998; Stanley, Hawley-Nelson, Yuspa, Shevach, & Katz,
1981). As a result, autoimmune response to differing collegen types is characteristically seen in
bullous pemphigoid. It is documented to have a higher incidence among the elderly and is
estimated to have an incidence in the general population of 6-7 cases per million. This estimate
increases to 150-330 cases per million in the population older than 80 years of age
(Kershenovich, Hodak, & Mimouni, 2014; Schmidt & Zillikens, 2013). With respect to the
environmental or genetic factors that could initiate an autoimmune response, there remains little
information on triggers. Our current understanding indicates that triggers for Bullous
Pemphigoid could include vaccines, medications, and possibly a variety of infections (Walmsley
& Hampton, 2011).
A clinical study was conducted by Giovanni Di Zenzo and his international associates
with the specific aim to appraise the development of IgG Abs during the course of Bullous
Pemphigoid development (Di Zenzo et al., 2011). Thirty-five patient volunteers diagnosed with
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Bullous Pemphigoid were selected for this multicenter study along with a control group of fifty
volunteers including both Bullous Pemphigoid patients and healthy individuals. All volunteers
were assessed at the initiation of the study as well as one, three, six, and twelve months during
the study while undergoing treatment. ELISA and immunoblotting assays specific for various
domains on BP180 and BP230 were utilized to assess the Abs present in patient sera. Their study
found that in three of the patients, BP180 Abs recognized the ectodomains of the protein before
developing Abs specific for the intracellular domains. Intermolecular epitope spreading was also
observed to occur during the course of the study. 17.6 percent of the volunteers developed an
IgG response that initially recognized either BP180 or BP230, to recognizing both proteins.
Analyzing the data collected during the study, it was observed that epitope spreading incidence
was higher during the first three months after diagnosis compared to any other time during the
study. It was noted that the spreading from ectodomains to intracellular domains and the
incidence rates are correlated with the severity of Bullous Pemphigoid (Di Zenzo et al., 2011).
During a previous clinical study, Epitope spreading was observed in the Ab response
progressing from collagen XVII to collagen VII (Fairley, Woodley, Chen, Giudice, & Lin,
2004). As has been previously mentioned, bullous pemphigoid has been observed to develop
after diagnosis of pemphigus foliaceus (Maeda et al., 2006; Peterson et al., 2007). Another
clinical report was submitted several years later with similar observations of intermolecular
epitope spreading resulting in the development of bullous pemphigoid from pemphigus foliaceus,
but with the additional information that the patient exhibited only IgG3 auto-Abs, not IgG1
(Recke et al., 2009). Antibody isotype switching was not noted during the 13-year course of
clinical observation as normally would be the case. This remains an area for further research with
regards to the role isotype switching, or the lack there of, has in epitope spreading.
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1.1.5 Treatment Strategies for B cell Epitope Spreading: Current Concepts and Perspectives
Currently there exist few options for treatment of autoimmune diseases. Clinicians and
researchers rely on generalized immunosuppressive treatments that are designed to block a
broad-spectrum of potential risk factors associated with such diseases. Consideration of both
efficacy and side effects of such treatments is vital. In a review published by Vanderlugt et. al.
they discuss the role of tactics that can be designed to slow and/or neutralize the effects of
epitope spreading in autoimmune function (C. L. Vanderlugt & Miller, 2002). Due to the
unknown biologic pathway and change in antigenic specificity, it is difficult to design drugs that
can treat epitope spreading. However, some of the available treatments have been demonstrated
to affect epitope spreading.
The use of various drugs to control and inhibit both B and T cell activity is currently the
most commonly used approach to autoimmune diseases, however these drugs typically suppress
the entire immune system and are non-specific in their approach (Hauser et al., 2008; C. L.
Vanderlugt & Miller, 2002). T-cells play a major role in recognizing foreign and self-Ags and
thus promote a cytokine response due to changes in epitope specificity leading to autoimmune
dysfunction. Vanderlugt et. al., utilizing EAE (experimental autoimmune encephalomyelitis)
induced SJL mice and focusing on co-stimulatory signaling centers of CD28-CD80/86 and
CD154-CD40, established anti-CD80 Ab fragments and monoclonal anti-CD154 Abs that were
administered during peak phase or during relapse of EAE. Both anti-CD80 and anti-CD154 Abs
showed significant inhibition of disease relapse. Epitope spreading has been thoroughly studied
in EAE mice, which serve as a model for multiple sclerosis. Other drugs such as interferon
pathway regulatory agents could provide a further targeted approach to management of
autoimmune activity (Dreyfus, 2011; Lichtman, Helfgott, & Kriegel, 2012). Most recently
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researchers are working to develop Th2 bystander suppression drugs to combat epitope
spreading, disease-specific immunologic drugs, and targeted cytokine inhibitors (C. L.
Vanderlugt & Miller, 2002). These treatments are not in common use at this point, and there is
very little available data regarding their effects on epitope spreading.
Rituximab and B Cell Depletion Therapy
Rituximab is becoming a commonly used immunosuppressive. It utilizes a CD20 binding
protein designed to deplete mature B cells. In one report discussing the multi-type efficacy of
Rituximab, patients with pemphigus, a severe autoimmune disease resulting in blisters of the
skin and skin and mucosal erosion, were treated with rheumatoid arthritis (RA) dosing schedules
of Rituximab. At 6 months of dosage treatment 90% of patients achieved remission. At 22
months there was a 67% relapse rate with patients, however Global CD4+T cell numbers were
preserved up to 3 months after treatment (Leshem et al., 2014). In conjunction with
corticosteroids and other cytotoxic agents, Rituximab has also been used to treat SLE and other
Ab mediated autoimmune diseases (Bekar et al., 2010; Leandro, Cambridge, Edwards,
Ehrenstein, & Isenberg, 2005).
Other B cell depleting therapies include ocrelizumab and epratuzumab, which bind CD20
and CD22 respectively (Kamal, 2014). Use of B-cell depletion therapy may be helpful for
patients that don’t respond to other immunosuppression therapies (Leandro et al., 2005; Looney
et al., 2004; C. L. Vanderlugt & Miller, 2002). Use of rituximab could potentially inhibit or
impede B cell epitope spreading due to the depletion of B cells during the course of therapeutic
treatment. However, there is no current evidence to support that B cell depletion significantly
disrupts B cell epitope spreading.
Belimumab and Cytokine Inhibition Therapy
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A promising treatment for SLE, Belimumab is a monoclonal Ab that binds B lymphocyte
stimulators (BLyS). This type of therapy prevents the differentiation and survival of B cells.
Used in various clinical studies, Belimumab has become recognized as a treatment with high
efficacy and tolerability (R. Furie et al., 2011; Kamal, 2014; La Cava, 2010). A large multicenter
phase III study performed on Belimumab by Furie et al. demonstrated the efficacy of the therapy.
819 anti-nuclear Ab or anti-double stranded DNA Ab positive patients participated in the
randomized placebo controlled study over a period of 52 weeks. Those treated with non-placebo
participants were randomly given a high or low dose of Belimumab, 10 mg/kg and 1mg/kg
respectively. At one-year post treatment start of the study it was found that the risk of severe
flares was reduced by 34% (P=0.023) for the low dose group and 23% (P=0.13) for the high dose
group. It was also calculated that the SRI rates were 44%, 51% (P=0.0129), and 58% (P=0.0006)
for the placebo, low, and high dose groups respectively (R. Furie et al., 2011). Similar results
have been observed in other studies and suggest that Belimumab could be a good alternate
treatment option for SLE patients.
Blisibimod and Tabalumab are two other BLyS targeting Abs that are currently in clinical
trials and show promise for the treatment of SLE. In a recent randomized, placebo controlled
clinical phase II study, 547 SLE patients were treated with Blisibimod at one of three dose levels
and monitored over a period of 24 weeks. It was reported that the most effective dose was the
highest at 200 mg/kg and that it significantly reduced levels of anti-double stranded DNA Abs
(p<0.001) after 24 weeks. This dosage also improved levels of C3 and C4 (p<0.01 and p<0.001,
respectively). It was also observed that the treatment significantly lowered levels of B cells
(p<0.001). The results of the study suggests that at 200 mg/kg, Blisibimod is most efficacious for
patients with severe SLE (R. A. Furie et al., 2014).
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Atacicept is a biologic treatment option that is in clinical trials and has been studied for
the treatment of SLE, RA, and MS (M. C. Genovese, Kinnman, de La Bourdonnaye, Pena Rossi,
& Tak, 2011; Isenberg et al., 2014; Kappos et al., 2014). Due to its fusion protein construction it
inhibits both BLyS and A proliferation inducing ligand (APRIL), which results in the prevention
of symptoms similar to other BLyS targeting therapies, inhibiting B cell differentiation. A phase
II clinical study published by Genovese et al. reported that Atacicept showed no significant
efficacy compared to the placebo group used in the study (M. C. Genovese et al., 2011). But,
they did demonstrate that Atacicept lowered rheumatoid factor and immunoglobulin levels even
though it did not decrease the levels of anti–citrullinated protein Abs. It was observed in a
recently published double blind, randomized, placebo controlled clinical phase II study of
Atacicept for the treatment of MS, that the treatment adversely affected the patients treated
compared to the control group (Kappos et al., 2014). The results of a randomized, double blind,
placebo controlled clinical study to determine the efficacy in treating SLE patients were recently
published by Isenberg et al. In this 52-week study 461 SLE patients were treated with 75 mg/kg,
150 mg/kg, or the placebo. They reported that the high dose group, 150 mg/kg, demonstrated
lower flare rates verses the placebo group (P=0.002). Both the low and high dose treated groups
showed reduced levels of total Ig and anti-double stranded DNA Abs (Isenberg et al., 2014). The
results of these recent studies suggest that Atacicept could be a possible biologic treatment
option for SLE. There is no published evidence to demonstrate that BLyS and APRIL therapeutic
strategies inhibit or impede B cell epitope spreading, aside from the lack of clinical signs and
symptoms demonstrated by patients during the clinical trials. It does stand to reason that such
treatment options would prevent or disrupt epitope spreading, inhibiting disease progression.
Abatacept and Co-receptor Inhibition
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A further strategy of treatment is utilized by Abatacept, which inhibits T cell activation
by binding the CD28 receptor on B cells. Approved by the FDA in 2005, Abatacept is currently
used in the treatment of RA and to slow the progression of joint damage. In a recent phase III
clinical study comparing Abatacept to Adalimumab, a tumor necrosis factor α (TNF- α) inhibitor
approved for the treatment of RA in 2002, demonstrated that subcutaneous Abatacept produced
similar results in the treatment of RA (Weinblatt et al., 2013). In a multicenter, phase IIb,
randomized, double-blind, placebo controlled study of Abatacept in the treatment of SLE it was
observed that patients treated experienced a similar frequency of adverse events, and that these
adverse events were typically worse in the treatment group compared to the placebo group
(Merrill et al., 2010). While there is no evidence demonstrating this treatment inhibits epitope
spreading, such a strategy shows promise as an effective way to inhibit disease progression and
possibly impede B cell epitope spreading in patients with RA (Mease et al., 2011).
1.1.6 Summary
Over the past two decades our understanding of B cell epitope spreading has broadened
substantially. It is well understood how the process of epitope spreading contributes to pathogen
clearance and several factors that contribute to its effectiveness. Molecular mimicry and
intrastructural T cell help allow B cells to expand their Ab repertoire, which diversity results in
higher affinity Abs and a more effective immune response. Through various intracellular
processes, stimulated B cells can generate novel target epitopes and present them in the context
of MHC class II molecules to T cells. During B cell endocytosis, an Ag is endocytosed after
stimulation of sIg molecules on the cell surface. GILT, endocytic proteases, and lysosomal
cathepsins selectively process the Ag. After which a digested peptide is selectively loaded into
the MHC II molecule post LI degradation and CLIP dissociation, allowing for various epitopes
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to be displayed by MHC class II molecules. Through somatic hypermutation a variety of higher
affinity Abs are produced granting opportunity for further diversification of epitope targets.
While this process contributes positively to our systemic defense against pathogenic
organisms and macromolecules, it is also responsible for the progression of autoimmune diseases
after self-tolerance is broken. Evidence from clinical studies and reports, a variety of animal
models, and serological collection analysis has yielded substantial evidence indicating such.
Both intermolecular and intramolecular epitope spreading are observed to happen congruously
with the progression of autoimmune disease. Potential auto-Ags are more likely to become
Antigenic targets to initiate epitope spreading after modification by reactive oxygen species
(Chung & Utz, 2004; Kurien & Scofield, 2008) and lipid oxidation products(Scofield, Kurien, et
al., 2005) or abnormal apoptosis (van Bavel et al., 2010) and citrullination (Kidd et al., 2008).
Various other environmental triggers for initiating epitope spreading in autoimmune afflictions
have been identified including assorted viruses, bacterial infections, and stress (Kivity et al.,
2014; B. D. Poole et al., 2006). Currently we lack treatments that can effectively stop detrimental
B cell epitope spreading. It can be considered that various treatments, B cell depletion and
immune repression included, partial impede epitope spreading (Choi, Kim, & Craft, 2012).
There are many aspects that still remain to be explored and would contribute to future
understanding of epitope spreading while the role of T cell interaction in epitope spreading is
fairly well understood, less work has been done investigating the role of B cells in epitope
spreading. Future research opportunities regarding B cell endocytosis include investigating into
the currently unknown regulatory factors that are involved in the loading of MHC class II
molecules and competitive inhibitory processes that regulate the selective processing of
Antigenic peptides by cathepsins. It is also unclear how various compartments in the endocytic
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pathway target each other. The extent to which B cell epitope spreading contributes in the
progression of many autoimmune diseases is still not well understood and could be better
researched. Comprehension of patterns involved in epitope spreading to allow the prediction and
potential therapy of epitope spreading in autoimmune diseases is also lacking. Treatments to
inhibit epitope spreading or eliminate the detrimental aspects of epitope spreading are areas
where future research could be conducted.
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Section 2: Known Effects, Indicators, and Prevalence of Depression in Lupus
Patients
Systemic lupus erythematosus is a widespread, often devastating autoimmune disease. It
is characterized by a diverse symptomatology, including arthritis, sun sensitivity, kidney
damage, hematologic manifestations, immunological manifestations, and neuropsychiatric
involvement. Symptoms can vary widely between patients. Genetic, environmental and
hormonal factors all contribute to lupus etiology.
Neuropsychiatric manifestations (NPSLE) are common in lupus. Major depression,
obsessive-compulsive disorder, and generalized anxiety disorder are the most common
manifestations of mood and anxiety disorders found in lupus, occurring in up to 47% of patients
(Postal et al., 2016; Uguz, Kucuk, Cicek, Kayhan, & Tunc, 2013). Depression and fatigue due to
lupus are among the most important factors in lowering the quality of life for lupus patients (S.
T. Choi et al., 2012; Hanly et al., 2010; Yilmaz-Oner et al., 2015). These symptoms normally
present early in the disease progress and are frequently found at diagnosis (De Marcaida & Reik,
1999). Some studies show a correlation between neuropsychiatric symptoms and disease activity,
with depression and anxiety being more common during active disease (Nery et al., 2007; Segui
et al., 2000). Other studies have not found associations between disease activity and depression
(van Exel et al., 2013), although still finding high prevalence of neuropsychiatric symptoms.
The depression associated with lupus is thought to be dependent on psychosocial factors,
iatrogenic effects and effects related to immunological anomalies associated with autoimmunity
(Agmon-Levin, Shaye, & Shoenfeld, 2009). Depression assessment and adequate treatment is
still a challenge given the emotional burden of the disease (Fonseca, Bernardes, Terroso, de
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Sousa, & Figueiredo-Braga, 2014) but represents an opportunity for optimized clinical
management and health system efficiency. A recent review (Palagini et al., 2013) concluded that
although psychosocial factors are the most frequently reported, identification of specific
biomarkers of depression is needed, since emerging evidence demonstrates an etiologic role for
immune activation and pro-inflammatory cytokines in depression (Leonard, 2010). For instance,
a study performed in patients with Multiple Sclerosis reported a positive correlation between
depression and IFN-γ production, and showed that antidepressants administration decreased IFNgamma production (Mohr, Goodkin, Islar, Hauser, & Genain, 2001).

1.2.1 Type 1 Interferon
Type one interferons are primarily antiviral cytokines. Stimulation of any of a variety of
pattern-recognition molecules such as toll-like receptors leads to activation of Interferon
regulatory factors, which activate interferon expression. Interferon then binds to Interferon
receptors (such as IFNAR1), leading to signal transduction and cellular responses, especially an
antiviral state.
There are multiple lines of association between type 1 interferon and systemic lupus
erythematosus (Niewold, Clark, Salloum, & Poole, 2010). Genetic factors, clinical findings, and
studies in lupus mouse models all point towards an association between IFN and lupus. Lupus
genetics is a complex area, with at least forty different loci being associated with risk for lupus
(Ghodke-Puranik & Niewold, 2013). Many of these are associated with the IFN pathway
(Ghodke-Puranik & Niewold, 2013). These include the transcription factors IRF5 (Graham et al.,
2006; Graham et al., 2007; Kawasaki et al., 2008; Niewold, Kelly, et al., 2008; Reddy et al.,
2007), IRF7 (International Consortium for Systemic Lupus Erythematosus et al., 2008; Salloum
et al., 2010; Suarez-Gestal et al., 2009), IRF8 (Lessard et al., 2012), the signal transducers
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STAT4 (Abelson et al., 2009; Sigurdsson et al., 2008), Tyk2 (Sigurdsson et al., 2005), the tolllike receptor 8 and 9 (Armstrong et al., 2009; C. J. Xu et al., 2009), and the intracellular sensor
IF1H1 (Zouk, Marchand, & Polychronakos, 2010).
One of the most striking findings of expression profiling in the peripheral blood of lupus
patients is the presence of a marked interferon signature (Crow, Kirou, & Wohlgemuth, 2003;
Crow & Wohlgemuth, 2003; Feng et al., 2006; Kirou et al., 2004; Kirou et al., 2005), where the
cells express genes that are activated by interferon. IFNα regulates some of the most
overexpressed genes observed in SLE patients (Crow et al., 2003). These IFNα induced genes
are observed to be significantly higher in SLE patients compared to other interferon inducible
genes (IFIGs), such as those regulated by IFNγ (Kirou et al., 2004). Expression studies using the
MRL/lpr lupus mouse model is consistent with these conclusions (Kwant & Sakic, 2004; Y. Li et
al., 2015). Other studies have similar findings, identifying type I IFNs as the main triggers for
IFIGs and showing that these increased levels correlate with disease development in SLE
(Dall'era, Cardarelli, Preston, Witte, & Davis, 2005; Kirou et al., 2005).
Serum levels of IFN are often higher in lupus patients than controls (Niewold, Adler, et
al., 2008; Niewold, Hua, Lehman, Harley, & Crow, 2007; Niewold, Kelly, et al., 2008). The IFN
signature and serum IFN levels have been shown to correlate with disease activity (Dall'era et al.,
2005), although they are not a consistent predictor of disease flare (Mackay et al., 2016). There
is certainly is a range of IFN levels displayed by SLE patients with some demonstrating an
extremely high IFN profile while others seem closer to that of control patients in cohort studies.
Niewold et al found that high IFNα levels were a heritable trait (Niewold et al., 2007). Their
findings indicate that elevated expression of IFNα can be considered a risk factor for SLE.

1.2.2 Contribution of IFN to SLE-associated depression
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It is easy to hypothesize IFN as a cause of NPSLE. Administration of therapeutic IFN to
treat viral infections or cancer can cause neuropsychiatric symptoms (Hoyo-Becerra, Schlaak, &
Hermann, 2014; Raison, Demetrashvili, Capuron, & Miller, 2005). Genetic disease that result in
excess IFN causes several neuroinflammatory disorders (McGlasson, Jury, Jackson, & Hunt,
2015).
IFN has been associated with SLE neuropathology perhaps as early as IFNα has been
correlated with SLE disease activity (Hooks et al., 1979; Ytterberg & Schnitzer, 1982). Several
studies identified IFN in the spinal fluid and central nervous system (CNS) of SLE patients that
were displaying neuropsychiatric manifestations (Lebon, Lenoir, Fischer, & Lagrue, 1983;
Schaefer et al., 2002; Winfield et al., 1983). The presence of IFN during neuropsychiatric
episodes and the subsequent lack of IFN once the neuropsychiatric symptoms passed is evidence
for the hypothesis that IFN plays an important role in SLE associated psychiatric conditions
(Isshi, Hirohata, Hashimoto, & Miyashita, 1994; Lebon et al., 1983). One study, conducted by
Shiozawa et al. investigated further the IFNα detected in the CNS of SLE patients (Shiozawa,
Kuroki, Kim, Hirohata, & Ogino, 1992). After comparing IFN levels of patients exhibiting
neuropsychiatric symptoms and their SLE psychiatric control groups, it was observed that only
those SLE patients exhibiting psychosis had significantly elevated levels of IFNα (Shiozawa et
al., 1992). Other studies have further confirmed that IFNα levels are associated with chronic
neuropathology, including in SLE (Jonsen et al., 2003; Morris, Berk, Galecki, Walder, & Maes,
2016). A recent study performed by Mostafavi et al. used a whole transcriptome gene expression
approach to study major depressive disorder (MDD) (Mostafavi et al., 2014). Their study used
463 identified MDD patients and 459 control patients who had never experienced a 2-week
depressed mood and two or more of the MDD criteria. Using RNASeq methods and analyzing
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whole blood to reflect the physiological state of the patient participants, their study found a
significant association with genes in the IFNα/β signaling pathways (Mostafavi et al., 2014).
While other IFNs may play a role in SLE-associated depression, it seems that type I IFNs play
the largest role in the neuropathology of depression in SLE patients.
Several studies have shown little or no direct evidence for a role for IFN in NPSLE (Brey
et al., 2002; Kirou et al., 2004; Morris et al., 2016; Uguz et al., 2013). A clinical study conducted
by Kellner and colleagues investigated the relationship between IFN, based on type I IFN
stimulated genes (ISGs) measured via pPCR, and depression (Kellner et al., 2010). Their cohort
consisted of 58 patients that met the American College of Rheumatology classification criteria
for SLE, and twenty other volunteers, chosen as healthy controls. Depression was measured
using the Beck Depression Inventory (BDI) system. BDI levels did not correlate with disease
severity indicators including SLE disease activity index (SLEDAI) scores, organ-specific
symptoms, complement levels, ACR criteria count, or autoantibody profiles. There was a
significant increase in ISGs from SLE patients in the study, as would be expected compared to
the control group.
To analyze if SLE patient IFN levels correlated with depression, a composite IFN score
was derived for each patient based on the measured ISGs. An IFN score 2 standard deviations
higher than the control was considered abnormally high. They categorized patients into two
groups, those with high IFN scores and those with normal (or close to normal) IFN. These two
groups were then compared. They found no significant difference in the BDI scores between the
two groups. To further test the hypothesis, they performed a longitudinal study since IFN levels
do fluctuate and could be the reason no significant difference was found between the high and
low IFN groups. This longitudinal analysis consisted of 22 patients observed over a period of 3
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to 6 months. While IFN levels and BDI scores did fluctuate during that period, there was still no
significant difference observed between the IFN high and IFN low SLE groups. Kellner et al
concluded based on their observations that type I IFN did not correlate to SLE-associated
depression in their study (Kellner et al., 2010). Jarpa et al. while investigating major depression
in SLE patients also found no correlation between depression and disease severity (Jarpa et al.,
2011).
Although these studies indicated that there is no association between IFN and depression
in lupus, there may be other ways IFN can contribute to NPSLE. Perhaps IFN plays a
contributing role but is not one of the main factors contributing to SLE-associated depression.
This principle was explained by Bertsias et al. as they described that it is not always possible to
distinguish between inflammatory and thrombotic processes that contribute to depression
(Bertsias & Boumpas, 2010). It is further possible that the healthy controls were experiencing
elevated levels of IFN, as healthy individuals can still have elevated levels of IFN, raising the
threshold for ‘normal’ IFN scores (Niewold et al., 2007). However, to account for these types of
variables with a human cohort is either unpractical now, would require a greater comprehension
of factors contributing to SLE-associated depression, or demand a longer-term analysis of an
SLE cohort.
It may be the case that IFN causes neurological damage, which then persists, and is not
influenced by fluctuations in cytokines or disease activity. This would provide a role for IFN in
NPSLE but explain why ongoing levels of IFN do not correlate with psychiatric symptoms.
Mouse models have found that treatment of disease after lupus has begun does not affect the
neurological symptoms (Stock et al., 2015). Perhaps the damage is done early and persists
despite subsequent changes in cytokine levels. Other mechanisms through which IFN could
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modulate NPSLE include through stimulation of other cytokines (J. L. Taylor & Grossberg,
1998) and modulation of the hypothalamus/pituitary/adrenal axis (Gisslinger et al., 1993).

1.2.3 Mechanisms of IFN-induced psychological symptoms
The mechanisms responsible for IFN-induced NPSLE-associated depression may be
similar to those observed in depression stemming from the administration of INFα as a
therapeutic agent (Figure 4). IFNα causes an increase in indoleamine 2,3-dioxygenase (IDO)
expression and overactivation in macrophage and microglial cells (Wichers & Maes, 2004). IDO
is one of the enzymes that catalyze the rate limiting and first step of the kynurenine pathway. By
diverting L-tryptophan, a serotonin precursor, into the kynurenine pathway- IDO lowers the
overall production of serotonin (Meszaros, Perl, & Faraone, 2012). Further, IFNα is thought to
increase guanosine triphosphate cyclohydrolase-1 (GHC1) levels via IFNγ in PBMCs (HoyoBecerra et al., 2014; Schoedon, Troppmair, Adolf, Huber, & Niederwieser, 1986). This enzyme
converts GTP into BH2, lowering the amount of BH4 produced and causing lower levels of
serotonin and dopamine to be produced. Type I IFN also enhances the reuptake of serotonin from
the intracellular space by increasing the amount of serotonin transporter (SERT) that is expressed
(Tsao et al., 2008). Thus, increased levels of IFNα could cause the neuropathology observed in
SLE associated depression by lowering the amount of serotonin and dopamine that are produced
by various cells and increasing the uptake of serotonin from the extracellular space (Figure 4).
To summarize, the connection between IFN and lupus presents an attractive hypothesis: that IFN
is responsible for the psychiatric manifestations of lupus. IFN is known to cause depression, in
both endogenous states and after therapeutic IFN administration. Therefore, it would make sense
that IFN, which is abundant in lupus patients, could cause the depression,
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anxiety, and other psychological symptoms associated with lupus. There is some support for this
hypothesis, specifically the finding of elevated levels of IFN in the cerebrospinal fluid of lupus
patients undergoing psychiatric problems and not others. However, subsequent studies
Figure 4. Pathways induced by INFα contributing to depression.

INFα induction in SLE patients is mediated a variety of ways including by auto-antibodies,
genetic risk factors (i.e. IRF5, etc.), viral infection, and toll like receptors (TLRs) (i.e. TLR9,
TLR7, etc.). INFα induces INFγ production and the subsequent conversion of Guanosine
triphosphate (GTP) to 7,8-dihydroneopterin (BH2) by guanosine triphosphate cyclohydrolase-1
(GHC1). Increased production of indoleamine 2,3-dioxygenase (IDO1) is a result of IFNα,
which leads to the sequestration of Tryptophan (Trp) to kynurenine (KYN) and the KYN
pathway. Further, INFα induces increased production of serotonin transporter (SERT) via the
glycogen synthase kinase (GSK)-3β-dependent pathway. These pathways result in lowered
production and depletion of serotonin, as well as, decreased production of dopamine.
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investigating such a link using peripheral levels of IFN or IFN response have for the most part
not shown an association between levels of IFN and psychiatric symptoms. While the hypothesis
that type I IFN contributes to SLE related depression is still worth pursuing, current data suggest
that these IFNs would not be reliable biomarkers for neuropsychiatric disorders such as
depression (Jarpa et al., 2011).
Several inhibitors of interferon, including antibodies and small molecule inhibitors, are
currently in Phase II or III trials for treatment of lupus (Mathian, Hie, Cohen-Aubart, & Amoura,
2015). These treatments will provide the experimental basis for a definitive answer to the
question of IFN involvement in NPSLE. If inhibition of IFN ameliorates neuropsychiatric
symptoms more than traditional treatments, it will finally provide strong evidence for a role of
IFN in lupus-associated psychological symptoms.
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Section 3: Introduction to Epstein-Barr Virus and Herpesvirus Influence Upon
Cellular Chemotaxis2
1.3.1 Epstein-Barr Virus
Prevalently infecting over 90% of the adult population, Epstein-Barr virus (EBV) is a
common, often unnoticed companion (Amon & Farrell, 2005). Only able to replicate in human
beings, this gamma-herpesvirus is genetically adept at immune evasion and persistence. These
attributes allow it to be a near universal part of the human experience. The only certain
exceptions are those with the genetic condition of X-linked agammaglobulinemia who lack
mature B cells and cannot be infected by the virus (Faulkner et al., 1999).
EBV is an amorphic shaped enveloped virus which contains a layer of tegument protein
surrounding a viral capsid housing the double stranded, 172 kb DNA genome. Typically, the
virus infects B lymphocytes, but has the ability to infect certain types of endothelial cells
(Toussirot & Roudier, 2008). The viral glycoprotein 350 binds to cellular CD21 and allows for
viral penetration. In B cells, the MHC class II molecules act as cofactors during viral infection
(Q. Li et al., 1997). The glycoproteins and cofactors allow the viral envelope to fuse with the cell
membrane and release the tegument proteins and viral capsid into the cell cytoplasm. Upon
entry, tegument proteins that are packaged as part of the viral particle, assist in degrading the
capsid, avoiding immune detection, and transporting and circularizing the EBV DNA in the cell
nucleus.

2

The majority of this section, comprising subsection 3.3, was published in the Journal of General Virology, see
Cornaby, Tanner, Stutz, Poole, & Berges, 2016.
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Often spread orally, EBV infects nasopharyngeal epithelial cells and mucosal B cells in
the associated tissue (J. I. Cohen, 2000). During the immune response to clear the infection many
infected cells are detected and killed, however a portion of infected cells remain. Once
intracellularly contained in B cells the virus sets up a latent infection in the memory B cell
population. By this means the virus can spread to the rest of the body as reactivation occurs and
other B cells become infected. It also aids the virus in establishing a lifelong persistence in the
host.
Latency and reactivation
Depending on the stage of maturation of the B cell infected, EBV expresses one of four
different programs when establishing latency. In the latency 0 program, no genes are expressed.
During latency I only one EBNA-1 is expressed. EBNA-1 binds to viral DNA and maintains the
circularity of the genomic episome while binding to the OriP site to regulate replication of the
episome during cell division (J. I. Cohen, 2000). In latency program II EBNA-1 and latent
membrane proteins (LMP-1, LMP-2A, and LMP-2B) are expressed. LMP-1 is an oncogene that
codes for a protein that mimics CD40 and binds to several tumor necrosis factors (Uchida et al.,
1999). This causes an up regulation of adhesion molecules and several cytokines, while inducing
B cell proliferation. LMP-2 prevents viral reactivation by blocking tyrosine kinase
phosphorylation (Kutok & Wang, 2006; Merchant et al., 2001). In the final type of latency, type
III latency, a total of nine proteins are expressed including all from the previous latency
programs and EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNA-LP. EBNA-2 assists in
up regulation of LMP-1 and LMP-2 expression and is the major viral transcription activator
while EBNA-3A, 3B, and 3C play important roles in the transformation of B cells (Abbot et al.,
1990; J. I. Cohen, 2000; White et al., 2010). It is suggested that they are active in repressing
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genes that would impede B cell proliferation. It is known that EBNA-LP acts as a co-activator
with EBNA-2 and is responsible for switching on both the EBNA promoter and the LMP
promoters (Ling et al., 2005; Tierney, Kao, Nagra, & Rickinson, 2011). Also expressed during
all of the programs are the non-polyadenylated RNA transcripts EBER1 and EBER2 which assist
in immune evasion (Maruo, Nanbo, & Takada, 2001; Young & Rickinson, 2004).
Infection of naïve B cells results in their transformation into lymphoblast B cells,
expressing a type III latency program (Babcock & Thorley-Lawson, 2000). Later the viral
expression pattern changes to that of a type II latency as the B cell differentiates and is induced
by LMP-1 and LMP-2 to form germinal centers (Casola et al., 2004). After B cell differentiation
to become a memory B lymphocyte, the viral proteins expressed will come to be more restricted
as the virus exhibits a type I or type 0 latency program (Babcock & Thorley-Lawson, 2000;
Thorley-Lawson, 2001). Upon latency set up inside memory B cells, they circulate undetected in
the peripheral blood (Amon & Farrell, 2005). During infectious mononucleosis, it has been
observed that only latently infected memory B cells are typically found in the peripheral blood
(Hochberg, Souza, et al., 2004). It has been suggested that this could be due to the immune
response in eliminating all infected lymphoblastoid cells prior to entering the peripheral blood
and not purely due to the change of viral latency programs (Amon & Farrell, 2005). During
regular B cell maturation to become a memory B cell, the cell is activated by foreign antigen and
differentiates according to the signals received from various immune cells and tissue. An EBV
formed memory B cell mimics this process, but the necessary signals are provided to the cell by
the virus, not by necessarily by the extracellular environment (Y. J. Liu & Arpin, 1997;
MacLennan, Liu, & Ling, 1988).
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Reactivation of the virus occurs during activation of memory B cells, such as becoming
plasma cells in response to a foreign antigen (Hochberg, Souza, et al., 2004). The viral episome
shares similar nucleosome positioning and spacing as human DNA. Because of this it comes as
no surprise that viral reactivation is regulated heavily by host proteins (Mansouri, Wang, &
Frappier, 2013). It has been shown that the EBV EBNA-1 recruits several histone chaperone
proteins including template-activating factor Iβ (TAF-Iβ), bromodomain-containing protein 4
(Brd4), and nucleosome assembly protein 1 (NAP1) to assist in activating BZLF1 by controlling
histone dimethylation and acetylation (A. Lin, Wang, Nguyen, Shire, & Frappier, 2008; S. Wang
& Frappier, 2009). BZLF1 as a homo-dimer is then able to activate various viral protein genes
involved in the lytic cycle by binding to the AP-1 and BZLF1 response element sites on the EBV
episome (Wille et al., 2013). BRF1, once expressed, assists BZLF1 in activation of the lytic
cycle having a similar capability to bind many of these promoter sites (Wille et al., 2013).
Immune evasion
In order to establish a successful latent infection, EBV has many factors that contribute to
its capacity to avoid immune detection and the subsequent death of the host cell. An effective
strategy used by EBV to prevent detection of viral infection is to inhibit the processing of
proteins and loading of MHC class I molecules. These MHC I molecules are constantly loaded
with endogenous proteins processed from the proteome. During cellular infection, foreign
proteins are processed and loaded in the MHC I molecules where they are transported to the
surface of the cell. They are then scanned by cytotoxic T cells that recognize non-self-protein
epitopes. Viral BNLF2a prevents the loading of the MHC I by blocking TAP, the protein that
loads peptides into the MHC I, from binding to peptides and ATP (Horst et al., 2009). Due to
this, there is a lower quantity of MHC I expressed on the cell surface. Other viral proteins
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prevent their own loading into MHC I molecules, such as EBNA-1 (Yin, Manoury, & Fahraeus,
2003).
Several viral proteins also impair the cell from initiating or completing the caspase
cascade that would result in cell apoptosis. BHFR1 inhibits cell apoptosis by acting as a
homologue of the human B-cell lymphoma-2 protein (bcl-2), which inhibit cell death (Henderson
et al., 1993). LMP-1 up regulates host bcl-2 and A20 to further inhibit this process (Kulwichit et
al., 1998). EBV also influences production of pro-inflammatory cytokines. By lowering or
keeping the inflammatory cytokine levels low during infection, less immune cells are recruited to
assist in clearance of the infection. The viral protein BARF1 acts as a soluble receptor for human
colony-stimulating factor 1 (CSF1) (J. I. Cohen & Lekstrom, 1999; Hsu et al., 1990). By binding
up CSF1, BARF1 lowers the efficiency of CSF1 to induce a higher expression of interferon-α
(INF-α). Another example of this type of viral manipulation is BCRF1, which mimics IL-10, an
anti-inflammatory cytokine that inhibits interferon-y (INF-y) (K. W. Moore et al., 1990). It has
also been observed that viral proteins manipulate cell chemotaxis, possibly to avoid detection
(Ehlin-Henriksson et al., 2009; Gatto & Brink, 2013).

1.3.2 Epstein-Barr Pathogenesis and Disease
Mononucleosis
Most EBV infections occur in the first few years of life of an individual and are
asymptomatic. However, some are exposed only later in life and experience an infection with a
more pronounced immune response, resulting in infectious mononucleosis. Symptoms typically
include fever, pharyngitis, and lymphadenopathy. The most likely cause of infectious
mononucleosis according to several studies is kissing (Balfour et al., 2005). This conclusion is
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reached based on the high titer of virus still orally shed while the disease was in convalescence
and the patients were asymptomatic. During viral infection, those who experience the clinical
symptoms have a heightened response of cytotoxic T cells and a subsequent cytokine mediated
immune response (Callan et al., 1996). In this scenario, CD8+ cytotoxic T cells specific for the
virus secrete INF-y and IL-2, driving the inflammatory response to the viral infection (McAulay
et al., 2007; Sitki-Green, Edwards, Covington, & Raab-Traub, 2004). Studies also indicate that
symptoms relating to the immune response are influenced by infection with more than one strain
of EBV (Sitki-Green et al., 2004). Studies further indicate that certain MHC class I
polymorphisms predispose individuals for infectious mononucleosis during viral infection
(McAulay et al., 2007).
Malignancies
While Epstein-Barr virus is directly responsible for the symptoms elicited during viral
infection in infectious mononucleosis, the virus is implicated in various other carcinomas,
lymphomas, and disorders. It many cases it is unknown exactly how EBV is involved in the
resulting conditions or to what extent, we do however know that EBV is associated and
contributes to disease progression. Since EBV was discovered in Burkitt’s Lymphoma cells, it
has been suspected that EBV plays some role in the development of the disease (Hochberg,
Middeldorp, et al., 2004; Young & Rickinson, 2004).
Burkitt’s Lymphoma is a B cell lymphoma were the MYC oncogene has been
translocated to be under control of the immunoglobulin chains, heavy or light (Z. Li et al., 2003;
Polack et al., 1996). Many tumors also have mutations of the TP53, which inhibits cell division
(Lindstrom & Wiman, 2002). EBV has been found in all patients with endemic Burkitt’s
Lymphoma (Young & Rickinson, 2004). It is suspected that these lymphoma cells originate in
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germinal centers due to the profile bearing so much similarity with germinal centroblast cells
(Chapman, Mockridge, Rowe, Rickinson, & Stevenson, 1995; Harris, Croom-Carter, Rickinson,
& Neuberger, 2001). While it is not known what viral gene products contribute to the
translocation or mutagenesis of lymphoma cells, several are suspected in various studies
including EBNA-1 and the EBER RNAs (Kutok & Wang, 2006; Young & Rickinson, 2004).
Burkitt’s Lymphoma is also common among HIV carriers with 30-40% of tumors from AIDS
patients being EBV positive (Davi et al., 1998; Young & Rickinson, 2004).
Another EBV associated disorder is Hodgkin’s lymphoma. This is characterized by
extremely large lymphocytes derived from B cells, called Reed-Sternberg (RS) cells (Kutok &
Wang, 2006). These cells all have a mutated IgV sequence which contributes to the
characteristics of the lymphoma and are also thought to have arisen from germinal center B cells
(Kuppers, Hansmann, & Rajewsky, 1998; Kuppers & Rajewsky, 1998). About 40% of all
lymphomas are EBV positive and in those tumors that are EBV positive, all of the RS cells are
infected with EBV (Kutok & Wang, 2006; Young & Rickinson, 2004). EBV infection in these
cells expresses a type II latency profile (Deacon et al., 1993). It is suspected that LMP-1 and
LMP-2 could contribute to the mutagenesis of the IgV, but if EBV assists in tumor genesis
besides this is unknown.
During epithelial cell infection, a possible outcome is the generation of malignant cells as
a result of the viral infection. Nasopharyngeal carcinoma and gastric carcinoma are both
potential cancers due to epithelial infection. Nasopharyngeal carcinoma contains malignant
mucosal epithelial cells of the pharynx with infiltrating lymphocytes, which seem to be vital for
the continued development of the cancer (Young & Rickinson, 2004). In these EBV malignant
cells, EBV expresses EBNA-1, LMP-2A and 2B proteins along with BamHI transcripts (Raab58

Traub, 2002). Some EBV positive cells also show expression of LMP-1. It has been suspected
that there is a genetic predisposition as those of Chinese descent have a higher incidence rate of
the disease, regardless of the geographical region (M. C. Yu & Yuan, 2002). Gastric carcinomas
also share a high rate of EBV positive tumors, with 10% of all gastric carcinoma malignancies
being EBV positive (Shibata & Weiss, 1992). EBV gene expression in EBV gastric carcinoma is
similar to that seen in nasopharyngeal carcinoma cells that are EBV positive. It is thought that
EBV infection in gastric carcinogenesis is a later event during the malignancy formation.
Another possible malignancy can occur in transplant patients. Post-transplant
lymphoproliferative disorder (PTLD) is an aggressive cancer for the immunosuppressed
transplant patients. Most PTLDs are due to EBV infected B cells from the donor (Moosmann et
al., 2010). If B cells are not removed from the donor transplant or if the T cell population is
depleted, the risk of PTLD increases. Further EBV associated malignancies include
Leiomyosarcoma, as well as, T cell and natural killer (NK) cell lymphomas.

1.3.3 Herpesviruses Influence Cellular Chemotaxis
1.3.3.1 Introduction
Cells respond to a variety of cytokines and chemokines that allow them to migrate in
different areas in the body depending on where they are needed. This process is essential for
appropriate tissue maintenance, homeostasis, formation, repair, and pathogen clearance (Turner,
Nedjai, Hurst, & Pennington, 2014; Zhou et al., 2014). Dysregulation of the delicate balance of
cellular signals and/or improper positioning could impede these processes. Aside from being
related to a range of diseases, viral-induced chemotaxis contributes to the epidemiology and
persistence of human herpesviruses. These viruses regulate a multitude of cellular genes that
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direct cellular chemotaxis, thereby manipulating these genes for the benefit of the invading virus.
Herpesviruses also produce various chemokines and chemokine receptors from genes in the viral
genome, further affecting cellular chemotaxis. In essence, viral infection results in the piracy of
cellular function as it directs cell movement in both infected and uninfected cell types.
The family Herpesviridae is divided into various subfamilies including
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae (Flint & American Society for
Microbiology., 2009; Yoshida & Yamada, 2006). The nine human herpesviruses (HHVs) include
herpes simplex virus type 1 (HHV-1 or HSV-1) and 2 (HHV-2 or HSV-2), Varicella Zoster virus
(HHV-3 or VZV), Epstein-Barr virus (HHV-4 or EBV), human cytomegalovirus (HHV-5 or
hCMV), human herpesvirus 6A (HHV-6A) and 6B (HHV-6B or Roseola virus), human
herpesvirus 7 (HHV-7) and Kaposi’s sarcoma-associated herpesvirus or human herpesvirus 8
(HHV 8 or KSHV) (Siakallis, Spandidos, & Sourvinos, 2009). All of these viral species share
similar structural characteristics with a genome composed of double stranded DNA, an
icosahedral capsid, an envelope studded with a variety of viral and host proteins, and viral
tegument proteins in an amorphous layer between the capsid and envelope (Flint & American
Society for Microbiology., 2009). Herpesviruses are able to remain latently infected in host cells
for the life of the individual, during which time viral particles are undetectable but viral nucleic
acids can be found and viral gene expression is very limited. Various stimuli can cause viral
reactivation, wherein viral gene expression re-commences, and infectious particles can be
detected and shed to new hosts. Herpesviruses encode a complex assortment of proteins that
manipulate cellular functions during infection in order to promote viral persistence. Human
herpesviruses are an integral part of human existence with over 90% of adults persistently
infected with at least one or more of these nine herpesviruses in their lifetimes. Although the
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incidence of serious herpesvirus-induced diseases is rare in most cases, the prevalence of
infection is so high that the overall disease burden takes a toll on society.
It has been hypothesized that several herpesvirus species affect development or
progression of diseases through interference with cellular chemotaxis, including lymphomas,
atherosclerosis, autoimmune disorders, and disruption of angiogenesis (Coupland, 2011; EhlinHenriksson et al., 2009; Franciotta, Salvetti, Lolli, Serafini, & Aloisi, 2008; Rosenkilde &
Schwartz, 2004; Stern & Slobedman, 2008; Streblow, Orloff, & Nelson, 2001; Velaga et al.,
2009). In this review we will elaborate on the known human herpesvirus mechanisms and
pathways that influence cellular chemotaxis during viral infection. Strategies for why
herpesviruses potentially evolved these mechanisms will be presented as well as the resulting
potential for their roles in disease development.
1.3.3.2 Alphaherpesvirinae
Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), and Varicella Zoster
virus (VZV) encompass the human pathogens of the Alphaherpesvirinae subfamily, typically
showing lytic replication in epithelial cells and harbored as a latent infection in neuronal cells.
HSV-1 is quite common in industrialized countries with a seroprevalence of around 90% (ViejoBorbolla et al., 2012) in the adult population of industrialized countries. Symptoms of viral
infection include cold sores and redness of the skin; however, many infections are asymptomatic.
HSV-1 transmittance only occurs when viral production has increased during a lytic outbreak.
The most common methods of transferring HSV-1 include direct skin contact and via saliva.
Similar to HSV-1, HSV-2 can mask its presence from the host’s immune system, demonstrating
a preference to lay dormant in the sacral ganglia (HSV-1 in trigeminal ganglia) and manifest
occasional lytic outbreaks, typically in the genital area. HSV-2 is one of the most common
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Table 2. Alphaherpesviruses change cellular receptors/chemokines

sexually transmitted diseases with a seroprevalence of 12-20% in the United States. HSV-2
infection is of greater concern in developing countries where seroprevalence is much higher
(Weiss, 2004; F. Xu et al., 2006). VZV primary infection results in the common childhood
disease varicella (chickenpox) after which the virus establishes latency in the ganglia of a variety
of neurons (Gilden, Nagel, & Cohrs, 2014). Reactivation of the virus results in zoster (shingles)
and other chronic pain diseases, which can be manifest in various places on the epithelium
(Gilden et al., 2014).
Until recently, not much was known about herpes simplex virus and how it affects
chemotaxis (see Table 2). In 2012, Borbolla and associates (Viejo-Borbolla et al., 2012) showed
that a secreted form of viral glycoprotein G (SgG) from both HSV-1 and HSV-2 binds
chemokines with high affinity. Membrane-bound glycoprotein G (gG) was shown to be
necessary for chemokine binding activity. They found that HSV SgG in both HSV-1 and HSV-2
increased chemotaxis of monocytes in infected individuals towards CXCL12 and that gG
attaches at the surface of cells to glycosaminoglycans (GAGs) without negative effects on Gprotein-coupled receptors (GPCRs). Another more recent study further investigated the
mechanism by which viral SgG enhances chemotaxis. It was found that gG binds to GAGs which
induces lipid raft clustering leading to increased CXCR4 incorporation. The conformational
change causes an increase in functional chemokine-receptor complexes at the cell surface
(Martinez-Martin et al., 2015). CXCL12 is the natural ligand for CXCR4 and is secreted
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constitutively in a variety of tissues including the lymph nodes, bone marrow, lungs, and adrenal
glands (Alkhatib, 2009; Luker & Luker, 2006). It is also known that CXCR4 signaling is
important in modulating the survival of neuronal cells and modulating synaptic function(Nash &
Meucci, 2014). The increased functionality of CXCR4 could potentially allow infected cells to
migrate to these areas in vivo. By migrating to areas secreting CXCL12, infected cells could
migrate to areas where cell movement could allow viral exposure to more target cells. Similar
results had been observed by Bellner et al. when they tested the chemotactic ability of HSV-2
glycoprotein G (gG-2p20) (Bellner et al., 2005). Using isolated human neutrophils and
monocytes, they found that these cell types followed a gradient of gG-2p20 via binding of the
formyl peptide receptor (FPR) on the surface of these cells. While the chemoattractant properties
have never been displayed using the full-length gG2 protein, several speculations can be made
based on the findings which suggest that neutrophils and monocytes could be attracted to areas
with infected cells expressing gG-2p20. This could possibly be beneficial for HSV-2 infection.
Attracting a large number of phagocytic cells would increase tissue damage and activated cells,
potentially enabling viral spread and propagation (Bellner et al., 2005). It was shown that gG2p20 is an FPR-activating agonist. Activation of FPR in vivo led to the downregulation of other
chemotactic receptors. These observations suggest the possibility that the change in expression
could lead to impaired clearance of HSV-2 during infection (Bellner et al., 2005). In summary, a
variety of studies have demonstrated the effectiveness of HSV-1 and HSV-2 in manipulating
CXCR4 in infected cells.
HSV-2 has demonstrated the ability to manipulate chemotaxis via a host chemokine as
well. A study performed by Huang and colleagues measured elevated expression of CXCL9 in
the cervical mucosa of HSV-2-positive women (Huang et al., 2012). Further research confirmed
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that HSV-2 regulated the expression of CXCL9 in human cervical epithelial cells by inducing the
phosphorylation and translocation of C/EBP-β to the nucleus where it transactivates CXCL9.
The known receptor for CXCL9 is CXCR3, which is expressed predominantly in non-resting T
cells (Van Raemdonck, Van den Steen, Liekens, Van Damme, & Struyf, 2015). Expression has
also been observed in epithelial, endothelial, fibroblast, and smooth muscle cells (Billottet,
Quemener, & Bikfalvi, 2013; Van Raemdonck et al., 2015). This upregulation of CXCL9 was
shown to result in increased migration of activated peripheral blood leukocytes (PBLs) and
CD4+ T lymphocytes (Huang et al., 2012). Huang and associates postulate that HSV-2 is
responsible for upregulating CXCL9, however, it was not shown what viral protein induced the
expression or if the increase in CXCL9 expression was a cellular response to viral infection. The
viral benefits for inducing migration of CD4+ T cells and PBLs to sites of infection are unclear.
The ability of HSV-2 in regulating CXCL9 could be investigated more in depth as this is the
only study demonstrating this type of subversion in epithelial cells.
Past research has also suggested that VZV could utilize glycoproteins as
chemoattractants, inducing migration of polymorphonuclear leukocytes (Ihara, Yasuda, Kamiya,
Torigoe, & Sakurai, 1991). No other recent research has been conducted to determine if VZV
affects chemotaxis of other infected cell types, although several studies and a case study do
provide evidence for how VZV might influence cellular chemotaxis(Desloges, Schubert, Wolff,
& Rahaus, 2008; Shavit, Shehadeh, Zmora, Avidor, & Etzioni, 1999; Steain, Gowrishankar,
Rodriguez, Slobedman, & Abendroth, 2011) We now understand that HSV-1 and HSV-2 can
manipulate monocytes through increasing the functionality of CXCR4 by making lipid rafts with
the viral SgG protein. HSV-2 can further change the migration of cells by increasing the
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expression of CXCL9 in infected epithelial cells, potentially attracting CD4+ T cells and PBLs to
sites of infection.
1.3.3.3 Betaherpesvirinae
Human Cytomegalovirus
Also known as human herpesvirus 5, human cytomegalovirus (hCMV) is a prominent
member of the Betaherpesvirinae subfamily. With a seroprevalence worldwide ranging from 45100%, hCMV is a common human pathogen that is often asymptomatic in infected adults and
children (Cannon, Schmid, & Hyde, 2010; Chen, Jiang, Lee, Liu, & Zhou, 1999; McGavran &
Smith, 1965). hCMV has gained public scrutiny and awareness due to further understanding of
its prevalence in causing congenital infections leading to birth defects (Bialas, Swamy, &
Permar, 2015). In the United States it is a more common cause of birth defects than many others
including fetal alcohol syndrome, Down syndrome, spina bifida, HIV/AIDS, Haemophilus
influenza type B and congenital rubella syndrome (Cannon & Davis, 2005). Like other
herpesviruses, hCMV is associated with various post-transplant complications and is a main viral
cause of solid organ transplant and hematopoietic stem cell transplant morbidity and mortality
(Ariza-Heredia, Nesher, & Chemaly, 2014; Gandhi & Khanna, 2004). It is also known to cause
severe disease in other immunocompromised individuals such as AIDS patients. Viral shedding
can occur via saliva, urine, breastmilk, semen, and tears. hCMV is known to infect various cell
types including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, dendritic cells,
and lymphocytes, typically remaining latently infected in the latter cell type for the life of the
host.
Using a variety of viral proteins to manipulate migration of host cells and potential target
cells, hCMV uses both surface receptors and secreted chemokines (see Table 3 and 4). Among
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Table 3. Human herpesvirus-encoded chemokine receptors

the viral chemokines secreted by hCMV-infected cells are the products of the UL128 and UL146
genes. Numerous studies have been performed demonstrating how these viral gene products
affect the migration of hCMV-infected cells. It had been noted that hCMV-infected monocytes
demonstrated a reduced chemotactic ability due to a downregulation of CCR1, CCR2, and CCR5
(Frascaroli et al., 2006). A similar downregulation of various chemokines was observed along
with an increase in migratory inhibitory factor (MIF) in hCMV-infected macrophages, resulting
in a lack of motility (Frascaroli et al., 2009). Later it was demonstrated by Frascaroli and
associates that in the presence of UL128 there was a resulting downregulation of CCR1, CCR2
and CCR5 in monocytes (Straschewski et al., 2011). Because of this impairment, monocytes
could no longer migrate following the chemokines CCL5 and CCL2 which are ligands of the
aforementioned receptors. CCL2 and CCL5 are known to be involved in the recruitment of
monocytes and T cells and are secreted as pro-inflammatory cytokines in response to tissue
damage or viral detection (Ansari, Kamarulzaman, & Schmidt, 2013; Soria & Ben-Baruch,
2008). Recently, using a UL128 transfected cell line (CHO-UL128) to produce UL128, Gao et
al. studied the effects of this β chemokine on cell migration (H. Gao, Tao, Zheng, Xu, & Shang,
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2013) (H. Gao et al., 2013). They found that UL128 acted as a chemoattractant for peripheral
blood mononuclear cells (PBMCs) in vitro and functioned similarly to CCL3 as a
chemoattractant. These results suggest that UL128 could act to prevent chemotaxis of monocytes
following other gradients, such as CCL5 and CCL2, and could use a separate receptor to attract
the monocytes to areas of infected cells (H. Gao et al., 2013). This increases the cells available to
be infected by hCMV, potentially furthering viral spread. The other known chemokine
produced, UL146, codes for an α chemokine and viral homologue to CXCL1 (vCXCL1)
(Penfold et al., 1999). Several studies demonstrated that vCXCL1 could induce the chemotaxis
of neutrophils in vitro (Luttichau, 2010; Penfold et al., 1999). It was found that vCXCL1 was a
ligand for CXCR1 and CXCR2 using calcium mobilization, chemotaxis, and
phosphatidylinositol turnover assays. CXCR1 and CXCR2 are both expressed on neutrophils and
it is expected that hCMV-infected endothelial cells express vCXCL1 as a chemoattractant to
increase the numbers of neutrophils and assist in viral spread to other endothelial cells
(Luttichau, 2010). In a study conducted by Smith et al. it was observed that hCMV-infected
Table 4. Human herpesvirus-encoded chemokines
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monocytes induced transendothelial migration in vitro, although the viral mechanism is
unknown (Smith, Bentz, Alexander, & Yurochko, 2004).
Regulating host cell chemokines can also result in chemotactic changes. hCMV UL144 is
a viral protein that activates NF-κB (E. Poole, King, Sinclair, & Alcami, 2006) (see Table 5).
This leads to a cascade of multiple pathways, including induced expression of host CCL22 which
acts as a chemoattractant for Th2 and regulatory T cells (Tregs). By recruiting these cells to sites
of viral infection it is possible to suppress T helper and CD8+ T cells, tapering the immune
response (Fielding, 2015). It has also been found that granulocyte macrophage progenitors
(GMPs) latently infected with hCMV demonstrate increased expression of CCL2 (Stern &
Slobedman, 2008). CCL2 is a pro-inflammatory cytokine that acts as a chemoattractant to
monocytes, macrophages, dendritic cells and T cells expressing CCR2. This increase in CCL2
acts to attract CD14+ monocytes to latently infected GMPs (Luther & Cyster, 2001; Rollins,
1997; Sozzani, 2005; Stern & Slobedman, 2008). This behavior of latently infected GMPs is
likely a viral strategy employed to recruit new leukocytes to be infected, however, too little is
known about in vivo hCMV reactivation to know if this spread and reactivation occurs before or
after GMPs develop into macrophages. Further research could be done into the manipulation of
hCMV infected GMPs as there is currently just one study demonstrating this change in
chemotaxis.
There are a variety of hCMV chemokine receptors shown to affect cell migration
including US27, US28, UL33, and UL78 (Fielding, 2015), all of which are homologous to
human GPCRs. US27 is expressed late during lytic infection and has no known ligand (FraileRamos et al., 2002; Stapleton, Arnolds, Lares, Devito, & Spencer, 2012). However, it was found
to potentiate CXCR4-mediated chemotaxis, increasing the expression and amount of surface
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CXCR4 (Arnolds, Lares, & Spencer, 2013). As previously explained, CXCR4 is a seven
membrane-spanning GPCR that allows the cell to follow the chemokine gradient of its natural
ligand, CXCL12 which is secreted constitutively in a variety of tissues including the lymph
nodes, thymus, bone marrow, lungs, and adrenal glands (Alkhatib, 2009; Luker & Luker, 2006).
The potentiation of CXCR4 resulted in increased migration to CXCL12 during in vitro migration
assays (Arnolds et al., 2013). It has been speculated that increased CXCR4 levels at appropriate
times could allow hCMV-infected cells to migrate to bone marrow or lymph nodes where there
would be an increased opportunity to spread to susceptible cells (Arnolds et al., 2013).
US28 was first shown to affect migration in vascular smooth muscle cells (SMCs)
(Streblow et al., 1999). It was found that US28 directed cell migration following the chemokines
CCL2 and possibly CCL5. In the absence of CCL2, there was no migration of hCMV-infected
SMCs (Streblow et al., 1999). This would allow infected SMCs to migrate to areas of
inflammation, potentially providing opportunity for viral spread to leukocytes. Later it was
demonstrated that US28 acted to control migration of both infected SMCs and infected
macrophages. Kledal and associates found that US28 also bound CX3CL1 (Kledal, Rosenkilde,
& Schwartz, 1998), which is a chemokine that is found on the cell surface and extracellularly in
a secreted form; this work was later followed up by others (Murphy, Caplice, & Molloy, 2008;
Vomaske et al., 2009). CX3CL1 is only known to be produced by endothelial cells and results in
the recruitment of inflammatory cells (Bazan et al., 1997; Vomaske et al., 2009). They found that
the presence of CX3CL1 inhibited the migration of hCMV-infected SMCs, but induced the
migration of hCMV-infected macrophages. It was also demonstrated that the inverse was true, in
the presence of CCL5, hCMV-infected macrophages US28-mediated migration was inhibited,
but hCMV-infected SMCs demonstrated normal chemotaxis as expected (Vomaske et al., 2009).
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This makes the viral GPCR US28 unique in that it is chemokine and cell-type specific. It seems
important for the virus to control cellular migration during hCMV infection. Evidence for how
US28 functions was provided by Tschische et al. when they found that hCMV chemokine
receptors heteromerize with each other (Tschische, Tadagaki, Kamal, Jockers, & Waldhoer,
2011). It was observed that UL33 and UL78 heteromerization resulted in silencing of US28
mediated activation of the NF-κB pathway. Tadagaki et al. investigated UL33 and UL78 and
found that these two GPCR homologues formed heteromers with CCR5 and CXCR4 on the
surface of infected THP-1 cells (Tadagaki et al., 2012). This was found to prevent cell
chemotaxis utilized via CCR5 and CXCR4 in vitro. CCR5 allows the cell to follow a variety of
chemokines including CCL3, CCL4, or CCL5, these being the best agonists, while CXCR4 is
known to be chemoattracted to CXCL12 (Alkhatib, 2009). The majority of chemokines that act
as CCR5 ligands are pro-inflammatory.
During hCMV infection the virus is able to regulate host receptors in various ways to
prevent chemotaxis. It has been demonstrated that hCMV prevents CCR7 expression in
monocyte-derived dendritic cells, preventing chemotaxis following CCL19 and CCL21
chemokine gradients in vitro (Moutaftsi, Brennan, Spector, & Tabi, 2004). hCMV-infected
Langerhans cells also demonstrate reduced chemotaxis in response to lymphoid chemokines (Lee
et al., 2006). After these observations it was found by Wagner et al. that hCMV UL18 inhibited
chemotaxis of dendritic cells in vitro (Wagner et al., 2008). The extracellular UL18 is expressed
late in hCMV infection and binds the LIR-1 molecule on the surface of dendritic cells. This
results in various changes including reduced chemotaxis, increased pro-inflammatory cytokine
production, upregulation of CD83 and inhibition of CD40 (Park et al., 2002; Wagner et al.,
2008). It was also observed that hCMV-infected dendritic cells showed downregulated
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chemokine expression and inhibited maturation due to vIL-10, a gene product of the hCMV
UL111A gene. Dendritic cells that were able to mature during hCMV-infection showed an
increase in chemotactic ability to follow the lymph node homing chemokine (W. L. Chang,
Baumgarth, Yu, & Barry, 2004). It has further been observed that chemotaxis is disrupted in
infected endothelial cells. Reinhardt et al. demonstrated how hCMV-infected human coronary
artery endothelial cell (HCAEC) chemotaxis to vascular endothelial growth factor (VEGF) is
inhibited (Reinhardt et al., 2014). HCAEC migration is important for repair post-vascular injury
(Deanfield, Halcox, & Rabelink, 2007; Waltenberger, 2007). While the observation explains how
hCMV can play a role in contributing to pro-atherosclerotic phenotypes, the viral strategy for
inhibiting HCAEC migration remains unknown. A further way to inhibit chemotaxis of cells is
by secreting chemokine binding proteins. hCMV-produced UL21.5 acts in this capacity by
binding CCL5, acting as a chemokine sink or decoy receptor (D. Wang, Bresnahan, & Shenk,
2004). This would prevent cellular receptors from being able to bind CCL5 and follow the
chemoattractant. hCMV also utilizes miR-UL148D to silence CCL5 protein synthesis in infected
cells(Kim et al., 2012). These studies emphasize the importance of CCL5 regulation during
hCMV infection. Preventing immune cell production and detection of CCL5 would assist in
preventing the attraction of monocytes and T cells to areas of hCMV infection. While a certain
number of monocytes would be beneficial for viral spread, an overabundance of monocytes and
the presence of T cells could result in the impairment of viral spread.
To better enhance viral spread, hCMV uses virally encoded chemokines UL128, UL146,
and vCXCL1 to attract target immune cells. The piracy of host chemokine CCL22 further assists
in this process. By upregulation of CCL22 in infected monocytes, Tregs are attracted and could
assist in downregulation of an immune response to viral infection. By increasing the
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functionality of CXCR4, chemotaxis of virally-infected cells to other tissues could be
encouraged. Manipulating host chemokine receptor CCR7, hCMV can avoid migration to
primary and secondary lymph tissue, evading possible detection. The dysregulation of viral
infected cell movement appears to allow hCMV the edge in evading immune detection and
increase the opportunity for viral spread (see Figure 1). Future studies investigating the function
of viral chemokines and chemokine receptors could examine their effects in vivo utilizing animal
models as has been done with hCMV US28(Bongers et al., 2010).
Human Herpesvirus 6 (HHV-6)
Human herpesvirus 6 (HHV-6), initially named human B lymphotropic virus, was first
discovered in 1986 in patients with lymphoproliferative disorders (Salahuddin et al., 1986).
HHV-6A and HHV-6B were recognized as different variants of the same species in 1992 and in
2012 the International Committee on Taxonomy of Viruses classified them as two distinct
viruses (D. Ablashi et al., 1993; Adams & Carstens, 2012). Because classification as two distinct
viruses has come relatively recently, it makes it difficult to distinguish between HHV-6A and
HHV-6B in some of the early literature. The seroprevalence of HHV-6 in adults worldwide is
83-100% (Hall et al., 2006).
HHV-6A
Human herpesvirus 6A is a betaherpesvirus that has primary tropism for CD4+ T cells
and can also infect CD8+ T cells, natural killer (NK) cells, gamma/delta T cells, human neural
stem cells, human progenitor-derived astrocytes, and oligodendrocyte progenitor cells (D.
Ablashi et al., 2014; Lusso et al., 1991; Lusso, Garzino-Demo, Crowley, & Malnati, 1995; Lusso
et al., 1993). It has also been shown to lytically infect B cells that have been immortalized with
EBV (D. V. Ablashi et al., 1989). HHV-6A can alter the expression of different cellular markers
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Figure 5. Changes in cellular chemotaxis resulting from hCMV infection.
hCMV uses virally encoded chemokines UL128, UL146 and vCXCL1 to attract target immune
cells such as neutrophils and PBMCs. Increases in CCL2 expression further assist in attracting
monocytes, macrophages and dendritic cells. Upregulation of CCL22 in infected monocytes
attracts Treg cells, which can assist in downregulation of an effective immune response to viral
infection. Increasing the functionality of CXCR4 allows virally infected cells to migrate to
other tissues, including secondary lymphoid tissues.
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Table 5. Betaherpesviruses change cellular receptors/chemokines

involved in cellular homing and trafficking which causes significant disruption to immune cell
function and viability. The virus has been implicated in a number of diseases including multiple
sclerosis, Hashimoto’s thyroiditis, and AIDS. In vitro studies show that HHV-6A causes
upregulation of CD4 on cells that do not typically express this marker, making these cells
susceptible to HIV infection and possibly contributing in the progression to AIDS (Lusso et al.,
2007; Lusso et al., 1991).
HHV-6 has one functional chemokine-like protein, U83 (see Table 4). The viral
chemokine U83A from HHV-6A is involved in chemoattraction and has selective specificity for
receptors CCR1, CCR4, CCR5, CCR6, and CCR8. These are found on T cells,
monocytes/macrophages and activated T lymphocytes (CCR1, CCR5, CCR8), skin-homing T
lymphocytes (CCR4, CCR8), immature dendritic cells (CCR1, CCR6), and skin-homing T
lymphocytes and NK cells (CCR8) (D. Ablashi et al., 2014; Catusse et al., 2008; Dewin, Catusse,
& Gompels, 2006). The difference in specificity of U83A (from HHV-6A) and U83B (from
HHV-6B) to attract diverse cell types could account for the tropic variability of the two viruses
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(D. J. Clark, Catusse, Stacey, Borrow, & Gompels, 2013). U83A is found in a full-length form as
well as a truncated splice variant (French et al., 1999). It is thought that because of the different
forms of the peptide, U83A could both block innate and adaptive immune responses, as well as
attract the cells involved in these responses for further infection (Dewin et al., 2006). U83A
induces chemotaxis and morphological changes in cells expressing CCR5 in a manner similar to
CCL4, but with a significantly delayed internalization of CCR5 compared to that of CCL4.
Interestingly, binding of U83A to CCR5 has been shown to inhibit CCR5 tropic HIV-1 infection
(Catusse, Parry, Dewin, & Gompels, 2007).
HHV-6 has two GPCRs, U12 and U51, which encode chemokine receptors (see Table 3).
U51, known to affect migration in HHV-6A infected cells, is expressed at early time points postinfection, whereas U12 is expressed late and influences chemotaxis of HHV-6B infected cells.
HHV-6A U51A has novel specificity for CCL5 and can also bind CCL2, CCL11, CCL7 and
CCL13. This makes U51A unique from other viral and cellular receptors in that it overlaps
activity with CCR1, CCR2, CCR3, and CCR5 in the binding of CCL5 (Catusse et al., 2008).
There is also overlap with CCR2, CCR4, US28, UL12, D6, and Duffy in the binding of CCL2;
CCR3 and E1 in the binding of CCL11; CCR1, CCR3, US28, and D6 in the binding of CCL7;
and CCR2 and CCR3 in the binding of CCL13. Unlike many viral GPCRs that have constitutive
signaling, U51A has been shown to perform both inducible and constitutive signaling (Catusse et
al., 2008; Fitzsimons et al., 2006).
U51A expression has been shown to cause a reduction of CCL5 expression using the
Hut78 human CD4+ T lymphocyte cell line. U51A has high relative affinity for XCL1, which
normally binds human receptor XCR1 found on NK cells and T lymphocytes. This binding could
have a number of effects including: prevent infected cells from interacting with NK cells, induce
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chemotaxis to T lymphocytes which could spread infection, and prevent apoptotic signals within
infected cells (Cerdan, Devilard, Xerri, & Olive, 2001). CCL19, normally bound by human
receptor CCR7, can also be bound by U51A. This could cause infected cells to migrate to the T
cell-rich lymph node, again promoting further infection. HHV-6A U83A chemokine does not
bind U51A. Expression of U51A ligands in the brain could also allow migration of infected cells
into the central nervous system. Damaged epithelial lung cells and airway parasympathetic
nerves express CCL2 and CCL11, which both bind U51A, and could promote migration of the
infected cells to these areas to be transmitted from host to host.
CCR7, which is expressed in various lymphoid tissues, is another receptor that is
modulated by herpesviruses (see Table 5). HHV-6A and HHV-6B upregulate CCR7 expression
in CD4+ T cells (Hasegawa, Utsunomiya, Yasukawa, Yanagisawa, & Fujita, 1994). CCR7 is
specific for CCL19 and CCL21 and plays roles in cell migration and proliferation (Tadagaki,
Nakano, & Yamanishi, 2005). This upregulation of CCR7 could be an important aspect of HHV6 pathogenesis as upregulation of CCR7 promotes migration of T cells and dendritic cells to the
paracortex in lymph nodes (where T cell priming occurs) and the periarteriolar lymphoid sheath
in the spleen, both of which are T cell-rich (Comerford et al., 2013).
As mentioned previously, HHV-6A can also downregulate cellular receptors. Along with
downregulation of CD46 (its cellular receptor) and CD3 (Grivel et al., 2003), CXCR4 is
downregulated by HHV-6A in primary CD4+ T lymphocytes and Jjhan T cells which affect the
chemotactic response of the cells to CXCL12, the natural ligand of CXCR4 (Yasukawa et al.,
1999). The disruption of CXCR4/CXCL12 signaling by downregulation of CXCR4 by HHV-6A
could prevent the retention of hematopoietic stem/progenitor cells (HSPC) and more mature
leukocytes in the bone marrow allowing these cells to be mobilized and enter into circulation
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(Karpova & Bonig, 2015). The migration of CXCR4-expressing thymocytes out of the thymus
was shown to occur in a CXCL12-dependent manner (Poznansky et al., 2002; Weinreich &
Hogquist, 2008), so the downregulation of CXCR4 by HHV-6A could be another way the virus
prevents migration away from areas where target cells are present. Additionally, the
downregulation of CXCR4 by HHV-6A could prevent homing of bone marrow-derived
precursor cells to the thymus (Calderón & Boehm, 2011), possibly preventing positive and
negative selection from occurring in these cells.
HHV-6 has been shown to cause modulations to CCL5. This chemokine has selective
chemoattractive activity on resting CD4+ memory T cells (Hasegawa et al., 1994) and has been
shown to be upregulated by HHV-6 in an ex vivo study where human tonsil blocks were infected
with both HHV-6 and HIV-1. This upregulation of CCL5 was shown to suppress HIV-1 CCR5tropic variants and possibly to stimulate replication of CXCR4-utilizing variants, which gives
evidence that HHV-6 may play a role in HIV pathogenesis by promoting the switch between
CCR5-tropic to CXCR4-tropic HIV-1 (Grivel et al., 2001). In contrast, CCL5 expression in
epithelial cells is downregulated by U51A from HHV-6A (Milne et al., 2000). Epithelial cells
expressing U51A also had morphological changes and exhibited increased spreading and
flattening, which could increase the ability of HHV-6 to spread to uninfected cells as it is
primarily spread by cell to cell contact (Milne et al., 2000). As has been observed with other viral
chemokines and chemokine receptors, their functions could be multipurpose in attracting cells to
the area of infection, and also in evading the immune cells of the host so replication and latency
can take place.
As described above, HHV-6A alters the expression of different cellular markers. Many of
these markers are involved in cellular homing and tracking to specific areas of the body, and
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when altered, can cause significant disruption to immune cell function and viability. Further
research into HHV-6A effects on cellular trafficking could serve as a critical guide for
developing new treatments to prevent these disease-causing disruptions.
HHV-6B
HHV-6B causes exanthem subitum (roseola) (Yamanishi et al., 1988) and is found in
~95-100% of adults worldwide. Unlike HHV-6A, HHV-6B has very little to no ability to infect
CD8+ T cells, NK cells, and gamma/delta T cells (Grivel et al., 2003; Martin, Schub, Dillinger,
& Moosmann, 2012). The cellular receptor for HHV-6B is CD134 which, like the cellular
receptor for HHV-6A, CD46, is expressed on almost all human cells (Tang et al., 2013),
indicating that other factors are at play for an effective viral infection to take place.
The HHV-6B viral chemokine U83B is specific for CCR2 and can cause chemoattraction
of CCR2 expressing cells (classical and intermediate monocytes) for infection (D. Ablashi et al.,
2014; D. J. Clark et al., 2013; Lüttichau et al., 2003) (see Table 4). U83 from HHV-6B induced
transient calcium mobilization and efficient migration in THP-1 cells (a monocyte cell line
derived from monocytic leukemia) (Zou et al., 1999). U83B has been shown to have a different
specificity from U83A as U83B chemoattracts CCR2-expressing monocytes, whereas U83A has
a broader but still selective specificity as mentioned previously (Catusse et al., 2008; Dewin et
al., 2006). The specificity of U83B for CCR2 appears to be due to its N-terminal region. Human
chemokines can induce rapid internalization of CCR2 upon binding, whereas in vitro
experiments show U83B does not cause CCR2 internalization. This finding is similar to the
delayed internalization of CCR5 observed with U83A. CCR2 expression is induced in proinflammatory conditions and interestingly HHV-6B is associated with inflammatory diseases
such as encephalitis and myocarditis (D. J. Clark et al., 2013).
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The HHV-6B GPCR U12 efficiently binds CCL2, CCL5, and CCL4 so it has overlapping
activity with the receptors for CCL2 and CCL5 as in HHV-6A, but also has overlapping activity
with the receptors for CCL4 (Balkwill, 2004; Isegawa, Ping, Nakano, Sugimoto, & Yamanishi,
1998) (see Table 3). The exact role of chemokine receptors with these viruses are still unknown
but could be multipurpose in that they could have been developed for immune evasion to
intercept chemokines that would otherwise be attracting immune cells to the area of infection, to
attract uninfected cells that could then be infected, to induce latency, or to transition from latency
to active replication.
Similar to HHV-6A, HHV-6B was shown to downregulate CXCR4 in CD4+ T
lymphocytes as well as MT-4 cells. This downregulation impaired the chemotactic response of
the cells to the natural ligand, CXCL12 (Yasukawa et al., 1999). Similar to HHV-6A, this could
induce mobilization of HSPCs into the circulation as well as prevent migration of cells out of the
thymus, both of which aid in the propagation and survival of the virus.

Human Herpesvirus 7
As part of the same subfamily as HHV-6A and 6B, human herpesvirus 7 (HHV-7) shares
similar characteristics, including also being a T lymphotropic virus, although it can infect other
cell types (D. V. Ablashi et al., 1995; Ward, 2005). Like other human herpesviruses, once HHV7 is acquired, the host is infected for life. The virus is shed in saliva and spread through this route
of transmission. Compared to the other human herpesviruses, much less research has been
conducted on HHV-7 infection and pathogenesis. Clinically it has been associated with the
development of pityriasis rosea, post-infectious myeloradiculoneuropathy, encephalopathy, and
other syndromes. There is some speculation on how involved HHV-7 is in the development and
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progression of these diseases (Chuh, Chan, & Zawar, 2004; Mihara et al., 2005; van den Berg et
al., 1999). HHV-7 infections can have a variety of symptoms including fever, rash, febrile
respiratory problems, vomiting, and diarrhea (D. A. Clark et al., 1997; van den Berg et al., 1999).
Infections typically occur in children and are most often asymptomatic (Ward, 2005).
HHV-7 has been shown to influence migration in human cells in a variety of ways (see
Tables 2 and 5). Yasukawa and associates showed that it downregulated transcription and surface
expression of CXCR4 in CD4+ T cells (Yasukawa et al., 1999). As described before, CXCR4 is
the receptor for CXCL12 which is secreted by various cells in the lymph nodes, bone marrow,
etc. With CXCR4 assistance, T cells can follow a CXCL12 gradient to sites of inflammation
(Domanska et al., 2013). After infection with HHV-7, Yasukawa and associates tested the
migration and intracellular levels of Ca2+ of CD4+ T cells. It was found that infected cells
demonstrated less migration following the CXCL12 gradient and decreased levels of intracellular
Ca2+ compared to the mock infected cells used as controls. It is currently unknown what viral
factor(s) contribute to the downregulation of CXCR4. It has been demonstrated that lower levels
of CXCR4 in HHV-7 positive T lymphocytes prevents infection by T lymphocyte trophic HIV
(Yasukawa et al., 1999). Future research could explore how HHV-7 manipulates CXCR4 in
infected cells and further confirm the findings of Yasukawa and associates as theirs is the only
study investigating this change in chemotaxis.
While CXCR4 is a cellular GPCR that is influenced post-viral infection, HHV-7 has two
known viral chemokine receptors, products of the HHV-7 genes U12 and U51. These genes were
identified as GPCR homologs and later Tadagaki et al. investigated the functionality of the
protein products of these genes (Nicholas, 1996; Tadagaki et al., 2005). They verified that these
proteins do accumulate on the surface of the cell. Further, they verified that they could act as
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functional chemokine signal receptors. Cells expressing U12 and U51 expressed heightened
levels of intracellular Ca2+ after appropriate signaling through the U12 and U51 GPCRs. Testing
the chemotactic effect of the expression of these proteins in the Jurkat T cell line using
microchannel migration techniques, it was found that cells expressing U12 migrated effectively
following a gradient of CCL19 and CCL21. This would make U12 a viral homolog of the
cellular GPCR CCR7, as it also responds to both CCL19 and CCL21. Both of these chemokines
are strongly expressed in the T cell zone of secondary lymph tissue and are important in
lymphocyte homing and migration (Nomura, Hasegawa, Kohno, Sasaki, & Fujita, 2001). It has
also been observed that CCR7 expression is upregulated during HHV-7 infection (Hasegawa et
al., 1994). While the strategy behind the manipulation of cellular chemotaxis following these
ligand chemokines is still unclear, it could be speculated that migration to such areas could be
beneficial for HHV-7 transmission as T cells are preferential targets of infection. Tadagaki et al.
have also speculated that expression of these viral proteins could aid in immune evasion and
viral replication (Tadagaki et al., 2005). Further research in murine L1.2 cells showed that U12
and U51 products could respond to CCL22 and CCL19 respectively (Tadagaki, Yamanishi, &
Mori, 2007). Gene products U12 and U51 could act with CCR4 and CCR7, respectively, to
direct migration in this cell line in response to CCL22 and CCL19 (Luther et al., 2002). If this
were to hold true in human cells infected with HHV-7, then infected cells would be expected to
migrate more to areas of inflammation, as CCL22 is a pro-inflammatory chemokine secreted by
a wide variety of cells, and areas of high T cell density as CCL19 is constitutively expressed by
stromal cells in the T cell zone (Luther et al., 2002). These areas would be attractive locations for
the viral spread of HHV-7.
1.3.3.4 Gammaherpesvirinae
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Epstein-Barr virus
Table 6. Gammaherpesvirus changes cellular receptors/chemokines

The main cause of viral mononucleosis, Epstein-Barr virus (EBV) infects nasopharyngeal
epithelial cells and B lymphocytes (Balfour et al., 2005; J. I. Cohen, 2000). Viral spread is
accomplished through shedding in saliva (Balfour et al., 2005). EBV gains access to appropriate
host cells by using viral gp350 to bind CD21 (a type 2 complement receptor) on the cell surface,
the viral envelope then fuses with the cell membrane releasing the viral capsid and associated
tegument proteins into the cytoplasm (Toussirot & Roudier, 2008). The virus uses MHC class II
molecules as cofactors when infecting B lymphocytes (Q. Li et al., 1997). During its latent
infection of host B cells, EBV expresses one of four possible latency programs depending on
cellular development and conditions (Young & Rickinson, 2004). It is likely that reactivation in
vivo of latent virus is due to the differentiation of infected memory B lymphocytes (Amon &
Farrell, 2005; Hochberg, Souza, et al., 2004). EBV is associated with a variety of malignancies
due to its ability to regulate cell proliferation, including Burkitt’s lymphoma, Hodgkin’s
lymphoma, nasopharyngeal carcinoma, gastric carcinoma, and post-transplant
lymphoproliferative disorder (PTLD) (Hochberg, Middeldorp, et al., 2004; Kutok & Wang,
2006; Shibata & Weiss, 1992; Young & Rickinson, 2004).
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During infection of B cells, EBV controls the expression of various endogenous
chemokines and chemokine receptors (see Table 6). One such manipulated receptor that is shown
to affect migration is CXCR4. As previously described it is the receptor for CXCL12 which is
secreted by various cells in a number of organs including the lymph nodes, lungs, liver, kidneys,
heart, and bone marrow (Teicher & Fricker, 2010). Henriksson et al. demonstrated that tonsillar
B cells infected with EBV showed reduced expression of CXCR4 (Ehlin-Henriksson, Mowafi,
Klein, & Nilsson, 2006). Assays of chemotactic migration further showed that infected tonsillar
B cells had decreased ability to migrate towards CXCL12. This decreased expression and the
subsequent lack of chemotaxis was demonstrated in EBV-immortalized B cells as well
(Nakayama et al., 2002). The inability to follow the CXCL12 gradient would prevent infected B
cells from migrating to tissues expressing only this chemokine. CCR7 is another host receptor
that is virally regulated during EBV infection. In a later study done by Henriksson and
associates, it was found that CCR7 is downregulated in tonsillar B cells post-infection. This
change in expression led to decreased migration following the natural chemokine ligand CCL21
(Ehlin-Henriksson et al., 2009). CCL21 is produced by stromal cells in primary and secondary
lymphoid tissues and lymphatic endothelial cells in the peripheral tissue (Comerford et al.,
2013). It is critical for directing the formation of secondary lymphoid tissues such as spleen,
Peyer’s patches, and lymph nodes (Ohl et al., 2003). It is has also been surmised that CCR7
ligands are influential in tertiary lymphoid organs (Comerford et al., 2013). Immortalized B
lymphoblast cell lines (LCLs) have been shown to have an increased expression of CCR7
compared to uninfected cells. This upregulation resulted in increased migration following a
CCL21 gradient in assays of chemotaxis (Nakayama et al., 2002). While these results may seem
to be paradoxical, it is possible that the difference in expression could be a result of a different
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Figure 6. Changes in cellular chemotaxis resulting from EBV infection.
EBV decreases expression of cellular CXCR4 and CCR7 to prevent migration to certain tissue
areas, probably to avoid immune detection. Increases in host chemokine CCR6 allow infected
cells to migrate to areas of inflammation. CCR10 function is also pirated, allowing infected cells
to migrate toward epithelial cells, such as mucosal epithelial cells. Downregulation of CXCL10
and CXCL11 could help in immune avoidance by suppressing the ability of infected cells to
attract T lymphocytes.
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latency program or stage of viral infection. Henriksson and colleagues used harvested tonsillar B
cells and measured the CCR7 expression and migration 7 days post-infection. In contrast, LCLs
are a result of EBV immortalization of B lymphocytes, the process taking several weeks to
establish the cell line and expressing a type III latency program (Young & Rickinson, 2004). The
difference in expression could be a result of either the length of infection or the latency program
employed by the virus post-infection.
In that same study of LCLs, it was found that they expressed increased amounts of CCR6
and CCR10, the natural ligands of which are CCL20 and CCL28, respectively. Migration assays
confirmed that this change resulted in increased chemotaxis towards CCL20 and CCL28
chemokine gradients (Nakayama et al., 2002). CCL20 is an inflammatory chemokine involved in
the recruitment of dendritic cells, CD4+ T lymphocytes, and B lymphocytes (Zhao, Xia, Wang,
& Xu, 2014). CCL28 is secreted by epithelial cells that line the mucosa and is used to recruit
IgA+ plasma cells (Vazquez, Catalan-Dibene, & Zlotnik, 2015; Wilson & Butcher, 2004).
CCL28 expression is highest in the salivary glands (G. X. Liu, Lan, Sun, Hu, & Jiang, 2012). It
would be in the best interest of EBV to regulate these receptors, allowing the virus to migrate to
mucosal tissues, such as the salivary gland, for effective viral spread. Chemotaxis to sites of
inflammation could result in viral reactivation and increased targets for further infection. A final
cellular receptor that is downregulated during infection effecting a change in chemotaxis is
CXCR5. The inability to migrate due to lowered levels of CXCR5 was observed in LCLs and
infected tonsillar B cells (Ehlin-Henriksson et al., 2009; Nakayama et al., 2002). CXCR5 allows
B cells to migrate in response to CXCL13 (Carlsen, Baekkevold, Morton, Haraldsen, &
Brandtzaeg, 2004). CXCL13 is an important chemokine for secondary lymphoid tissue
development, and the main cells responsible for secretion of CXCL13 are follicular dendritic
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cells (Cyster et al., 2000; Legler et al., 1998). It is expressed in vascular tissue, Peyer’s patches,
and inflamed lymphoid tissue (Ebisuno et al., 2003; Mazzucchelli et al., 1999; Okada et al.,
2002; Shi et al., 2001). A recent study of murine B lymphocyte positioning in CXCR5-negative
mice demonstrated that CXCR5 is important for the retention of B cells in Peyer’s patches
(Schmidt & Zillikens, 2013). While avoiding tissue types expressing CXCL13 could be
beneficial for the virus, possibly assisting in immune avoidance, the exact reason for regulating
CXCR5 is still unclear. Another receptor thought to be influenced by EBV is Epstein-Barr virusinduced gene 2 (EBI2). Infected B cells display a heightened expression of EBI2 (Birkenbach,
Josefsen, Yalamanchili, Lenoir, & Kieff, 1993; Kelly, Pereira, Yi, Xu, & Cyster, 2011). While it
remains unknown how EBV manipulates EBI2 expression in B lymphocytes, it has been
observed that EBI2+ cells migrate following a 7α-OHC gradient (Preuss, 2014). 7α-OHC is the
natural ligand of EBI2 and is expressed by stromal cells of secondary lymph tissue, assisting in
directed migration during cell chemotaxis in these areas (Gatto & Brink, 2013; Hannedouche et
al., 2011). Exaggerated expression of EBI2 by EBV could result in migration to the outer
follicular zone in secondary lymph tissue, preventing migration toward T cell zones and germinal
centers (Cyster, 2010).
The viral regulation of host lymphocytes extends to controlling various chemokines
produced during infection, resulting in a change in the chemotaxis of uninfected cells. EBNA3C, a viral product essential in establishing latency and immortalization of B cells, acts to
regulate two host produced chemokines, CXCL10 and CXCL11 (McClellan et al., 2012).
EBNA-3C has been found to interact with both transcriptional corepressors and coactivators
(Cotter & Robertson, 2000; Radkov et al., 1999; Touitou, Hickabottom, Parker, Crook, &
Allday, 2001). Using the EBV-negative cell line, BJAB, McClellan et al. showed that expression
86

of EBNA-3C reduces expression of these two chemokines. The result is decreased migration of
CXCR3+ cells (McClellan et al., 2012). Cells that express and migrate in response to CXCL10
and CXCL11 via CXCR3 include various T lymphocytes, including CD8+ T cells. CXCL10 and
CXCL11 are typically expressed to attract Th1 cells in response to infection. EBV has also been
also demonstrated the ability to influence the expression of chemokines via microRNAs. miRBHRF1-3, an EBV-produced miRNA, has the ability to silence CXCL11 protein synthesis (Xia
et al., 2008). Downregulation of these chemokines suggests that immune avoidance could be a
reason behind viral manipulation. Repression of CXCL11 would prevent attraction of cytotoxic
T cells that might recognize virally infected B lymphocytes.
The chemokine receptor CXCR4 is a popular target for manipulation and EBV, like other
herpesviruses, uses it to prevent cell migration to certain tissue areas, probably to avoid immune
detection. To achieve this same purpose, EBV also downregulates CCR7. During infection the
virus increases the host chemokine CCR6, allowing infected cells to more readily migrate to
areas of inflammation. CCR10 function is also pirated, allowing infected cells to migrate toward
epithelial cells, such as mucosal epithelial cells. This is likely vital for the spread of EBV.
Reduction in expression of CXCL10 and CXCL11 could help in immune avoidance by
suppressing the ability to attract T lymphocytes via these chemokines (see Figure 2).
Kaposi Sarcoma Herpesvirus
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8
(HHV-8), is named after Moritz Kaposi who originally described a unique skin lesion in the
1870s. The discovery of the association of herpesviral DNA sequences in Kaposi’s sarcoma (KS)
did not occur until 1994 (Y. Chang et al., 1994; Ganem, 2010). KS presents as tumors most often
found in the dermis but can also be found in lungs, liver, and intestines (P. S. Moore & Chang,
87

2003). KSHV is also linked to primary effusion lymphoma (PEL) and multicentric Castleman’s
disease (MCD) (Avey, Brewers, & Zhu, 2015; Cesarman, Chang, Moore, Said, & Knowles,
1995; Soulier et al., 1995).
KSHV encodes three secreted chemokines; vCCL1 (ORF K6 or vMIP-I/MIP-1a), vCCL2
(ORF K4 or vMIP-II/MIP-1b), and vCCL3 (ORF K4.1 or vMIP-III/BCK) which activate CCR8,
CCR3, and CCR4 respectively (see Table 4). This set of chemokines antagonizes the recruitment
of Th1 and NK cells. This re-directs the immune response from a Th1-like response towards a
Th2 profile. vCCL2 has also been shown to prevent CCL5-mediated chemotaxis of Th1-like
lymphocytes (P. S. Moore & Chang, 2003; Stebbing, Portsmouth, & Bower, 2003; Weber et al.,
2001). The receptor XCR1, which normally binds the ligand XCL1 and is involved in T-cell
recruitment, is selectively activated by vCCL3 but is also blocked by vCCL2. The opposing
function and differing time of expression of the two viral chemokines could indicate the
importance of the regulation of the XCR1 receptor in KSHV infection and pathogenesis.
Neutrophils have high levels of XCR1 and vCCL3 chemoattracts these cells, which may indicate
that neutrophils play a role in viral spread (Lüttichau, Johnsen, Jurlander, Rosenkilde, &
Schwartz, 2007). vCCL1 and vCCL2 expression were also shown to induce migration of
monocytes. This could play a role in the process of tumor development in Kaposi’s sarcoma as
circulating monocytes could be recruited to KSHV-infected cells, thus propagating the infection
(Nakano et al., 2003).
KSHV encodes a GPCR (vGPCR or ORF74) that is homologous to CXCR2 and has a
high level of constitutive activity (Arvanitakis, Geras-Raaka, Varma, Gershengorn, & Cesarman,
1997; Cesarman et al., 1996; Hensbergen et al., 2004; Pati et al., 2001) (see Table 3).
Constitutive expression of ORF74 in microvascular lung endothelial cells inhibits migration and
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increases cell survival. This inhibitory effect on migration can be reversed by endogenous
chemokines CXCL10 and CXCL12. These act as inverse agonists of ORF74 as seen in an in
vitro wound closure assay where CXCL10 increased migration of ORF74-expressing cells.
Limiting migration of infected cells may aid in immune evasion and KSHV survival.
Constitutive expression of ORF74 has also been shown to attract uninfected endothelial cells
which could then be infected and propagate the infection (Couty, Lupu-Meiri, Oron, &
Gershengorn, 2009).
ORF74 has been shown to activate the transcriptional activators NF-κB and activator
protein 1 (AP-1), leading to the downstream production of signals including IL-6, IL-8,
granulocyte-macrophage colony-stimulating factor (GM-CSF), and CCL5 (Pati et al., 2001;
Schwarz & Murphy, 2001; Shepard et al., 2001). Elevated levels of CXCL8 are observed in KS
patients and can activate KSHV-infected cell growth and induce chemotaxis (J. F. Wang et al.,
2004). CXCR1 and CXCR2, receptors that bind CXCL8, have been found in KS lesions. CXCR4
has also been found expressed on cells in these lesions, which is important as this receptor acts as
a co-receptor for CXCR4 tropic strains of HIV (Masood et al., 2001; Pati et al., 2001; J. F. Wang
et al., 2004). These combined effects of KSHV-GPCR could stimulate the proliferation,
migration, and chemotaxis of endothelial cells in KS.
KSHV encodes a homologue of IL-6, vIL-6, that has been shown to promote migration of
endothelial cells in both an autocrine and paracrine fashion. Inhibition of this migration can be
specifically inhibited by a DNA methyltransferase 1 (DNMT1) inhibitor, suggesting that the
mechanism of vIL-6 is dependent on enhancing expression of DNMT1. As the control of DNA
methylation is crucial for gene expression and other cellular processes, disruption of methylation
could be a mechanism for KS tumorigenesis (J. Wu et al., 2014).
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There are a number of different cellular chemotactic proteins shown to be upregulated by KSHV,
including: CCL2, CXCL7, CCL5, GM-CSF, CXCL16, and angiogenin (ANG) (Y. Xu & Ganem,
2007) (see Table 6). Some of these, such as CCL5 and GM-CSF, likely increase migration of
endothelial cells toward KSHV-GPCR-expressing KS cells (Bussolino et al., 1989; Pati et al.,
2001). In contrast, CXCL16 appears to play an indirect role in tumor growth and expansion
through migration of activated T cells (Y. Xu & Ganem, 2007). KSHV also causes
downregulation of certain genes. The KSHV microRNA (miRNA), miR-K12-10a,
downregulates the cytokine receptor tumor necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) receptor (TWEAKR). This inhibits the proinflammatory response and also provides
protection from TWEAK-induced apoptosis (Abend, Uldrick, & Ziegelbauer, 2010).
Latency-associated nuclear antigen 1 (LANA-1 encoded by ORF73), a latently expressed
gene, has been shown to hinder neutrophil chemotaxis which interferes with recruitment of
neutrophils to infected areas and could be a way in which latent KSHV survives host-induced
acute inflammation. Neutrophil recruitment is restored in LANA-1 knockdowns, although not to
the level of uninfected cells, indicating that other factors of KSHV play a part in repressing
neutrophil recruitment (X. Li, Liang, Lin, Robertson, & Lan, 2011).
As seen with other herpesviruses, KSHV can induce or inhibit cellular migration,
according to what is most beneficial for viral infection at the given stage. It not only interferes
with cellular marker expression, it also induces increased production of specific chemokines and
cytokines which leads to other issues in cellular function and trafficking.
1.3.3.5 Summary
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With the exposure to human herpesviruses being very high, it is important to understand
how these infectious human pathogens influence infected and uninfected cell types. The
Alphaherpesvirinae use glycoprotein G to increase the functionality of CXCR4, leading to
increased chemotaxis to a variety of tissues while being able to manipulate cellular chemokines,
such as CXCL9, to attract PBLs. Betaherpesvirinae, also capable of producing and manipulating
chemokine and chemokine receptors, influence a variety of cells during infection. hCMV inhibits
migration in infected monocytes and potentially attracts monocytes, PBMCs, macrophages,
dendritic cells, and regulatory T cells to sites of infection. Similarly, through its ability to attract
target cells, HHV-6 is able to induce chemotaxis of T lymphocytes, monocytes, immature
dendrocytes, and NK cells to areas of infected cells using viral U83. T cells infected with HHV-6
are further manipulated as viral and cellular GPCRs allow cells to migrate to sites of
inflammation and areas rich in T cells. Also manipulating T cells, HHV-7 prevents infected T
lymphocytes from migrating to various organs and tissues by downregulating CXCR4. However,
it too potentially encourages migration to inflammatory sites and locations high in T cells by
inducing cells to follow chemokine gradients of CCR7, CCL21, CCL22, and CCL19.
Further masters of cellular piracy, Gammaherpesvirinae also influence cellular
chemotaxis to avoid immune detection and spread viral infection throughout the host until
latency can be established. To prevent newly infected cells from potentially migrating to lymph
tissue and other organs, EBV reduces expression of CXCR4, CCR7, and CXCR5. By
downregulating the chemokines CXCL10 and CXCL11, EBV could prevent infected cells from
attracting cytotoxic T cells. To regulate chemotaxis of cells during infection, KSHV regulates the
attraction or avoidance of neutrophils and monocytes by several viral chemokines vCCL1, 2, and

91

3. KSHV would be able to induce the chemotaxis of uninfected endothelial cells by upregulating
various cellular chemokines and activating the NF-ᴋB pathway, enabling viral spread.
Though our current understanding of how human herpesviruses affect host cell migration
during infection is rather expansive, there still remain various areas for future research
opportunities. In this review we have elaborated on the cells potentially affected by virallyencoded and virally-induced chemokines. However, the full range of cells affected by these
chemokines remains to be tested and investigated further. Several virally-regulated cell
chemokine receptors suspected of influencing viral spread and immune avoidance are in need of
confirmatory scientific inquiry. While various human herpesviruses, including the
Alphaherpesvirinae and HHV-7 have not been studied as much in terms of how they affect
cellular chemotaxis. These areas leave a variety of opportunities for future research that could
contribute to our understanding of how these viruses lead to disease pathogenesis and
progression.
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Chapter 2. In Naïve B Lymphocytes, Epstein-Barr Virus Induced Gene 2
(EBI2) is Controlled by Epstein-Barr Virus (EBV) During Viral
Infection3

2.1 Summary
Epstein–Barr virus-induced gene 2 (EBI2) is an important chemotactic receptor that is
involved in proper B-cell T-cell interactions. Epstein–Barr virus (EBV) has been shown to
upregulate this gene upon infection of cell lines, but the timing and mechanism of this
upregulation, as well as its importance to EBV infection, remain unknown. This work
investigated EBV’s manipulation of EBI2 expression of primary naive B cells. EBV infection
induces EBI2 expression resulting in elevated levels of EBI2 after 24 h until 7 days postinfection, followed by a dramatic decline (P=0.027). Increased EBI2 expression was not found in
non-specifically stimulated B cells or when irradiated virus was used. The EBV lytic gene
BRRF1 exhibited a similar expression pattern to EBI2 (R2=0.4622). BRRF1-deficient EBV
could not induce EBI2. However, B cells transduced with BRRF1 showed elevated expression of
EBI2 (P=0.042), a result that was not seen with transduction of a different EBV lytic transfection
factor, BRLF1. Based on these results, we conclude that EBI2 expression is directly influenced
by EBV infection and that BRRF1 is necessary and sufficient for EBI2 upregulation during
infection.

3

The content of this chapter was published in the Journal of General Virology, see Cornaby et al, 2017.
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2.2 Introduction
Epstein-Barr virus (EBV), a human B-lymphotropic herpes virus, infects over 90% of
adults (Amon & Farrell, 2005; J. I. Cohen, 2000; Henle, Henle, & Lennette, 1979). Primary EBV
infection usually occurs in childhood (Toussirot & Roudier, 2008). Although most infections are
asymptomatic, delayed infection into adolescence commonly causes infectious mononucleosis
(McAulay et al., 2007; Sitki-Green et al., 2004). In this case the virus is spread via saliva and
infects permissive epithelial cells of the oropharynx (Shannon-Lowe, Neuhierl, Baldwin,
Rickinson, & Delecluse, 2006). During this time the virus also infects mucosal B cells, however,
once B cells are infected the virus enters a stage of latency. This results in the expansion of an
LCL-like population of B lymphocytes in the tonsils (Hislop, Taylor, Sauce, & Rickinson, 2007).
This also allows the virus to avoid immune detection and remain with the host for the rest of
their life, persisting in the B lymphocyte population. Infection with EBV is also associated and
suspect of being responsible for several types of cancers (Robertson, 2012). It is a strongly
associated agent of Burkitt’s lymphoma, as well as various types of non-Hodgkin’s lymphomas,
nasopharyngeal carcinoma, immunoproliferative disorders and is associated as an environmental
trigger in autoimmune diseases such as Systemic Lupus Erythematosus (Cornaby, Gibbons, et
al., 2015; Hochberg, Middeldorp, et al., 2004; Kawa, 2000; Moosmann et al., 2010; B. D. Poole
et al., 2008). Post infection, EBV is adept at controlling lymphocyte expression, likely
manipulating EBV-Induced Gene 2 (EBI2) expression, among others, as a means of controlling
B lymphocyte migration.
EBI2 is a member of the rhodopsin-like subfamily of seven-transmembrane G proteincoupled receptors (GPCRs). Sequence alignments have grouped EBI2 with lipid receptors and it
shows highest similarity with GPR18 (Norregaard, Benned-Jensen, & Rosenkilde, 2011;
94

Rosenkilde et al., 2006). EBI2 expression is found to be naturally highest in secondary lymphoid
tissues (Hannedouche et al., 2011; Rosenkilde et al., 2006). Chemotaxis of naïve B cells within
the follicle is mediated through the expression of EBI2, CCR7, and CXCR5. Varying expression
levels of EBI2 affect the positioning and migration of the B cells throughout the follicle (Gatto,
Paus, Basten, Mackay, & Brink, 2009; Pereira, Kelly, Xu, & Cyster, 2009). When EBI2
expression is highest, the B cell migrates to the outer areas of the B cell follicles (Pereira et al.,
2009). Likewise, low levels of EBI2 expression lead B cells to accumulate in the FDC-dense
region in the center of the follicle or the interface of the T cell zone (Gatto et al., 2009). These
expression patterns are kept in a fine balance as positioning within the follicle, directly affects
both B cell proliferation and differentiation (Pereira, Kelly, & Cyster, 2010).
EBV controls expression of EBI2 upon infection. This control could affect EBV infected
cells in several ways. These include B cell chemotaxis, improper positioning of B cells within
the follicle and immune deficiency or other disruptions to cell hematopoiesis and function
(Casola et al., 2004). Altered positioning and chemotaxis of B cells is also thought to be
necessary for the development and progression of lymphomas (Coupland, 2011). Understanding
how EBV controls lymphocyte positioning could allow for improved control of infection and
response to EBV-induced malignancies. To enhance our understanding of EBV infection, we
investigated the expression profile of EBI2 during EBV infection and potential viral mechanisms
responsible for tampering with EBI2 expression.

2.3 Material and Methods
Generation and Harvesting of viral stocks
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Viral stock was generated using the Bac B95-8 EBV producing HEK 293 cell line as
previously constructed and described by Delecluse et al. (Delecluse, Hilsendegen, Pich, Zeidler,
& Hammerschmidt, 1998). To summarize, the strain has been engineered with an F factor origin
of replication, partitioning proteins A and B, chloramphenicol-resistance gene, hygromycinresistance gene, and an EGFP reporter. Cells were seeded in T-75 flasks (Corning) to attain a
confluence of 50 to 60 percent. The cells were then transfected with pUltra+BZLF1,
pUltra+BRRF1, and pUltra+BRLF1 plasmids using calcium phosphate transfection. Media was
changed 16 hours post transfection to RPMI and cells were allowed to incubate for 7 to 10 days.
Viruses were harvested in the RPMI media, filtered using a 0.45 μm filter, collected in 15 mL
conical vials, and stored at -80 oC. The titer of Epstein-Barr viral infectious units was determined
using green Raji cell assays following a previously described protocol (Hong et al., 2004). To
summarize, 2x105 Raji cells were suspended in 0.5 ml of viral supernatant. The cells were
allowed to incubate for 3 hours and then 1.5 ml of RPMI media was added to the wells. At day 2
post infection, sodium butyrate and Phorbol-12-myristate-3-acetate (PMA; ACROS) were added
to a final concentration of 3 mM sodium butyrate and 50 ng of PMA/ml. The cells were allowed
to incubate another 16 to 24 hours and then the GFP positive cells were quantified by
fluorescence microscopy.
The BRLF1 and BRRF1-deficient Epstein-Barr virus (R-KO EBV) was kindly was given
to us by Dr. Henri-Jacques Delecluse from the German Cancer Research Center, having been
described and used in previous studies (Hagemeier, Barlow, Kleman, & Kenney, 2011; Hong et
al., 2004; Hong et al., 2005). For specific information on the construction and testing of this
virus, the reader is referred to previous publications by Hong et al, 2004; Hagemeier et al, 2011;
and Feederle et al, 2000 (Feederle et al., 2000; Hagemeier et al., 2011; Hong et al., 2004). R-KO
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EBV viral stocks were generated by transfecting HEK 293 cells containing the R-KO EBV-Bac
with pUltra+BZLF1, pUltra+BRRF1, and pUltra+BRLF1 plasmids using calcium-phosphate
transfection. Seven to ten days’ post transfection viral supernatant was collected and filter
sterilized as described for the B95-8 viral stock. The titer of viral infectious units was determined
using green Raji cell assays following a previously described protocol (Hong et al., 2004) and as
described.
The lentiviruses (LVs) pUltra+BZLF1, pUltra+BRRF1 and pUltra+BRLF1 DNA were
grown in DH5alpha Escherichia coli cells and extracted using plasmid extraction kits (Qiagen).
The plasmid DNA was then transfected into the PHX cell line using calcium-phosphate
transfection. The supernatant was harvested and filter sterilized using a 0.45 µm filter. Lentiviral
vector concentrations were quantified by placing 100 µl of lentiviral media with one ml of Raji
cells at a concentration of 1x105 cells per ml. Cells were allowed to incubate for 48 hours and
then counted by fluorescence microscopy to determine the LV titer.

UV irradiation of EBV
EBV supernatants in 15 ml centrifuge conical tubes were exposed to ultra violet light
(200-280 nm) in a biosafety cabinet hood for a period of 4 hours. The UV irradiated virus was
then used to infect isolated B cells.

Human B Cell Isolation
Human naïve B cells were isolated using lymphocyte separation media (Cellgro) and
EASYSEP negative selection magnetic separation (STEMCELL Technology). Peripheral blood
mononuclear cells (PBMC)s were isolated from 30 ml of peripheral blood collected from healthy
volunteers after informed consent using lymphocyte separation medium (Cellgro). PBMCs were
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then re-suspended in PBS + 2% FBS with 1 mM EDTA added. Naïve B cells were separated
from other lymphocytes by magnetic cell separation using the Human B cell enrichment kit
(STEMCELL Technology) following the EASYSEP protocol.

Infection assays and RNA extraction
Using standard twelve well plates, 2 x 106 naïve B cells were placed in each well in one
mL of medium. One mL B95-8 EBV viral stock was added to each well. Media without EBV
was added to the negative controls. Cells were collected by centrifugation. Using the
RNAqueous-Micro RNA extraction kit (Ambion) and procedure, RNA was extracted and
suspended in elution solution.
For infection with R-KO EBV, isolated naïve B cells at a concentration of 2x106 cells per
ml were incubated with R-KO EBV supernatant at an MOI of 15. At each time point samples
were pelleted and treated as previously described for RNA extraction.
For lentiviral transduction, either pUltra+BRRF1 or pUltra+BRLF1, at an MOI of 15,
was added to isolated naïve B cells at a concentration of 2x106 cells per ml. At 24 hours postinfection, the cells were pelleted and treated as previously described for RNA extraction.

Quantification of gene expression by Q-PCR
Reverse-transcriptase quantitative PCR was performed using StepOne Plus software and
equipment with Power SYBR Green PCR master mix (Applied Biosystems). Samples were
analyzed using GAPDH as the housekeeping gene. Q-PCR Primers for all target genes were
designed using Primer Express 3.0 (Applied Biosystems). Primer sequences can be found in
figure 4.6.
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Statistical analysis
In all cases two-tailed paired t-tests and an alpha value of 0.05 was used to determine
significant differences in relative mRNA expression levels. To analyze correlations between the
expression of EBV genes and EBI2, linear regression analysis was performed using JMP Pro 10
statistical analysis software.

LCL cell line generation
PBMCs were re-suspended at 2x106 cells/ml in complete RPMI. 5 ml of cells suspended
in media and 5 ml of B95-8 EBV cell culture supernatant were placed together in a T-25 flask
with cyclosporin A or actinomycin D. Cells were incubated for 3 weeks, pipetted weekly to
break up cell clumps. LCL cell lines are maintained in complete RPMI and passaged frequently.

Lentivirus generation
The lentiviral vector pUltra+BRRF1 was constructed using pUltra, a 3rd generation
lentivirus obtained from Addgene. The BRRF1 gene was PCR amplified from wild type B95.8
EBV using forward (TCTAGAATGGCTAGTAGTAACAGAGGAAATG) and reverse
(TGATCATTATTTGTATTGCATGGCAGAACAGT) primers with an XbaI and BclI restriction
site extensions added respectively. BRRF1 was then cloned into pUltra cut with XbaI and BclI
restriction enzymes. The ligated pUltra+BRRF1 was then transfected into DH5alpha E. coli
cells. Using a BRRF1-specific forward primer and a pUltra specific reverse primer, the colony
containing the complete pUltra+BRRF1 plasmid was verified by sequencing. The plasmid used
for transfecting EBV producing HEK cells pUltra+BZLF1 was produced using pUltra with the
BZLF1 gene cloned into the construct. Forward (GTCGACTCAAAGAGAGCCAACAGGAAG)
and reverse (GAATTCAAAGGGGAGATGTTAGACAGGT) primers with SalI and EcoRI
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restriction site extensions added respectively. The PCR amplified BZLF1 gene was cloned into
pUltra cut with SalI and EcoRI. The ligated pUltra+BZLF1 was transfected into DH5alpha E.
coli cells. Using a BZLF1 specific forward primer and a pUltra specific reverse primer, the
colony containing the complete pUltra+BZLF1 plasmid was verified. The lentiviral vector
pUltra+BRLF1 was constructed using the same pUltra lentivirus as afore mentioned. The BRLF1
gene was PCR amplified from wild type B95.8 EBV using forward
(TCTAGAATGGTCGGGCATTTCCTCTG) and reverse
(TGATCACCAAAAGAGGAGGAGGCAGT) primers with XbaI and BclI restriction site
extensions added respectively. The PCR amplified BRLF1 gene was cloned in to pUltra cut with
XbaI and BclI. The ligated construct of pUltra+BRLF1 was then transfected into DH5alpha E.
coli cells. All primers for cloning the desired the PCR products were designed using Primer 3
software. All lentiviral constructs were verified by sequencing and expression of the cloned
genes were verified by RT-Q-PCR. Q-PCR efficiency and primers used during this study can be
found in Figure 18.

Western Blot
One ml of Raji cells at a concentration of 2x106 cells per ml were infected with EBV at
an MOI of 15. At time of sample collection, the cells were pelleted and re-suspended in lysis
buffer (Thermo Scientific). Cells were then vortexed and passed through a 25-gauge needle,
followed by incubation in Laemmli sample buffer (BIO RAD) and 5% 2-Mercaptoethanol
(Sigma) for 5 minutes at 95 oC. The samples were then subject to electrophoresis in a 12%
polyacrylamide gel and transferred to a nitrocellulose membrane (Thermo Scientific). Blots were
blocked with 2.5% (w/v) non-fat dry milk. EBI2 polyclonal goat anti-human IgG obtained from
Santa Cruz Biotechnology at a diluted 1:1000 was used as the primary Ab. Rabbit anti-goat IgG100

HRP obtained from Santa Cruz Biotechnology was used as the secondary Ab. ECL Plus (GE
Healthcare) Lumigen reagents and C-DiGit blot scanner (LI-COR) were used to image the
Western blot.

2.4 Results
Time course of EBI2 expression after EBV infection
EBI2 is vital in directing migration of primary B cells to areas in secondary lymph tissue
where they can potentially detect antigenic proteins (Cyster, 2010). To investigate the way EBI2
expression was influenced by viral infection, naive human B cells were infected with EBV.
Levels of EBI2 expression were measured and compared to uninfected control naive B cells
(Figure 8). EBV-infected cells showed, on average, a threefold higher relative mRNA expression
of EBI2 than uninfected cells. When the EBI2 expression found in infected B cells is compared
to the expression in cell lines that contain EBV, there is a significant difference of gene
expression. Freshly isolated naive B cells demonstrated a much higher expression of EBI2 when
compared to the expression observed in the EBV- positive LCL (P=0.012) and Raji cell lines
(P=0.027), which are primarily in a latent state.
To determine the pattern of EBI2 expression during the course of EBV infection, isolated
naive B cells were infected with EBV and EBI2 expression was measured at intervals over a 21day period of time. An expression time line was constructed starting with pre-infection and
ending 21 days post infection Between 3 and 6 h post infection, there was a significant decrease
in EBI2 expression (P=0.002). There is also a significant increase in expression at 24 h post
infection (P=0.027) (Figure 8). This heightened level of EBI2 expression persisted for as long as

101

Figure 7. EBI2 expression is modulated during the course of EBV infection.
(a) Twenty-four hours after infection, EBI2 expression in infected isolated naive B cells increased
by a mean of threefold over that of uninfected B cells. Expression of EBI2 in EBV-infected B cells
was significantly higher than in the EBV-containing LCL B-cell-derived cell lines (***P=0.012)
and the EBV-containing Ramos cell line (****P=0.027), n=4. (b) Isolated naive B cells
demonstrated significantly decreased expression of EBI2 by 6 h p.i. with EBV. After this initial
downregulation, EBI2 expression increased to remain at a heightened level of expression for
several days (*P<0.007, **P0.027). Seven days p.i., EBI2 expression decreased to levels equal to
or lower than those observed prior to EBV infection. (c) Non-specific gene regulation was
controlled by measuring the expression of the REEP5 gene at all time points, n=5. Error bars
indicate standard error.
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7 days post infection At this point, there was a large variance in the samples. This could be
indicative of EBV induction of EBI2 ending prior to this time in some samples received from
different donors while others are still maintained. However, by days 8 and 9 post infection, the
levels of EBI2 expression have decreased to levels equal to or lower than those observed in
uninfected control naive B cells (Figure 8). Non-specific gene regulation in infected cells was
controlled for by measuring the expression of the REEP5 gene at every time point. This gene
expression was stable throughout the time course of infection, except that it decreased between 3
and 6 h post infection, as did EBI2. This suggests that some genes are downregulated
immediately upon EBV infection, and the initial dip in EBI2 may be part of an overall pattern of
gene expression that is separate from the increase seen by 24 h.
To determine if increased RNA expression corresponded to increased protein levels,
naive B cells were infected with EBV and proteins were harvested at 24 h post infection Western
blots were performed to determine the ratio of EBI2 protein between the control and infected
cells (Figure 9). At 24 h post infection, the EBV-infected cells displayed more than twice the
amount of protein compared to uninfected cells (P=0.015).

Cell activation alone is not sufficient to increase EBI2 expression
It is important to establish if EBI2 expression could possibly be induced by a mechanism
such as B-cell activation due to viral infection. For this purpose, isolated naive B cells were
treated with imiquimod. Imiquimod binds to Toll-like receptor 7 (TLR7), which normally
recognizes ssRNA, and leads to B-cell activation (Yang et al., 2005). We used imiquimod to
stimulate naive B cells instead of using other methods, such as CD40 and IL-4, because we
wanted to investigate whether the TLR pathway could be responsible for the induction of EBI2
(H. Wang et al., 2006; K. Zhang, Clark, & Saxon, 1991). The imiquimod treatment activated the
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B cells, as shown by increased IL-1 and IL-6 transcription after treatment, but no increase in
EBI2 expression was noted (Figure 9).
To further establish that upregulation of EBI2 expression was due to EBV genes
expressed during infection, naïve B cells were treated with UV-irradiated EBV. Media
containing EBV was UV irradiated as described and then used to treat naive B cells. The
irradiation inactivates viral particles, preventing replication after entering the cell due to DNA
damage. After incubation with the UV-irradiated EBV, EBI2 expression was measured. The
relative mRNA expression in the B cells treated with the UV-irradiated EBV did not differ from
that found in uninfected naive B cells (Figure 9).

BRRF1 demonstrates a similar pattern of expression as EBI2 during EBV infection of B
cells
EBV uses various viral proteins to regulate cellular gene expression (Lu et al., 2011;
Price et al., 2010). Significant regulation of EBI2 was observed beginning between 3 and 6 h
post infection, indicating that an immediate early or early gene product would most likely be
responsible for regulating EBI2 expression. Various EBV genes that are expressed during this
period were selected as candidates for investigation. These included BARF1, BHRF1, BRRF1,
BMLF1, LMP1, LMP2, BRLF1 and BZLF1. Analysis was first begun on these genes, with the
intention of examining other viral genes if strong correlation values could not be found upon
comparing the expression pattern of these EBV genes to EBI2.
Expression of these genes at three different time points during naive B-cell infection by
EBV was measured using reverse-transcriptase quantitative PCR (RT-pPCR) and a pattern of
expression was established for each one (Figure 10). These time points were chosen due to the
104

Figure 8. EBI2 protein expression is highly upregulated only by infection with infectious
EBV.
(a) EBI2 protein levels correlate with RNA levels. Twenty-four hours p.i. of naive B cells
infected with EBV demonstrate heightened protein levels compared to uninfected naive B cells.
(b) EBI2 protein signal measured was twofold higher than the uninfected cells as observed by
Western blot (*P=0.015), n=4. EBI2 was normalized to b-actin, which was used as a loading
control. (c) Both Toll-like receptor 7 stimulation with imiquimod and incubation with UVirradiated EBV showed expression levels of EBI2 similar to unstimulated naive B cells, while
EBV-infected naive B lymphocytes demonstrated significantly higher levels of EBI2 mRNA
expression (**P<0.028), n=3. (d) IL-1 and IL-6 mRNA expression was measured in all
imiquimod-treated samples. Heightened mRNA levels indicate successful imiquimod stimulation
compared to unstimulated cells. Error bars indicate standard error, n=3.

105

distinct difference of EBI2 expression observed during EBV infection. Epstein– Barr
virus nuclear antigen 1 (EBNA1) was used to control for viral gene expression as it is expressed
throughout EBV infection. It was also chosen as the control to standardize for viral infection, and
even though the multiplicity of infection. used was the same for each experiment, there is still
variation observed in the samples treated with EBV. Therefore, all viral gene levels are relative
to EBNA1 in this experiment. Upon comparing the expression patterns of the viral genes to the
expression pattern of EBI2, BRRF1 demonstrated a similar expression pattern with the highest R
value (Figure 10). Linear regression analysis comparing EBI2 gene expression to the mRNA
expression of the various viral genes revealed that BRRF1 shared more similarity than any other
gene screened (R2=0.4622). Between 3 and 6 hours post infection, there is a significant decrease
in expression (P=0.033) and by 12 h post infection, expression had increased to a level similar to
that observed at 3 h post infection These results suggest a possible connection between BRRF1
and EBI2 expression.

BRRF1 induces a heightened expression of EBI2 in B lymphocytes during EBV infection
BRRF1 is an early lytic gene product (Hong et al., 2004; Segouffin-Cariou, Farjot,
Sergeant, & Gruffat, 2000) encoding a transcription factor (Na), which plays an important part in
regulating between latent and lytic EBV infection (Hagemeier et al., 2011). In high enough
concentrations, BRRF1 presence alone has been shown to induce EBV lytic gene expression
(Hagemeier et al., 2011). To determine if upregulation of EBI2 was caused by BRRF1, naive B
lymphocytes were infected with BRRF1-deficient (BRLF1/BRRF1 knockout, R-KO) EBV. The
R-KO EBV was used and described in previous studies (Hagemeier et al., 2011; Hong et al.,
2004). To summarize, the R- KO EBV strain is a bac engineered B95.8 Epstein–Barr virus
(V01555). It lacks the ability to express both the BRLF1 and BRRF1 lytic genes resulting in the
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Figure 9. BRRF1 demonstrates a similar pattern of expression to EBI2 in EBV infected B
cells.
(a) EBI2 protein levels correlate with RNA levels. Twenty-four hours p.i. of naive B cells
infected with EBV demonstrate heightened protein levels compared to uninfected naive B cells.
(b) EBI2 protein signal measured was twofold higher than the uninfected cells as observed by
Western blot (*P=0.015), n=4. EBI2 was normalized to b-actin, which was used as a loading
control. (c) Both Toll-like receptor 7 stimulation with imiquimod and incubation with UVirradiated EBV showed expression levels of EBI2 similar to unstimulated naive B cells, while
EBV-infected naive B lymphocytes demonstrated significantly higher levels of EBI2 mRNA
expression (**P<0.028), n=3. (d) IL-1 and IL-6 mRNA expression was measured in all
imiquimod-treated samples. Heightened mRNA levels indicate successful imiquimod stimulation
compared to unstimulated cells. Error bars indicate standard error, n=3.
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absence of the subsequent gene products, Rta and Na, respectively. Without the BRLF1 gene, it
would be predicted that the virus would not be able to induce expression of various genes that
depend on Rta response elements in their promoters including BMLF1, BMRF1, BALF2,
BARF1 and BLRF2 (Heilmann, Calderwood, Portal, Lu, & Johannsen, 2012). Rta is one of the
main proteins involved in EBV reactivation and is thought to be essential for viral reactivation
and lytic cycle induction, along with Zta. Na is known to act with Rta as a co-activator and
assists in inducing transcription of BZLF1 and the subsequent protein synthesis of Zta
(Hagemeier et al., 2011; Hong et al., 2004). It has been hypothesized that it helps regulate Rta
transcriptional effects (Kenney & Mertz, 2014).
The EBI2 mRNA expression was measured at 0 and 24 h post infection in naive B
lymphocytes with R-KO EBV (Figure 10). The mRNA was extracted from cells and quantified
by pPCR. Following infection of naive B lymphocytes with Na- and Rta-deficient R-KO EBV,
no significant change in expression of EBI2 was detected at 24 h post infection (Figure 10). To
verify that our R-KO infection assays were not yielding low EBI2 levels of expression due to
low R-KO EBV infection rate, we measured the mRNA expression of EBNA1 in samples that
were EBV or R-KO EBV infected at 24 h post infection (Figure 10). If our R-KO EBI2
expression was a result of low viral infection, we would expect the measured EBNA1 expression
to be less than that measured in samples from EBV-infected B cells. However, our results show
that EBNA1 expression is not lower in samples from R-KO-infected B cells. This suggests that
lower levels of EBI2 expression are not a result of a poor R- KO infection.
To confirm our findings from the R-KO EBV assay and verify that low EBI2 levels were
a result of the lack of BRRF1 and not due to the lack of expression of other viral genes, such as
BRLF1, we first transduced naive B lymphocytes with a lentivirus containing the BRRF1 gene
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Figure 10. BRRF1 is necessary and sufficient to induce expression of EBI2 in B
lymphocytes.
(a) EBI2 expression was measured in naive B lymphocytes infected with the BRRF1-deficient RKO EBV. There was no significant change in expression at 24 h p.i. with the BRRF1- deficient
EBV, n=6. (b) Naive B cells were transduced with BRRF1 using a lentiviral vector
pUltra+BRRF1) and EBI2 expression was measured. There was a significant increase in EBI2
expression at 24 h (**P=0.042) post-lentiviral treatment with BRRF1. Naive B cells were
transduced with BRLF1 using a lentiviral vector (pUltra+BRLF1) and expression was measured.
There was no significant difference in EBI2 expression measured at 24 h post-transfection when
BRLF1 was expressed. Error bars indicate standard error (*P=0.049; ***P=0.05), n=6. (c) Relative
EBNA1 expression measured in EBV and R-KO EBV-infected B cells 24 h p.i. This demonstrates
that the RKO EBV could establish an infection in the naive B cells, evidenced by the expression of
viral genes, n=6. (d) As a negative control, REEP5 mRNA expression was measured and found to
be similar in all experiments, demonstrating no significant difference, n=6. (e) BRRF1 and BRLF1
mRNA expression was measured in lentiviral-transduced naive B-cell samples and wild-type EBVinfected naïve B cells and compared. The levels of BRRF1 and BRLF1 mRNA expression in
pUltra+BRRF1 and pUltra+BRLF1-transduced samples, respectively, are similar. Error bars
indicate standard error, n=6.
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(pUltra+BRRF1). The relative EBI2 expression was measured at 0 and 24 h (see Figure 10).
Heightened expression of EBI2 was observed at 24 h post-transduction (P=0.042) when naive B
lymphocytes were transduced with pUltra+BRRF1. Second, to test whether BRRF1 was
specifically causing EBI2 upregulation and confirm that the increased levels of EBI2 expression
were not the product of transactivation by a viral DNA-binding gene, the viral gene BRLF1 was
transduced into naive B cells (pUltra+BRLF1). The relative EBI2 mRNA expression was
measured at 0 and 24 h post-transduction. In contrast with BRRF1, there was not a significant
increase in EBI2 expression after treatment with BRLF1 (Figure 10).
It was probable that most of our blood donor volunteers had previously been infected
with EBV. It was not expected that EBV reactivation would contribute to the heightened EBI2
expression levels observed since EBV genomes are only present in approximately 1 in 106
circulating B cells. However, to verify that latent EBV from prior infection was not interfering
with the results from our pUltra+BRRF1 and pUltra+BRLF1 transduced samples, BZLF1 was
measured in the EBV-infected naive B cells and the lentivirus-transduced naive B cells. BZLF1
expression was greater, estimated at 2x104 fold higher, in EBV-infected B- cell samples
compared to the pUltra+BRRF1-transduced B-cell samples. In most cases, BZLF1 expression
was not detectable in B cells transduced with the BRRF1-expressing lentivirus. This would
suggest that potential reactivation of EBV by the pUltra+BRRF1 in EBV-positive primary B
cells is not responsible for the resulting increase in EBI2 expression observed.
It could also be suggested that perhaps high expression of an EBV lytic gene could nonspecifically induce EBI2 expression. To investigate this possibility, we measured BRRF1
transcripts in pU+BRRF1-transduced, EBV-infected and control samples. We found that there
was about three-fold more BRRF1 expression in pU+BRRF1-transduced samples compared to
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EBV-infected samples. This difference can be attributed to the effectiveness of the human
ubiquitin promoter used to drive expression of BRRF1 post-transduction compared to the BRLF1
and BRRF1 promoter used by wild-type EBV. These results combined with the lack of
upregulation in cells transfected with BRLF1 using the same promoter led us to conclude that
BRRF1 expression alone can induce EBI2 and that EBI2 expression is not a result of nonspecific binding or latent EBV reactivation.

2.5 Discussion
Regulation of EBI2 is crucial to B cell chemotaxis in secondary lymph tissue (Cyster,
2010; Gatto & Brink, 2013). Up-regulation of EBI2 generally occurs during cellular migration in
secondary lymph tissue (Cyster, 2010). When expressed, EBI2 allows the cell to follow a 7a,25dihydroxycholesterol (7a,25-OHC) gradient(Gatto & Brink, 2013; Hannedouche et al., 2011; C.
Liu et al., 2011). B cells upregulate EBI2 at key times to maneuver the cell away from the
follicular region to the outer and inter-follicular regions. It has been suggested that these
movements allow the naïve B cells to potentially be exposed to any antigens that are present in
that region (Figure 11) (Cyster, 2010). Down regulation of EBI2 allows for the naïve B cells to
return to the follicular area and migrate to the T cell zone for a time before exiting the secondary
lymph tissue. The migration of B cells through this pattern allows for exposure to areas with
different antigens as well as the possibility to be primed by T cells.
EBV is known to manipulate cellular genes in order to avoid the immune system, control
viral replication, and prevent apoptosis (Ehlin-Henriksson et al., 2009; Kulwichit et al., 1998;
Thorley-Lawson & Allday, 2008). EBV had been previously shown to influence EBI2
(Birkenbach et al., 1993; Cornaby, Tanner, Stutz, Poole, & Berges, 2015; Kelly et al., 2011).
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Figure 11. Proposed effects on B-cell migration during EBV infection due to modulation of
EBI2 expression.
(A) This illustration demonstrates the regular pattern of naive B-cell migration in the lymph node.
(1) CXCR5 is expressed, allowing cells to follow a CXCL13 gradient and enter the follicular
region. CXCR5 is constitutively expressed to assist in cell migration. (2) EBI2 is upregulated and
the cells follow a 7a,25-OHC gradient to the outer or inter-follicular region. (3) Downregulation of
EBI2 allows the naive B cells to return to the follicular area and (4) upregulation of CCR7 permits
the cell to follow the CCL21 chemokine gradient to the T-cell zone. If B cells remain inactivated,
they will leave via the cortical sinus of the lymph node. If they become activated, they will be
directed back to the follicular and germinal center area. (B) This figure depicts the predicted
pattern of migration during EBV infection of naive B cells. (1) Upon entry into the lymph node,
the B cell will follow the 7a,25-OHC gradient to the outer and inter-follicular region of the lymph
node. (2) The cell will be unable to migrate to the follicular region.
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Various studies have researched EBI2 expression during EBV infection; however, it has
yet to be deter- mined if the virus induces EBI2 or if heightened EBI2 expression is a result of
the cellular response to viral infection (Cahir-McFarland et al., 2004; Craig et al., 2007; Dirmeier
et al., 2005; Rosenkilde et al., 2006). Previously, it has been hypothesized that EBI2 expression
is a result of the immune response to viral infection since EBI2 has been shown to be induced
during EBV latency program I. Normally, only EBNA1 is highly expressed (Birkenbach et al.,
1993; Rosenkilde et al., 2006). It has also been hypothesized that the increase of EBI2 expression
observed during EBV infection is a result of viral manipulation to promote a successful
persisting EBV infection, allowing for the virus to direct infected cells to areas that would
provide a better survival niche for viral persistence (Hannedouche et al., 2011; C. Liu et al.,
2011). The results of this study provide evidence for the later explanation of why heightened
EBI2 expression is observed during EBV infection.
It is possible that the EBV-induced upregulation of EBI2 could have been the result of
non-specific activation, as a cellular response to EBV infection. However, the B-cell- stimulating
agent imiquimod did not cause an upregulation in EBI2 expression, nor did incubation with
inactivated EBV. These findings indicate that EBI2 upregulation is not likely due to cellular
activation by TLR7, and that viral tegument or surface proteins are not responsible for the
upregulation of EBI2.
Screening for viral gene candidates that could be responsible for the regulation of EBI2
post-EBV infection found that BRRF1 shares a similar mRNA expression pattern as EBI2.
BRRF1 encodes a viral transcription factor, Na. Na is responsible for assisting in the activation
of viral lytic genes in various latently infected epithelial cells (Hagemeier et al., 2011) and has
been found to associate with human TNF receptor-associated factor 2 in a yeast two-hybrid assay
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(Calderwood et al., 2007). Due to its function as a transcription factor and its expression pattern
being similar to that of EBI2, BRRF1 seemed the best candidate of those screened. To ascertain
if BRRF1 expression could directly influence EBI2 expression, the BRRF1-deficient R- KO
EBV was used to infect isolated naive B cells. R-KO EBV has been used in several studies and
has the R gene, BRF1, knocked out as well as the promoter of BRRF1 resulting in EBV that
cannot express BRRF1 (Hagemeier et al., 2011). R acts with BZLF1 to activate latent EBV and
can bind to various EBV promoters (Gruffat et al., 1992; Gruffat, Manet, Rigolet, & Sergeant,
1990; Wille et al., 2013). The results show no upregulation of EBI2 expression upon infection
with the BRRF1-negative EBV. This would suggest that BRLF1 or BRRF1 was inducing EBI2
expression. To further verify that BRRF1 could induce EBI2 expression, the pUltra+BRRF1
lentivirus was used to treat isolated naive B cells. This resulted in a significant increase in EBI2
expression. These results demonstrate that the expression of BRRF1 was necessary and sufficient
to induce EBI2 expression. While the mechanism that BRRF1 uses to induce this expression in B
cells is unknown, it is possible that Na acts as a transcription factor at the EBI2 promoter site.
Further research needs to be performed in order to ascertain if this is the case.
It is probable that cell migration would be influenced by the EBV-induced regulation of
EBI2. With a heightened concentration of EBI2 on the surface of the infected B cells, it is no
stretch to infer that EBI2 might override other migratory signaling pathways and direct the cell to
follow a 7a,25- OHC gradient, which is the natural ligand of chemoattractant receptor EBI2 (see
Figure 11) (Hannedouche et al., 2011; C. Liu et al., 2011). 7a,25-OHC is only produced by
stromal cells of secondary lymph tissue (Yi et al., 2012). Following this gradient would cause
infected B cells to migrate and remain in the outer follicular and interfollicular regions of
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secondary lymph tissue. This type of control over cell migration could allow the virus to avoid
immune detection until latency has been established, assisting in immune evasion.
It is also possible that increased levels of EBI2 might influence B-cell proliferation.
Benned-Jensen et al. (Benned-Jensen et al., 2011) found that overexpression of EBI2 in antibody
stimulated murine B cells resulting in increased proliferation. By increasing the proliferation of
infected B cells during a specific time, it would increase the chances of viral persistence in the
infected host. The results of this study emphasize the importance of EBI2 regulation during viral
infection. It is possible that the use of EBI2 antagonists, or inverse agonists, could be used as
EBV antiviral treatment options or to disrupt the viral life cycle in an animal model (Ardecky et
al., 2010; Benned-Jensen et al., 2011; Daugvilaite, Arfelt, Benned-Jensen, Sailer, & Rosenkilde,
2014).
During our study, we have established that EBI2 is controlled during EBV infection of B
cells. Different EBV expression profiles result in different levels of EBI2 expression. Higher
levels of EBI2 mRNA expression result in higher levels of EBI2 protein. We have further
established that EBI2 is induced by an EBV gene, BRRF1. Potential research for the future can
address to what degree heightened expression of EBI2 possibly changes migration of EBVinfected B cells. It would also be beneficial to verify the mechanism used by BRRF1 to induce
EBI2 expression.
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Figure 12. Primers and consistency of RT-pPCR analysis.
(a) This table contains the pPCR forward and reverse primer sequences used in the experiments
described. (b) GAPDH cycle threshold (CT) scores for the various figures have been compiled to
verify that they are similar. There is no significant difference when comparing the GAPDH CT
scores from the different experiments.
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Chapter 3. Correlation between physical markers and psychiatric health
in a Portuguese systemic lupus erythematosus cohort: the role of
suffering in chronic autoimmune disease

3.1 Summary
Background. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects
a large number of people throughout the world. Anxiety, depression and fatigue are common
companions of SLE that substantially contribute to decreased quality of life. This study
investigates the interplay between physical and psychiatric manifestations of lupus. To this end,
an SLE patient cohort was examined for correlations between clinical presentation, laboratory
tests, and psychological indicators.

Methods. Seventy-two lupus patients were evaluated for psychological status using a battery of
instruments, including assessments for fatigue (CFS & FSS), depression (HADS), anxiety
(HADS), overall health (SF-36 & PSQI) and intimate relationship satisfaction (RAS & CSI).
Scores from these assessments were correlated with lupus clinical profiles and laboratory test
values

Results. The prevalence of depression in the SLE patient cohort was 41.7 %, as measured by the
hospital depression and anxiety scale. The study identified that pain (p = 0.001), body mass
index (p = 0.026), Chalder’s fatigue scale (p < 0.001), fatigue severity scale (p < 0.001), and
anxiety (p = 0.001) are all positively correlated with depression in SLE patients. Total
complement (CH50) (p = 0.032), and SF-36 physical and mental characteristic assessments are
negatively correlated with depression. Longitudinal analysis indicated that the disease related
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complaint alopecia (p = 0.008) and relationship assessment scale scores (p= 0.004) may also be
correlated to depression in SLE patients. Multivariant scrutiny of the clinical and psychosocial
characteristics identified the fatigue severity scale (p = 0.026), SF-36 physical function (p =
0.040), physical role function (0.030), and mental health (p = 0.002) as the best indicators
directly correlated with depression for the SLE cohort.

Conclusion. These results reveal the influence of physical manifestations of lupus including
fatigue, pain, body mass index and anxiety, as well as decreased physical and mental function,
on depression. Fatigue is the strongest factor correlated to depression in SLE patients in the
cohort. Both physical and social/psychological aspects likely contribute to the depression and
anxiety in lupus.

3.2 Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect a wide
variety of organ systems. Symptoms vary and can include fever, arthritis, fatigue, weight loss,
lymphadenopathy, a characteristic “butterfly rash”, renal disease and cytopenia, in a pleomorphic
clinical presentation. Depression and fatigue are very common, early symptoms of lupus that are
major contributors to diminished quality of life (S. T. Choi et al., 2012; Yilmaz-Oner et al.,
2016). Despite the prevalence of these psychiatric manifestations in lupus, they are not well
understood. Increased study of variables such as emotional stressors, culture, social and
environmental factors, age, sex, and disease duration, as well as indicators of disease activity,
may clarify the causes and contributions of depression and fatigue in lupus (Ad Hoc Committee
on Systemic Lupus Erythematosus Response Criteria for, 2007).
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Young women are predominantly affected by lupus, which brings significant costs into
their personal, family and professional lives. Depressive symptoms can occur as the first
manifestation of lupus, accompany more active stages or be regarded as a consequence of
therapeutic interventions (H. X. Gao et al., 2009; Jorge et al., 2017). A complete understanding
of the nature of depression in SLE is confounded by many factors that lupus can bring to a
person’s life, such as weight and activity changes, fatigue and sleep disturbances. Moreover, a
depressive disorder must be differentiated from more transient depressive symptoms (Iverson,
Woodward, & Green, 2001). Examination of the quality of depression, more than its prevalence,
might yield more clues to the underlying mechanisms (Denburg, Carbotte, & Denburg, 1997)
For these reasons, the causes of depression in lupus are not clear. Biological mechanisms
have been implicated because depression in lupus is associated with other CNS diseases, higher
disease activity and more severe clinical manifestations (Nery et al., 2007; Segui et al., 2000).
Brain inflammation, interaction of auto-antibodies with antigens on neuronal cells membrane,
and cytokine expression triggering neurotransmitter dysfunction have been regarded as possible
causes of depression in SLE patients and in rodent SLE models (Lapteva et al., 2006; Lawrence,
Bolivar, Hudson, Mondal, & Pabello, 2007; Postal et al., 2016; Sakic et al., 2005; Stojanovich,
Zandman-Goddard, Pavlovich, & Sikanich, 2007; Tsai et al., 1994). Cytokines are thought to
modify neuroplasticity and neurogenesis, induce biochemical changes and decrease
neurotransmitters’ bioavailability causing depression (Braga & Campar, 2014). Peripheral
proinflammatory cytokines levels were found to be correlated with the presence of depressive
symptoms, and a reciprocal relationship has been consistently reported between TNF-α, IL-6,
IL1 and major depression (Postal et al., 2016).
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Fatigue and pain are common symptoms in SLE, affecting up to 90% of the patients, who
rate these symptoms as severe manifestations of the disease (Petri et al., 2013; Ramsey-Goldman
& Rothrock, 2010; Zonana-Nacach et al., 2000). Both are considered the result of a complex
interplay between numerous variables – physical activity, sleep quality, cognitive function,
mood, quality of life, medication and comorbid conditions. Disease activity and medication fail
to predict self-reported levels of pain and fatigue (Jump et al., 2005). The progression of SLE as
a chronic disease may be better monitored by clinicians studying fatigue and depression and its
association with immune activation (Fonseca et al., 2014).

3.3 Methods
Patients
The studied population included 72 Caucasian lupus patients and 13 controls, recruited in
northern Portugal. All SLE patients were previously diagnosed and followed at an outpatient
unit. No selection was done besides willingness to participate. Diagnosis and stage of disease
activity was established according to the American College of Rheumatology Criteria (ACR) and
the duration of the disease was measured from the time when the patients first met at least the
classification criteria. The control group of patients with depression but without SLE was
undergoing treatment at a private psychiatric clinic at the time of the study.
To obviate inter-interviewer variation, psychiatric evaluation and psychometric markers
were tested by one psychiatrist and one psychologist to establish the severity of depression. A
convenience age matched sample of healthy women was also recruited. Exclusion criteria
comprised history of substance abuse, personality disorders and or other major psychopathology
than depression. Patients and controls were subsequently interviewed by phone by trained
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interviewers. The literature corroborates phone interviews as valid and precise tools for
psychological data collection (B. B. Cohen & Vinson, 1995; Rohde, Lewinsohn, & Seeley, 1997;
Siemiatycki, 1979).
Participants’ socio-demographic data included age, educational level, employment status
(active/non-active) and marital status (Table 7). Laboratory and SLE clinical evaluations were
obtained for the SLE patients through the clinical records (Table 8-12). Lab tests included
leukocytes (109/L), lymphocytes (percentage), neutrophils (percentage), platelets (109/L),
erythrocyte sedimentation rate (mm/h), anti-dsDNA antibody titer (IU/ml), C3 level (g/L), C4
level (g/L), CH50 level (U/ml), and C-reactive protein level (mg/dl). Other clinical
symptomology also recorded from patients included cutaneous manifestations, photosensitivity,
foot and mouth ulcers, arthritis, alopecia, headaches, kidney disease, neurological symptoms,
pulmonary disease, musculoskeletal pathology, history of hypertension, and acute confusion
syndrome (ACS). Smoking and alcohol consumption were also recorded.
The study was submitted and approved by the Ethical Committee of the São João
Hospital IRB (EPE) according with the Declaration of Helsinki. All participants gave informed
consent.

Psychosocial evaluation
Socio-demographic characterization included age, education measured as years of school,
marital status and socio-economic class evaluation. Psychological evaluations were obtained
through a battery of standardized instruments.
Fatigue Severity Scale (FSS)
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The short form of the FSS allows evaluation of self-reported fatigue (Krupp, LaRocca,
Muir-Nash, & Steinberg, 1989). The Portuguese version includes nine-items and is
recommended as the instrument of choice for research purposes in studies involving patients
diagnosed with SLE (Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
for, 2007).
The FSS demonstrates good psychometric properties (Cronbach's α= 0.89 and test-retest
reliability 0.84). A final score is obtained from the mean of all scored items, with higher scores
revealing higher severity of fatigue. Presence of clinical levels of fatigue was defined by a FSS
score >3. The scale has proved to be sensitive to change and reliable for telephone interviewing.
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a self-rating scale with good
psychometric properties (Cronbach's alpha coefficients of 0.94), designed to measure anxiety and
depression in physically ill individuals (Zigmond & Snaith, 1983). Translated and adapted for
Portugal (Ferreira, 2000; Pais-Ribeiro et al., 2007), it is subdivided in two subscales of 7 items
that measure independently anxiety and depression. The partial result of each scale varies
between 0 and 21. Scores ranging from 8 to 10 are considered mild, from 11 to 14 moderate and
15 to 21 severe(Marcolino, Suzuki, Alli, Gozzani, & Mathias, 2007) and the authors suggest 8 as
the cutoff point, considering values below as indicating the absence of anxiety and
depression(Zigmond & Snaith, 1983). It is important to note that the scale is indicative of
depressive symptoms in the last week, and not necessarily clinical depression.
Pittsburgh Sleep Quality Index (PSQI)
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This instrument presents good psychometric properties, with high reliability (Cronbach’s
alpha = 0.83) and validity. The seven components evaluated - sleep latency, sleep disturbances,
sleep duration, sleep quality, sleep efficiency, use of sleep medications and daytime dysfunction
allow the gathering of a global score varying from 0 to 21 (Buysse, Reynolds, Monk, Berman, &
Kupfer, 1989; Carpenter & Andrykowski, 1998). The PSQI is reliable for sleep quality
assessment in telephone interviews and permits the identification of poor sleepers (score > 5)
(Monk et al., 2013; Palmieri, Chipman, Canetti, Johnson, & Hobfoll, 2010).
Chalder Fatigue Scale (CFS)
The Chalder Fatigue Scale (Chalder et al., 1993), is an instrument with 11 items that
evaluates the extent and severity of mental and physical fatigue in a four-point scale. Higher
scores indicate higher fatigue.
Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)
The SF-36 (Ware & Sherbourne, 1992), Portuguese version (Ferreira, 2000), is a 36 item
questionnaire that measures functional health and well-being in eight domains: physical
functioning, role-physical, bodily pain, general health, vitality, social functioning, roleemotional, mental health and reported health transition. The instrument allows a score for each
domain, as well as a global score. Higher scores indicate better health.
Couples Satisfaction Index (CSI)
The CSI (Funk & Rogge, 2007) (Portuguese experimental version from Barbosa &
Figueiredo-Braga, 2014) is a 32 item questionnaire that measures couple satisfaction in the
relationship. Higher scores indicate greater satisfaction.
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Relationship Assessment Scale (RAS)
The RAS (S., 1988) (Portuguese experimental version from Mesquita, Barbosa, &
Figueiredo-Braga, 2014) is a 7 item instrument, with a five-point scale that measures general
satisfaction with the relationship.

Statistical analysis
Differences in the demographic, clinical, and psychological variables between the total
SLE subjects, SLE non-depressed, SLE depressed, and depressed control subjects was
determined using the independent t-test, Fisher’s exact chi-squared, Mann-Whitney U, Wilcoxon
rank sum, or Welch’s tests when appropriate. Fisher’s exact chi-squared was used in place of the
standard chi-squared test, which would typically be utilized, due to the smaller sample size of the
groups compared. The statistical test used for the comparisons are indicated in the table legends.
Multivariant analysis was performed using a generalized linear model. The best fit model was
determined using the model with the appropriate number of variables (less than or equal to 8
variables) and the highest pseudo R2 value with the lowest approximate AICc value. In the
multivariate analysis, the HADS depression score for all SLE subjects was used as the dependent
variable and all candidate models included the confounding variables of age, education in years
(socioeconomic status indicator), and body mass index. Statistical analysis was performed using
the statistical software R and SPSS (IBM). An alpha value less than or equal to 0.05 was
considered significant.

3.4 Results
The systemic lupus erythematosus (SLE) patient cohort consisted of 72 females with a
mean age of 44.31 years. 41.7% of SLE patients demonstrated pathological HADS depression
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scores. A cohort of thirteen physically healthy females diagnosed and being treated for
depression acted as a control group. This group was slightly older than the lupus cohort with a
mean age of 57.69 years. For several analyses the SLE cohort was divided into two groups, those
who demonstrated normal HADS depression scores (HADS ≤ 7) and those who recorded above
normal HADS depression scores (HADS ≥ 8). To ensure that the depressed control group was
comparable with the lupus depression group, despite the selection of the lupus depression group
by HADS score, the depressed non-lupus group was also stratified by depression, and only the
depressed patients with HADS scores of >8 were compared to the lupus depression group. This
selection still significantly demonstrated the same patterns that were observed using the entire
depressed patient cohort.
The SLE patients experiencing pathological depression display fewer years of formal
education compared to the SLE patients with normal HADS scores (p = 0.005). When years of
education are compared between SLE non-depressed patients and depressed controls, the
depressed cohort is significantly lower (p = 0.030), but there is no significant difference between
depressed SLE patients and depressed controls (p = 0.871) (Table 7). Aside from these
sociodemographic differences, the SLE cohort sub groups and the depressed patient control
cohort share similar marital and employment status distributions.

Clinical Manifestations
The laboratory data were similar between the SLE depressed and non-depressed groups
save for the total complement (CH50) levels. These levels are significantly lower on average in
the SLE depressed patients, who had a mean CH50 level of 9.81 (± 39.07) U/ml compared to the
SLE non-depressed group that had a mean CH50 level of 45.88 (± 86.24) U/ml. This large
difference is statistically significant (p = 0.032) (Figure 8).
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Table 7. Sociodemographic Characteristics of the Patient Cohort
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Table 8. SLE Study Cohort Clinical Characteristics
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Table 9. SLE & Depression Study Cohort Clinical Characteristics.
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Figure 13. Lupus manifestations show correlation with HADS depression scores.
Body mass index, total complement (CH50), and pain show significant correlation with HADS
depression scores. This correlation is displayed by comparing the SLE non-depressed and SLE
depressed measurements. It is further demonstrated by displaying the variable measurements
from all SLE patients on the y-axis of the scatter plots, with the HADS depression scores on the
x-axis.
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The SLE depressed patients reported higher pain scores than the SLE non-depressed
subjects (p = 0.001). The SLE depressed group recorded a median pain score of 7.5, compared to
4 for the non-depressed SLE group. As HADS depression scores increase, the pain scores also
increase (Figure 8). Along with the increase in pain, the SLE depressed patients further reported
a higher frequency of headaches (p = 0.004) with 76.7 % compared to 40.5 % of the SLE nondepressed patients.
An increase in body mass index (BMI) was observed in the SLE depressed cohort (p =
0.026) (Figure 8). SLE non-depressed subjects had a mean BMI of 23.16 (± 3.63) compared to
26.49 (± 7.24) in the SLE depressed group. The control depressed subjects had a mean BMI of
26.15 (± 5.38) (Table 9). Interestingly, both the SLE depressed and control depressed subjects
have significantly higher BMI than the SLE non-depressed group (p = 0.025). There was a
higher percentage of subjects from the depressed group that regularly consumed alcoholic
beverages compared to the SLE cohort, with 38.5 % compared 10 % and 7.1 %, for the SLE
depressed and SLE non-depressed subjects respectively (p = 0.013 and p =0.042).

Psychosocial Function
Both psychological tools used to assess fatigue severity demonstrated significantly
different levels of fatigue between the SLE depressed group and the SLE non-depressed patients
(Table 10). Lower scores on the CFS indicate less fatigue, while higher scores indicate more
fatigue. The SLE non-depressed subjects had less physical, mental, and overall fatigue than the
SLE-depressed patients (p = 0.001, p = 0.001, p < 0.001, respectively) (Figure 2). The
depression-only group CFS scores are slightly higher than the SLE non-depressed patients, but
lower than the SLE depressed group and not statistically significant from either group.
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Table 10. Study Cohort Psychological Characteristics.
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Figure 14. Psychosocial variables show correlation with HADS depression scores.
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Figure 14. Psychosocial variables show correlation with HADS depression scores.
A variety of psychosocial assessments demonstrate a correlation with HADS depression
scores including the Chalder Fatigue Scale (CFS), SF-36 sub categories, HADS anxiety, and
fatigue severity scale (FSS). The box and whisker plots compare the SLE non-depressed, SLE
depressed, and depressed control cohort’s assessment scores.
The second fatigue assessment, the fatigue severity scale (FSS), also found statistical
differences in fatigue between the SLE depressed and SLE non-depressed subjects (p < 0.001).
The SLE non-depressed patients demonstrated a mean FSS score of 4.12 (± 1.65) compared to
the SLE depressed subjects (5.59 ± 0.85) (Figure 9). Interestingly, the SLE depressed subjects
had higher levels of fatigue compared to the depressed control cohort (3.68± 1.09) (p < 0.0001).
To assess the patients’ perception of their general health, the SF-36 assessment was used.
This psychological tool yields eight sub scores, each of which was found to be different between
the SLE depressed and SLE non-depressed subjects (Table 10). The ranking of the SF-36
assessment gives a higher score for patients that feel healthier in that sub category, with lower
scores indicating lower health. The SLE non-depressed cohort reported a median physical
function score of 24, a median physical role function score of 14. The SLE depressed patients
demonstrated significantly lower physical function and physical role function scores, with
median scores of 17.5 and 9.5 respectively (p < 0.001 and p = 0.001, respectively) (Figure 14).
The SLE non-depressed patients exhibited a mean general health score of 13.32 ± 3.44 and a
median health transition score of 3, which was significantly higher than the SLE depressed
patients, (general health 10.97 ± 2.46, health transition 4), (p = 0.002 and p = 0.001,
respectively). The final sub score for physical health, bodily pain, in the SLE non-depressed
cohort was had a mean of 7.43± 2.93, with the SLE depressed patients recording a mean of 4.75
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± 1.87. This difference in scores indicates a significantly higher level of perceived pain in the
SLE depressed subjects (p < 0.001) (Table 10 & Figure 14).
The mental health assessment portion of the SF-36 consists of the variable sub scores
including vitality, social role function, emotional role function, and mental health. SLE nondepressed patients exhibited higher vitality and social role function scores (p < 0.001 and p <
0.001, respectively) with a median score of 11 and 8 respectively, than the SLE depressed
patients, which had a median score of 7.5 and 6, respectively. Emotional health assessed by the
SF-36 recorded that the SLE non-depressed subjects had a median score of 11, while the SLE
depressed patients had a lower median score of 7.5 (p < 0.001). The final sub score calculated for
the SLE non-depressed cohort, mental health, had a median score of 16.5 and the SLE depressed
patients had a median score of 13 (p < 0.001). Surprisingly, the depressed control subjects scores
were quite similar to the SF-36 sub categorical scores of the SLE non-depressed cohort (Table
10). Upon comparing the depressed controls to the SLE depressed patients, distinct differences in
all the SF-36 categories, save for that of social role function, were found. In these seven
categories, the SLE depressed patients reported significantly worse scores (Table 10).
The SLE depressed patients were highly anxious, with 90% demonstrating heightened
anxiety scores, compared to the SLE non-depressed subjects with 52.4 % of the patients with
HADS anxiety scores exceeding what is considered normal (p=0.001). The depressed control
cohort exhibited similar anxiety scores as the SLE non-depressed control with 53.8 % of the
subjects having higher than normal anxiety scores. These values are significantly lower than
those observed in the SLE depressed patients (p = 0.014).

Longitudinal Impact
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Table 11. SLE subjects with reduced HADS scores.
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Approximately one month after the initial clinical and psychosocial assessment, patients from the
SLE cohort were reassessed. Of thirty SLE patients that exhibited pathological HADS depression
scores, five of them had normal HADS depression scores during this second assessment. While
five patients compose a rather small group, these differences might be of interest in later studies.
In the first assessment, every one of these patients exhibited alopecia as a disease related
complaint, however, in the second assessment, all five no longer had alopecia (p = 0.008). A
further difference identified was the strong increase in relationship assessment scale (RAS)
scores (p = 0.004). The first assessment revealed a mean relationship assessment scale score of
22.40 ± 1.52, while the second assessment recorded a mean relationship assessment scale score
of 30.60 ± 2.79 (Table 11).

Table 12. Multivariate Model for SLE Cohort

Multivariate Analysis
To determine what variables might play a role as the best indicators of increased HADS
depression scores relative to the SLE cohort, we utilized generalized linear regression models for
the multivariate analysis. A list of candidate models was compiled and compared to one another
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based on the number of variables included, pseudo R2, and AICc values. Each model included
the confounding sociodemographic variables that were identified as significantly different
between the SLE depressed and SLE non-depressed subjects, namely age, body mass index, and
years of education. All other variables that were found to be significantly different between the
SLE non-depressed and SLE depressed patients were included as possible variables in the
multivariant analysis. The only significant variable not included as a candidate variable was
HADS anxiety scores. This variable was omitted due to the close correlation with the HADS
depression score and because they are derived from the same assessment. The best fit model,
identifies the best indicators of depression for this SLE cohort. Of the variables included in the
model, several were considered significant. These include three SF-36 scores, physical function
(p = 0.040), physical role function (p = 0.030), and mental health (p = 0.002), as well as fatigue
severity scale scores (p = 0.029). Of these, the latter is likely the most sensitive to changes in
HADS depression scores as indicated by the odds ratio of 1.11 (1.01-1.22), which is slightly
higher than other significant variables.

3.5 Discussion
The overwhelming finding of this study is that lupus patients with depression are
experiencing extreme suffering. They present higher number of depressive symptoms even than
patients for whom depression is the primary diagnosis. They are also more prone to experience
anxiety. In addition to being more depressed and anxious than primary depression patients, they
suffer more physical symptoms than lupus patients without depression. These depressed lupus
patients are living in the worst of both worlds.
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The study examined the relationship between various clinical and psychosocial variables
that could contribute to or indicate an increase in depression in patients with systemic lupus
erythematosus. Fatigue is directly correlated to an increased risk for depression among lupus
patients (Morris et al., 2016; van Exel et al., 2013; Wiseman et al., 2017; Yilmaz-Oner et al.,
2016). This was observed in the univariate analysis, in the Chalder Fatigue Scale and Fatigue
Severity Scale, and the multivariate analysis, making the measurement of fatigue an excellent
indicator of depression in SLE patients (Table 10 & Figure 14).
Interestingly, the SLE depressed subjects and SLE non-depressed cohort did not show a
significant difference in sleep quality. While the prevalence of poor sleepers is equal to or higher
than that observed in the general population, it is does not appear to be correlated with
depression indicating that a poor sleep quality is not causing depressive symptoms, and perhaps
is not one of the significant factors contributing to such drastically high levels of fatigue among
lupus patients (Inoue et al., 2017). Other studies have found that fatigue was strongly correlated
with an increase in body mass index in SLE patients (Wiseman et al., 2017). The trends observed
in past studies would suggest that as fatigue increases, depression and body mass index scores
would also increase. The data supports this trend (Table 8 & Figure 14). Increased body mass
index scores were found to correlate with increased levels of depression amongst in SLE cohort.
These results emphasize the importance of assisting patients alleviate chronic fatigue, as fatigue
seems to be associated with a variety of psychosocial and clinical aspects of SLE. The findings
from the fatigue assessments demonstrate that the depressed lupus cohort suffers from both
physical and mental fatigue. The need for continued research to better understand how to best
treat both types of patient fatigue is necessary.
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The data from the cohort analyzed further found that the SF-36 psychosocial assessments
were also excellent indicators of depression for the lupus cohort. All the physical and mental
categories were found to be negatively correlated with depression (Table 10 & Figure 14). Two
of the SF-36 physical components were found to be directly correlated to depression scores in
multivariate analysis, that of physical and physical role function. These findings support multiple
studies that indicate SF-36 scores are negatively correlated with depression in SLE subjects
(Mak, Tang, & Ho, 2013; Yilmaz-Oner et al., 2016). Interestingly, the depressed control group
show significantly higher scores in these three categories and most of the other SF-36 categories
when compared to the SLE depressed subjects. These results suggest that the SLE depressed
patients decreased physical and mental health is likely a result of SLE disease activity as
opposed to depression. Another hypothesis could be the cumulative burden of the disability
imposed by an autoimmune and a mental disorder severely impinges quality of life.
Heightened pain is correlated with increased depression. This evidence confirms various
studies demonstrating that increased pain is related to greater risk for depression in SLE patients
(Karol, Criscione-Schreiber, Lin, & Clowse, 2013; Xie, Wu, & Chen, 2016). Also of interest is
the higher frequency of headaches observed in the SLE depressed population compared to the
SLE non-depressed patients. A final interesting clinical characteristic is the decreased levels of
total complement (CH50) observed in the depressed patients. This supports previously observed
changes in complement levels in patients with neuropsychiatric lupus and animal models
(Alexander, Jacob, Bao, Macdonald, & Quigg, 2005; Karol et al., 2013; Stock, Wen, &
Putterman, 2013). Low complement is a marker of inflammation and disease activity in lupus,
and suggests that heightened immune dysfunction and associated disease activity correlates with
more depression. Interestingly, other commonly used indicators of disease activity, such as C139

reactive protein levels or Sedimentation Rate, do not correlate with depression. These tests also
failed to correlate with any lupus symptoms in this cohort.
From the assessment of patients, a month after their first contact, several significant
differences indicating possible correlations were observed. All of these patients had alopecia on
their first contact, but it was gone by their second assessment. Lastly, they also rated their
relationships higher. This longitudinal observation of the data indicates a possible correlation
between these variables and depression. It is the belief of the authors that the increased
satisfaction with a close relationship in SLE patients is likely a protective factor resulting in
decreased depressive symptoms. Supporting and gratifying relationships are known to alleviate
depression associated with other chronic and debilitating diseases (Manne & Badr, 2010).
However, with the small sample size and the nature of the experiment, no conclusive
directionality can be imposed upon the data at this time.
In the SLE cohort we observed a high prevalence of depression, 41.7 %, above the
threshold for depression as indicated by the hospital depression and anxiety assessment. A still
higher proportion of SLE subjects reported above average anxiety scores, 65.9 %. This
prevalence, while high, is not uncommonly so for SLE populations (Figueiredo-Braga et al.,
2009; L. Zhang, Fu, Yin, Zhang, & Shen, 2017).
In summary, this cohort provides a variety of insights into the relationship between
depression in SLE patients and clinical and psychosocial variables that are associated with both
the neuropsychological and physiological symptoms. The findings highlight the importance of
assisting patients with both physical and mental health care. Beyond clinical and laboratory
monitoring of immune dysfunction, attentive clinicians are aware of the value of more discrete
symptoms as fatigue, pain, anxiety and depression. It has been demonstrated in past studies that
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treatment of the neuropsychological symptoms improves overall health, and appropriate
treatment of physical symptoms assists in the improvement of psychological manifestations
(Karol et al., 2013; E. H. Lin et al., 2003).
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Chapter 4. Interrelation between the physical and the psychological in
inflammatory disease: Comparison of clinical, immunological and
psychosocial factors between Lupus and Rheumatoid Arthritis patients
in a Portuguese cohort.

4.1 Summary
Objective To increase the understanding of the relationship between depression and various
psychosocial, clinical, and immunological factors relevant to systemic lupus erythematosus
(SLE) were examined in a cohort of SLE patients using healthy, depressed, and arthritic patients
for comparison.

Methods The cohort consisted of seventy-seven Caucasian patients. Physiological, clinical, and
psychosocial data was collected from all patients and compared using a variety of statistical
analysis to determine correlation and identify similarities and differences between the SLE
patients and control cohorts. ELISA was used to measure cytokine levels.

Results The prevalence of moderate to severe depression in the SLE cohort as determined by the
Hospital Anxiety and Depression Index was forty percent with six times greater chance of having
depression when compared to the healthy control subjects. Pain, IL-6, and Pittsburg quality
sleeping index values were all significantly higher in SLE patients compared to the healthy
control group (p < 0.001, p = 0.038, and p = 0.005, respectively). Anxiety levels were
significantly higher in SLE patients compared to healthy and arthritic control patients (p = 0.020
and 0.011, respectively). Serum IL-10 concentrations, relationship assessment scale, and fatigue
severity scale values were found to be directly correlated to depression among the SLE patients
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(p = 0.036, p = 0.007, and p = 0.001, respectively). Relationship assessment and fatigue severity
scale scores were found to be the best indicators of depression for the SLE patients (p = 0.042
and 0.028, respectively).

Conclusion Fatigue Severity, relationship satisfaction, and IL-10 concentrations are correlated
with depression in the SLE patients and are potential indicators of depression in lupus patients.
By comparing our clinical and psychosocial assessments from our lupus patients with our
arthritic patients we were able to identify that inflammatory symptoms likely contribute to
measured levels of IL-10 and fatigue, while the drastically decreased relationship satisfaction
recorded from SLE patients is likely a psychiatric disease manifestation. These results emphasize
the importance of clinical and psychological patient care in the treatment of SLE.

4.2 Introduction
Systemic lupus erythematosus (SLE) is a common autoimmune disease afflicting 1 – 12
people per 5,000 worldwide (Alarcon et al., 2004; Ghodke-Puranik & Niewold, 2015). Often
characterized by autoantibody production, cutaneous epidermal manifestations, and various
rheumatic symptoms, lupus pathophysiology is marked by abnormal T and B cell behavior, misregulated apoptosis, complement function, immune complex clearance, and nucleosome
processing, among others (Cornaby, Gibbons, et al., 2015; Cornaby et al., 2017; Mak & Kow,
2014). These result in a multitude of physiological complications and organ involvement.
Symptoms often include fever, arthritis, fatigue, weight loss, lymphadenopathy to a characteristic
“butterfly rash”, renal disease and cytopenia, in a pleomorphic clinical presentation. Early
symptoms of lupus that contribute to diminished quality of life also include depression and
fatigue.
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Ninety percent of lupus patients are women with the disease typically manifesting in
earlier years. With disease manifestation early on, it causes difficulties for the family, and the
patients emotional and professional lifestyle. Because of these conditions, it is no surprise that
SLE patients commonly suffer from psychological disorders (Nery et al., 2007; Nery et al., 2008;
Uguz et al., 2013). Interesting, depressive symptoms can be one of the early manifestations of
SLE disease activity(H. X. Gao et al., 2009; Jorge et al., 2017). Also, depression and anxiety
seem to be more acute during disease activity (Nery et al., 2007; Segui et al., 2000). Higher rates
of depression have been observed consistently in SLE populations worldwide (L. Zhang et al.,
2017). Even with psychological disorders involved so often with SLE, little research has been
invested in understanding the mechanisms involved in disorder development compared to endorgan failure and peripheral pathology (Y. Li et al., 2015).
Fatigue and pain are frequently rated by SLE patients as being severe manifestations of
the disease (Petri et al., 2013; Ramsey-Goldman & Rothrock, 2010; Zonana-Nacach et al., 2000).
Both disease indicators and medication fail to satisfactorily predict fatigue and pain in SLE
patients, making it difficult to estimate patient discomfort and subsequently apply appropriate
treatments in a timely manner (Jump et al., 2005). Laboratory and clinical relationship to fatigue
and pain are still ambiguous. However, these symptoms are frequently associated with mood
disorders, including depression.
It is likely the psychosocial impact of SLE contributes to the often-observed disease
association with depression. With such a large number of confounding variables involved with
disease progression including age, disease activity, weight, fatigue, sleep and physical activity, it
is no simple matter to identify both psychological and physical factors that play into mood
disorder involvement in SLE patients. Due to these reasons, the causes related to the high
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prevalence of depression and anxiety in SLE is largely misunderstood. Increased disease
severity, SLE related autoimmune dysfunction, and psychological stress of having a major
chronic systemic disease are all hypotheses to explain this increased prevalence, however, there
remain a large gap in the understanding that only further research into pathophysiology and
psychosocial understanding of depression onset in SLE patients will sate (van Exel et al., 2013).
To better understand the relationship between depression in SLE patients and the variety
of factors that could contribute to its prevalence, we investigated the involvement of these
variables utilizing laboratory and clinical results alongside psychosocial assessments to aid in
this endeavor. Further, the study also included several cohort subgroups to allow comparisons
with the SLE patients, giving us a unique perspective into possible disease related factors that are
correlated with and can predict depression among the SLE patients. By comparing our SLE
cohort findings to those of arthritic patients, we can better comprehend what symptoms
correlated with depression are likely the result of a chronic inflammatory disease. Our Depressed
cohort further allows us to predict what variables are likely caused by psychological
complications, rather than inflammatory disease.

4.3 Methods
Study Patients
The study included 77 total Caucasian patients, 15 patients with systemic lupus
erythematosus (SLE), 21 rheumatoid arthritis (RA) patients, 20 healthy control subjects, and 21
depressed control subjects. All patients were recruited from northern Portugal. All SLE patients
were previously diagnosed and followed at an outpatient unit. No selection was done except the
patient’s willingness to participate in the study. Diagnosis and stage of disease activity was
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established according to the American Rheumatism Association Classification Criteria (ACR)
and the duration of the disease was measured from the time when the patients first met at least
fthe classification criteria. All Ra patients were also previously diagnosed prior to the study by a
physician as defined by the ACR. The control group of depressed control subjects was
undergoing treatment at a private psychiatric clinic at the time of the study.
To obviate inter-interviewer variation, psychiatric evaluation and psychometric markers
were tested by one psychiatrist and one psychologist to establish the severity of depression. A
convenience age matched sample of healthy women was also recruited. Exclusion criteria
comprised history of substance abuse, personality disorders and or other major psychopathology
than depression. Patients and controls were subsequently interviewed by phone by trained
interviewers. The literature corroborates phone interviews as valid and precise tools for
psychological data collection (B. B. Cohen & Vinson, 1995; Rohde et al., 1997; Siemiatycki,
1979).
Participants’ socio-demographic data included age, educational level, employment status
(active/non-active) and marital status (Table 13). Laboratory and SLE clinical evaluations were
obtained for the SLE patients through the clinical records (Table 14-15). Lab tests included
leukocytes (109/L), lymphocytes (percentage), platelets (109/L), erythrocyte sedimentation rate
(mm/h), anti-dsDNA antibody titer (IU/ml), and C-reactive protein level (mg/dl). Serum
collected from participants from the all members of the cohort was obtained and levels of IL-6
(pg/ml), IL-10 (pg/ml, and TNF-α (pg/ml) were measured using standardized ELISA assays,
utilized per manufactures instructions (SIGMA). The confounding variables of smoking and
alcohol consumption were also recorded. Further, physical activity of the patients was assessed
based on patient involvement in active sport activities.
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The study was submitted and approved by the Ethical Committee of the São João
Hospital IRB (EPE) in accordance with the Declaration of Helsinki. The nature and the purpose
of the study were explained to all participants who signed the informed consent form before they
entered the study.

Psychosocial evaluation
Socio-demographic characterization included age, education measured as years of school,
marital status and socio-economic class evaluation. Psychological evaluations were obtained
through a battery of standardized instruments.
Fatigue Severity Scale (FSS)
The short form of the FSS allows evaluation of self-reported fatigue (Krupp et al., 1989).
The Portuguese version includes nine items and is recommended as the instrument of choice for
research purposes in studies involving patients diagnosed with SLE (Ad Hoc Committee on
Systemic Lupus Erythematosus Response Criteria for, 2007).
The FSS demonstrates good psychometric properties (Cronbach's α= 0.89 and test-retest
reliability 0.84). A final score is obtained from the mean of all scored items, with higher scores
revealing higher severity of fatigue. Presence of clinical levels of fatigue was defined by a FSS
score >3. The scale has proved to be sensitive to change and reliable for telephone interviewing.
The FSS has also been shown to be reliable across different patient populations (Johansson,
Kottorp, Lee, Gay, & Lerdal, 2014).
Hospital Anxiety and Depression Scale (HADS)
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The Hospital Anxiety and Depression Scale (HADS) is a self-rating scale with good
psychometric properties (Cronbach's alpha coefficients of 0.94), designed to measure anxiety and
depression in physically ill individuals (Zigmond & Snaith, 1983). Translated and adapted for
Portugal(Ferreira, 2000; Pais-Ribeiro et al., 2007), it is subdivided in two subscales of 7 items
that measure independently anxiety and depression. The partial result of each scale varies
between 0 and 21. Scores ranging from 8 to 10 are considered mild, from 11 to 14 moderate and
15 to 21 severe(Marcolino et al., 2007) and the authors suggest 8 as the cutoff point, considering
values below as indicating the absence of anxiety and depression (Zigmond & Snaith, 1983). It is
important to note that the scale is indicative of depressive symptoms in the last week, and not
necessarily clinical depression.
Pittsburgh Sleep Quality Index (PSQI)
This instrument presents good psychometric properties, with high reliability (Cronbach’s
alpha = 0.83) and validity. The seven components evaluated - sleep latency, sleep disturbances,
sleep duration, sleep quality, sleep efficiency, use of sleep medications and daytime dysfunction
allow the gathering of a global score varying from 0 to 21 (Buysse et al., 1989; Carpenter &
Andrykowski, 1998). The PSQI is reliable for sleep quality assessment in telephone interviews
and permits the identification of poor sleepers (score > 5) (Monk et al., 2013; Palmieri et al.,
2010).
Relationship Assessment Scale (RAS)
The RAS (S., 1988) (Portuguese experimental version from Mesquita, Barbosa, &
Figueiredo-Braga, 2014) is a 7 item instrument, with a five-point scale that measures general
satisfaction with the relationship.
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Statistical analysis
Significant differences in the demographical, clinical, and psychological variables
between the SLE subjects, healthy controls, RA subjects, and depressed control subjects was
determined using the independent t-test, Fisher’s exact chi-squared, Mann-Whitney U, Wilcoxon
rank sum, or Welch’s tests when considered appropriate. Fisher’s exact chi-squared was used in
place of the standard chi-squared test, which would typically be utilized, this is due to the smaller
sample size of the groups compared. The statistical test used for the comparisons are indicated in
the table legends. Univariate analysis was accomplished by using generalized linear regression
with HADS depression scores as the dependent variable and the individual variable suspected of
showing a correlation to depression as the independent variable. Multivariant analysis was
performed using a generalized linear model. The best fit model was determined using the model
with the appropriate number of variables (less than or equal to 2 variables due to the small SLE
cohort) and the highest pseudo R2 value with the lowest approximate AICc value. In the
multivariate analysis, the HADS depression score for the SLE subjects was used as the
dependent variable. Statistical analysis was performed using the statistical software R and SPSS
(IBM). An alpha value less than or equal to 0.05 was considered significant in all analysis.

4.4 Results
In the study cohort, we investigated the prevalence and levels of multiple symptomatic
and clinical characteristics that are relevant to the lupus patients. by using several different
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Table 13. Sociodemographic of the Study Cohort
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groups as controls, we could identify potential indicators and factors that demonstrated
correlations with depression in the lupus subjects. By comparing the SLE patients to another
group of patients that have a similar chronic rheumatic inflammatory disease, in this case,
rheumatoid arthritis, similarities would help us understand what is a possible result of chronic
disease, and what is specific to lupus. When comparing the SLE patients to the healthy controls
we identify factors that are different from a healthy population and could be a result of
psychological or physical disease. Differences and similarities observed between the SLE
subjects help identify characteristics that are potentially strictly related to psychological or
physiological disease.
The study was comprised of seventy-seven Caucasian men and women with a mean age
of 48.38 ± 12.17 years. The sociodemographic information gathered about the cohort is
displayed in Table 13. Of the seventy-seven subjects, 15 were diagnosed systemic lupus
erythematosus patients, 21 were diagnosed rheumatoid arthritis patients, 20 subjects were
healthy controls, and 21 were individuals being treated for depression at a private psychiatric
clinic. The lupus patients had an average age of 49 ± 8.21 years. The arthritis patients had an
average age of 52.71 ± 11.17 years, while the healthy and depressed control subjects had a mean
of 43.95 ± 11.77 and 47.81 ± 14.8 years, respectively. There is some variability between the
mean ages of the groups, but it was not enough to be considered significant between any of the
groups (Table 13).
The level of education received based on years in school is similar for the SLE,
depressed, and RA subjects. However, the healthy control group has a higher percentage of welleducated members (p < 0.001). The distribution of marital status was similar for all the study
groups with the majority of subjects currently in a marital relationship. There were some slight
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differences in employment status between the cohort groups. The distribution between the SLE
and RA patients is similar, with 33% of patients from both groups currently employed, while the
healthy and depressed control groups had 70% and 62% of the study subjects currently
employed, respectively. The differences between the employment status of the study cohort
groups was not considered significantly different (Table 13).

Clinical manifestations
Table 14 and 15 contain the clinical and psychological assessment data from the cohort
with SLE patient data compared to all other control groups in Table 14 and logistical regression
comparison displayed from the SLE cohort in Table 15. The HADS depression score was used as
the dependent variable with only the indicated characteristic as the independent variable. The
SLE cohort had a mean disease duration of 17.80 ± 7.32 years, which was similar to the mean
duration of disease among the rheumatoid arthritis subjects, 17.57 ± 10.24 (Table 14). The mean
body mass index scores were fairly similar for all groups. It is important to note that the potential
confounding variables of smoking, drinking, and physical activity are similar between the groups
being compared in the study (Table 14). The SLE patients, not uncharacteristically, demonstrated
higher pain scores on average than all of the other groups with the median score being 7.0.
However, it was only significantly higher than the healthy control group (p < 0.001).
Interestingly the depressed control cohort, while lower on average than the SLE patients, was not
significantly different from the SLE patients. Further, univariate regression analysis found that
none of these characteristics showed direct correlation with depression among the SLE patients
(Table 15).
The SLE patients demonstrated typical levels of sedimentation velocity (mm/h),
leukocyte concentrations (109/L), and lymphocyte percentage. These measurements were similar
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Table 14. The Clinical, Laboratory, and Psychological Characteristics
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Figure 15. Cytokine serum concentrations differ between cohort subgroups.
SLE IL-6 and IL-10 serum concentrations are statistically higher than healthy subjects. RA
patients demonstrate slightly higher average serum levels of pro-inflammatory cytokines IL-6
and TNF-α. Depressed and SLE patients demonstrate slightly higher concentrations of IL-10 on
average than other cohort subjects.

between the SLE and RA subjects with no significant differences identified (Table 14).
However, RA patients had elevated levels of c-reactive protein compared to the SLE patients (p
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= 0.010) (Figure 11). This is normally the case and has often been seen when comparing SLE
and RA laboratory data (Keenan, Swearingen, & Yazici, 2008). Serum levels of Il-6, IL-10, and
TNF-alpha were measured for all subjects (Figure 15). The SLE patients exhibited increased
levels of both IL-6 and IL-10 compared to the healthy subjects (p = 0.038 and p = 0.016,
respectively). While there are some slight differences between the levels of IL-6, IL-10, and
TNF-α between the other groups, these differences are not significantly different. Univariate
regression analysis demonstrated a direct correlation between IL-10 levels and depression in the
SLE subjects (p = 0.036) (Table 15) (Figure 15). Aside from IL-10, univariate analysis did not
show any of the other characteristics being directly correlated to depression in the SLE cohort.

Psychosocial function
Of the subgroups of the cohort, the SLE subjects had the highest percentage with
moderate to severe depression as measured by the hospital anxiety and depression assessment.
Forty percent of the SLE patients demonstrated HADS depression scores above 10 (Table 14). In
fact, the SLE patients showed a 6-fold greater likely hood than the healthy control group to have
moderate or severe depression. The SLE patients had significantly higher depression scores than
the healthy control subjects (p = 0.007), but not higher than the depressed or RA subjects. Not
surprising either was the fact that the SLE subjects experienced higher levels of anxiety
compared to both the healthy controls and the RA patients (p = 0.020 and p = 0.011,
respectively). However, the depressed group had similar anxiety scores.
Upon examination of the quality of sleep that the study patients were receiving, as
recorded by the Pittsburg Sleep Quality Index (PSQI) assessment, the SLE cohort had a mean
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Figure 16. Clinical and Psychosocial Assessments differ between patient cohorts.
Measured serum levels of CRP are significantly higher in the RA patients compared to the SLE
subjects. SE patients demonstrate elevated HADS anxiety scores compared to healthy and RA
control cohorts. Further, SLE patients demonstrate decreased relationship assessment scale
scores, indicating lower relationship satisfaction.
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Table 15. Univariate Analysis of the SLE Cohort
index of 7.67 ± 3.06, which was higher than the healthy control subjects (p = 0.005). A higher
PSQI indicates a lower quality of sleep where as a higher quality of sleep is indicated by lower
scores. Normal PSQIs are reported being anywhere between zero and five. Any index above five
indicates poor sleep quality for the patient. In this case, the SLE cohort had 67% report poor
sleep quality based on the PSQI standard. This distribution of patients that experienced lower
quality of sleep is similar in the SLE cohort compared to the depressed, and RA subjects (Table
14).
All married and cohabitating cohort patients had their relationship satisfaction measured
based on the relationship assessment scale criteria. This scale provides a higher value based on
the patients perceived satisfaction with their significant other or spouse. Interestingly, the SLE
patients record having on average less satisfaction in their relationship than the averages
recorded for all the other subgroups, with a mean scale score of 24.75 ± 4.81 (Figure 11). This
score was significantly lower than both the healthy control and RA patients (p = 0.050 and p =
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Figure 17. Linear regression identifies clinical and psychological assessments that are
correlated with depression in SLE patients.
Univariate analysis found IL-10, relationship assessment scale, and fatigue severity scale values to
be correlated with depression in our SLE cohort. IL-10 and relationship satisfaction are negatively
correlated with depression while fatigue severity is positively correlated.
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0.015, respectively). This was a surprise considering that the RA patients, also suffering from a
chronic and debilitating autoimmune disease, had a mean relationship assessment scale score of
30.82 ± 5.69. It was also recognized that the reported scores for SLE patients from the
relationship assessment scale showed a distinct negative correlation with HADS depression
scores (p = 0.007) (Table 15) (Figure 17).
To measure the combination of both physical and mental fatigue that the patients were
experiencing, the fatigue severity scales was utilized. The assessment assigns a higher score the
higher the fatigue felt by the patient. The SLE patients reported a mean score of 4.6 ± 1.30 which
was similar to the arthritis patients who reported a fatigue score of 4.93 ± 1.62 (Table 14).
However, it was significantly more than the healthy control subjects (p = 0.002) (Figure 11). Of
interest, is the fact that the depressed patients did not have significantly lower fatigue than the
SLE subjects (p = 0.234). The distribution of those in the cohort that experienced heightened
fatigue was similar between the SLE and RA subgroups. In contrast, the SLE patients were
nearly 4.57 times more likely to have heightened levels of fatigue compared to the healthy
control patients. Further, a direct positive correlation was observed between fatigue severity
scale scores and depression levels in the SLE patients (p = 0.001) (Table 15) (Figure 17).

Multivariate analysis
Of the data collected from the clinical and psychosocial assessment of the SLE patients,
we investigated which characteristics correlated with depression could best indicate depression.
Due to the relatively small SLE cohort of this study, the model could not compensate for age or
socioeconomic status as would be appropriate for a larger cohort. However, it can still indicate
which variables among those identified in the study show the closest correlation with depression
among the patients and thus might be the best indicators of depression for the patients. Candidate
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variables that showed a direct correlation with depression or were significantly different from the
healthy control and arthritis patients, but not different from the depressed patients, were
considered for the multivariate model. Anxiety was not included as a candidate of for the
multivariate model due to the co-relatedness with the HADS depression score and because it was
derived from the same assessment as the depression score. Of the variables significantly different
from the healthy control subjects and correlated with depression in the univariate models, both
the fatigue severity (p = 0.028) and relationship assessment (p = 0.042) scales were indicated as
strong correlates and predictors of depression among the SLE cohort (Table 16).

Table 16. Multivariant model for SLE Study Cohort 2

4.5 Discussion
The study utilized the comparison of multiple control groups as well as linear regression
to identify potential indicators of depression in patients with systemic lupus erythematosus. The
multiple subgroups of the cohort used as controls allows unique comparisons with the SLE
subgroup. By considering what is similar between the arthritis patients and the SLE patients we
can understand what might be a result of a chronic inflammatory disease. With the depression
group acting as a control, indicating what factors could be the result of or related to
psychological illness. Taken together, the control groups offer a new perspective on factors that
could be relevant to depression in the SLE patients. As this is the first study of its kind to
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approach depression in an SLE population using these groups as comparison controls, it offers
credence to results gleaned from other studies.
Our results support other studies in that our SLE cohort had increased pain levels
compared to the healthy control cohort, but not to either the depressed or arthritis patients. This
offers support for the idea that pain and depression are strongly interwoven. Pain has often been
correlated with depression in past studies (Karol et al., 2013; Xie et al., 2016). While we did not
observe a direct correlation between pain and depression in the study, it is possible this could be
due to the small sample size of the SLE cohort.
We observed elevated levels of IL-6 in our SLE cohort compared to the healthy patients.
Increased levels of IL-6 in SLE and RA patients provides supporting evidence for past studies,
but it was surprising that they are not significantly different from the depressed cohort (Ishihara
& Hirano, 2002; Linker-Israeli et al., 1991). This is likely due to the large standard deviation in
the depressed patient cohort. While most depressed patients had levels like those observed in the
healthy control group, several had elevated IL-6 levels. We do not believe that IL-6 would be a
good indicator of depression as nearly all of the depressed patients display relatively normal
levels of IL-6 and there was no direct correlation observed between. Also, we did not observe
any correlation with TNF-α and depression in the SLE cohort. TNF-α serum concentrations,
while certainly higher on average in SLE and RA patients, was not significantly different than
those levels observed in the healthy and depressed subjects. This is different than was observed
in a study conducted by Postal and associates who recorded a direct correlation between TNF-α
serum concentrations and depression and anxiety as measured by the Beck Depression Inventory
(BDI) (Postal et al., 2016). However, their study had a larger SLE study cohort, measured
depression using a different depression and anxiety assessment, and utilized spearman
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correlation to determine statistically significant correlation relationships. While we did not
observe the same trend, this could be due to a variety of differences between the studies.
The study suggests a negative trend associated with IL-10 and depression, where
decreasing levels of IL-10 predict a higher risk for depression. Of the clinical data collected, IL10 results were of great interest. The SLE cohort displayed increased serum concentrations of IL10 compared to the healthy control subjects. However, the IL-10 levels measured from our SLE
patients were actually lower on average than those measured from our depressed subjects,
although the difference in IL-10 concentrations was not significant. It is still unclear if IL-10 is
related to depression as there are conflicting reports in the literature with regard to human studies
(Hiles, Baker, de Malmanche, & Attia, 2012). It has been observed in animal models that IL-10
imbalance does affect depressive behaviors (Mesquita et al., 2008). Also, in studies involving
SLE patients it has been observed that heightened levels of IL-10 are likely correlated with
depression and neuropsychiatric disorders (Efthimiou & Blanco, 2009; Svenungsson et al.,
2001). In a recent animal study using MRL/lpr mice, they found that they developed depression
like behavior before developing autoantibody titers. What is more, these mice had differing
levels of various cytokines including IL-10, suggesting that these imbalanced levels might be
good biomarkers for neuropsychiatric SLE (Y. Li et al., 2015). The SLE study cohort
demonstrated a direct correlation between depression and IL-10, adding evidence that levels of
IL-10 might be a good candidate as a clinical predictor for depression in SLE patients.
The SLE patients presented elevated anxiety scores, significantly more than the healthy
and arthritis subjects. This supports observations of other studies (Mak et al., 2013). Anxiety
scores, although slightly higher on average in the lupus patients, were not drastically different
from the depressed patients. These results indicate that the increased levels of anxiety are not
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likely due to chronic inflammation or disease etiologies that are similar between SLE and RA.
More research is certainly necessary to corroborate these findings and help narrow down the
potential factors involved in causing the high incidence of anxiety observed in lupus patients.
Unique to this study was the correlation observed between relationship assessment scale
(RAS) and HADS depression scores. It is of interest that the SLE patients have the lowest
average RAS score between all the subgroups in the study, significantly lower than the healthy
and arthritis patients. In addition, the RAS scores reported from the SLE patients were
significantly correlated to depression in the univariate and multivariate analysis (Table 15 & 16).
This is the first study to the knowledge that demonstrates a strong correlation between the
relationship assessment scale score and depression. While a large quantity of studies have
observed that quality of life is negatively affected in SLE patients and is correlated with
depression, none have utilized the relationship assessment scale to quantify relationship
satisfaction. The finding that the RA patients have high relationship satisfaction indicates that it
is likely the psychological symptoms of lupus that affect the relationship rather than the physical
limitations of chronic disease. The directionality of the correlation is still unknown, is it that
depression that is so common among SLE patients results in lower relationship satisfaction? Or
is it that due to disease conditions, relationship satisfaction decreases and contributes to factors
causing depression? Whatever the case may be, this study provides evidence that depression and
relationship satisfaction show a correlation in the SLE patients.
A final relationship that we observed in the study was between the fatigue severity scale
and depression in the SLE patients. Markedly higher in the SLE patients than in either the
healthy or arthritis subjects, the fatigue severity scale shows correlation with depression in both
the univariate and multivariate analysis (Table 15 & 16). Studies have shown that fatigue is
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typically higher in SLE patients that in the general population(Wiseman et al., 2017; YilmazOner et al., 2016). Multiple studies have also observed that there is a correlation between fatigue
and depression among lupus patients. In a recent cross-sectional study of Chinese SLE patients,
it was observed that higher levels of fatigue predicted higher risk of depression(Xie et al., 2016).
Our results support the findings from other human studies, that fatigue is highly correlated to
depression in SLE populations (van Exel et al., 2013). With such a high prevalence of fatigue in
SLE patients, up to 76 % reported by some studies, the necessity for improved management of
fatigue in SLE patients seems paramount to helping prevent and/or improve patient care and
quality of life(Ahn & Ramsey-Goldman, 2012; Morris et al., 2016). Unfortunately, most of the
factors that contribute to fatigue in SLE patients have yet to be identified, making treatment of
fatigue along with other symptoms quite challenging. There is evidence implicating increased
levels of proinflammatory cytokines, oxidative and nitrosative stresses, mitochondrial
dysfunction, and increased activation of toll-like receptors via pathogen and damage associated
molecular patterns as causes for increased stress in patients with chronic fatigue (Maes, Kubera,
Leunis, & Berk, 2012; Morris & Maes, 2013, 2014; Perl, 2013). Poor sleep quality can
contribute to fatigue as well (Inoue et al., 2017). In this study we found the SLE cohort to have
higher PSQI values, indicating poor sleep compared to the healthy control group, but these
values were not significantly different from the arthritic and depressed patients. These results
suggest that the sleep quality of SLE patients, while not good, do not likely contribute directly to
depression. For the time being, treatment of fatigue remains an obstacle for patients and health
care professionals to continue surmounting in tandem.
In summary, the study has proffered further evidence supporting various other SLE
studies indicating correlator relationships between IL-10 serum concentrations, anxiety, fatigue
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severity scale and depression. In addition, this research cohort has identified a negative
correlation between relationship satisfaction, utilizing the relationship assessment scale, and
depression. This research emphasizes the need for more research into predictors of depression
and improved treatment options for fatigue in SLE patients.
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Chapter 5: Concluding Remarks and Future Directions

This work highlights several key factors that potentially influence systemic lupus
erythematosus disease progression. First, our studies have confirmed recent findings of several
indicators of depression and anxiety in SLE patients, as well as providing evidence for several
psychosocial tests that might better indicate depressive behavior in patients that could be utilized
by care providing personnel. This research provides evidence for several clinical variables that
can be measured and potentially used to indicate the presence of the neuropsychiatric disorder of
depression. Finally, our studies have identified that EBV does indeed regulate EBI2 in human
naïve B lymphocytes and that it does this through the viral gene product Na. Additionally, we
postulate how this likely contributes to disease onset and immune system mis-regulation.

5.1 Effects of Epstein-Barr virus on B Lymphocyte Chemotactic Receptor EBI2
Expression via Viral BRRF1
EBI2 is vital in B lymphocytes for the detection of 7α,25-OHC and the subsequent
migration to peripheral areas of secondary lymph tissue (Cyster, 2010). In murine models it has
been found that when EBI2 is not expressed in B lymphocytes, they remained in follicle centers,
failing to migrate to other areas of secondary lymph tissue (Pereira et al., 2009). Further, in that
same study they observed that when wild type murine B cell EBI2 expression was antagonized,
their participation in germinal centers was impaired. Another murine study found that
upregulation of EBI2 in B lymphocytes had the outcome of increasing B cell proliferation
(Benned-Jensen et al., 2011). As with the regulation of many genes, EBI2 expression, impaired
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or overexpressed, likely results in mis-regulation of B lymphocytes affecting chemotaxis,
germinal center formation, and proliferation.
Our study has demonstrated that EBV modulates EBI2 expression during viral infection
of naïve B lymphocytes and that EBI2 is only upregulated beyond normal levels of expression
upon infection with active EBV. In addition, we have identified that the EBV gene product Na is
necessary and sufficient alone to induce expression of EBI2 in human naïve B lymphocytes
(Cornaby et al., 2017).
Understanding that by adulthood, nearly 90% of any given human population has been
infected with EBV, it is of interest to know how the modulation of EBI2 by EBV affects the
immune systems of the majority of the human race. We have proposed that the regulation of
EBI2 in EBV infected B cells results in these cells spending extensive amounts of time in the
peripheral areas of secondary lymph tissue. While it is unknown exactly how this would benefit a
virally infected B cell, we hypothesize that such positioning of infected B lymphocytes might aid
in immune evasion. However, the effects of EBI2 upregulation and subsequent down regulation
in B lymphocytes days later might have effects that have yet to be recognized as important for
the viral life cycle. We suspect that increased time in the peripheral regions of secondary lymph
tissue might provide increased risk of activating B cells by self-antigens that typically would not
induce B cell activation because of the brevity of B lymphocyte presence in peripheral secondary
lymph tissue.
Future research into these hypotheses and assumptions is certainly necessary to provide
clarification. The mechanism by which EBV regulates EBI2 would be important to understand.
Does the virus directly modulate EBI2 utilizing the BRRF1 gene product Na to induce
expression? Or is there a more complex pathway involved? A Chromatin Immunoprecipitation
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(ChIP) assay could be used to confirm or exclude the former hypothesis and would likely be the
next logical step in whittling down this question. ChIP is a type of protein foot printing assay
where you first fix the cell with formaldehyde, lyse the cells, digest the DNA that is not bound
by the protein, harvest the protein of interest using a protein specific antibody, separate the
remaining DNA from the protein of interest, and sequence it. This could be done for BRRF1 to
determine what DNA site(s) the gene product Na recognizes.
Since we already have lentivirus constructs containing the gene BRRF1, it would not be
necessary to infect human B lymphocytes with EBV, just transduce them with the lentivirus
containing BRRF1, pUltra+BRRF1. In our studies we have been able to produce high titer
lentivirus stocks that have been able to transduce 20 to 50 percent of naïve B lymphocytes.
Seeding a plate with about 2x106 to 4x106 B lymphocytes and then transducing them with
pUltra+BRRF1 should generate cells containing enough Na to isolate using Na specific
antibodies, the appropriate bead congregated antibodies, and a magnetic bead isolation column
post formaldehyde fixation, cell lysis, and sample treatment with Micrococcal Nuclease.
Another possible research objective would include confirming that increased EBI2
expression results in increased cell migration following the 7α,25-OHC gradient that is present in
secondary lymph tissue. Our lab has tried these studies using naïve B cells overexpressing EBI2
in trans-well migration plates, however, naïve B cell migration was very poor, even for the
positive control. Thus, if there was an increase in migration, this method was not sensitive
enough to detect it due to the lack of naïve B cell migration using these trans-well migration
plates. Another method would be to use a different type of B cell overexpressing EBI2, either
primary cells or a specific B cell line.
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It would be preferable to use primary human B lymphocytes, however, there are various
B cell lines that would likely work well including LCL, Raji, and Ramos, as all these cell lines
express little EBI2. Since all B lymphocytes are susceptible to infection by EBV, any mature
primary B cells should also work well. A good general protocol for mature B cell isolation and
measurement of chemotaxis via transwell migration plates (Costar) is outlined by Corcione et al.
in their work demonstrating that mesenchymal stem cells modulate B-cell activity (Corcione et
al., 2006). In short, isolated B lymphocytes could be transduced with our already functional and
tested lentiviruses that contain EBI2 or EBI2 siRNA. This would allow for EBI2 overexpression
or silencing in the transduced cells. Upon transduction with the lentivirus about 5x105 isolated B
lymphocytes would be seeded to the upper chamber of each well. Chemotaxis would be observed
in response to various chemokines including CXCL13, 7α,25-OHC, and CCL21. Cell migration
to the lower well would be measured via flow cytometry and transduced cells, with
overexpressed or silenced EBI2, could be identified as all the lentivirus vectors contain eGFP
reporters. EBI2 overexpression and silencing conditions in mature B lymphocytes could be
compared to control conditions to determine if increased EBI2 results in increased chemotaxis as
hypothesized. Further, mature B lymphocytes could also be transduced with pUltra+BRRF1
which also increased EBI2 expression due to BRRF1 expression, these treated cells could also be
utilized in the transwell migration assay as further verification that BRRF1 induces EBI2 and
affects B cell migration.
An additional option would be to use another tool to measure migration, such as visual
analysis of cellular migration in a gap closer assay. In this assay cells are placed on one point of
a slide and the chemokines at another. Using a microscope to record and software to track cell
movement, it can be used to quantify the rate cells move and the number of cells that migrate in
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response to chemokines. This assay might even be more sensitive to subtle changes in cell
migration as you are able to accurately count individual cells during the assay. To perform this
assay transduced cells overexpressing EBI2 or with EBI2 expression silenced would need to be
sorted from non-transduced cells using the FACS cell sorter.

5.2 Depression in Patients with Systemic Lupus Erythematosus
Depression in patients with chronic diseases is strongly associated with poor clinical
outcomes, as well as higher health costs (Julian et al., 2009; Panopalis et al., 2008). The
recognition of neuropsychiatric disorders in systemic lupus erythematosus patients and the
appropriate treatment of these disorders has been shown to improve clinical end points, decrease
perceived pain, and improve the overall quality of life (Katon et al., 2010; E. H. Lin et al., 2003).
These observations emphasize the importance of better understanding the biological mechanisms
involved in neuropsychiatric disorders in SLE patients and improve accurate diagnosis of these
disorders.
This being the case, it is necessary to identify potential clinical or psychosocial variables
that might denote neuropsychiatric disorders in our patient population. Clinical variables in
particular would be useful as regular visits to a clinician or rheumatologist along with regular
clinical tests is common for SLE patients and necessary to insure proper medical care. Various
potential biomarkers for depression have been suggested including: IL-2, IL-6, IL-8, IL-10,
TNF-α, and INF among others (Efthimiou & Blanco, 2009). A recent murine study found that
NP-SLE mice exhibited increased levels of IL-10, Haptoglobin, CXCL-10, Lymphotactin, CCL19, CCL-2, CCL-7, CCL-12, VCAM-1, CD-40, IL-1β, and FGF-basic (Y. Li et al., 2015).
Several studies, previously published, looking into this question have found that depression in
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SLE patients is correlated with some of these biomarkers. A study conducted in Sweden found
that TNF-α, INF-γ, and IL-10 were significantly higher in NP-SLE patients (Svenungsson et al.,
2001). Additionally, another study conducted by researchers at Duke University Medical Center
identified low complement levels and ds-DNA concentrations to be associated with depression in
SLE patients (Karol et al., 2013).
Our studies, contained in chapters 2 and 3, conducted with collaborators at the University
of Porto, Instituto de Investigação e Inovação em Saúde, and Hospital of São João EPE, found
several clinical variables demonstrate a correlation with depression in SLE patients. Univariate
analysis revealed during these studies that pain, total complement, BMI, and IL-10 showed
correlation with depression in our SLE patients. While other suggested variables that were
recorded did not, such as IL-6, TNF-α, SV, CRP, lyeukocyte count, lymphocyte percentages, and
anti-dsDNA antibodies among other clinically relevant measurements. These results provide
evidence that IL-10 and complement might be ready indicators of depression in SLE patients.
Further research is necessary to better understand how well recorded levels of these biomarkers
correlate to neuropsychiatric disease progression and severity. It would be particularly good to
conduct studies with more longitudinal scope, allowing for the measurement of biomarkers over
time to determine their sensitivity and accuracy.
A quandary of interest to those involved in researching depression among SLE patients is
if the increased prevalence of depression and anxiety is due to chronic inflammation or unique to
lupus pathophysiology. Several studies have investigated the association of SLE disease severity
with depression to shed some light on this dilemma, however, there seems to be conflicting
evidence as some studies found that disease severity was correlated with depression among SLE
patients while others did not (Karol et al., 2013; van Exel et al., 2013). Our cohort study sought
171

to investigate this question of interest by including a group of RA patients to compare alongside
our SLE, healthy, and depressed patients. We found depression scores to be higher in our SLE
patients and to have higher prevalence when compared to the RA patients. Further, anxiety
scores were also higher and more prevalent among SLE patients compared to RA subjects.
However, these scores were not drastically different from our subjects being treated for
depression. These results would indicate that it is not just chronic inflammation responsible for
depression in SLE patients. Certainly, more research is necessary to clarify this question further
and isolate what factors specifically are responsible for the increased prevalence of depression
and anxiety in SLE patients.
In the future, it would also be interesting to investigate if biologics influenced depression
in patients with lupus, and if certain treatments had stronger associations with depression
prevalence. The understanding of which treatment types could lead to neuropsychiatric disorders
would allow physicians to monitor their patient’s mental health and better anticipate potential
problems.
Outlining several factors involved in SLE disease activity, this work provides a foot hold
for future research that can continue to elucidate disease pathophysiology. It is predicted that
investigations into these topics can help identify key ways to continue improving care for SLE
patients and increase our understanding of the biology responsible for the pathophysiology of
SLE.
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a b s t r a c t
While a variety of factors act to trigger or initiate autoimmune diseases, the process of epitope spreading
is an important contributor in their development. Epitope spreading is a diversiﬁcation of the epitopes
recognized by the immune system. This process happens to both T and B cells, with this review focusing on B cells. Such spreading can progress among multiple epitopes on a single antigen, or from one
antigenic molecule to another. Systemic lupus erythematosus, multiple sclerosis, pemphigus, bullous
pemphigoid and other autoimmune diseases, are all inﬂuenced by intermolecular and intramolecular B
cell epitope spreading. Endocytic processing, antigen presentation, and somatic hypermutation act as
molecular mechanisms that assist in driving epitope spreading and broadening the immune response in
autoimmune diseases. The purpose of this review is to summarize our current understanding of B cell
epitope spreading with regard to autoimmunity, how it contributes during the progression of various
autoimmune diseases, and treatment options available.
© 2014 Elsevier B.V. All rights reserved.

1. Introduction
In many immune responses, the initial antigens, and epitopes of
those antigens (Ag)s, that are recognized by the adaptive immune
system are limited. Over time, the T and B cell response can grow
to include many other epitopes and even additional antigenic
molecules. This process is known as epitope spreading. This process is an important contributor to the efﬁciency and breadth of the
immune system. However, epitope spreading is also implicated in
multiple autoimmune diseases [1,2]. Epitope spreading is known
to be a major component of systemic lupus erythematosus and
bullous pemphigous, and is implicated in multiple other autoimmune diseases ranging from multiple sclerosis to diabetes (Table 1).
In B cell epitope spreading, the antibody (Ab) speciﬁcity develops
from the initial Ag that triggered the response to include other epitopes of these Ags, or other Ags altogether. B cell epitope spreading
can potentially occur through many mechanisms, including interactions with T cells, endocytic processing of antigens, and somatic
hypermutation in the B cell.
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The contribution of epitope spreading in the progression of
autoimmune disease was ﬁrst recognized in print during the study
of experimental autoimmune encephalomyelitis (EAE) in Lewis rat
and mouse models [3,4]. In these studies it was found that rats and
mice immunized with Myelin oligodendrocyte glycoprotein (MOG)
induced a T cell encephalitogenic and B cell Ab immune response
resulting in demyelination. During this study it was demonstrated
that the antigenic targets of the Abs changed and diversiﬁed during
the course of EAE. It was later shown that epitope spreading was
the cause of the Ab diversiﬁcation. We now understand that B cell
epitope spreading assists in the progression of many autoimmune
diseases, acting as a two edged sword for many that are affected
by autoimmune diseases [1,2]. Epitope spreading is essential for an
effective adaptive immune response, at the same time contributing to the progression of self-targeting disorders. It is important to
better understand epitope spreading due to its inﬂuence in autoimmune progression and the potential to develop more advanced
strategies to assist in the treatment and prevention of autoimmune
diseases.
While much research has been done to determine the significance of T cell epitope spreading in disease, far less is known
about B cell epitope spreading. This review will address B cell
epitope spreading and its involvement in the progression of
various autoimmune diseases. The current understanding about
factors contributing to B cell epitope spreading and intracellular
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Table 1
Compiled evidence implicating B cell epitope spreading in various autoimmune diseases. The autoimmune diseases are listed with the completed cumulative research that
provided provocative evidence for B cell epitope spreading. It is speciﬁed for each evidenced example of epitope spreading a sentence summary of the example, what type
of experiment was performed to obtain the data, the type of epitope spreading involved, and the reference for that example.
Disease

Evidence of epitope spreading

Reference

Type of experiment

Type of B cell epitope
spreading

Bullous
pemphigoid

Ab diversiﬁcation to epitopes of BP180 and BP230

[108,130]

Clinical study

Heymann nephritis
Multiple
sclerosis
Pemphigus

Ab spread from collagen XVII to collagen VII
Bullous pemphigoid develops after pemphigus foliaceus
Immunization with CC2 peptides induces EAC, then DCM
Diversiﬁcation of Abs to include ICA, GADA, IA-2, and IAA
Ab diversiﬁcation from thyroglobulin AA2471-2490 to other epitopes
Intramolecular epitope spreading on TSHR protein molecule
Ab diversiﬁcation on the TSHR protein molecule
Ab spreading to various epitopes on Megalin protein
Ab spreading from MOG peptide 92–106 to intramolecular epitopes
PLP Abs spread to target other myelin proteins
Ab diversiﬁcation to various regions of desmoglein 1 and 3

[109]
[13,14]
[91]
[56]
[6]
[78,79]
[80,81]
[94]
[60]
[52]
[100]

Clinical report
Clinical report
Lewis rat model
Clincal study
NZW rabbit model
BALB/c mice model
Transgenic mice model
Lewis rat model
RR-EAE mice model
EAE mice model
Clinical study

Rueumtoid arthritis
Scleroderma
Sjogrens syndrome

Development of paraneoplastic pemphigus from Lichenoid Dermatitis
Abs diversify from ACPA to include anti-CCP
Auto-Abs to differing centrosome domains were present in the same sera
Ab spread from Ro/SSA to La/SSB and to unimmunized epitopes of Ro/SSA

[101,102]
[46]
[85]
[71]

Clinical report
Serum collection analysis
Serum collection analysis
BALB/c mice model

Ab diversiﬁcation from 1.5 to 3 out of 7 auto-Ags screened
Ab spread from SmD to SmB and A-RNP molecules
Intermolecular more common than intramolecular epitope spreading

[65]
[66]
[7]

Serum collection analysis
A/J mice model
A/J mice model

Intramolecular and
intermolecular
Intermolecular
Intermolecular
Intermolecular
Intermolecular
Intramolecular
Intramolecular
Intramolecular
Intramolecular
Intramolecular
Intermolecular
Intramolecular and
intermolecular
Intermolecular
Intermolecular
Intramolecular
Intramolecular and
intermolecular
Intermolecular
Intermolecular
Intramolecular and
intermolecular

Cardiomyopathy
Diabetes (Type 1)
Graves’ disease

Systemic lupus
erythematosis

mechanisms involved in this process will be discussed. Areas for
future research and gaps in our understanding of B cell epitope
spreading will also be commented upon. The purpose of this review
is to provide a summary of our current understanding about B cell
epitope spreading mechanisms, involvement in autoimmune disease, and the importance of epitope spreading in treatment options.

2. Potential mechanisms of B lymphocyte epitope
spreading

destruction or it is delayed, relying on processing and presentation to achieve activated T cells that, through intrastructural T cell
help, activate reciprocal B cells. In ﬁne, the independent scenario
exists when there are environmental conditions such that T cells
can recognize cryptic, or novel, epitopes without the processing
and presentation by APCS, such as B cells and dendritic cells. The
dependent circumstance relies upon APC processing and presentation to T cells in order for the immune system to recognize cryptic
epitopes.

2.1. Types of epitope spreading

2.2. Intermolecular epitope spreading

There are two different types of epitope spreading, intermolecular and intramolecular [5]. The latter describes a type of spreading
where the immune response is directed against different epitopes
of the same molecule, while the former is a diversiﬁcation of the
immune response against two or more different molecules [6]. By
expanding the antigenic epitopes that the immune system recognizes, responses to these foreign Ags becomes optimized, allowing
for neutralization via Abs, recognition by various immune cells, and
clearance of the pathogen.
Intermolecular epitope spreading is not dependent on intramolecular epitope spreading [7]; rather these different types of
epitope spreading are independent of each other. Diversiﬁcation
takes place only after Ag recognition by cells of the immune
system. B cell activation by CD 4 + T cells or by surface clustering immunoglobin bound to the speciﬁc Ag epitope initiate this
process. Through clonal expansion and afﬁnity maturation, the
spreading of epitopes for a given Ag expand and continue to
broaden the longer the immune response continues. It has been
shown that there are two ways to initiate B cell epitope spreading in
autoimmune diseases. McCluskey et al. describe the ﬁrst to be independent of a physical association with immune cells presenting
the Ag, while the second is dependent [1]. In an Ag presenting cell
(APC) independent scenario, inﬂammation and activation cytokines
are sufﬁcient enough to allow T cells to recognize cryptic epitopes
and activate complementary B cells. This is observed in non-obese
diabetic (NOD) and EAE animal models [8]. On the other hand,
a dependent response happens typically when there is no tissue

Many of the Ags recognized in autoimmune diseases are part of
multi-antigenic complexes. For example, the splicesome is a common target for autoAbs in lupus, and consists of multiple proteins
and nucleic acids that are associated with each other. T cells speciﬁc for one epitope of a multi-antigenic complex can activate B
cells that are speciﬁc for other Ags of the complex [9]. T cell help
allows B cells to target a range of Ags to proliferate, differentiate,
and produce Abs, even against Ags that were not originally involved
in either the B cell or the T cell response [10,11].
An experimental example of this concept was illustrated by
Deshmukh et al. during their study of Systemic Lupus Erythematosus [7]. To induce lupus-like symptoms in a mouse model,
female A/J mice were immunized with various SmD peptides. This
stimulates an immune response against the small nuclear ribonucleoprotein (snRNP) complex that is characteristic of systemic
lupus erythematosus. Immunoprecipitation assays were used to
determine Ab reactivity to SmD, SmB, and associated ribonecleoprotein (A-RNP) molecules. It was found that immunization with
the SmD52–66 lead to the development of Abs against not only
regions of the SmD protein, but also to the U1 A-RNP. The Ab diversiﬁcation from the SmD protein to the A-RNP is a demonstration
of intermolecular epitope spreading. During their study of viral
triggers leading to SLE, Poole et al. observed a similar example
of intermolecular epitope spreading [12]. Immunization of rabbits
with the protein peptide PPPGMRPP from Epstein–Barr virus (EBV)
protein EBNA-1, lead to the development of antibodies to SmB,
SmD, nRNPs and La/SSB.
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Clinical studies and reports continue to provide evidence for this
process. Maeda et al. described a case where a 64 year old Brazilian male developed bullous pemphigoid twelve years after being
diagnosed with pemphigus foliaceus [13]. He was diagnosed with
bullous pemphigoid when subepidermal blistering was observed
and immunoblotting assays revealed Ab activity against BP180.
A congruous event was recorded by Peterson et al. where they
observed similar results from a 86 year old African American male
[14]. This development of bullous pemphigoid after pemphigus
foliaceus is a clinical manifestation of intermolecular spreading.
Autoimmune targets resulting in pemphigus foliaceus are typically
desmoglein proteins, particularly desmoglein 1. The cause of bullous pemphigoid is an autoimmune reaction against several bullous
pemphigoid proteins (BP180 and BP230) of the hemidesmosome. In
ﬁne, the incidences reported above indicate an intermolecular epitope spreading event from the desmoglein proteins to the bullous
pemphigoid proteins.
It does not take a large variety of T cells to drive a diverse B cell
response leading to intermolecular epitope spreading. An example
of this was shown by Milich et al. in using mouse T cells primed for
the Hepatitis B nucleocapsid to invoke an immune response against
the Hepatitis B virus. The result was Ab production against Hepatitis B surface Ags [15]. This demonstrates CD 4 + T cells speciﬁc
for priming recognition of just one region, leading to an immune
response that diversiﬁed to include the surface Ag and nucleocapsid Ag of Hepatitis B. Intrastructural T cell help is necessary for B cell
epitope spreading to elicit an immune response against pathogens
and contributes during development of immune diseases [16,17].
2.3. Intramolecular epitope spreading
After B cells are activated in response to Ag and T cell stimulation, they respond by progressing through clonal expansion and
afﬁnity maturation. Upon processing of the Ag, these cells can in
turn present novel cryptic epitopes to CD 4+ T cells in the context of
MHC class II molecules. Cryptic eptitopes are understood to be epitopes that were previously un-recognized by the immune system.
These cryptic epitopes allow for the priming of reciprocal T cells
and the activation of complementary B cells. This process allows
the immune response to recognize various epitopes from the same
molecule, or associated molecules, and thus contributes to epitope
spreading. Afﬁnity maturation allows for selection of the clonally
expanded B cell population for those cells that have a higher afﬁnity
for the Ag. Because of this selection, intramolecular epitope spreading can occur as B cells with higher afﬁnity for a different epitope
of the Ag are selected [9].
Endocytic processing and the subsequent MHC class II presentation is a further mechanism that can promote intramolecular
epitope spreading. During endocytic antigen processing the antigen is endocytized, selectively cleaved and loaded into a compatible
MHC class II complex that is then displayed on the cell surface.
This process allows for presentation of previously unrecognized
epitopes and the broadening of the immune response to various
epitopes on the endocytized molecule (Fig. 1).
A clinical study of pemphigus foliaceus in Brazil provided
evidence that intramolecular epitope spreading contributes to
autoimmune disease development [18]. Sera from patients were
collected pre-disease onset and while the patients were exhibiting clinical symptoms of skin lesions. Using immunoprecipitation
assays to analyze the sera from the patients, several interesting
observations came to light. Patients still in the pre-clinical phase
of the disease developed Abs for the COOH-terminus region of the
desmoglein 1 protein. During the study several patients progressed
from the pre-clinical phase to the clinical phase of the disease.
Testing of the serum during clinical onset of pemphigus foliaceus
revealed Abs against the EC1 and EC2 domains of the NH2 terminal

Fig. 1. Intramolecular B cell epitope spreading. (A) Once activated through T cell
intrastructural help or (B) clustering of the BCRs attached to a speciﬁc epitope on
the Ag, B cells endocytise the Ag, selectively cleave it, load selected peptides in MHC
II molecules and display it in this context to T cells. Once a T cell is activated by
the B cell for a new epitope presented via MHC II, it can then activate a reciprocal B
cell which will then express Abs speciﬁc for that epitope. This process is known as
intramolecular B cell epitope spreading.

region of the desmoglein 1 protein. Another example is presented
by Poole et al. In a serum analysis study of SLE patients collected at
the Oklahoma Clinical Immunology Serum Repository, it was found
that intramolecular epitope spreading occurred during the progression to SLE [19]. Using autoantibody analysis of the extensive serum
samples, it was observed that antibody diversiﬁcation happened
over time during disease progression to various epitopes on the
nRNP-A and nRNP-C proteins. Anti-nRNP-A antibodies were found
to bind to the N-terminus of the protein more frequently in later
samples when compared to the initial samples. This diversiﬁcation
of Abs from one region of the protein to the other region demonstrates intramolecular epitope spreading and provides evidence of
the role it plays in the progression of autoimmune disease.

2.4. Molecular mimicry and cross-reactivity
B cell epitope spreading after molecular mimicry is a mechanism
by which the body likely begins to break self-tolerance, leading to
the development of autoimmune disease. Molecular mimicry has
been indicated as a contributing factor in autoimmune diseases
such as type I diabetes [20], rheumatoid arthritis, multiple sclerosis,
glomerulonephritis [21], and systemic lupus erythematosus.
Molecular mimicry exists when an auto-Ag is similar enough to
an antigen from a pathogen or other environmental source that Abs
generated against the pathogen will also bind to the autoantigen
[21]. Cross-reactivity is a phenomenon that occurs in the immune
system when a single Ab reacts with multiple Ags varying in structure and composition. The immunochemical evidence in recent
literature suggests that conformation as well as structure is essential for an effective Antigenic mimic [22]. This was demonstrated
by Mariuzza et al. at the University of Maryland when they showed
that the anti-idiotopic Ab E5.2 was a mimic for lysozyme in the way
that it bound to D1.3 [23]. Mariuzza’s group further showed that it
was a binding group mimic and shared no homologous sequence
between the Ag and Ab E5.2 [24]. These ﬁndings veriﬁed that the
binding of Abs is not determined by amino acid sequence alone,
but by the conformation of the epitope to which it binds. While
certain amino acid sequences tend to display select conformations
and structures, there is variability due to protein folding, molecular interaction, and binding. These ﬁndings indicate that an Ag, or
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auto-Ag, does not need to share homologous amino acid sequences
in order to be an effective mimic.
The mechanisms of molecular mimicry and cross-reactivity are
thought to be key contributors in B cell epitope spreading. One
example of molecular mimicry was explored by Poole at al. in
experiments tying Epstein–Barr Virus (EBV) infection to the development of the autoimmune disease systemic lupus erythematosus
(SLE). The EBV nuclear Ag-1 (EBNA-1) contains a peptide sequence,
PPPGRRP, that closely resembles the PPPGMRPP region on the
Smith Ag (Sm) targeted by autoAbs in SLE patients. Immunization
with the PPPGRRP sequence from EBNA-1 lead to development of
cross-reactive antibodies that recognized both epitopes, as well as
further epitope spreading leading to autoimmunity against Sm and
nRNP complexes. Also, 5 out of the 6 rabbits immunized developed
SLE like symptoms over the course of the experiment indicating
that the mechanism of molecular mimicry involving EBNA-1 can
lead to development of systemic lupus erythematosus-like disease
[25]. Clinical evidence shows similar results with respect to the
spreading of epitopes in SLE. After an individual loses tolerance for
60 kDa Ro/SSA and beings to produce Abs that speciﬁcally target
Ro/SSA, later blood samples reveal Abs against Sm B’, SmD1, nRNP
A and C, and eventually La/SSB [19].

3. Intracellular mechanisms of B lymphocyte epitope
spreading
3.1. Endocytic processing and Ag presentation
B cell endocytosis and Ag presentation to T cells contribute
to epitope spreading. Endocytosis takes place after Ag binding to
B cell receptors [26]. During this process of B cell endocytosis,
Ag processing and presentation determines what peptides will be
loaded into MHC class II molecules and displayed on the cell surface. This determines what epitopes will be presented to T cells,
ultimately identifying what epitopes should be targeted by the
immune system. There are various circumstances that affect this
processing.
The ﬁrst part of endocytosis to affect processing is the BCR to
which the Ag is bound [27,28]. Binding to the BCR can affect the
selection of epitopes presented to T cells [29], however, it is not
known exactly how BCR binding impacts processing of Ags and the
loading of class II MHC complexes [30,31]. Thanks to McGovern
et al. we now understand that the difference in Ag processing and
presentation is due to BCR signaling and not due to the signalinginduced changes in the biology of the cell [30]. It has been suggested
that stability between the Ag and the surface immunoglobin (sIg)
to which it is bound inﬂuences processing [32]. Another proposed
reason for the difference in the processing of Ags might be related to
targeting as a consequence of the sIg cytoplasmic tail, the Ig␣/Ig␤
associated chains, or both [33]. These various components of the
BCR play a role in internalization and processing, however, it is
unknown how they affect this process in detail. It has been demonstrated that Ig␣ and Ig␤ selectively target Ags to be loaded into
MHC II [34].
A second point of processing selection is due to the selective
cleavage of proteases contained in the lysosome. This selective
processing of Ag into smaller peptide fragments depends on
the proteases present in the lysosome, including their relative
concentration and activity which is regulated by various endogenous cytokines and competitive inhibitors [35]. These competitive
inhibitors vie with protein that is being digested, regulating what
proteases are more active in the cleaving of the endocytized Ag.
Cytokines can affect endocytic proteases by adjusting their activity, synthesis, or stability. Various cytokines have been shown to
affect the endosomal pH, increasing or decreasing the ability of
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protease activity [36,37]. In this way, cytokines can stimulate or
inhibit enzymes involved in Ag cleavage and degradation, affecting what peptide segments are available to be loaded into MHC II
complexes (Fig. 2).
A ﬁnal mechanism affecting the presentation of epitopes proposed is the loading of MHC II molecules. HLA-DM and the MHC
II complex load only peptides that have an appropriate length and
afﬁnity. Peptides need to display speciﬁc amino acid motifs to be
loaded [38]. Two other factors affecting this loading include endosomal environment, including pH, and the HLA-DM [39,40]. Age
of the individual is also a factor that affects cellular efﬁciency.
It is known that Ag presentation is better in younger individuals and declines with age [41]. Recycled and newly synthesized
MHC II molecules also play a role in selection. They are known to
associate with different peptides [42], thus levels of recycled and
newly synthesized MHC class II molecules could affect the peptides
selectively loaded. Many questions remain unanswered about peptide selection for MHC class II loading and Ag processing. Future
investigation include determining regulatory factors responsible
for endocytic compartment targeting to lysosomes in the endocytic
pathway and regulation of proteases in the cell, endogenous competitive inhibitors, and cytokines are other areas for research into
selective processing of Ag.
It has also been demonstrated that through endocytosis,
molecules that are associated together, non-covalently, can be presented in the context of MHC class II molecules as well [1]. The
event where an Ag and the associated molecule are processed
and part of the Ag associated molecule is presented via MHC II to
T cells has been termed intermolecular/intrastructural help [43].
Such processing leads to intermolecular epitope spreading. Understanding of these events in concert with B cell processing and
selection is essential for adequate comprehension of how and to
what extent epitope spreading contributes to the human immune
response, disorders, and diseases.
3.2. Somatic hypermutation
During afﬁnity maturation, B lymphocytes undergo somatic
hypermutation (SHM) which can contribute to the spreading of epitopes [9]. This process takes place in germinal centers to improve
B cell Ab afﬁnity for an Ag (Fig. 3). At this period of time SHM of the
IgV gene region experiences single nucleotide substitutions. These
happen at a frequency of about 10−3 per base pair in each B lymphocyte generation [44]. The consequence of SHM results in Abs with a
higher afﬁnity for the Ag presented by dendritic cells in secondary
lymphoid tissue during afﬁnity maturation. It has been suggested
that SHM also leading to B cell epitope spreading, contributes in
the progression of autoimmune diseases. Autoreactive Abs can be
generated against dsDNA through SHM in the development of systemic lupus erythematosus [45]. It is uncertain to what extent SHM
contributes to B cell epitope spreading. Investigating this question
and determining if SHM contributes to other autoimmune diseases
remains an area for future research that is lacking at this time.
4. B cell epitope spreading in autoimmune disease
4.1. Rheumatoid arthritis
The most common inﬂammatory arthritis worldwide, rheumatoid arthritis (RA) affects nearly 1% of the global population, and can
cause severe debilitation and joint deformity within the ﬁrst few
years of clinical symptoms due to joint inﬂammation and tissue
degradation [46–48]. While joint damage is the most characteristic and common symptom, the inﬂammation produced can also
affect organs such as the cardiovascular and pulmonary systems
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Fig. 2. The endocytic pathway is a primary mechanism in B cell epitope spreading. (A) The binding of the sIg to the Ag can affect the epitope that is selected for and loaded
into MHC II. (B) The endosome fuses with the lysome, containing GILT, cathepsins, and other proteases. These enzymes selectively digest the Ag into peptide segments. This
provides another point for selection of epitopes and the exclusion of others based on the cleavage sites. (C) With the disassociation of CLIP, peptides are selectively loaded
into the MHC II molecule based on amino acid motifs, pH, HLA-DM association, among other enodsomal environmental factors (D) Once these various selective processes are
accomplished the resulting epitope chosen is displayed via the MHC II on the surface of the cell. Because of the many factors involved, various peptides could be displayed.

[48]. Although the speciﬁc causes that lead to RA are unclear, it
is thought to be the result of interplaying genetic factors, environmental agents, and chance, similarly observed among other
autoimmune diseases. Certain Abs, including rheumatoid factor
and Anti-Citrullinated Protein Abs (ACPA) are important contributors to RA [47]. Rheumatoid factor is a high-afﬁnity autoAb
against the FC region of immunoglobulins [48]. These Abs often
develop years before clinical disease, preceding the development
of rheumatoid arthritis, with the number of targeted proteins
gradually increasing until the time of diagnosis [46,49,50]. Interestingly, increasing Ab targets correlate with increased inﬂammatory

cytokine levels [46] and the disease course of RA. ACPAs can be
directed against a multitude of targets [51]. This wide range of
targets arises because citrullinated proteins result when arginine
residues in proteins are converted to citrulline residues due to a
post-translational modiﬁcation by peptidylargenine deiminase, a
process that is not speciﬁc to a single protein [52].
Epitope spreading is seen in the development of the ACPA
repertoire. It is hypothesized that the neoAgs that result from citrullination could evoke an initial immune response, which then
develops into a polyclonal Ab response against the entire protein
or protein-complex due to epitope spreading [47]. This process

Fig. 3. Somatic Hypermutation (SHM) as a mechanism of B cell epitope spreading. After B cell activation in response to Antigenic detection, in secondary lymph tissue, B
cells produces large quantities of daughter cells through the process of clonal expansion. These daughter cells independently induce changes in the variable regions of the
immunoglobulin gene. These changes allow for a higher or lower afﬁnity binding to the Ag, higher afﬁnity binding B cells are selected for and proceed to produce various
classes of Abs while low afﬁnity binding cells are signaled to apoptose. Because of the induced mutation of the Ab variable region, it is possible to develop Abs that bind to
various domains on an Ag after the process of afﬁnity maturation and SHM.
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is restricted mainly to genetically susceptible individuals, and the
mechanism that triggers the initial citrullination is still unclear [47].
Additionally, the reason why a systemic loss of self-tolerance leads
to localized joint inﬂammation is also unclear [48].
An investigation into United States Armed Services personnel
clinically diagnosed with Rheumatoid Arthritis revealed unique
information about Ab development and epitope spreading during
the development of RA [46]. Using clinical Ab assays and a novel
multiplex autoAb assay, it was possible to process serum samples
obtained from the Department of Defense Serum Repository and
screen for various Abs unique to RA patients. The samples used
predated and preceded clinical symptoms and diagnosis of RA.
Upon analysis, it was noted that the Ab diversiﬁcation increases
with the progression of RA and occurs before the onset of clinical symptoms. ACPAs were observed prior to the development of
anti-cyclic citrullinated peptides (anti-CCP). These ﬁndings indicate
both intramolecular and intermolecular B cell epitope spreading
during the progression of rheumatoid arthritis. It is hypothesized
that this epitope spreading was initiated by B cells stimulated by
citrullinated ﬁbrinogen complexes [46]. These examples indicate
that B cell epitope spreading takes place during disease progression in rheumatoid arthritis and that citrullination of peptides
contributes to these epitope spreading events.
4.2. Type 1 diabetes
Type I diabetes (T1D) results when an autoimmune reaction
attacks and destroys the insulin producing beta cells of the pancreas. T cells speciﬁc for a number of diabetogenic auto-Ags are
responsible for the destruction of the pancreatic islet cells. T1D
is the most prevalent chronic disorder among children, and the
loss of glucose level homeostasis that results can cause polydipsia,
polyuria, weight loss, and potential complications of hypoglycemia
such as hypoglycemic shock [53].
Autoimmunity may ﬁrst be triggered against the B9-23 region of
insulin [53] and progression to overt disease is mediated by epitope
spreading to an array of beta cell Ags. It was shown that non-obese
diabetic (NOD) mice that lacked mature B cells could not develop
this autoimmunity, suggesting a crucial role of B cells in the mechanism of epitope spreading. In this experiment, two to three week
old NOD mice were transfused with naive T and B cells, or only naïve
T cells, and the T cell response to various beta cell Ags was measured
at four and ten weeks after transfusion. The TB NOD mice demonstrated progressive autoimmunity development to glutamic acid
decarboxylase (GAD), heat shock protein 277 (HSP277) and insulin
B-chain, while the T NOD mice showed no T cell response to any of
the beta cell Ags tested. Researchers showed that NOD mice B cells
have deﬁcient tolerance to auto-Ags, and are relatively resistant
to activation-induced cell death, which could explain why autoimmunity was able to develop [54]. In C57BL/KsJ db/db mice, it was
found that the retroviral p73 protein, a group-speciﬁc Ag, acts as a
molecular mimic of insulin [55]. It is speculated that presentation
of this retroviral Ag to T-helper cells may stimulate B-lymphocytes
producing the cross-reactive anti-p73 Ab, which also bind insulin
[55]. Once the initial self-tolerance to insulin is broken, epitope
spreading can contribute to the development of autoimmunity. The
currently proposed model is that an initial wave of activated T cells
causes B cell activation through T–B cell interaction and cytokine
release. This enhances the Ag presenting functions of the B cells,
causing them to capture and present beta cell Ags to T cells, causing
the expansion of T cell autoimmunity [54].
A clinical study further demonstrated epitope spreading as a
mechanism leading to disease progression and clinical diagnosis
[56]. During an average of 30 months, 25 volunteers at risk for
type 1 diabetes donated blood for analysis. These individuals were
classiﬁed as ‘at risk’ due to the detection of islet cell Abs (ICA),
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Glutamic acid decarboxylase Abs (GADA), islet cell Ab-2 (IA-2), or
insulin autoAbs (IAA). Serum samples obtained were tested for the
four Abs using speciﬁc Ab assays for ICA, GADA, IA-2, and IAA. Out
of the 25 at risk volunteers under observation, seven developed
clinical type 1 diabetes. All seven of these volunteers displayed
serological evidence of intermolecular B cell epitope spreading. One
patient, during pre-clinical T1D only displayed ICA in the serum. By
the end of the study the B cell repertoire had diversiﬁed to include
all four Abs. Other at risk volunteers not diagnosed with clinical
type 1 diabetes also displayed evidence of intermolecular B cell
epitope spreading [56].

4.3. Multiple sclerosis
An autoimmune disease of the central nervous system, multiple sclerosis results from the degradation of myelin proteins that
sheath the neurons. The demyelization is caused by the attacking
immune cells, particularly T and B cells, causing inﬂammation and
a subsequent autoimmune response. With the destruction of the
myelin sheath, biochemical electrical impulses from the brain are
not transmitted efﬁciently. A variety of symptoms result including: fatigue, pain, movement, coordination, cognitive, and visual
problems [57]. Citrullination, via peptidylargenine deiminase, is
thought to be caused by inﬂammation of target tissues and occurs
in many circumstances normally. Myelin basic protein (MBP) is
partially citrullinated in healthy brain tissue, but in those with
MS there is an increase of citrullination. It is hypothesized that
citrullination contributes to the progression of multiple sclerosis
[58]. AutoAbs derived during mouse model studies were between
two and 20-fold more reactive against citrullinated MBP compared to non-citrullinated MBP [52]. In addition, these autoAbs
were found to be reactive against epitopes derived from ␣Bcrystalline, the most abundant early gene transcript. Recent studies
have shown that development of B cells into tertiary lymphoid
tissue near CNS regions further contribute to the progression of
MS [59].
The essential role of B cell epitope spreading in MS was demonstrated clearly in SJL/J mice with remitting-relapsing experimental
autoimmune enchephalomylitis (RR-EAE) [60]. These transgenic
mice spontaneously develop RR-EAE affecting various central nervous system tissues and have a TCR speciﬁc for mouse myelin
oligodendrocyte glycoprotein (MOG) peptide 92–106. The study
showed that with the SJL/J mice, the endogenous B cells secreted
Abs for new epitopes besides the peptide sequence the T cells targeted. Their ﬁndings also showed that there was no spontaneous
EAE development in B cell deﬁcient mice and that B cells enhanced
the pathogenesis of EAE in the RR-EAE mouse model. The spreading
of the B cell repertoire to other MOG epitopes besides the targeted
amino acid sequence suggests that in EAE, the mouse model equivalent of multiple sclerosis, B cells are essential for the development
of the disease, with a likely role for epitope spreading [60].
A different study conducted using EAE mice models contributed
further to our understanding by showing that epitope spreading
was found to directly correlate with disease progression [52]. In
a mouse model, proteiolipid proteins (PLP) where used to induce
EAE. Various regions of these PLPs became targets for Abs, along
with the targeting of additional epitopes on other myelin proteins, both citrullinated and non-citrullinated. This is indicative of
both intramolecular and intermolecular B cell epitope spreading.
These results add credence to previous research demonstrating the
development of cryptic epitopes during disease development and
provides an explanation for why this occurs [61]. Epitope spreading
has been shown to lead to the development of multiple sclerosis in
mice during infection by Theiler’s virus [62], indicating viruses as a
potential trigger for the development of CNS autoimmune diseases.
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4.4. Systemic lupus erythematosus

4.5. Sjogrens syndrome

Systemic lupus erythematosus (SLE) is an autoimmune disease
caused by immune reacting with targets at diverse locations in
the human body leading to a variety of clinical manifestations. SLE
affects approximately 1 in every 2000 individuals with a 9:1 ratio
for female vs. male diagnosis respectively [63]. Auto-Abs in SLE are
often raised against double-stranded DNA as well as ribonuclearproteins (RNPs) of the Sm complex found in splicesomes [5,25,63].
This autoimmune response causes an accumulation of immune
complexes and immune-mediated attack of various organs. Symptoms of SLE include: butterﬂy rash, chest pain, sensitivity to light,
joint pain, and kidney damage [9,64].
Arbuckle et al. explored the clinical evidences of B cell epitope
spreading by comparing the presence of autoAbs from the serum
of pre-diagnosed and post diagnosed SLE patients [65]. This was
made possible through The Department of Defense Serum Repository, containing over 30 million serum samples from members
of the U.S. Armed Forces. Serum is collected at the time of enlistment and on average every year thereafter. This allowed Arbuckle
et al. to identify SLE patients and then go back and observe the
development of autoAbs prior to SLE diagnosis. 130 SLE patients
were selected and then tested for the presence of the major SLE
autoantibodies including: anti-double-stranded DNA, anti-Ro, antiLa, anti-Sm, anti-nuclear ribonucleoprotein, and antiphospholipid.
The presence of auto-Abs was conﬁrmed via indirect immunoﬂuorescence with HEp-2000 cells and ELISA assays. Arbuckle at el.
observed that pre-diagnosis of SLE patients autoAb detection recognized on average 1.5 of 7 auto-Ags associated with SLE. At the time
of clinical SLE diagnosis typically 3 of 7 auto-Ags were recognized,
on average, by the Abs showing a spread of autoAb speciﬁcity over
time [65]. These results indicate the occurrence of intermolecular B
cell epitope spreading during the progression of preclinical to clinical autoimmune manifestation as well as during the progression
of the pathogenesis of SLE.
Another investigation demonstrated the role of epitope spreading in SLE by studying autoAb diversiﬁcation in response to small
nuclear ribonuclearproteins (snRNP’s) Ags [66]. SLE patients often
show diverse autoAb reactivity to snRNP’s. To demonstrate this
phenomenon, A/J mice were vaccinated with recombinant Smith
D (SmD), Smith B (SmB), and A ribonuclearprotein (A-RNP) and the
speciﬁcity of the Abs that developed were observed. Using western
blots and immunoprecipitation assays to identify Ab speciﬁcity, it
was observed that mice immunized with SmD also developed Abs
speciﬁc against SmB and A-RNP. Likewise, mice immunized with
SmB showed a development of Ab speciﬁcity against A-RNP and
A-RNP immunized mice developed Abs against SmB as well as the
70-kDa protein A of the U1-snRNP. These results demonstrated that
autoAb reactivity can spread from a single Antigenic site in a multi
protein complex to associated complex proteins [66].
Studies by van Bavel et al. have investigated new antigenic epitopes presented after cell apoptosis that have been linked with SLE
[67]. They found that acetylated epitopes of chromatin could allow
for increased pathogenesis and epitope spreading. Scoﬁeld and
associates studied a related line of research that indicate modiﬁcation of Ro/SSA with lipid oxidation products, 4-hydroxy-2-alkenals
in particular, increases the antigenicity and opportunity for B cell
epitope spreading [68]. Research using A/J mice has also lead to the
understanding that in some cases it is possible that intermolecular epitope spreading is more likely to occur than intramolecular
epitope spreading [7]. As has been mentioned previously, environmental factors have been implicated leading to the breaking of
tolerance and subsequent initiation of epitope spreading via molecular mimicry [25]. Thanks to recent and past research, it is apparent
that B cell epitope spreading plays a crucial role in the pathogenesis
of SLE once self-tolerance is broken.

Sjogren’s syndrome (SS) is an autoimmune disease that is associated with lymphocytic inﬁltration of the salivary and lacrimal
glands resulting in dry mouth and eyes [69]. The immune response
can result in the damage and destruction of the glands. When
only exocrine glands are involved in the autoimmune response it
is considered primary Sjogren’s syndrome, after other connective
tissue becomes involved it is considered secondary Sjogren’s syndrome. In SS, autoAbs commonly develop against the Ro/SSA and
La/SSB ribonucleoprotein particle linking SS to SLE through a common autoantigenic site. SS is the second most common rheumatic
disease but frequently goes without diagnosis due to its common
symptoms. While a portion of the disease can be contributed to
genetic risk factors, other stimuli are hypothesized to play a role
in the development of SS, such as hormone imbalance and stress.
Several environmental factors are thought to be triggers for SS
including Epstein–Barr virus, Hepatitis C, tuberculosis, and malaria
among others [70].
Scoﬁeld et al. explored the role of epitope spreading in SS by
vaccinating BALB/c mice with different amino acid sequences from
60-kDa Ro/SSA and observed whether autoAbs against the entire
60-kDa Ro/SSA protein would develop [71]. In the experiment 10
mice were vaccinated with Ro/SSA 480 and 10 separate mice were
vaccinated with Ro/SSA 274. The results showed that mice developed Abs against their respective peptide sequence in 2–3 weeks
and then over the course of several months developed autoAbs that
were reactive against the entire Ro/SSA and La/SSB complex. They
further observed that mice vaccinated with 60-kDa Ro peptides
not only developed SS associated autoAbs but that the vaccinated
mice developed salivary gland lymphocyte inﬁltrates and salivary gland dysfunction that resembled symptoms seen in human
SS [71].
It is important to continue research investigating risk factors
related to the development of SS. Recent studies have reported
HLA class II speciﬁc genetic markers as risk factor for SS and
leading to B cell epitope spreading [69,72,73]. Routsias et al.
recently suggested that intermolecular B cell epitope spreading
in SS may begin via molecular mimicry in the RRM region of
La/SSB [74]. Further studies on possible risk factors and mechanisms of epitope spreading are needed to better understand the
initiation and advancement of SS. Increased understanding in these
areas would allow for the potential development of therapeutic
treatments.
4.6. Graves disease
Also known as Basedow disease, Graves’ disease is a condition
where Abs develop that bind thyrotrophin receptors of the thyroid causing their activation and a subsequent up regulation of
cyclic adenosine monophosphate and thyroid hormone synthesis
[75,76]. This stimulation leads to hyperthyroidism and hyperplasia
of the thyroid. Pathological symptoms include goiter development, insomnia, pretibial myxedema, muscle weakness, itching
and Graves’ ophthalmopathy [76,77].
B cell epitope spreading has been related to thyroid diseases
in clinical settings. Kim et al. found that in the serum analyzed
during their study, Ab targets changed during disease progression.
Since that time various experimental animal models have provided evidence of B cell epitope spreading in Graves’ disease. Using
New Zealand White rabbits in a study to determine if B cell epitope spreading plays a role in the pathogenesis of Graves’ disease,
Thrasvoulides et al. immunized their rabbits with three different
peptides from thyroglobulin [6]. Using afﬁnity chromatography and
ELISA assays, they conﬁrmed that when they immunized the rabbits
with peptide AA2471-2490, after a period of several weeks there
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was intramolecular epitope spreading resulting in Abs binding to
other epitopes on the thyroglobulin protein other than the initial
peptide used during immunization.
Using Balb/c mice, evidence was found indicating intramolecular B cell epitope spreading [78]. In later mouse model
studies, similar results were noted. When Balb/c and C57BL/6 mice
where immunized with TSH receptor protein (TSHR), the Ab diversiﬁed from recognizing only the N-terminus domain to additional
epitopes including the TSHR ectodomain [79]. Using more speciﬁc
methods, Inaba et al. immunized breeding stock mice transgenic
for HLA-DR3 and HLADR2 with 41 different TSHR peptides [80].
When mice where immunized with peptides AA70-88, AA83-102,
or AA105-118 there was an Ab diversiﬁcation outside of the original
peptide epitope presented. More recently, it has been demonstrated that B cell epitope spreading occurs more rapidly than T
cell epitope spreading [81]. The variety of research using animal and
clinical means establishes B cell epitope spreading as a participant
process in the development of Graves’ disease.
4.7. Scleroderma
Scleroderma, or systemic sclerosis, is an autoimmune disease
that involves connective tissue damage, most notably endothelial
cells and ﬁbroblasts of the extracellular matrix [82]. Scleroderma
is characterized by ﬁbrosis of various organs throughout the body.
The hardening of the organs is thought to be caused by an overproduction of collagen. An early symptom indicative of scleroderma,
termed Raynaud’s phenomenon, is when extremities such as ﬁngers or toes, experience an exaggerated response to temperatures
and distress. These areas will often feel numb or pained and may
change color. B cells have often been shown to over express CD19,
an activating receptor, during autoimmune progression. AutoAbs
for various targets are seen in patients with scleroderma including
anti-endothelial cell, anti-ﬁbroblast, anti-MMP, and anti-ﬁbrillin-1
among others, which involve targeting many DNA binding proteins including DNA topoisomerase [82,83]. These autoimmune
responses results in inﬂammation and tissue damage in the affected
regions [84].
In scleroderma, B cell epitope spreading is initiated for a variety of reasons such as molecular mimicry or displays of previously
cryptic domains which are displayed by enzymatic degradation,
in which portions of the protein are degraded and novel domains
are available for recognition. Furthermore, modiﬁcation of target
Ags may occur, such as the modiﬁcation of U1-70 kd Ag modiﬁed
by reactive oxygen species [8,82]. Cryptic domains may also be
exposed after vascular spasms, and the release of reactive oxygen
[85]. Few studies in recent years have investigated into epitope
spreading and the development of scleroderma. In two studies,
autoAbs to differing centrosome domains were present in the same
sera, suggesting intermolecular spreading [85].
B cell epitope spreading has been observed as novel Ags are identiﬁed in patients with scleroderma. Of particular note is anti-PM/Scl
Abs, antinucleolar Abs. Though further studies are necessary, it
is thought that novel auto-Ags are targeted during disease progression. In a study conducted by Henry et al., autoAbs were
shown to have higher incidences to certain auto-Ags than to other
target auto-Ags [83]. For example, reactivity toward Scl-70 was
much higher than topoisomerase I epitopes. These differences
were concluded to occur because of the greater number of conformational determinants, which are larger than linear domains.
This could explain the development of auto-Ags later in disease
development resulting from the protein preference and subsequent epitope spreading events. The continued identiﬁcation of
novel auto-Ags and how B cell epitope spreading contributes to the
pathogenesis of scleroderma remain areas for substantial future
research.
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4.8. Cardiomyopathy
A disease resulting in the weakening and enlarging of the
myocardium, dilated cardiomyopathy (DCM) is a fatal disorder
causing various cardiovascular problems and a frequent culprit of
heart failure. Dilated cardiomyopathy generated as an autoimmune
response is a consequence of Abs reactive to heart associated protein [86]. Anti-myosin IgG Abs are commonly observed in patients
with autoimmune cardiomyopathy along with other auto Abs
including anti-C protein Abs [87–89]. A clinical familial study conducted by Catorio et al. found that the production of cardiac speciﬁc
Abs usually precludes disease development [90]. The occurrence
of dilated cardiomyopathy is due to several factors both genetic
and environmental. Potential triggers for dilated cardiomyopathy
include enteroviruses and other myopathic diseases [62,88].
One of the few examples showing the involvement of B cell epitope spreading in cardiomyopathy, Matsumoto et al., observed this
event in Lewis rats immunized with C protein fragment 2 (CC2) [91].
During their study they immunized Lewis rats with various peptides derived from CC2, peptide segments P1 through P12. All CC2
peptide mixes induced experimental autoimmune carditis (EAC)
and lead to DCM, with the exception of P12, which only lead to the
development of EAC. Mixes of P1 to P3, P4 to P6, P7 to P9, P10 to
P12, and several individual peptide segments were used to inoculate the Lewis rats. After immunization, it was observed that the
Ab response diversiﬁed to include not only the Abs against the mix
of segments used to immunize the rats, but also against various
other peptide segments on CC2. All of the Lewis rats immunized
P1 through P11 demonstrated this diversiﬁcation and eventually
progressed from EAC to DCM. While those Lewis rats immunized
with CC2P12 only developed Abs against that region and did not
develop DCM, but remained expressing EAC symptoms [91]. The
study evidences the inﬂuence that B cell epitope spreading plays in
the progression of dilated cardiomyopathy.
4.9. Heymann nephritis
Heymann nephritis (HN) disease models using Lewis rats are
one of the most valuable tools for researchers to use in understanding the immunopathology of glomerular subepithelial immune
deposit formation and mechanisms by which such deposits injure
glomeruli. The Lewis rat model of induced active Heymann nephritis ﬁrst described in 1959 closely resembles that of glomerular
injury and nephropathy in humans. Mechanisms of renal sodium
retention, edema formation, and metabolic abnormalities have
been observed as a guide to treating primary and secondary human
glomerulonephritis diseases [92,93]. Inducing active HN in rats is
conducted by immunizing susceptible strains of rats with certain
fractions of homologous or heterologous proximal tubular brush
border. Granular glomerular capillary wall deposits of rat IgG and
subepithelial electron-dense deposits characterize the disease after
three to four weeks. Primary manifestations of HN include proteinuria (developing in 30–80% of induced rats), changes in glomerular
hemodynamics, tubular function, and alterations in renal hormone
production. These disease manifestations are closely related to
human nephropathy disease manifestations, and demonstrate that
active HN is indeed an autoimmune-induced disease [92–94].
Megalin, or more speciﬁcally gp330, was found in 1982 and
determined to be the glycoprotein and target Ag within the pits
of glomerular and proximal tubular epithelia. The pathogenesis of
HN includes the binding of circulating Abs to glomerular components. Megalin and RAP (receptor associated protein – 44kd) are
the target Ags for nephritic activity and it was determined that RAP
binds to Megalin [94,95].
Megalin is a complex Ag with four discrete ligand-binding
domains (LBDs) that may contain epitopes to which pathogenic
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autoAbs are directed. In a recent study a 236-residue N-terminal
fragment (termed “L6”) that spans the ﬁrst LBD was shown to
induce autoAbs and severe disease in Megalin-immunized HN rats
[94]. Sera obtained from test results of rats that had received an
L6 fragment showed reactivity only with the ﬁrst LBD after a 4week period. However, after 8 weeks the same L6 fragment showed
reactivity with all four recombinant LBDs. The study demonstrated
that the L6 immunogen did not contain the epitopes responsible
for reactivity with the LBD fragments and therefore suggest intramolecular epitope spreading as the key variant to the increased
severity and reactivity of HN rats. Further correlation of epitope
spreading to the pathogenesis of HN disease indicated by the study
was the onset of proteinuria. Proteinuria in rats immunized with
L6 was seen at 6–8 weeks. ELISA of antisera indicated peak titers
against L6 at weeks 4–6, however reactivity of LBDs arose after
week 6 and had maximal values at week 9. Thus induction of proteinuria with serum reactivity was indicative of epitope spreading
[94,95]. Treatment in HN Lewis rats with DNA vaccinations resulted
in lowered proteinuria and promise for future treatment [96,97].
4.10. Pemphigus
Pemphigus is classiﬁed as a rare form of skin blistering caused by
an autoimmune response against desmosomal adhesion proteins.
These proteins are responsible for the homeostasis and attachment
of epidermal cell layers [98]. There are four distinct forms and each
is classiﬁed according to clinical signs and symptoms. Pemphigus
vulgarius is the most common and is diagnosed by the presence
of anti-Desmoglein 3 protein IgG Abs, with the initiation of sores
in the oral mucosa and spreading to blisters on the face, limbs,
and trunk of the body [99]. Pemphigus foliaceus is characterized
by Desmoglein 1 autoAbs and superﬁcial blister formation on the
extremities. P. foliaceus tends to be one of the least severe forms of
pemphigus. Immunoglobulin A pemphigus is identiﬁed by the characteristic IgA Abs directed against desmoglein, and in some cases,
desmocollin, proteins. The ﬁnal and most severe form, Paraneoplastic pemphigus, is often associated with a secondary malignancy.
The product is a wide spread autoimmune response causing severe
cutaneous blistering in potentially any epidermal or mucosal tissue of the body. The cause of the autoimmune response in this case
is unknown, although it is suspect that disease initiation may be
related to insect bites [99].
To demonstrate that intermolecular and intramolecular epitope spreading occurs in Pemphigus, Valerie K. Salato, Mong-Shang
Lin, and their associates at the Medical College of Wisconsin collected and analyzed sera from pemphigus vulgaris (PV) positive
volunteers [100]. These samples were taken at various times during the course of disease progression. In their study 14% of their
volunteers transitioned from mucosal PV to mucocutaneous PV.
They evaluated their Ab proﬁles during the progression of PV
by immunoprecipitation and competition indirect immunoﬂorescence assays. Giving an example of one of these patients, early
assays and detailed epitope mapping showed that they had Abs
autoreactive for region AA405-566 of Desmoglein 3. Several years
later that same patient transitioned to produce auto-Abs that
reacted with regions AA1-88 and AA87-566 of Desmoglein 3,
demonstrating the spread of the B cell repertoire and offering evidence of intramolecular spreading. This same patient also showed
evidence of intermolecular epitope spreading when they developed
Abs that were auto-reactive with human skin cells. Samples collected earlier in the study showed no human skin auto-Abs while six
years later, after the patient had transitioned to mucocutaneous PV,
samples taken exhibited these auto-Abs. This hypothesis of intermolecular spreading was further supported when they conﬁrmed
the Abs auto-reactive for desmoglein 1in later samples [100]. Their
study demonstrates how B cell epitope spreading contributes to

the progression of pemphigus vulgarius from displaying strictly
mucosal legions to cutaneous legions.
Further observations give credence to the phenomenon of epitope spreading and its role in the development of pemphigus
when Bowen et al. described the development of paraneoplastic
pemphigus from patients displaying Lichenoid Dermatitis [101].
They speculate that the intramolecular spreading could be due to
lichenoid sores and the subsequential inﬂammation predisposing
patients via a heightened immune response. This theory was further compared to other leading ideas as to the cause for disease
progression in paraneoplastic pemphigus and was suggested as a
possible area for future research [102]. In a study done in a Brazilian
community it was proposed that epitope spreading was the cause
for the development of pemphigus foliaceus in patients diagnosed
with Fogo Selvagem, loosely translated as “wild ﬁre” disease [18].
In their study, Li et al. proposed that a genetic predisposition may
contribute along with epitope spreading leading to pemphigus foliaceus. In a unique case, clinical evidence suggests that B cell epitope
spreading can contribute to the progression of pemphigus to bullous pemphigoid [14]. B cell epitope spreading has been observed
to play a role in the progression of pemphigus and contribute in the
development to more severe symptoms.
4.11. Bullous pemphigoid
Similar to pemphigus, bullous pemphigoid is a cutaneous
blistering autoimmune disease. Patients suffering from bullous
pemphigoid do not typically experience mucosal lesions and the
disease is often marked by pruritic blisters on the trunk of the body,
epithelial areas of the joints, and the extremities. The autoimmune
response in this case is characterized by the development of Abs
against bullous pemphigoid Ag 1 and 2 (BP230 and BP180 respectively), also known as BPAG 1 and BPAG2, which compose part of
the hemidesmosome and assist with cell to matrix adhesion in the
epithelium [103,104]. As a result, autoimmune response to differing collegen types is characteristically seen in bullous pemphigoid.
It is documented to have a higher incidence among the elderly and
is estimated to have an incidence in the general population of 6–7
cases per million. This estimate increases to 150–330 cases per million in the population older than 80 years of age [105,106]. With
respect to the environmental or genetic factors that could initiate an autoimmune response, there remains little information on
triggers. Our current understanding indicates that triggers for bullous pemphigoid could include vaccines, medications, and possibly
a variety of infections [107].
A clinical study was conducted by Giovanni Di Zenzo and
his international associates with the speciﬁc aim to appraise the
development of IgG Abs during the course of bullous pemphigoid
development [108]. Thirty-ﬁve patients volunteers diagnosed with
bullous pemphigoid were selected for this multicenter study along
with a control group of 50 volunteers including both bullous
pemphigoid patients and healthy individuals. All volunteers were
assessed at the initiation of the study as well as one, three, six,
and twelve months during the study while undergoing treatment.
ELISA and immunoblotting assays speciﬁc for various domains
on BP180 and BP230 were utilized to assess the Abs present in
patient sera. Their study found that in three of the patients, BP180
Abs recognized the ectodomains of the protein before developing
Abs speciﬁc for the intracellular domains. Intermolecular epitope
spreading was also observed to occur during the course of the
study. 17.6 percent of the volunteers developed an IgG response
that initially recognized either BP180 or BP230, to recognizing both
proteins. Analyzing the data collected during the study, it was
observed that epitope spreading incidence was higher during the
ﬁrst three months after diagnosis compared to any other time during the study. It was noted that the spreading from ectodomains to
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intracellular domains and the incidence rates are correlated with
the severity of bullous pemphigoid [108].
During a previous clinical study, Epitope spreading was
observed in the Ab response progressing from collagen XVII to
collagen VII [109]. As has been previously mentioned, bullous pemphigoid has been observed to develop after diagnosis of pemphigus
foliaceus [13,14]. Another clinical report was submitted several
years later with similar observations of intermolecular epitope
spreading resulting in the development of bullous pemphigoid
from pemphigus foliaceus, but with the additional information that
the patient exhibited only IgG3 autoAbs, not IgG1 [110]. Antibody
isotype switching was not noted during the 13 year course of clinical observation as normally would be the case. This remains an
area for further research with regard to the role isotype switching,
or the lack there of, has in epitope spreading.
5. Treatment strategies for B cell epitope spreading:
current concepts and perspectives
Currently there exist few options for treatment of autoimmune diseases. Clinicians and researchers rely on generalized
immunosuppressive treatments that are designed to block a broadspectrum of potential risk factors associated with such diseases.
Consideration of both efﬁcacy and side effects of such treatments
is vital. In a review published by Vanderlugt and Miller discuss the
role of tactics that can be designed to slow and/or neutralize the
effects of epitope spreading in autoimmune function [2]. Due to the
unknown biologic pathways and change in antigenic speciﬁcity, it
is difﬁcult to design drugs that can treat epitope spreading. Very little, if any, research has been done investigating the effects of these
therapeutics on epitope spreading. Because these treatments each
have speciﬁc effects on B cells, from killing them to inhibiting speciﬁc signaling pathways, investigations into their effects on epitope
spreading could reveal insights into the mechanisms and function
of this important immune process.
The use of various drugs to control and inhibit both B and T cell
activity is currently the most commonly used approach to autoimmune diseases, however these drugs typically suppress the entire
immune system and are non-speciﬁc in their approach [2,111]. Tcells play a major role in recognizing foreign and self-Ags and thus
promote a cytokine response due to changes in epitope speciﬁcity
leading to autoimmune dysfunction. Vanderlugt et al., utilizing EAE
(experimental autoimmune encephalomyelitis) induced SJL mice
and focusing on co-stimulatory signaling centers of CD28-CD80/86
and CD154-CD40, established anti-CD80 Ab fragments and monoclonal anti-CD154 Abs that were administered during peak phase or
during relapse of EAE. Both anti-CD80 and anti-CD154 Abs showed
signiﬁcant inhibition of disease relapse. Epitope spreading has been
thoroughly studied in EAE mice, which serve as a model for multiple sclerosis. Other drugs such as interferon pathway regulatory
agents could provide a further targeted approach to management
of autoimmune activity [112,113]. Most recently researchers are
working to develop Th2 bystander suppression drugs to combat
epitope spreading, disease-speciﬁc immunologic drugs, and targeted cytokine inhibitors [2]. These treatments are not in common
use at this point, and there is very little available data regarding
their effects on epitope spreading.
5.1. Rituximab and B cell depletion therapy
Rituximab is becoming a commonly used immunosuppressive.
It utilizes a CD20 binding protein designed to deplete mature B
cells. In one report discussing the multi-type efﬁcacy of Rituximab,
patients with pemphigus, a severe autoimmune disease resulting
in blisters of the skin and skin and mucosal erosion, were treated
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with rheumatoid arthritis (RA) dosing schedules of Rituximab. At
6 months of dosage treatment 90% of patients achieved remission.
At 22 months there was a 67% relapse rate with patients, however Global CD 4 + T cell numbers were preserved up to 3 months
after treatment [114]. In conjunction with corticosteroids and other
cytotoxic agents, Rituximab has also been used to treat SLE and
other Ab mediated autoimmune diseases [115,116].
Other B cell depleting therapies include ocrelizumab and
epratuzumab, which bind CD20 and CD22 respectively [117]. Use
of B-cell depletion therapy may be helpful for patients that don’t
respond to other immunosuppression therapies [2,115,118]. Use of
rituximab could potentially inhibit or impede B cell epitope spreading due to the depletion of B cells during the course of therapeutic
treatment. However, there is no current evidence to support that B
cell depletion signiﬁcantly disrupts B cell epitope spreading.
5.2. Belimumab and cytokine inhibition therapy
A promising treatment for SLE, Belimumab is a monoclonal Ab
that binds B lymphocyte stimulators (BLyS). This type of therapy
prevents the differentiation and survival of B cells. Used in various
clinical studies, Belimumab has become recognized as a treatment
with high efﬁcacy and tolerability [117,119,120]. A large multicenter phase III study performed on Belimumab by Furie et al.
demonstrated the efﬁcacy of the therapy. 819 anti-nuclear Ab or
anti-double stranded DNA Ab positive patients participated in the
randomized placebo controlled study over a period of 52 weeks.
Those treated with non-placebo participants were randomly given
a high or low dose of Belimumab, 10 mg/kg and 1 mg/kg respectively. At one year post treatment start of the study it was found
that the risk of severe ﬂares was reduced by 34% (p = 0.023) for the
low dose group and 23% (p = 0.13) for the high dose group. It was
also calculated that the SRI rates were 44%, 51% (p = 0.0129), and
58% (p = 0.0006) for the placebo, low, and high dose groups respectively [120]. Similar results have been observed in other studies
and suggest that Belimumab could be a good alternate treatment
option for SLE patients.
Blisibimod and Tabalumab are two other BLyS targeting Abs that
are currently in clinical trials and show promise for the treatment
of SLE. In a recent randomized, placebo controlled clinical phase
II study, 547 SLE patients were treated with Blisibimod at one of
three dose levels and monitored over a period of 24 weeks. It was
reported that the most effective dose was the highest at 200 mg/kg
and that it signiﬁcantly reduced levels of anti-double stranded DNA
Abs (p < 0.001) after 24 weeks. This dosage also improved levels of
C3 and C4 (p < 0.01 and p < 0.001, respectively). It was also observed
that the treatment signiﬁcantly lowered levels of B cells (p < 0.001).
The results of the study suggests that at 200 mg/kg, Blisibimod is
most efﬁcacious for patients with severe SLE [121].
Atacicept is a biologic treatment option that is in clinical trials and has been studied for the treatment of SLE, RA, and MS
[122–124]. Due to its fusion protein construction it inhibits both
BLyS and A proliferation inducing ligand (APRIL), which results in
the prevention of symptoms similar to other BLyS targeting therapies, inhibiting B cell differentiation. A phase II clinical study
published by Genovese et al. reported that Atacicept showed no
signiﬁcant efﬁcacy compared to the placebo group used in the
study [123]. But, they did demonstrate that Antacicept lowered
rheumatoid factor and immunoglobulin levels even though it did
not decrease the levels of anti-citrullinated protein Abs. It was
observed in a recently published double blind, randomized, placebo
controlled clinical phase II study of Atacicept for the treatment
of MS, that the treatment adversely affected the patients treated
compared to the control group [124]. The results of a randomized, double blind, placebo controlled clinical study to determine
the efﬁcacy in treating SLE patients were recently published by
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Isenberg et al. In this 52 week study 461 SLE patients were treated
with 75 mg/kg, 150 mg/kg, or the placebo. They reported that the
high dose group, 150 mg/kg, demonstrated lower ﬂare rates verses
the placebo group (p = 0.002). Both the low and high dose treated
groups showed reduced levels of total Ig and anti-double stranded
DNA Abs [122]. The results of these recent studies suggest that
Atacicept could be a possible biologic treatment option for SLE.
There is no published evidence to demonstrate that BLyS and APRIL
therapeutic strategies inhibit or impede B cell epitope spreading,
aside from the lack of clinical signs and symptoms demonstrated
by patients during the clinical trials. It does stand to reason that
such treatment options would prevent or disrupt epitope spreading, inhibiting disease progression.
5.3. Abatacept and co-receptor inhibition
A further strategy of treatment is utilized by Abatacept, which
inhibits T cell activation by binding the CD28 receptor on B cells.
Approved by the FDA in 2005, Abatacept is currently used in the
treatment of RA and to slow the progression of joint damage. In a
recent phase III clinical study comparing Abatacept to Adalimumab,
a tumor necrosis factor ␣ (TNF-␣) inhibitor approved for the treatment of RA in 2002, demonstrated that subcutaneous Abatacept
produced similar results in the treatment of RA [125]. In a multicenter, phase IIb, randomized, double-blind, placebo controlled
study of Abatacept in the treatment of SLE it was observed that
patients treated experienced a similar frequency of adverse events,
and that these adverse events were typically worse in the treatment group compared to the placebo group [126]. While there is
no evidence demonstrating this treatment inhibits epitope spreading, such a strategy shows promise as an effective way to inhibit
disease progression and possibly impede B cell epitope spreading
in patients with RA [127].
6. Concluding remarks
Over the past two decades our understanding of B cell epitope
spreading has broadened substantially. It is well understood how
the process of epitope spreading contributes to pathogen clearance
and several factors that contribute to its effectiveness. Molecular
mimicry and Intrastructural T cell help allow B cells to expand
their Ab repertoire, which diversity results in higher afﬁnity Abs
and a more effective immune response. Through various intracellular processes, stimulated B cells can generate novel target epitopes
and present them in the context of MHC class II molecules to T
cells. During B cell endocytosis, an Ag is endocytosed after stimulation of sIg molecules on the cell surface. GILT, endocytic proteases,
and lysosomal cathepsins selectively process the Ag. After which a
digested peptide is selectively loaded into the MHC II molecule post
LI degradation and CLIP dissociation, allowing for various epitopes
to be displayed by MHC class II molecules. Through somatic hypermutation a variety of higher afﬁnity Abs are produced granting
opportunity for further diversiﬁcation of epitope targets.
While this process contributes positively to our systemic
defense against pathogenic organisms and macromolecules, it is
also responsible for the progression of autoimmune diseases after
self-tolerance is broken. Evidence from clinical studies and reports,
a variety of animal models, and serological collection analysis has
yielded substantial evidence indicating such. Both intermolecular
and intramolecular epitope spreading are observed to happen congruously with the progression of autoimmune disease. Potential
auto-Ags are more likely to become Antigenic targets to initiate
epitope spreading after modiﬁcation by reactive oxygen species
[8,82] and lipid oxidation products [68] or abnormal apoptosis [67]
and citrullination [52]. Various other environmental triggers for

initiating epitope spreading in autoimmune afﬂictions have been
identiﬁed including assorted viruses, bacterial infections, and stress
[25,70]. Currently we lack treatments that can effectively stop detrimental B cell epitope spreading. It can be considered that various
treatments, B cell depletion and immune repression included, partial impede epitope spreading [128].
There are many aspects that still remain to be explored and
would contribute to future understanding of epitope spreading,
while the role of T cell interaction in epitope spreading is fairly
well understood, less work has been done investigating the role of B
cells in epitope spreading. Future research opportunities regarding
B cell endocytosis include investigating into the currently unknown
regulatory factors that are involved in the loading of MHC class
II molecules and competitive inhibitory processes that regulate
the selective processing of Antigenic peptides by cathepsins. It is
also unclear how various compartments in the endocytic pathway
target each other. The extent to which B cell epitope spreading contributes in the progression of many autoimmune diseases is still not
well understood and could be better researched. Comprehension of
patterns involved in epitope spreading to allow the prediction and
potential therapy of epitope spreading in autoimmune diseases is
also lacking. Treatments to inhibit epitope spreading or eliminate
the detrimental aspects of epitope spreading are areas where future
research could be conducted.
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Cellular chemotaxis is important to tissue homeostasis and proper development. Human
herpesvirus species influence cellular chemotaxis by regulating cellular chemokines and
chemokine receptors. Herpesviruses also express various viral chemokines and chemokine
receptors during infection. These changes to chemokine concentrations and receptor
availability assist in the pathogenesis of herpesviruses and contribute to a variety of diseases
and malignancies. By interfering with the positioning of host cells during herpesvirus infection,
viral spread is assisted, latency can be established and the immune system is prevented from
eradicating viral infection.

INTRODUCTION
Cells respond to a variety of cytokines and chemokines that
allow them to migrate in different areas in the body
depending on where they are needed. This process is essential for appropriate tissue maintenance, homeostasis,
formation, repair and pathogen clearance (Turner et al.,
2014; Zhou et al., 2014). Dysregulation of the delicate
balance of cellular signals and/or improper positioning
could impede these processes. Aside from being related
to a range of diseases, viral-induced chemotaxis contributes
to the epidemiology and persistence of human herpesviruses. These viruses regulate a multitude of cellular
genes that direct cellular chemotaxis, thereby manipulating
these genes for the benefit of the invading virus. Herpesviruses also produce various chemokines and chemokine
receptors from genes in the viral genome, further affecting
cellular chemotaxis. In essence, viral infection results in the
piracy of cellular function as it directs cell movement in
both infected and uninfected cell types.
The family Herpesviridae is divided into various subfamilies
including Alphaherpesvirinae, Betaherpesvirinae, and
Gammaherpesvirinae (Flint & American Society for Microbiology, 2009; Yoshida & Yamada, 2006). The nine human
herpesviruses (HHVs) include herpes simplex virus
type 1 (HHV-1 or HSV-1) and 2 (HHV-2 or HSV-2),
varicella–zoster virus (HHV-3 or VZV), Epstein–Barr
virus (HHV-4 or EBV), human cytomegalovirus (HHV-5
or hCMV), human herpesvirus 6A (HHV-6A) and 6B
(HHV-6B or roseola virus), human herpesvirus 7 (HHV-7)
and Kaposi’s sarcoma-associated herpesvirus (HHV-8 or
KSHV) (Siakallis et al., 2009). All of these viral species
share similar structural characteristics with a genome
000370 G 2016 The Authors

composed of double-stranded DNA, an icosahedral
capsid, an envelope studded with a variety of viral and
host proteins, and viral tegument proteins in an amorphous layer between the capsid and envelope (Flint &
American Society for Microbiology, 2009). Herpesviruses
are able to remain latent in host cells for the life of the individual, during which time viral particles are undetectable
but viral nucleic acids can be found, and viral gene
expression is very limited. Various stimuli can cause viral
reactivation, wherein viral gene expression recommences
and infectious particles can be detected and shed to new
hosts. Herpesviruses encode a complex assortment of
proteins that manipulate cellular functions during
infection in order to promote viral persistence. Human
herpesviruses are an integral part of human existence,
with over 90% of adults being persistently infected with
one or more of these nine herpesviruses in their lifetimes.
Although the incidence of serious herpesvirus-induced
diseases is rare in most cases, the prevalence of infection
is so high that the overall disease burden takes a toll on
society.
It has been hypothesized that several herpesvirus species
affect development or progression of diseases, including
lymphomas, atherosclerosis, autoimmune disorders, and
disruption of angiogenesis, through interference with cellular chemotaxis (Ehlin-Henriksson et al., 2009; Franciotta
et al., 2008; Rosenkilde & Schwartz, 2004; Stern & Slobedman, 2008; Streblow et al., 2001). In this review we will
elaborate on the known human HHV mechanisms and
pathways that influence cellular chemotaxis during viral
infection. Potential benefits to herpesviruses in evolving
these mechanisms will be presented as well as the resulting
potential for their roles in disease development.
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ALPHAHERPESVIRINAE
HSV-1, HSV-2 and VZV encompass the human pathogens
of the subfamily Alphaherpesvirinae, typically showing lytic
replication in epithelial cells and harboured as a latent
infection in neuronal cells. HSV-1 is quite common in
industrialized countries, with a seroprevalence of around
90% (Viejo-Borbolla et al., 2012) in the adult population.
Symptoms of viral infection include cold sores and redness
of the skin; however, many infections are asymptomatic.
HSV-1 transmittance only occurs when viral replication
takes place, either during primary infection or in a reactivation event. The most common methods of transferring
HSV-1 include direct skin contact and via saliva. Similar
to HSV-1, HSV-2 can mask its presence from the host’s
immune system, demonstrating a preference to lie
dormant in the sacral ganglia (HSV-1 in trigeminal
ganglia) and manifest occasional lytic outbreaks, typically
in the genital area. HSV-2 is one of the most common
sexually transmitted diseases, with a seroprevalence of
12–20% in the USA. HSV-2 infection is of greater concern
in developing countries, where seroprevalence is much
higher (Weiss, 2004; Xu et al., 2006). VZV primary infection results in the common childhood disease varicella
(chickenpox) after which the virus establishes latency in
the ganglia of a variety of neurons (Gilden et al., 2014).
Reactivation of the virus results in zoster (shingles) and
other chronic pain diseases, which can be manifest in
various places on the epithelium (Gilden et al., 2014).
Until recently, not much was known about HSV and how it
affects chemotaxis; however, current work has demonstrated that HSV infection has a strong influence on
chemotaxis (see Table 1). Viejo-Borbolla et al. (2012)
showed that a secreted form of viral glycoprotein G
(SgG) from both HSV-1 and HSV-2 binds chemokines
with high affinity. Membrane-bound glycoprotein G (gG)
was shown to be necessary for chemokine-binding activity.
They found that HSV SgG in both HSV-1 and HSV-2
increased chemotaxis of monocytes in infected individuals
towards CXCL12 and that gG attaches to glycosaminoglycans (GAGs) at the surface of cells without negative
effects on G-protein-coupled receptors (GPCRs). Another,
more recent, study further investigated the mechanism by
which viral SgG enhances chemotaxis. It was found
that gG binds to GAGs, which induces lipid raft
clustering, leading to increased CXCR4 incorporation.
The conformational change causes an increase in

functional chemokine–receptor complexes at the cell surface (Martinez-Martin et al., 2015). CXCL12 is the natural
ligand for CXCR4 and is secreted constitutively in a variety
of tissues, including the lymph nodes, bone marrow, lungs
and adrenal glands (Alkhatib, 2009; Luker & Luker, 2006).
It is also known that CXCR4 signalling is important in
modulating the survival of neuronal cells and modulating
synaptic function (Nash & Meucci, 2014). The increased
functionality of CXCR4 could potentially allow infected
cells to migrate to these areas in vivo. By migrating to
areas secreting CXCL12, infected cells could come into
contact with more target cells. Similar results had been
observed by Bellner et al. (2005) when they tested the
chemotactic ability of HSV-2 gG (gG-2p20). These authors
found that isolated human neutrophils and monocytes
followed a gradient of gG-2p20 via binding of the formyl
peptide receptor (FPR) on the surface of these cells. While
the chemoattractant properties have never been displayed
using the full-length gG2 protein, several speculations can
be made based on the findings that suggest that neutrophils
and monocytes could be attracted to areas with infected
cells expressing gG-2p20. This could possibly be beneficial
for HSV-2 infection. Attracting a large number of phagocytic cells would increase tissue damage and activated cells,
potentially enabling viral spread and propagation (Bellner
et al., 2005). It was shown that gG-2p20 is an FPR-activating
agonist. Activation of FPR in vivo led to the downregulation
of other chemotactic receptors. These observations suggest
the possibility that the change in expression could lead to
impaired clearance of HSV-2 during infection (Bellner
et al., 2005). In summary, a variety of studies have demonstrated the effectiveness of HSV-1 and HSV-2 in manipulating CXCR4 in infected cells.
HSV-2 has demonstrated the ability to manipulate chemotaxis via a host chemokine as well. A study performed by
Huang et al. (2012) demonstrated an elevated expression
of CXCL9 in the cervical mucosa of HSV-2-positive
women. Further research confirmed that HSV-2 regulated
the expression of CXCL9 in human cervical epithelial
cells by inducing the phosphorylation and translocation
of C/EBP-b to the nucleus, where it transactivates
CXCL9. The known receptor for CXCL9 is CXCR3,
which is expressed predominantly in non-resting T cells
(Van Raemdonck et al., 2015). Expression has also been
observed in epithelial, endothelial, fibroblast and smooth
muscle cells (SMCs) (Billottet et al., 2013; Van Raemdonck

Table 1. Alphaherpesviruses change cellular receptors/chemokines
Cell type

Receptor or chemokine

Virus

Amount or functionality

References

Monocyte

CXCR4

HSV-1, HSV-2

Increase

Neutrophil
Epithelial

CXCR4
CXCL9

HSV-1, HSV-2
HSV-2

Increase
Increase

Bellner et al. (2005);
Viejo-Borbolla et al. (2012)
Bellner et al. (2005)
Huang et al. (2012)
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et al., 2015). This upregulation of CXCL9 was shown to
result in increased migration of activated peripheral
blood leukocytes (PBLs) and CD4+T lymphocytes
(Huang et al., 2012). Huang and associates postulate that
HSV-2 is responsible for upregulating CXCL9; however,
it was not shown what viral protein induced the expression
or if the increase in CXCL9 expression was a cellular
response to viral infection. The viral benefits for inducing
migration of CD4+T cells and PBLs to sites of infection
are unclear. The ability of HSV-2 to regulate CXCL9
could be investigated more in depth as this is the only
study demonstrating this type of subversion in epithelial
cells.
Past research has also suggested that VZV could utilize
glycoproteins as chemoattractants, inducing migration of
polymorphonuclear leukocytes (Ihara et al., 1991).
No other recent research has been conducted to determine
if VZV affects chemotaxis of other infected cell types,
although several studies do provide evidence for how
VZV might influence cellular chemotaxis (Desloges et al.,
2008; Shavit et al., 1999; Steain et al., 2011). We now
understand that HSV-1 and HSV-2 can manipulate monocytes through increasing the functionality of CXCR4 by
making lipid rafts with the viral SgG protein. HSV-2 can
further change the migration of cells by increasing the
expression of CXCL9 in infected epithelial cells, potentially
attracting CD4+T cells and PBLs to sites of infection.

BETAHERPESVIRINAE
Human cytomegalovirus (hCMV)
Also known as human herpesvirus 5, hCMV is a prominent
member of the Betaherpesvirinae subfamily. With a seroprevalence worldwide ranging from 45 to 100%, hCMV

is a common human pathogen that is often asymptomatic
in infected adults and children (Cannon et al., 2010; Chen
et al., 1999; McGavran & Smith, 1965). hCMV has gained
public scrutiny and awareness owing to further understanding of its prevalence in causing congenital infections
leading to birth defects (Bialas et al., 2015). In the USA it
is a more common cause of birth defects than many
other causes, including fetal alcohol syndrome, Down syndrome, spina bifida, HIV/AIDS, Haemophilus influenzae
type B and congenital rubella syndrome (Cannon &
Davis, 2005). Like other herpesviruses, hCMV is associated
with various post-transplant complications and is a main
viral cause of solid organ transplant and haematopoietic
stem cell transplant morbidity and mortality (ArizaHeredia et al., 2014; Gandhi & Khanna, 2004). It is also
known to cause severe disease in other immunocompromised individuals, such as AIDS patients. Viral shedding
can occur via saliva, urine, breast milk, semen and tears.
hCMV is known to infect various cell types, including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, dendritic cells and lymphocytes, the latter cell type
typically remaining latently infected for the life of the host.
Using a variety of viral proteins to manipulate migration of
host cells and potential target cells, hCMV uses both surface
receptors and secreted chemokines (see Tables 2 and 3).
Among the viral chemokines secreted by hCMV-infected
cells are the products of the UL128 and UL146 genes.
Numerous studies have been performed demonstrating
how these viral gene products affect the migration of
hCMV-infected cells. It has been noted that hCMVinfected monocytes demonstrate a reduced chemotactic
ability owing to a downregulation of CCR1, CCR2 and
CCR5 (Frascaroli et al., 2006). A similar downregulation
of various chemokines was observed along with an increase
in migratory inhibitory factor in hCMV-infected macrophages, resulting in a lack of motility (Frascaroli et al., 2009).

Table 2. Human herpesvirus-encoded chemokine receptors
Virus
hCMV

Viral receptor
US27
US28
UL33 and UL78

HHV-6A

U51

HHV-6B

U12

HHV-7

U51
U12
KSHV-GPCR

KSHV

http://jgv.microbiologyresearch.org

Result
Potentiates CXCR4, increases migration
to various tissues
Migration of infected cells to areas
of inflammation
Prevents migration to sites of inflammation
and certain tissues
Prevents NK cell interaction and prevents
apoptotic signals
Migrates to inflammatory and T cell-rich
zones
Migration of infected cells to T cell-rich
and inflammatory areas
Increases cell survival

References
Arnolds et al. (2013)
Streblow et al. (1999); Vomaske et al. (2009)
Tadagaki et al. (2012); Tschische et al. (2011)
Catusse et al. (2008); Fitzsimons et al. (2006)
Isegawa et al. (1998)
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Table 3. Human herpesvirus-encoded chemokines
Virus

Viral chemokine

VZV

GP I and GP II

HSV
hCMV
hCMV

gG2
UL146
UL128 and UL146

HHV-6A

U83A

HHV-6B
KSHV
KSHV

U83B
vCCL1
vCCL2

KSHV

vCCL3

KSHV

vIL-6

Result
Chemoattractant for polymorphonuclear
leukocytes
Chemoattractant for monocytes
Chemoattractant for neutrophils
Attracts PBMCs and
prevents monocyte migration
Chemoattractant for T cells,
monocytes and immature
dendritic cells
Chemoattractant for monocytes
Chemoattractant for monocytes
Prevents Th1 T cell chemotaxis
and attracts monocytes
Inhibits chemotaxis of Th1 T cells
and NK cells
Attracts endothelial cells

Later it was demonstrated by Frascaroli and associates that
in the presence of UL128 there was a resulting downregulation of CCR1, CCR2 and CCR5 in monocytes
(Straschewski et al., 2011). Because of this impairment,
monocytes could no longer migrate following the chemokines CCL5 and CCL2, which are ligands of the aforementioned receptors. CCL2 and CCL5 are known to be
involved in the recruitment of monocytes and T cells and
are secreted as pro-inflammatory cytokines in response to
tissue damage or viral detection (Ansari et al., 2013; Soria
& Ben-Baruch, 2008). Recently, using a UL128-transfected
cell line (CHO-UL128) to produce UL128, Gao et al.
(2013) studied the effects of this b chemokine on cell
migration. They found that UL128 acted as a chemoattractant for peripheral blood mononuclear cells (PBMCs)
in vitro and functioned similarly to CCL3 as a chemoattractant. These results suggest that UL128 could act to prevent
chemotaxis of monocytes following other gradients, such as
CCL5 and CCL2, and could use a separate receptor to
attract the monocytes to areas of infected cells (Gao
et al., 2013). This increases the cells available to be infected
by hCMV, potentially furthering viral spread. The other
known chemokine produced, UL146, codes for an
a chemokine and viral homologue to CXCL1 (vCXCL1)
(Penfold et al., 1999). Two studies demonstrated that
vCXCL1 could induce the chemotaxis of neutrophils
in vitro (Lüttichau, 2010; Penfold et al., 1999). Using
calcium mobilization, chemotaxis and phosphatidylinositol
turnover assays, it was found that vCXCL1 was a ligand for
CXCR1 and CXCR2. CXCR1 and CXCR2 are both
expressed on neutrophils, and it is expected that hCMVinfected endothelial cells express vCXCL1 as a chemoattractant to increase the numbers of neutrophils and
assist in viral spread to other endothelial cells (Lüttichau,
2010). In a study conducted by Smith et al. (2004), it
was observed that hCMV-infected monocytes induced
546
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transendothelial migration in vitro, although the viral
mechanism is unknown (Smith et al., 2004).
Regulating host cell chemokines can also result in chemotactic changes (see Table 4). hCMV UL144 is a viral protein
that activates NF-kB (Poole et al., 2006). This leads to a
cascade of multiple pathways, including induced
expression of host CCL22, which acts as a chemoattractant
for Th2 and regulatory T cells (Tregs). By recruiting these
cells to sites of viral infection it is possible to suppress
T helper and CD8+T cells, tapering the immune response
(Fielding, 2015). It has also been found that granulocyte
macrophage progenitors (GMPs) latently infected with
hCMV demonstrate increased expression of CCL2 (Stern
& Slobedman, 2008). CCL2 is a pro-inflammatory cytokine
that acts as a chemoattractant to monocytes, macrophages,
dendritic cells and T cells expressing CCR2. This increase in
CCL2 acts to attract CD14+ monocytes to latently infected
GMPs (Stern & Slobedman, 2008). This behaviour of
latently infected GMPs is likely a viral strategy employed
to recruit new leukocytes to be infected; however, too
little is known about in vivo hCMV reactivation to know
if this spread and reactivation occurs before or after
GMPs develop into macrophages. Further research could
be done into the manipulation of hCMV-infected GMPs
as there is currently just one study demonstrating this
change in chemotaxis.
There are a variety of hCMV chemokine receptors shown
to affect cell migration, including US27, US28, UL33 and
UL78 (Fielding, 2015), all of which are homologous to
human GPCRs. US27 is expressed late during lytic infection and has no known ligand (Fraile-Ramos et al., 2002;
Stapleton et al., 2012). However, it was found to potentiate
CXCR4-mediated chemotaxis, increasing the expression
and amount of surface CXCR4 (Arnolds et al., 2013).
As previously explained, CXCR4 is a seven-membrane-
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Table 4. Betaherpesviruses change cellular receptors/chemokines
Cell type
Dendritic cell

GMP
Monocyte

T cell

Receptor or chemokine

Virus

Amount or functionality

References

CCR7
CCR1
CCR5
CCL2
CCR1
CCR2
CCR5
CCL22
CCL5
CCR7
CXCR4
CXCR4
CCR7

hCMV
hCMV
hCMV
hCMV
hCMV
hCMV
hCMV
hCMV
HHV-6A
HHV-6
HHV-6
HHV-7
HHV-7

Decrease
Decrease
Decrease
Increase
Decrease
Decrease
Decrease
Increase
Decrease/increase
Increase
Decrease
Decrease
Increase

Moutaftsi et al. (2004)
Varani et al. (2005)
Varani et al. (2005)
Stern & Slobedman (2008)
Frascaroli et al. (2006, 2009);
Straschewski et al. (2011)

spanning GPCR that allows the cell to follow the chemokine gradient of its natural ligand, CXCL12, which is
secreted constitutively in a variety of tissues, including
the lymph nodes, thymus, bone marrow, lungs and adrenal
glands (Alkhatib, 2009; Luker & Luker, 2006). The potentiation of CXCR4 resulted in increased migration to
CXCL12 during in vitro migration assays (Arnolds et al.,
2013). It has been speculated that increased CXCR4 levels
at appropriate times could allow hCMV-infected cells to
migrate to bone marrow or lymph nodes, where there
would be an increased opportunity to spread to susceptible
cells (Arnolds et al., 2013).
US28 was first shown to affect migration in vascular SMCs
(Streblow et al., 1999). It was found that US28 directed cell
migration following the chemokines CCL2 and possibly
CCL5. In the absence of CCL2, there was no migration of
hCMV-infected SMCs (Streblow et al., 1999). This would
allow infected SMCs to migrate to areas of inflammation,
potentially providing opportunity for viral spread to leukocytes. Later it was demonstrated that US28 acted to control
migration of both infected SMCs and infected macrophages. Kledal et al. (1998) found that US28 also bound
CX3CL1, which is a chemokine that is found on the cell
surface and extracellularly in a secreted form; this work
was later followed up by others (Murphy et al., 2008;
Vomaske et al., 2009). CX3CL1 is only known to be produced by endothelial cells and results in the recruitment
of inflammatory cells (Bazan et al., 1997; Vomaske et al.,
2009). These authors found that the presence of CX3CL1
inhibited the migration of hCMV-infected SMCs, but
induced the migration of hCMV-infected macrophages.
It was also demonstrated that the inverse was true, in the
presence of CCL5, hCMV-infected macrophages US28mediated migration was inhibited, but hCMV-infected
SMCs demonstrated normal chemotaxis, as expected
(Vomaske et al., 2009). This makes the viral GPCR US28
unique in that it is chemokine- and cell-type-specific.
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Poole et al. (2006)
Cerdan et al. (2001)
Hasegawa et al. (1994)
Yasukawa et al. (1999)
Yasukawa et al. (1999)
Hasegawa et al. (1994)

It seems important for the virus to control cellular
migration during hCMV infection. Evidence for how
US28 functions was provided by Tschische et al. (2011),
when they found that hCMV chemokine receptors heteromerize with each other. It was observed that UL33 and
UL78 heteromerization resulted in silencing of US28mediated activation of the NF-kB pathway. Tadagaki
et al. (2012) investigated UL33 and UL78, and found that
these two GPCR homologues formed heteromers with
CCR5 and CXCR4 on the surface of infected THP-1 cells.
This was found to prevent cell chemotaxis facilitated by
CCR5 and CXCR4 in vitro. CCR5 allows the cell to
follow a variety of chemokines, including CCL3, CCL4
and CCL5, these being the best agonists, while CXCR4 is
known to be chemoattracted to CXCL12 (Alkhatib,
2009). The majority of chemokines that act as CCR5
ligands are pro-inflammatory.
During hCMV infection the virus is able to regulate host
receptors in various ways to prevent chemotaxis. It has
been demonstrated that hCMV prevents CCR7 expression
in monocyte-derived dendritic cells, preventing chemotaxis
following CCL19 and CCL21 chemokine gradients in vitro
(Moutaftsi et al., 2004). hCMV-infected Langerhans cells
also demonstrate reduced chemotaxis in response to lymphoid chemokines (Lee et al., 2006). After these observations it was found by Wagner et al. (2008) that hCMV
UL18 inhibited chemotaxis of dendritic cells in vitro. The
extracellular UL18 is expressed late in hCMV infection
and binds the leukocyte immunoglobulin-like receptor 1
molecule on the surface of dendritic cells. This results in
various changes, including reduced chemotaxis, increased
pro-inflammatory cytokine production, upregulation of
CD83 and inhibition of CD40 (Park et al., 2002; Wagner
et al., 2008). It was also observed that hCMV-infected dendritic cells showed downregulated chemokine expression
and inhibited maturation due to vIL-10, a product of the
hCMV UL111A gene. Dendritic cells that were able to
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CCL5 would assist in preventing the attraction of monocytes and T cells to areas of hCMV infection. While a certain number of monocytes would be beneficial for viral
spread, an overabundance of monocytes and the presence
of T cells could result in the impairment of viral spread.

mature during hCMV infection showed an increase in
chemotactic ability to follow the lymph node homing chemokine (Chang et al., 2004). It has further been observed
that chemotaxis is disrupted in infected endothelial cells.
Reinhardt et al. (2014) demonstrated how hCMV-infected
human coronary artery endothelial cell (HCAEC) chemotaxis to vascular endothelial growth factor is inhibited.
HCAEC migration is important for repair post-vascular
injury (Deanfield et al., 2007; Waltenberger, 2007). While
the observation explains how hCMV can play a role in contributing to pro-atherosclerotic phenotypes, the viral strategy for inhibiting HCAEC migration remains unknown.
A further way to inhibit chemotaxis of cells is by secreting
chemokine-binding proteins. hCMV-produced UL21.5 acts
in this capacity by binding CCL5, acting as a chemokine
sink or decoy receptor (Wang et al., 2004a). This would
prevent the cellular receptor from being able to bind
CCL5 and follow the chemoattractant. hCMV also utilizes
miR-UL148D to silence CCL5 protein synthesis in infected
cells (Kim et al., 2012). These studies emphasize the
importance of CCL5 regulation during hCMV infection.
Preventing immune cell production and detection of

To better enhance viral spread, hCMV uses virally encoded
chemokines UL128, UL146 and vCXCL1 to attract target
immune cells. The piracy of host chemokine CCL22 further
assists in this process. By upregulation of CCL22 in infected
monocytes, Tregs are attracted, and could assist in downregulation of an immune response to viral infection.
By increasing the functionality of CXCR4, chemotaxis of
virally infected cells to other tissues could be encouraged.
By manipulating host chemokine receptor CCR7, hCMV
can avoid migration to primary and secondary lymph
tissue, evading possible detection. The dysregulation of
virus-infected cell movement appears to allow hCMV the
edge in evading immune detection and increase the opportunity for viral spread (see Fig. 1). Future studies investigating the function of viral chemokines and chemokine
receptors could examine their effects in vivo utilizing

ThP1 cell
PBMCs

Neutrophils
UL146

Lymph tissue

Endothelial cells
CMV-infected
cells
GMP

Smooth muscle
cells

CCL2
CCL22
Dendritic cells
Macrophage

Treg cells

Fig. 1. Changes in cellular chemotaxis resulting from hCMV infection. hCMV uses virally encoded chemokines UL128,
UL146 and vCXCL1 to attract target immune cells such as neutrophils and PBMCs. Increases in CCL2 expression further
assist in attracting monocytes, macrophages and dendritic cells. Upregulation of CCL22 in infected monocytes attracts Treg
cells, which can assist in downregulation of an effective immune response to viral infection. Increasing the functionality of
CXCR4 allows virally infected cells to migrate to other tissues, including secondary lymphoid tissues.
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animal models, as has been done with hCMV US28
(Bongers et al., 2010).
Human herpesvirus 6 (HHV-6)
HHV-6, initially named human B lymphotropic virus, was
first discovered in 1986 in patients with lymphoproliferative disorders (Salahuddin et al., 1986). HHV-6A and
HHV-6B were recognized as different variants of the
same species in 1992, and in 2012 the International Committee on Taxonomy of Viruses classified them as two
distinct viruses (Ablashi et al., 1993; Adams & Carstens,
2012). Because classification as two distinct viruses has
come relatively recently, it makes it difficult to distinguish
between HHV-6A and HHV-6B in some of the early literature. The seroprevalence of HHV-6 in adults worldwide is
approximately 83–100% (Hall et al., 2006).
HHV-6A
HHV-6A is a betaherpesvirus that has primary tropism for
CD4+T cells and can also infect CD8+T cells, natural
killer (NK) cells, gamma/delta T cells, human neural stem
cells, human progenitor-derived astrocytes, and oligodendrocyte progenitor cells (Ablashi et al., 2014; Lusso et al.,
1991, 1993, 1995). It has also been shown to lytically
infect B cells that have been immortalized with EBV
(Ablashi et al., 1989). HHV-6A can alter the expression
of different cellular markers involved in cellular homing
and trafficking, which causes significant disruption to
immune cell function and viability. The virus has been
implicated in a number of diseases including multiple
sclerosis, Hashimoto’s thyroiditis, and AIDS. In vitro studies
show that HHV-6A causes upregulation of CD4 on cells
that do not typically express this marker, making these
cells susceptible to HIV infection and possibly contributing
in the progression to AIDS (Lusso et al., 1991, 2007).
HHV-6 has one functional chemokine-like protein, U83
(see Table 3). The viral chemokine U83A from HHV-6A
is involved in chemoattraction and has selective specificity
for receptors CCR1, CCR4, CCR5, CCR6 and CCR8. These
are found on T cells, monocytes/macrophages and activated T lymphocytes (CCR1, CCR5, CCR8), skin-homing
T lymphocytes (CCR4, CCR8), immature dendritic cells
(CCR1, CCR6) and NK cells (CCR8) (Ablashi et al.,
2014; Catusse et al., 2008; Dewin et al., 2006). The difference in specificity of U83A (from HHV-6A) and U83B
(from HHV-6B) to attract diverse cell types (see Table 3)
could account for the variable tropism of the two viruses
(Clark et al., 2013). U83A is found in a full-length form
as well as a truncated splice variant (French et al., 1999).
It is thought that, because of the different forms of the peptide, U83A could block both innate and adaptive immune
responses, as well as attract the cells involved in these
responses for further infection (Dewin et al., 2006). U83A
induces chemotaxis and morphological changes in cells
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expressing CCR5 in a manner similar to CCL4, but with
a significantly delayed internalization of CCR5 compared
with CCL4. Interestingly, binding of U83A to CCR5 has
been shown to inhibit CCR5 tropic HIV-1 infection
(Catusse et al., 2007).
HHV-6 has two GPCRs, U12 and U51, which encode
chemokine receptors (see Table 2). U51, known to affect
migration in HHV-6A infected cells, is expressed at early
time points post-infection, whereas U12 is expressed late
and influences chemotaxis of HHV-6B-infected cells.
HHV-6A U51A has novel specificity for CCL5 and can
also bind CCL2, CCL11, CCL7 and CCL13. This makes
U51A unique among viral and cellular receptors in that it
overlaps activity with CCR1, CCR2, CCR3 and CCR5 in
the binding of CCL5 (Catusse et al., 2008). There is also
overlap with CCR2, CCR4, US28, UL12, D6 and Duffy in
the binding of CCL2; CCR3 and E1 in the binding of
CCL11; CCR1, CCR3, US28 and D6 in the binding of
CCL7; and CCR2 and CCR3 in the binding of CCL13.
Unlike many viral GPCRs that have constitutive signalling,
U51A has been shown to perform both inducible and
constitutive signalling (Catusse et al., 2008; Fitzsimons
et al., 2006).
U51A expression has been shown to cause a reduction of
CCL5 expression using the Hut78 human CD4+T lymphocyte cell line. U51A has high relative affinity for
XCL1, which normally binds human receptor XCR1
found on NK cells and T lymphocytes. This binding
could have a number of effects, including: preventing
infected cells from interacting with NK cells; inducing
chemotaxis to T lymphocytes, which could spread infection; and preventing apoptotic signals within infected
cells (Cerdan et al., 2001). CCL19, normally bound by
human receptor CCR7, can also be bound by U51A. This
could cause infected cells to migrate to the T cell-rich
lymph node, promoting viral spread. HHV-6A U83A chemokine does not bind U51A. Expression of U51A ligands
in the brain could also allow migration of infected cells
into the central nervous system. Damaged epithelial lung
cells and airway parasympathetic nerves express CCL2
and CCL11, which both bind U51A, and could promote
migration of the infected cells to these areas to be transmitted to new hosts.
CCR7, which is expressed in various lymphoid tissues, is
another receptor that is modulated by herpesviruses (see
Table 4). HHV-6A and HHV-6B upregulate CCR7
expression in CD4+T cells (Hasegawa et al., 1994).
CCR7 is specific for CCL19 and CCL21 and plays roles in
cell migration and proliferation (Tadagaki et al., 2005).
This upregulation of CCR7 could be an important aspect
of HHV-6 pathogenesis as upregulation of CCR7 promotes
migration of T cells and dendritic cells to the paracortex in
lymph nodes (where T cell priming occurs) and the periarteriolar lymphoid sheath in the spleen, both of which
are T cell-rich (Comerford et al., 2013).
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As mentioned previously, HHV-6A can also downregulate
cellular receptors. Along with downregulation of CD46
(its entry receptor) and CD3 (Grivel et al., 2003), CXCR4
is downregulated by HHV-6A in primary CD4+ T lymphocytes and the Jjhan T cell line, which affect the chemotactic
response of the cells to CXCL12, the natural ligand of
CXCR4 (Yasukawa et al., 1999). The disruption of
CXCR4/CXCL12 signalling by downregulation of CXCR4
by HHV-6A could prevent the retention of haematopoietic
stem/progenitor cells (HSPCs) and more mature leukocytes
in the bone marrow, allowing these cells to be mobilized and
enter into circulation (Karpova & Bonig, 2015). The
migration of CXCR4-expressing thymocytes out of the
thymus was shown to occur in a CXCL12-dependent
manner (Poznansky et al., 2002; Weinreich & Hogquist,
2008); so the downregulation of CXCR4 by HHV-6A
could be another way the virus prevents migration away
from areas where target cells are present. Additionally, the
downregulation of CXCR4 by HHV-6A could prevent
homing of bone marrow-derived precursor cells to the
thymus (Calderón & Boehm, 2011), possibly preventing
positive and negative selection from occurring in these cells.
HHV-6 has been shown to cause modulations to CCL5
expression. This chemokine has selective chemoattractive
activity on resting CD4+ memory T cells (Hasegawa
et al., 1994) and has been shown to be upregulated by
HHV-6 in an ex vivo study where human tonsil blocks
were infected with both HHV-6 and HIV-1. This upregulation of CCL5 was shown to suppress HIV-1 CCR5-tropic
variants and possibly to stimulate replication of CXCR4utilizing variants, which gives evidence that HHV-6 may
play a role in HIV pathogenesis by promoting the switch
between CCR5-tropic to CXCR4-tropic HIV-1 (Grivel
et al., 2001). In contrast, CCL5 expression in epithelial
cells is downregulated by U51A from HHV-6A (Milne
et al., 2000). Epithelial cells expressing U51A also had
morphological changes and exhibited increased spreading
and flattening, which could increase the ability of HHV-6
to spread to uninfected cells as it is primarily spread by
cell-to-cell contact (Milne et al., 2000). As has been observed
with other viral chemokines and chemokine receptors, their
functions could be multipurpose in attracting cells to the
area of infection, and also in evading the immune cells of
the host so replication and latency can take place.
As described above, HHV-6A alters the expression of
different cellular markers. Many of these markers are
involved in cellular homing and tracking to specific areas
of the body, and when altered can cause significant disruption to immune cell function and viability. Further research
into HHV-6A effects on cellular trafficking could serve as a
critical guide for developing new treatments to prevent
these disease-causing disruptions.
HHV-6B
HHV-6B causes exanthem subitum (roseola) (Yamanishi
et al., 1988) and is found in approximately 95–100% of
550

adults worldwide. Unlike HHV-6A, HHV-6B has very
little to no ability to infect CD8+T cells, NK cells and
gamma/delta T cells (Grivel et al., 2003; Martin et al.,
2012). The cellular receptor for HHV-6B is CD134
which, like the cellular receptor for HHV-6A, CD46, is
expressed on almost all human cells (Tang et al., 2013),
indicating that other factors are required for effective
viral replication.
The HHV-6B viral chemokine U83B is specific for CCR2
and can cause chemoattraction of CCR2-expressing cells
(classical and intermediate monocytes) for infection
(Ablashi et al., 2014; Clark et al., 2013; Lüttichau et al.,
2003) (see Table 3). U83 from HHV-6B induced transient
calcium mobilization and efficient migration in THP-1
cells (a monocyte cell line derived from monocytic leukaemia) (Zou et al., 1999). U83B has been shown to have a
different specificity from U83A as U83B chemoattracts
CCR2-expressing monocytes, whereas U83A has a broader
but still selective specificity as mentioned previously
(Catusse et al., 2008; Dewin et al., 2006). The specificity
of U83B for CCR2 appears to be due to its N-terminal
region. Human chemokines can induce rapid internalization of CCR2 upon binding, whereas in vitro experiments
show U83B does not cause CCR2 internalization. This
finding is similar to the delayed internalization of CCR5
observed with U83A. CCR2 expression is induced in
pro-inflammatory conditions and, interestingly, HHV-6B
is associated with inflammatory diseases such as encephalitis and myocarditis (Clark et al., 2013).
The HHV-6B GPCR U12 efficiently binds CCL2, CCL5 and
CCL4, so it has overlapping activity with the receptors for
CCL2 and CCL5 as in HHV-6A, but also has overlapping
activity with the receptors for CCL4 (Balkwill, 2004;
Isegawa et al., 1998) (see Table 2). The exact role of chemokine receptors with these viruses is still unknown, but they
could be multipurpose, in that they could have been developed for immune evasion to intercept chemokines that
would otherwise be attracting immune cells to the area of
infection, to attract uninfected cells that could then be
infected, to induce latency, or to transition from latency
to active replication.
Similar to HHV-6A, HHV-6B was shown to downregulate
CXCR4 in CD4+T lymphocytes as well as MT-4 cells. This
downregulation impaired the chemotactic response of the
cells to the natural ligand, CXCL12 (Yasukawa et al.,
1999). Similar to HHV-6A, this could induce mobilization
of HSPCs into the circulation as well as prevent migration
of cells out of the thymus, both of which aid in the propagation and survival of the virus.

Human herpesvirus 7 (HHV-7)
As part of the same subfamily as HHV-6A and -6B, HHV-7
shares similar characteristics, including also being a
T-lymphotropic virus, although it can infect other cell
types (Ablashi et al., 1995; Ward, 2005). Like other human
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herpesviruses, once HHV-7 is acquired, the host is infected
for life. The virus is shed in saliva and spread through
this route of transmission. Compared with the other
human herpesviruses, much less research has been conducted on HHV-7 infection and pathogenesis. Clinically it
has been associated with the development of pityriasis
rosea, post-infectious myeloradiculoneuropathy, encephalopathy and other syndromes. There is some speculation
on the involvement of HHV-7 in the development and
progression of these diseases (Chuh et al., 2004; Mihara
et al., 2005; van den Berg et al., 1999). HHV-7 infections
can have a variety of symptoms, including fever, rash, febrile
respiratory problems, vomiting and diarrhoea (Clark et al.,
1997; van den Berg et al., 1999). Infections typically occur in
children and are most often asymptomatic (Ward, 2005).
HHV-7 has been shown to influence migration in human
cells in a variety of ways (see Tables 1 and 4). Yasukawa
et al. (1999) showed that it downregulated transcription
and surface expression of CXCR4 in CD4+T cells.
As described before, CXCR4 is the receptor for CXCL12,
which is secreted by various cells in the lymph nodes,
bone marrow, etc. With CXCR4 assistance, T cells can
follow a CXCL12 gradient to sites of inflammation
(Domanska et al., 2013). After infection with HHV-7,
Yasukawa et al. (1999) tested the migration and intracellular levels of Ca2+ of CD4+T cells. It was found that
infected cells demonstrated less migration following the
CXCL12 gradient and decreased levels of intracellular
Ca2+ compared with the mock-infected cells used as
controls. It is currently unknown what viral factor(s)
contribute to the downregulation of CXCR4. It has been
demonstrated that lower levels of CXCR4 in HHV-7positive T lymphocytes prevent infection by CXCR5tropic HIV-1 (Yasukawa et al., 1999). Future research
could explore how HHV-7 manipulates CXCR4 in infected
cells and further confirm the findings of Yasukawa et al.
(1999), as theirs is the only study investigating this
change in chemotaxis.
While CXCR4 is a cellular GPCR that is influenced postviral infection, HHV-7 has two known viral chemokine
receptors, products of the U12 and U51 genes. These
genes were identified as GPCR homologues and later Tadagaki et al. investigated the functionality of the protein products of these genes (Nicholas, 1996; Tadagaki et al., 2005).
They verified that these proteins do accumulate on the
surface of the cell. Further, they verified that they could
act as functional chemokine signal receptors. Cells expressing U12 and U51 expressed heightened levels of intracellular Ca2+ after appropriate signalling through the U12 and
U51 GPCRs. Testing the chemotactic effect of the
expression of these proteins in the Jurkat T cell line using
microchannel migration techniques, it was found that
cells expressing U12 migrated effectively following a gradient of CCL19 and CCL21. This would make U12 a viral
homologue of the cellular GPCR CCR7, as it also responds
to both CCL19 and CCL21. Both of these chemokines are
strongly expressed in the T cell zone of secondary lymphoid
http://jgv.microbiologyresearch.org

tissues and are important in lymphocyte homing and
migration (Nomura et al., 2001). It has also been observed
that CCR7 expression is upregulated during HHV-7 infection (Hasegawa et al., 1994). While the strategy behind the
manipulation of cellular chemotaxis following these ligand
chemokines is still unclear, it could be speculated that
migration to such areas could be beneficial for HHV-7
transmission as T cells are preferential targets of infection.
Tadagaki et al. (2005) also speculated that expression of
these viral proteins could aid in immune evasion and
viral replication. Further research in murine L1.2 cells
showed that U12 and U51 products could respond to
CCL22 and CCL19, respectively (Tadagaki et al., 2007).
Gene products U12 and U51 could act with CCR4 and
CCR7, respectively, to direct migration in this cell line in
response to CCL22 and CCL19 (Luther et al., 2002).
If this were to hold true in human cells infected with
HHV-7, then infected cells would be expected to migrate
more to areas of inflammation, as CCL22 is a pro-inflammatory chemokine secreted by a wide variety of cells, and
areas of high T cell density as CCL19 is constitutively
expressed by stromal cells in the T cell zone (Luther
et al., 2002). These areas would be attractive locations for
the viral spread of HHV-7.

GAMMAHERPESVIRINAE
Epstein – Barr virus (EBV)
The main cause of viral mononucleosis, EBV infects nasopharyngeal epithelial cells and B lymphocytes (Balfour
et al., 2005; Cohen, 2000). Viral spread is mainly accomplished through shedding in saliva (Balfour et al., 2005).
EBV gains access to appropriate host cells by using viral
gp350 to bind CD21 (a type 2 complement receptor) on
the cell surface; the viral envelope then fuses with the cell
membrane, releasing the viral capsid and associated tegument proteins into the cytoplasm (Toussirot & Roudier,
2008). The virus uses major histocompatibility complex
class II molecules as cofactors when infecting B lymphocytes (Li et al., 1997). During its latent infection of host
B cells, EBV expresses one of four possible latency
programmes, depending on cellular development and
conditions (Young & Rickinson, 2004). It is likely that
reactivation in vivo of latent virus is due to the differentiation of infected memory B lymphocytes (Amon &
Farrell, 2005; Hochberg et al., 2004b). EBV is associated
with a variety of malignancies owing to its ability to regulate cell proliferation, including Burkitt’s lymphoma,
Hodgkin’s lymphoma, nasopharyngeal carcinoma, gastric
carcinoma, and post-transplant lymphoproliferative
disorder (Hochberg et al., 2004a; Kutok & Wang, 2006;
Shibata & Weiss, 1992; Young & Rickinson, 2004).
During infection of B cells, EBV controls the expression of
various endogenous chemokines and chemokine receptors
(see Table 5). One such manipulated receptor that is shown
to affect migration is CXCR4. As previously described it is
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Table 5. Gammaherpesvirus changes cellular receptors/chemokines
Cell type
B cell

Endothelial

Receptor or chemokine

Virus

Amount or functionality

CXCR4
CCR7
CCR6
CCR10
CXCR5
EBI2
CXCL8
CCL2
CCL5
CXCL7
CXCL16

EBV
EBV
EBV
EBV
EBV
EBV
KSHV
KSHV
KSHV
KSHV
KSHV

Decrease
Decrease/increase
Increase
Increase
Decrease
Increase
Increase
Increase
Increase
Increase
Increase

the receptor for CXCL12, which is secreted by various cells
in a number of organs, including the lymph nodes, lungs,
liver, kidneys, heart and bone marrow (Teicher & Fricker,
2010). Ehlin-Henriksson et al. (2006) demonstrated that
tonsillar B cells infected with EBV showed reduced
expression of CXCR4 (Ehlin-Henriksson et al., 2006).
Assays of chemotactic migration further showed that
infected tonsillar B cells had decreased ability to migrate
towards CXCL12. This decreased expression and the subsequent lack of chemotaxis was demonstrated in EBVimmortalized B cells as well (Nakayama et al., 2002). The
inability to follow the CXCL12 gradient would prevent
infected B cells from migrating to tissues expressing only
this chemokine. CCR7 is another host receptor that is virally
regulated during EBV infection. In a later study by EhlinHenriksson et al. (2009), it was found that CCR7 is downregulated in tonsillar B cells post-infection. This change in
expression led to decreased migration following the natural
chemokine ligand CCL21. CCL21 is produced by stromal
cells in primary and secondary lymphoid tissues and lymphatic endothelial cells in the peripheral tissue (Comerford
et al., 2013). It is critical for directing the formation of secondary lymphoid tissues such as spleen, Peyer’s patches, and
lymph nodes (Ohl et al., 2003). It has also been surmised
that CCR7 ligands are influential in tertiary lymphoid
organs (Comerford et al., 2013). Immortalized B lymphoblast cell lines (LCLs) have been shown to have an increased
expression of CCR7 compared with uninfected cells. This
upregulation resulted in increased migration following a
CCL21 gradient in assays of chemotaxis (Nakayama et al.,
2002). While these results may seem to be paradoxical, it
is possible that the difference in expression could be a
result of a different latency programme or stage of viral
infection. Ehlin-Henriksson et al. (2009) used harvested
tonsillar B cells and measured CCR7 expression and cellular
migration 7 days post-infection. In contrast, LCLs are a
result of EBV immortalization of B lymphocytes, the process
taking several weeks to establish the cell line and expressing
a type III latency programme (Young & Rickinson, 2004).
The difference in expression could be a result of either the
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length of infection or the latency programme employed by
the virus post-infection.
In that same study of LCLs, it was found that they
expressed increased amounts of CCR6 and CCR10, the
natural ligands of which are CCL20 and CCL28, respectively. Migration assays confirmed that this change resulted
in increased chemotaxis towards CCL20 and CCL28
chemokine gradients (Nakayama et al., 2002). CCL20 is
an inflammatory chemokine involved in the recruitment
of dendritic cells, CD4+T lymphocytes and B lymphocytes
(Zhao et al., 2014). CCL28 is secreted by epithelial cells that
line the mucosa and is used to recruit IgA+ plasma cells
(Vazquez et al., 2015; Wilson & Butcher, 2004). CCL28
expression is highest in the salivary glands (Liu et al.,
2012). It would be in the best interest of EBV to regulate
these receptors, allowing the virus to migrate to mucosal
tissues, such as the salivary gland, for effective viral
spread. Chemotaxis to sites of inflammation could result
in viral reactivation and increased targets for further infection. A final cellular receptor that is downregulated during
infection, effecting a change in chemotaxis, is CXCR5. The
inability to migrate owing to lowered levels of CXCR5 was
observed in LCLs and infected tonsillar B cells (EhlinHenriksson et al., 2009; Nakayama et al., 2002). CXCR5
allows B cells to migrate in response to CXCL13 (Carlsen
et al., 2004). CXCL13 is an important chemokine for secondary lymphoid tissue development, and the main cells
responsible for secretion of CXCL13 are follicular dendritic
cells (Cyster et al., 2000; Legler et al., 1998). It is expressed
in vascular tissue, Peyer’s patches, and inflamed lymphoid
tissue (Ebisuno et al., 2003; Mazzucchelli et al., 1999;
Okada et al., 2002; Shi et al., 2001). A recent study of
murine B lymphocyte positioning in CXCR5-negative
mice demonstrated that CXCR5 is important for the retention of B cells in Peyer’s patches (Schmidt & Zillikens,
2013). While avoiding tissue types expressing CXCL13
could be beneficial for the virus, possibly assisting in
immune avoidance, the exact reason for regulating
CXCR5 is still unclear. Another receptor thought to be
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influenced by EBV is EBV-induced gene 2 (EBI2). Infected
B cells display a heightened expression of EBI2 (Birkenbach
et al., 1993; Kelly et al., 2011). While it remains unknown
how EBV manipulates EBI2 expression in B lymphocytes, it
has been observed that EBI2+ cells migrate following a
7a-OHC gradient (Liu et al., 2011). 7a-OHC is the natural
ligand of EBI2 and is expressed by stromal cells of secondary lymph tissue, assisting in directed migration during cell
chemotaxis in these areas (Gatto & Brink, 2013; Hannedouche et al., 2011). Exaggerated expression of EBI2 by
EBV could result in migration to the outer follicular zone
in secondary lymph tissue, preventing migration toward
T cell zones and germinal centres (Cyster, 2010).
The viral regulation of host lymphocytes extends to
controlling various chemokines produced during infection,
resulting in a change in the chemotaxis of uninfected cells.
EBNA-3C, a viral product essential in establishing latency
and immortalization of B cells, acts to regulate two hostproduced chemokines, CXCL10 and CXCL11 (McClellan
et al., 2012). EBNA-3C has been found to interact with
both transcriptional co-repressors and co-activators
(Cotter & Robertson, 2000; Radkov et al., 1999; Touitou
et al., 2001). Using the EBV-negative BJAB cell line,
McClellan et al. (2012) showed that expression of EBNA3C reduces expression of these two chemokines. The
result is decreased migration of CXCR3+ cells (McClellan
et al., 2012). Cells that express and migrate in response to
CXCL10 and CXCL11 via CXCR3 include various T lymphocytes, including CD8+T cells. CXCL10 and CXCL11
are typically expressed to attract Th1 cells in response to
infection. EBV has also demonstrated the ability to influence the expression of chemokines via microRNAs
(miRNAs). miR-BHRF1-3, an EBV-produced miRNA,
has the ability to silence CXCL11 protein synthesis (Xia
et al., 2008). Downregulation of these chemokines suggests
that immune avoidance could be a reason behind viral
manipulation. Repression of CXCL11 would prevent
attraction of cytotoxic T cells that might recognize virally
infected B lymphocytes.
The chemokine receptor CXCR4 is a popular target for
manipulation, and EBV, like other herpesviruses, uses it
to prevent cell migration to certain tissue areas, probably
to avoid immune detection. To achieve this same purpose,
EBV also downregulates CCR7. During infection, the virus
increases the host chemokine CCR6, allowing infected cells
to more readily migrate to areas of inflammation. CCR10
function is also pirated, allowing infected cells to migrate
toward epithelial cells, such as mucosal epithelial cells.
This is likely vital for the spread of EBV. Reduction in
expression of CXCL10 and CXCL11 could help in
immune avoidance by suppressing the ability to attract
T lymphocytes via these chemokines (see Fig. 2).
Kaposi’s sarcoma herpesvirus (KSHV)
KSHV, also known as human herpesvirus 8 (HHV-8), is
named after Moritz Kaposi, who originally described a
http://jgv.microbiologyresearch.org

unique skin lesion in the 1870s. The discovery of the association of herpesviral DNA sequences in Kaposi’s sarcoma
(KS) did not occur until 1994 (Chang et al., 1994;
Ganem, 2010). KS presents as tumours most often found
in the dermis but can also be found in lungs, liver and
intestines (Moore & Chang, 2003). KSHV is also linked
to primary effusion lymphoma and multicentric Castleman’s disease (Avey et al., 2015; Cesarman et al., 1995;
Soulier et al., 1995).
KSHV encodes three secreted chemokines; vCCL1 (ORF K6
or vMIP-I/MIP-1a), vCCL2 (ORF K4 or vMIP-II/MIP-1b)
and vCCL3 (ORF K4.1 or vMIP-III/BCK), which activate
CCR8, CCR3 and CCR4, respectively (see Table 3). This
set of chemokines antagonizes the recruitment of Th1
and NK cells. This redirects the immune response from a
Th1-like response towards a Th2 profile. vCCL2 has also
been shown to prevent CCL5-mediated chemotaxis of
Th1-like lymphocytes (Moore & Chang, 2003; Stebbing
et al., 2003; Weber et al., 2001). The receptor XCR1,
which normally binds the ligand XCL1 and is involved in
T-cell recruitment, is selectively activated by vCCL3 but
is also blocked by vCCL2. The opposing function and differing time of expression of the two viral chemokines could
indicate the importance of the regulation of the XCR1
receptor in KSHV infection and pathogenesis. Neutrophils
have high levels of XCR1, and vCCL3 chemoattracts these
cells, which may indicate that neutrophils play a role in
viral spread (Lüttichau et al., 2007). vCCL1 and vCCL2
expression were also shown to induce migration of monocytes. This could play a role in the process of tumour development in KS as circulating monocytes could be recruited
to KSHV-infected cells, thus propagating the infection
(Nakano et al., 2003).
KSHV encodes a GPCR (vGPCR or ORF74) that is homologous to CXCR2 and has a high level of constitutive
activity (Arvanitakis et al., 1997; Cesarman et al., 1996;
Hensbergen et al., 2004; Pati et al., 2001) (see Table 2).
Constitutive expression of ORF74 in microvascular lung
endothelial cells inhibits migration and increases cell
survival. This inhibitory effect on migration can be reversed
by endogenous chemokines CXCL10 and CXCL12. These
act as inverse agonists of ORF74, as seen in an in vitro
wound closure assay, where CXCL10 increased migration
of ORF74-expressing cells. Limiting migration of infected
cells may aid in immune evasion and KSHV survival.
Constitutive expression of ORF74 has also been shown to
attract uninfected endothelial cells, which could then be
infected and propagate the infection (Couty et al., 2009).
ORF74 has been shown to activate the transcriptional
activators NF-kB and activator protein 1 (AP-1), leading
to the downstream production of signals including IL-6,
IL-8, granulocyte-macrophage colony-stimulating factor
(GM-CSF) and CCL5 (Pati et al., 2001; Schwarz &
Murphy, 2001; Shepard et al., 2001). Elevated levels of
CXCL8 are observed in KS patients and can activate
KSHV-infected cell growth and induce chemotaxis (Wang
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Site of
inflammation
CCL20

Mucosal epithelium
CCL28
Decrease of
CXCL10 & CXCL11

T cell
Infected cell

Decrease of
CXCR5, CXCR4,
CCR7

To 2nd lymph tissue

B cell

Fig. 2. Changes in cellular chemotaxis resulting from EBV infection. EBV decreases expression of cellular CXCR4 and
CCR7 to prevent migration to certain tissue areas, probably to avoid immune detection. Increases in host chemokine CCR6
allow infected cells to migrate to areas of inflammation. CCR10 function is also pirated, allowing infected cells to migrate
toward epithelial cells, such as mucosal epithelial cells. Downregulation of CXCL10 and CXCL11 could help in immune
avoidance by suppressing the ability of infected cells to attract T lymphocytes.

et al., 2004b). CXCR1 and CXCR2, receptors that bind
CXCL8, have been found to be expressed in KS lesions.
CXCR4 has also been found to be expressed on cells in
these lesions, which is important as this receptor acts as a
co-receptor for CXCR4-tropic strains of HIV (Masood
et al., 2001; Pati et al., 2001; Wang et al., 2004b). These
combined effects of ORF74 could stimulate the proliferation, migration and chemotaxis of endothelial cells in KS.
KSHV encodes a homologue of IL-6, vIL-6, that has been
shown to promote migration of endothelial cells in both
autocrine and paracrine fashions. Inhibition of this
migration can be specifically inhibited by a DNA methyltransferase 1 (DNMT1) inhibitor, suggesting that the
mechanism of vIL-6 is dependent on enhancing expression
of DNMT1. As the control of DNA methylation is crucial
for gene expression and other cellular processes, disruption
of methylation could be a mechanism for KS tumorigenesis
(Wu et al., 2014).
There are a number of different cellular chemotactic
proteins shown to be upregulated by KSHV, including:
CCL2, CXCL7, CCL5, GM-CSF, CXCL16 and angiogenin
(Xu & Ganem, 2007) (see Table 5). Some of these, such
as CCL5 and GM-CSF, likely increase migration of endothelial cells toward KSHV-GPCR-expressing KS cells

554

(Bussolino et al., 1989; Pati et al., 2001). In contrast,
CXCL16 appears to play an indirect role in tumour
growth and expansion through migration of activated T
cells (Xu & Ganem, 2007). KSHV also causes downregulation of certain genes. The KSHV miRNA miR-K12-10a
downregulates the cytokine receptor TNF-like weak inducer of apoptosis (TWEAK) receptor. This inhibits the
pro-inflammatory response and also provides protection
from TWEAK-induced apoptosis (Abend et al., 2010).
Latency-associated nuclear antigen 1 (LANA-1; encoded by
ORF73), a latently expressed gene, has been shown to
hinder neutrophil chemotaxis, which interferes with
recruitment of neutrophils to infected areas and could be
a way in which latent KSHV survives host-induced acute
inflammation. Neutrophil recruitment is restored in
LANA-1 knockdowns, although not to the level of uninfected cells, indicating that KSHV has other mechanisms
to repress neutrophil recruitment (Li et al., 2011).
As seen with other herpesviruses, KSHV can induce or
inhibit cellular migration, according to what is most
beneficial for viral infection at the given stage. It not only
interferes with cellular marker expression, it also induces
increased production of specific chemokines and cytokines,
which leads to other issues in cellular function and trafficking.
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CONCLUDING REMARKS
With exposure to human herpesviruses being very
common, it is important to understand how these infectious human pathogens influence infected and uninfected
cell types. The viruses of the subfamily Alphaherpesvirinae
use gG to increase the functionality of CXCR4, leading to
increased chemotaxis to a variety of tissues while being
able to manipulate cellular chemokines, such as CXCL9,
to attract PBLs. Viruses of the subfamily Betaherpesvirinae,
also capable of producing and manipulating chemokine
and chemokine receptors, influence a variety of cells
during infection. hCMV inhibits migration in infected
monocytes and potentially attracts monocytes, PBMCs,
macrophages, dendritic cells and regulatory T cells to
sites of infection. Similarly, through its ability to attract
target cells, HHV-6 is able to induce chemotaxis of T lymphocytes, monocytes, immature dendritic cells, and NK
cells to areas of infected cells using viral U83. T cells
infected with HHV-6 are further manipulated, as viral
and cellular GPCRs allow cells to migrate to sites of inflammation and areas rich in T cells. Also manipulating T cells,
HHV-7 prevents infected T lymphocytes from migrating to
various organs and tissues by downregulating CXCR4.
However, it too potentially encourages migration to
inflammatory sites and locations high in T cells by inducing cells to follow chemokine gradients of CCR7,
CCL21, CCL22 and CCL19.
Further masters of cellular piracy, viruses of the subfamily
Gammaherpesvirinae also influence cellular chemotaxis to
avoid immune detection and spread viral infection
throughout the host until latency can be established.
To prevent newly infected cells from potentially migrating
to lymph tissue and other organs, EBV reduces expression
of CXCR4, CCR7 and CXCR5. By downregulating the chemokines CXCL10 and CXCL11, EBV could prevent
infected cells from attracting cytotoxic T cells. To regulate
chemotaxis of cells during infection, KSHV regulates the
attraction or avoidance of neutrophils and monocytes by
viral chemokines vCCL1, 2 and 3. KSHV would be able
to induce the chemotaxis of uninfected endothelial cells
by upregulating various cellular chemokines and activating
the NF-kB pathway, enabling viral spread.
Though our current understanding of how human herpesviruses affect host cell migration during infection is rather
expansive, there still remain various areas for future
research opportunities. In this review we have elaborated
on the cells potentially affected by virally encoded and
virally induced chemokines and chemokine receptors.
However, the full range of cells affected by these chemokines remains to be tested and investigated further. Several
virally regulated cell chemokine receptors suspected of
influencing viral spread and immune avoidance are in
need of confirmatory scientific inquiry. Several human
herpesviruses have not been studied extensively for effects
on cellular chemotaxis, such as the viruses of the subfamily
Alphaherpesvirinae and HHV-7. These areas leave a variety
of opportunities for future research that could contribute
http://jgv.microbiologyresearch.org

to our understanding of how these viruses lead to disease
pathogenesis and progression.
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Abstract
Epstein–Barr virus-induced gene 2 (EBI2) is an important chemotactic receptor that is involved in proper B-cell T-cell
interactions. Epstein–Barr virus (EBV) has been shown to upregulate this gene upon infection of cell lines, but the timing and
mechanism of this upregulation, as well as its importance to EBV infection, remain unknown. This work investigated EBV’s
manipulation of EBI2 expression of primary naive B cells. EBV infection induces EBI2 expression resulting in elevated levels
of EBI2 after 24 h until 7 days post-infection, followed by a dramatic decline (P=0.027). Increased EBI2 expression was not
found in non-specifically stimulated B cells or when irradiated virus was used. The EBV lytic gene BRRF1 exhibited a similar
expression pattern to EBI2 (R2=0.4622). BRRF1-deficient EBV could not induce EBI2. However, B cells transduced with BRRF1
showed elevated expression of EBI2 (P=0.042), a result that was not seen with transduction of a different EBV lytic
transfection factor, BRLF1. Based on these results, we conclude that EBI2 expression is directly influenced by EBV infection
and that BRRF1 is necessary and sufficient for EBI2 upregulation during infection.

INTRODUCTION
Epstein–Barr virus (EBV), a human B-lymphotropic herpes
virus, infects over 90 % of adults [1–3]. Primary EBV infection
usually occurs in childhood [4]. Although most infections are
asymptomatic, delayed infection into adolescence commonly
causes infectious mononucleosis [5, 6]. In this case, the virus
is spread via saliva and infects permissive epithelial cells of the
oropharynx [7]. During this time, the virus also infects mucosal B cells. Once B cells are infected, the virus enters a stage of
latency. This results in the expansion of an lymphoblastoid
cell lines (LCL)-like population of B lymphocytes in the tonsils
[8]. This also allows for the virus to avoid immune detection
and remain with the host for the rest of their life, persisting in
the B-lymphocyte population. Infection with EBV is also associated with and suspected of being responsible for several
types of cancers [9]. It is a strongly associated agent of Burkitt’s lymphoma, as well as various types of non-Hodgkin’s
lymphomas, nasopharyngeal carcinoma and immunoproliferative disorders, and is associated as an environmental trigger
in autoimmune diseases such as systemic lupus erythematosus
[10–14]. Post-infection (p.i.), EBV is adept at controlling lymphocyte gene expression, likely manipulating EBV-induced

gene 2 (EBI2) expression, among others, as a means of controlling B-lymphocyte migration. However, after a time, the
virus lowers the expression of most viral genes and enters a
latent state.
Following the establishment of latency, it is possible for EBV
to reactivate due to environmentally induced stimulation. This
is a problem of particular concern during tissue and organ
transplants and can result in post-transplant lymphoproliferative disease [15]. Key to this process of reactivation are the
various EBV lytic transcription factors, mainly BZLF1, BRLF1
and BRRF1, that assist in initiating the cascade of transcription needed to achieve viral lytic replication [16, 17].
These and various other EBV genes can also be transiently
expressed early after infection. This transient expression of
EBV genes before latency is often called pre-latency [18]. Prelatency is thought to be important for viral immune evasion as
various pre-latently expressed proteins assist in immune
avoidance by suppressing intracellular and extracellular
detection.
EBI2 is a member of the rhodopsin-like subfamily of seventransmembrane G protein-coupled receptors. Sequence alignments have grouped EBI2 with lipid receptors, and it shows
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highest similarity with GPR18 [19, 20]. EBI2 expression is
found to be naturally highest in secondary lymphoid tissues
[20, 21]. The natural ligand of EBI2 is an oxysterol, 7a,25dihydroxycholesterol (7a,25-OHC), which is expressed primarily in secondary lymph tissue by stromal cells. Chemotaxis
of naive B cells within the follicle is mediated through the
expression of EBI2, CCR7 and CXCR5. Varying expression
levels of EBI2 affect the positioning and migration of the
B cells throughout the follicle [22–24]. When EBI2 expression
is highest, the B cell migrates to the outer areas of the B-cell
follicles [22]. Likewise, low levels of EBI2 expression lead B
cells to accumulate in the Follicular dendritic cell (FDC)-dense
region in the centre of the follicle or the interface of the T-cell
zone [23]. These expression patterns are kept in a fine balance
as positioning within the follicle, which directly affects both Bcell proliferation and differentiation [25].
EBV controls expression of EBI2 upon infection. This control could affect EBV-infected cells in several ways. These
include B-cell chemotaxis, improper positioning of B cells
within the follicle and immune deficiency or other disruptions to cell haematopoiesis and function [26]. Altered positioning and chemotaxis of B cells is also thought to be
necessary for the development and progression of lymphomas [27]. Understanding how EBV controls lymphocyte
positioning could allow for improved control of infection
and response to EBV-induced malignancies. To enhance
our understanding of EBV infection, we investigated the
expression profile of EBI2 during EBV infection and potential viral mechanisms responsible for tampering with EBI2
expression.

RESULTS
Time course of EBI2 expression after EBV infection
EBI2 is vital in directing migration of primary B cells to areas
in secondary lymph tissue where they can potentially detect
antigenic proteins [28]. To investigate the way EBI2 expression was influenced by viral infection, naive human B cells
were infected with EBV. Levels of EBI2 expression were measured and compared to uninfected control naive B cells
(Fig. 1). EBV-infected cells showed, on average, a threefold
higher relative mRNA expression of EBI2 than uninfected
cells. When the EBI2 expression found in infected B cells is
compared to the expression in cell lines that contain EBV,
there is a significant difference of gene expression. Freshly isolated naive B cells demonstrated a much higher expression of
EBI2 when compared to the expression observed in the EBVpositive LCL (P=0.012) and Raji cell lines (P=0.027), which
are primarily in a latent state.
To determine the pattern of EBI2 expression during the
course of EBV infection, isolated naive B cells were infected
with EBV and EBI2 expression was measured at intervals
over a 21-day period of time. An expression time line was
constructed starting with pre-infection and ending 21 days
p.i. Between 3 and 6 h p.i., there was a significant decrease
in EBI2 expression (P=0.002). There is also a significant
increase in expression at 24 h p.i. (P=0.027) (Fig. 1). This

heightened level of EBI2 expression persisted for as long as
7 days p.i. At this point, there was a large variance in the
samples. This could be indicative of EBV induction of EBI2
ending prior to this time in some samples received from different donors, while others are still maintained. However,
by days 8 and 9 p.i., the levels of EBI2 expression have
decreased to levels equal to or lower than those observed in
uninfected control naive B cells (Fig. 1).
Non-specific gene regulation in infected cells was controlled
for by measuring the expression of the REEP5 gene at every
time point. This gene expression was stable throughout the
time course of infection, except that it decreased between 3
and 6 h p.i., as did EBI2. This suggests that some genes are
downregulated immediately upon EBV infection, and the
initial dip in EBI2 may be part of an overall pattern of gene
expression that is separate from the increase seen by 24 h.
To determine if increased RNA expression corresponded to
increased protein levels, naive B cells were infected with
EBV and proteins were harvested at 24 h p.i. Western blots
were performed to determine the ratio of EBI2 protein
between the control and infected cells (Fig. 2). At 24 h p.i.,
the EBV-infected cells displayed more than twice the
amount of protein compared to uninfected cells (P=0.015).

Cell activation alone is not sufficient to increase
EBI2 expression
It is important to establish if EBI2 expression could possibly
be induced by a mechanism such as B-cell activation due to
viral infection. For this purpose, isolated naive B cells were
treated with imiquimod. Imiquimod binds to Toll-like
receptor 7 (TLR7), which normally recognizes ssRNA, and
leads to B-cell activation [29]. We used imiquimod to stimulate naive B cells instead of using other methods, such as
CD40 and IL-4, because we wanted to investigate whether
the TLR pathway could be responsible for the induction of
EBI2 [30, 31]. The imiquimod treatment activated the
B cells, as shown by increased IL-1 and IL-6 transcription
after treatment, but no increase in EBI2 expression was
noted (Fig. 2).
To further establish that upregulation of EBI2 expression
was due to EBV genes expressed during infection, naive
B cells were treated with UV-irradiated EBV. Media containing EBV was UV irradiated as described and then used
to treat naive B cells. The irradiation inactivates viral particles, preventing replication after entering the cell due to
DNA damage. After incubation with the UV-irradiated
EBV, EBI2 expression was measured. The relative mRNA
expression in the B cells treated with the UV-irradiated
EBV did not differ from that found in uninfected naive B
cells (Fig. 2).

BRRF1 demonstrates a similar pattern of
expression as EBI2 during EBV infection of B cells
EBV uses various viral proteins to regulate cellular gene
expression [32, 33]. Significant regulation of EBI2 was
observed beginning between 3 and 6 h p.i., indicating that
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Fig. 1. EBI2 expression is modulated during the course of EBV infection. (a) Twenty-four hours after infection, EBI2 expression in
infected isolated naive B cells increased by a mean of threefold over that of uninfected B cells. Expression of EBI2 in EBV-infected B
cells was significantly higher than in the EBV-containing LCL B-cell-derived cell lines (***P=0.012) and the EBV-containing Ramos cell
line (****P=0.027), n=4. (b) Isolated naive B cells demonstrated significantly decreased expression of EBI2 by 6 h p.i. with EBV. After this
initial downregulation, EBI2 expression increased to remain at a heightened level of expression for several days (*P<0.007, **P0.027).
Seven days p.i., EBI2 expression decreased to levels equal to or lower than those observed prior to EBV infection. (c) Non-specific gene
regulation was controlled by measuring the expression of the REEP5 gene at all time points, n=5. Error bars indicate standard error.

an immediate early or early gene product would most likely
be responsible for regulating EBI2 expression. Various EBV
genes that are expressed during this period were selected as
candidates for investigation. These included BARF1,
BHRF1, BRRF1, BMLF1, LMP1, LMP2, BRLF1 and BZLF1.
Analysis was first begun on these genes, with the intention
of examining other viral genes if strong correlation values
could not be found upon comparing the expression pattern
of these EBV genes to EBI2.
Expression of these genes at three different time points during naive B-cell infection by EBV was measured using
reverse-transcriptase quantitative PCR (RT-qPCR) and a
pattern of expression was established for each one (Fig. 3).
These time points were chosen due to the distinct difference
of EBI2 expression observed during EBV infection. Epstein–
Barr virus nuclear antigen 1 (EBNA1) was used to control

for viral gene expression as it is expressed throughout EBV
infection. It was also chosen as the control to standardize
for viral infection, and even though the m.o.i. used was the
same for each experiment, there is still variation observed in
the samples treated with EBV. Therefore, all viral gene levels
are relative to EBNA1 in this experiment. Upon comparing
the expression patterns of the viral genes to the expression
pattern of EBI2, BRRF1 demonstrated a similar expression
pattern with the highest R2 value (Fig. 3). Linear regression
analysis comparing EBI2 gene expression to the mRNA
expression of the various viral genes revealed that BRRF1
shared more similarity than any other gene screened (R2
=0.866). Between 3 and 6 h p.i., there is a significant
decrease in expression (P=0.033) and by 12 h p.i., expression
had increased to a level similar to that observed at 3 h p.i.
These results suggest a possible connection between BRRF1
and EBI2 expression.
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Fig. 2. EBI2 protein expression is highly upregulated only by infection with infectious EBV. (a) EBI2 protein levels correlate with RNA
levels. Twenty-four hours p.i. of naive B cells infected with EBV demonstrate heightened protein levels compared to uninfected naive B
cells. (b) EBI2 protein signal measured was twofold higher than the uninfected cells as observed by Western blot (*P=0.015), n=4. EBI2
was normalized to b-actin, which was used as a loading control. (c) Both Toll-like receptor 7 stimulation with imiquimod and incubation with UV-irradiated EBV showed expression levels of EBI2 similar to unstimulated naive B cells, while EBV-infected naive B lymphocytes demonstrated significantly higher levels of EBI2 mRNA expression (**P<0.028), n=3. (d) IL-1 and IL-6 mRNA expression was
measured in all imiquimod-treated samples. Heightened mRNA levels indicate successful imiquimod stimulation compared to unstimulated cells. Error bars indicate standard error, n=3.

BRRF1 induces a heightened expression of EBI2 in
B lymphocytes during EBV infection
BRRF1 is an early lytic gene product [17, 34] encoding a
transcription factor (Na), which plays an important part in
regulating between latent and lytic EBV infection [35]. In
high enough concentrations, BRRF1 presence alone has

been shown to induce EBV lytic gene expression [35]. To
determine if upregulation of EBI2 was caused by BRRF1,
naive B lymphocytes were infected with BRRF1-deficient
(BRLF1/BRRF1 knockout, R-KO) EBV. The R-KO EBV was
used and described in previous studies [17, 35]. To summarize, the R-KO EBV strain is a bac engineered B95.8
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Fig. 3. BRRF1 demonstrates a similar pattern of expression to EBI2 in EBV infected B cells. (a) Several EBV early genes were
screened using qPCR to measure relative mRNA expression, n=5. (b) BRRF1 demonstrated the most similar pattern of expression to
that of EBI2. This correlation (R2=0.4622) suggests that there might be a connection between the expression of BRRF1 and EBI2.
(c) BZLF1 and BRLF1 expression patterns were also compared to EBI2 expression. The resulting correlation plot demonstrates that
these other EBV lytic genes demonstrate lower correlation values with EBI2 mRNA expression.

Epstein–Barr virus (V01555). It lacks the ability to express
both the BRLF1 and BRRF1 lytic genes resulting in the
absence of the subsequent gene products, Rta and Na,
respectively. Without the BRLF1 gene, it would be predicted
that the virus would not be able to induce expression of various genes that depend on Rta response elements in their
promoters including BMLF1, BMRF1, BALF2, BaRF1 and
BLRF2 [36]. Rta is one of the main proteins involved in
EBV reactivation and is thought to be essential for viral
reactivation and lytic cycle induction, along with Zta. Na is
known to act with Rta as a co-activator and assists in inducing transcription of BZLF1 and the subsequent protein synthesis of Zta [17, 35]. It has been hypothesized that it helps
regulate Rta transcriptional effects [37].

The EBI2 mRNA expression was measured at 0 and 24 h p.i.
in naive B lymphocytes with R-KO EBV (Fig. 4). The
mRNA was extracted from cells and quantified by qPCR.
Following infection of naive B lymphocytes with Na- and
Rta-deficient R-KO EBV, no significant change in expression of EBI2 was detected at 24 h p.i. (Fig. 4). To verify that
our R-KO infection assays were not yielding low EBI2 levels
of expression due to low R-KO EBV infection rate, we measured the mRNA expression of EBNA1 in samples that were
EBV or R-KO EBV infected at 24 h p.i. (Fig. 4). If our R-KO
EBI2 expression was a result of low viral infection, we would
expect the measured EBNA1 expression to be less than that
measured in samples from EBV-infected B cells. However,
our results show that EBNA1 expression is not lower in

Downloaded from www.microbiologyresearch.org by
IP: 128.187.116.16
439
On: Fri, 21 Jul 2017 18:48:10

Cornaby et al., Journal of General Virology 2017;98:435–446

(a)

(b)

(c)
5.0

1.5
1.0
0.5

3.5
3.0
2.5
2.0
1.5
1.0

6
5
4
3
2
1

LF
1
R

R

ltr
a+
B

R

pU

pU

ltr
a+
B

V
co ect
nt or
ro
l

V
EB
RKO

w
tE

BV

Un
in
fe
ct
ed

F1

0

5
4
3
2
1

LF

1

BV

0

B

R

tE

a+
ltr

0

6

pU

0.5

7

w

1.0

F1

1
LF

a+
ltr

ltr
pU

pU

a+

B

B

R

R

R

tro
on

ce
ns

rc

Ve
c

tra
Un

to

du

EB

F1

l

d

0

1.5

R

0.2

2.0

R

0.4

2.5

B

0.6

3.0

a+

0.8

3.5

ltr

1.0

4.0

pU

1.2

4.5

BV

1.4

5.0

w

1.6

tE

Relative BRRF1 mRNA expression

1.8

V

BV
tE
w

2.0

KO
R-

Un

in

fe

ct

ed

1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0

Relative BRLF1 mRNA expression

(e)
Relative REEPS mRNA expression

(d)
Relative REEPS mRNA expression

7

0

0.5

0

8

BV

2.0

4.0

w
tE

2.5

9
Relative EBNA1 mRNA expression

3.0

∗∗∗

∗∗

4.5

Un
in
fe
ct
ed
RKO
EB
V

∗

3.5

Relative EBI2 mRNA expression

Relative EBI2 mRNA expression

4.0

Fig. 4. BRRF1 is necessary and sufficient to induce expression of EBI2 in B lymphocytes. (a) EBI2 expression was measured in naive B
lymphocytes infected with the BRRF1-deficient R-KO EBV. There was no significant change in expression at 24 h p.i. with the BRRF1deficient EBV, n=6. (b) Naive B cells were transduced with BRRF1 using a lentiviral vector (pUltra+BRRF1) and EBI2 expression was
measured. There was a significant increase in EBI2 expression at 24 h (**P=0.042) post-lentiviral treatment with BRRF1. Naive B cells
were transduced with BRLF1 using a lentiviral vector (pUltra+BRLF1) and expression was measured. There was no significant difference in EBI2 expression measured at 24 h post-transfection when BRLF1 was expressed. Error bars indicate standard error (*P=0.049;
***P=0.05), n=6. (c) Relative EBNA1 expression measured in EBV and R-KO EBV-infected B cells 24 h p.i. This demonstrates that the RKO EBV was able to establish an infection in the naive B cells, evidenced by the expression of viral genes, n=6. (d) As a negative control, REEP5 mRNA expression was measured and found to be similar in all experiments, demonstrating no significant difference, n=6.
(e) BRRF1 and BRLF1 mRNA expression was measured in lentiviral-transduced naive B-cell samples and wild-type EBV-infected naive
B cells and compared. The levels of BRRF1 and BRLF1 mRNA expression in pUltra+BRRF1 and pUltra+BRLF1-transduced samples,
respectively, are similar. Error bars indicate standard error, n=6.

samples from R-KO-infected B cells. This suggests that
lower levels of EBI2 expression are not a result of a poor RKO infection.
To confirm our findings from the R-KO EBV assay and verify that low EBI2 levels were a result of the lack of BRRF1
and not due to the lack of expression of other viral genes,
such as BRLF1, we first transduced naive B lymphocytes
with a lentivirus containing the BRRF1 gene (pUltra
+BRRF1). The relative EBI2 expression was measured at 0
and 24 h (see Fig. 4a). Heightened expression of EBI2 was
observed at 24 h post-transduction (P=0.042) when naive B
lymphocytes were transduced with pUltra+BRRF1. Second,
to test whether BRRF1 was specifically causing EBI2 upregulation and confirm that the increased levels of EBI2
expression were not the product of transactivation by a viral
DNA-binding gene, the viral gene BRLF1 was transduced
into naive B cells (pUltra+BRLF1). The relative EBI2

mRNA expression was measured at 0 and 24 h post-transduction. In contrast with BRRF1, there was not a significant
increase in EBI2 expression after treatment with BRLF1
(Fig. 4).
It was probable that most of our blood donor volunteers
had previously been infected with EBV. It was not expected
that EBV reactivation would contribute to the heightened
EBI2 expression levels observed since EBV genomes are
only present in approximately 1 in 106 circulating B cells.
However, to verify that latent EBV from prior infection
was not interfering with the results from our pUltra
+BRRF1- and pUltra+BRLF1-transduced samples, BZLF1
was measured in the EBV-infected naive B cells and the lentivirus-transduced naive B cells. BZLF1 expression was
greater, estimated at 2104 fold higher, in EBV-infected Bcell samples compared to the pUltra+BRRF1-transduced Bcell samples. In most cases, BZLF1 expression was not
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detectable in B cells transduced with the BRRF1-expressing
lentivirus. This would suggest that potential reactivation of
EBV by the pUltra+BRRF1 in EBV-positive primary B cells
is not responsible for the resulting increase in EBI2 expression observed.
It could also be suggested that perhaps high expression of
an EBV lytic gene could non-specifically induce EBI2
expression. To investigate this possibility, we measured
BRRF1 transcripts in pU+BRRF1-transduced, EBV-infected
and control samples. We found that there was about threefold more BRRF1 expression in pU+BRRF1-transduced
samples compared to EBV-infected samples. This difference
can be attributed to the effectiveness of the human ubiquitin
promoter used to drive expression of BRRF1 post-transduction compared to the BRLF1 and BRRF1 promoter used by
wild-type EBV. These results combined with the lack of
upregulation in cells transfected with BRLF1 using the same
promoter led us to conclude that BRRF1 expression alone
can induce EBI2 and that EBI2 expression is not a result of
non-specific binding or latent EBV reactivation.

DISCUSSION
Regulation of EBI2 is crucial to B-cell chemotaxis in secondary lymph tissue [28, 38]. Upregulation of EBI2 generally
occurs during cellular migration in secondary lymph tissue
[28]. When expressed, EBI2 allows the cell to follow a
7a,25-OHC gradient [21, 38, 39]. 7a,25-OHC is produced
by stromal cells of secondary lymph tissue and is the only
identified natural ligand for the EBI2 chemokine receptor. B
cells upregulate EBI2 at key times to manoeuvre the cell
away from the follicular region to the outer and inter-follicular regions [24]. It has been suggested that these movements allow the naive B cells to potentially be exposed to
any antigens that are present in that region (Fig. 5) [28].
Downregulation of EBI2 allows for the naive B cells to
return to the follicular area and migrate to the T-cell zone
for a time before exiting the secondary lymph tissue. The
migration of B cells through this pattern allows for exposure
to areas with different antigens as well as the possibility to
be primed by T cells.
EBV is known to manipulate cellular genes to avoid the
immune system, control viral replication and prevent apoptosis [40–42]. EBV had been previously shown to influence
EBI2 [43–45]. Various studies have researched EBI2 expression during EBV infection; however, it has yet to be determined if the virus induces EBI2 or if heightened EBI2
expression is a result of the cellular response to viral infection [20, 46–48]. Previously, it has been hypothesized that
EBI2 expression is a result of the immune response to viral
infection since EBI2 has been shown to be induced during
EBV latency program I. Normally, only EBNA1 is highly
expressed [20, 43]. It has also been hypothesized that the
increase of EBI2 expression observed during EBV infection
is a result of viral manipulation to promote a successful persisting EBV infection, allowing for the virus to direct
infected cells to areas that would provide a better survival

niche for viral persistence [22, 49]. The results of this study
provide evidence for the later explanation of why heightened EBI2 expression is observed during EBV infection.
It is possible that the EBV-induced upregulation of EBI2
could have been the result of non-specific activation, as a
cellular response to EBV infection. However, the B-cellstimulating agent imiquimod did not cause an upregulation
in EBI2 expression, nor did incubation with inactivated
EBV. These findings indicate that EBI2 upregulation is not
likely due to cellular activation by TLR7, and that viral tegument or surface proteins are not responsible for the upregulation of EBI2.
Screening for viral gene candidates that could be responsible
for the regulation of EBI2 post-EBV infection found that
BRRF1 shares a similar mRNA expression pattern as EBI2.
BRRF1 encodes a viral transcription factor, Na. Na is
responsible for assisting in the activation of viral lytic genes
in various latently infected epithelial cells [35] and has been
found to associate with human TNF receptor-associated factor 2 in a yeast two-hybrid assay [50]. Due to its function as
a transcription factor and its expression pattern being similar to that of EBI2, BRRF1 seemed the best candidate of
those screened. To ascertain if BRRF1 expression could
directly influence EBI2 expression, the BRRF1-deficient RKO EBV was used to infect isolated naive B cells. R-KO
EBV has been used in several studies and has the R gene,
BRF1, knocked out as well as the promoter of BRRF1 resulting in EBV that cannot express BRRF1 [35]. R acts with
BZLF1 to activate latent EBV and can bind to various EBV
promoters [16, 51, 52]. The results show no upregulation of
EBI2 expression upon infection with the BRRF1-negative
EBV. This would suggest that BRLF1 or BRRF1 was inducing EBI2 expression. To further verify that BRRF1 could
induce EBI2 expression, the pUltra+BRRF1 lentivirus was
used to treat isolated naive B cells. This resulted in a significant increase in EBI2 expression. These results demonstrate
that the expression of BRRF1 was necessary and sufficient
to induce EBI2 expression. While the mechanism that
BRRF1 uses to induce this expression in B cells is unknown,
it is possible that Na acts as a transcription factor at the
EBI2 promoter site. Further research needs to be performed
in order to ascertain if this is the case.
It is probable that cell migration would be influenced by the
EBV-induced regulation of EBI2. With a heightened concentration of EBI2 on the surface of the infected B cells, it is
no stretch to infer that EBI2 might override other migratory
signalling pathways and direct the cell to follow a 7a,25OHC gradient, which is the natural ligand of chemoattractant receptor EBI2 (see Fig. 5b) [21, 39]. 7a,25-OHC is only
produced by stromal cells of secondary lymph tissue [53].
Following this gradient would cause infected B cells to
migrate and remain in the outer follicular and interfollicular regions of secondary lymph tissue. This type of
control over cell migration could allow the virus to avoid
immune detection until latency has been established, assisting in immune evasion.
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Fig. 5. Proposed effects on B-cell migration during EBV infection due to modulation of EBI2 expression. (a) This illustration demonstrates the regular pattern of naive B-cell migration in the lymph node. (1) CXCR5 is expressed, allowing cells to follow a CXCL13 gradient and enter the follicular region. CXCR5 is constitutively expressed to assist in cell migration. (2) EBI2 is upregulated and the cells
follow a 7a,25-OHC gradient to the outer or inter-follicular region. (3) Downregulation of EBI2 allows the naive B cells to return to the
follicular area and (4) upregulation of CCR7 permits the cell to follow the CCL21 chemokine gradient to the T-cell zone. If B cells
remain inactivated, they will leave via the cortical sinus of the lymph node. If they become activated, they will be directed back to the
follicular and germinal centre area. (b) This figure depicts the predicted pattern of migration during EBV infection of naive B cells. (1)
Upon entry into the lymph node, the B cell will follow the 7a,25-OHC gradient to the outer and inter-follicular region of the lymph node.
(2) The cell will be unable to migrate to the follicular region.

It is also possible that increased levels of EBI2 might influence B-cell proliferation. Benned-Jensen et al. [54] found
that overexpression of EBI2 in antibody stimulated murine
B cells resulting in increased proliferation. By increasing the
proliferation of infected B cells during a specific time, it
would increase the chances of viral persistence in the
infected host. The results of this study emphasizes the
importance of EBI2 regulation during viral infection. It is
possible that the use of EBI2 antagonists, or inverse agonists, could be used as EBV antiviral treatment options or to
disrupt the viral life cycle in an animal model [54–56].

During our study, we have established that EBI2 is controlled during EBV infection of B cells. Different EBV
expression profiles result in different levels of EBI2
expression. Higher levels of EBI2 mRNA expression result
in higher levels of EBI2 protein. We have further established that EBI2 is induced by an EBV gene, BRRF1.
Potential research for the future can address to what
degree heightened expression of EBI2 possibly changes
migration of EBV-infected B cells. It would also be beneficial to verify the mechanism used by BRRF1 to induce
EBI2 expression.
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METHODS
Generation and harvesting of viral stock
Viral stock was generated using the Bac B95-8 EBV producing HEK 293 cell line as previously constructed and
described by Delecluse et al. [57]. To summarize, the strain
has been engineered with an F factor origin of replication,
partitioning proteins A and B, chloramphenicol-resistance
gene, hygromycin-resistance gene and an EGFP reporter.
Cells were seeded in T-75 flasks (Corning) to attain a confluence of 50 to 60 %. The cells were then transfected with
pUltra+BZLF1, pUltra+BRRF1 and pUltra+BRLF1 plasmids
using calcium-phosphate transfection. Media was changed
16 h post-transfection to RPMI and cells were allowed to
incubate for 7–10 days. Viruses were harvested in the RPMI
media, filtered using a 0.45 µm filter, collected in 15 ml conical vials and stored at 80  C. The titre of Epstein–Barr viral
infectious units was determined using green Raji cell assays
following a previously described protocol [17]. To summarize, 2105 Raji cells were suspended in 0.5 ml of viral
supernatant. The cells were allowed to incubate for 3 h and
then 1.5 ml of RPMI media was added to the wells. At day 2
p.i., sodium butyrate and phorbol-12-myristate-3-acetate
(PMA; ACROS) were added to a final concentration of
3 mM sodium butyrate and 50 ng of PMA ml 1. The cells
were allowed to incubate for another 16–24 h and then the
GFP-positive cells were quantified by fluorescence
microscopy.
The BRLF1- and BRRF1-deficient Epstein–Barr virus (RKO EBV) was kindly given to us by Dr Henri-Jacques Delecluse from the German Cancer Research Center, having
been described and used in previous studies [17, 35, 58]. For
specific information on the construction and testing of this
virus, the reader is referred to previous publications by
Hong et al. [17], Hagemeier et al. [35] and Feederle et al.
[59]. R-KO EBV viral stocks were generated by the same
method previously described for B95-8 EBV production.
The titre of viral infectious units was determined using
green Raji cell assays following a previously described protocol [17] and as described.
The lentiviruses pUltra+BZLF1, pUltra+BRRF1 and pUltra
+BRLF1 DNA were grown in Escherichia coli DH5a cells
and extracted using plasmid extraction kits (Qiagen). The
plasmid DNA was then transfected into the PHX cell line
using calcium-phosphate transfection. The supernatant was
harvested and filter sterilized using a 0.45 µm filter. Lentiviral vector concentrations were quantified by placing 100 µl
of lentiviral media with 1 ml of Raji cells at a concentration
of 1105 cells ml 1. Cells were allowed to incubate for 48 h
and then counted by fluorescence microscopy to determine
the lentivirus titre.

UV irradiation of EBV
EBV supernatants in 15 ml centrifuge conical tubes were
exposed to ultraviolet light (200–280 nm) in a biosafety cabinet hood for a period of 4 h. The UV-irradiated virus was
then used to infect isolated B cells.

Human B-cell isolation
Human naive B cells were isolated using lymphocyte separation media (Cellgro) and EASYSEP negative selection magnetic separation (STEMCELL Technology). PBMCs were
isolated from 30 ml of peripheral blood collected from
healthy volunteers after informed consent using lymphocyte
separation medium (Cellgro). PBMCs were then resuspended in PBS +2 % FBS with 1 mM EDTA added. Naive
B cells were separated from other lymphocytes by magnetic
cell separation using the Human B cell enrichment kit
(STEMCELL Technology) following the EASYSEP protocol.
Infection assays and RNA extraction
Using standard 12-well plates, 2106 naive B cells were
placed in each well in 1 ml of medium. EBV viral stock was
added to each well at an m.o.i. of 15. An equal volume of
media without EBV was added to the negative controls.
Cells were collected by centrifugation. Using the RNAqueous-Micro RNA extraction kit (Ambion) and procedure,
RNA was extracted and suspended in elution solution. Since
in naive B cells high rates of infection with EBV are difficult
to obtain, we used the highest m.o.i. that was practical.
Using an m.o.i. of 15, we typically obtained infection of
about 15–25 % of naive B cells. All viral infection experiments were repeated at least three or more times in
duplicate.
For infection with R-KO EBV, isolated naive B cells at a
concentration of 2106 cells ml 1 were incubated with RKO EBV supernatant at an m.o.i. of 15. At each time point,
samples were pelleted and treated as previously described
for RNA extraction.
For lentiviral transduction, either pUltra+BRRF1 or pUltra
+BRLF1, at an m.o.i. of 15, was added to isolated naive
B cells at a concentration of 2106 cells ml 1. At 24 h p.i.,
the cells were pelleted and treated as previously described
for RNA extraction.

Quantification of gene expression by qPCR
Reverse-transcriptase quantitative PCR (RT-qPCR) was
performed using StepOne Plus software and equipment
with Power SYBR Green PCR master mix (Applied Biosystems). Samples were analysed using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the housekeeping gene.
As a control for non-specific gene regulation, levels of the
REEP5 gene were also measured using RT-qPCR. qPCR primers for all target genes were designed using Primer Express
3.0 (Applied Biosystems). Primer sequences as well as the
consistency between experiments can be found in Fig. 6.
Statistical analysis
In most cases, two-tailed paired t-tests and an alpha value of
0.05 were used to determine significant differences in relative mRNA expression levels. Since our experiments were
run and analysed in tandem, it allows us to use the paired
tests when doing our statistical analysis when comparing
variable conditions in the same experiment. There was one
exception when determining the significance of the EBI2
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Fig. 6. Primers and consistency of RT-qPCR analysis. (a) This table contains the qPCR forward and reverse primer sequences used in
the experiments described. (b) GAPDH cycle threshold (CT) scores for the various figures have been compiled to verify that they are
similar. There is no significant difference when comparing the GAPDH CT scores from the different experiments.

expression between the pUltra+BRRF1-transduced samples
and the pUltra+BRLF1-transduced samples 24 h posttransduction: some of the samples were lost during harvesting and new samples were transduced and harvested. Due
to this event, the experiment was analysed using Welch’s
unpaired t-test, and an alpha value of 0.05 was still considered significant. To analyse correlations between the expression of EBV genes and EBI2, linear regression analysis was
performed using R statistical analysis software. In this analysis, EBI2 expression was compared to the expression of
each gene in turn and R2 values calculated [EBI2 ~ (EBV
gene of interest)].

LCL cell line generation
PBMCs were re-suspended at 2106 cells ml 1 in complete
RPMI. Then 5 ml of cells suspended in media and 5 ml of
B95-8 EBV cell culture supernatant were placed together in
a T-25 flask with cyclosporin A or actinomycin D. Cells
were incubated for 3 weeks, pipetted weekly to break up cell
clumps. LCL cell lines are maintained in complete RPMI
and passaged frequently.
Lentivirus generation
The lentiviral vector pUltra+BRRF1 was constructed using
pUltra, a third-generation lentivirus obtained from Addgene. The BRRF1 gene was PCR amplified from wild-type
B95.8 EBV using forward (TCTAGAATGGCTAGTAG
TAACAGAGGAAATG) and reverse (TGATCATTATTTG
TATTGCATGGCAGAACAGT) primers with XbaI and
BclI restriction site extensions added, respectively. BRRF1

was then cloned into pUltra cut with XbaI and BclI restriction enzymes. The ligated pUltra+BRRF1 was then transfected into E. coli DH5a cells. Using a BRRF1-specific
forward primer and a pUltra-specific reverse primer, the
colony containing the complete pUltra+BRRF1 plasmid was
verified by sequencing. The plasmid used for transfecting
EBV producing HEK cells pUltra+BZLF1 was produced
using pUltra with the BZLF1 gene cloned into the construct.
Forward
(GTCGACTCAAAGAGAGCCAACAGGAAG)
and reverse (GAATTCAAAGGGGAGATGTTAGACAGG
T) primers with SalI and EcoRI restriction site extensions
were added, respectively. The PCR-amplified BZLF1 gene
was cloned into pUltra cut with SalI and EcoRI. The ligated
pUltra+BZLF1 was transfected into E. coli DH5a cells and
verified as described previously using a BZLF1-specific forward primer and a pUltra-specific reverse primer. The lentiviral vector pUltra+BRLF1 was constructed using the same
pUltra lentivirus as aforementioned. The BRLF1 gene was
PCR amplified from wild-type B95.8 EBV using forward
(TCTAGAATGGTCGGGCATTTCCTCTG) and reverse
(TGATCACCAAAAGAGGAGGAGGCAGT) primers with
XbaI and BclI restriction site extensions added, respectively.
The PCR-amplified BRLF1 gene was cloned in to pUltra cut
with XbaI and BclI. The ligated construct of pUltra+BRLF1
was then transfected into E. coli DH5a cells and verified as
described previously. All primers for cloning the desired the
PCR products were designed using Primer 3 software. All
lentiviral constructs were verified by sequencing and expression of the cloned genes were verified by RT-qPCR.
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Western blot
One millilitre of naive B cells at a concentration of 2106
cells ml 1 was infected with EBV at an m.o.i. of 15. At the
time of sample collection, the cells were pelleted and resuspended in lysis buffer (Thermo Scientific). Cells were
then vortexed and passed through a 25-gauge needle, followed by incubation in Laemmli sample buffer (BIO RAD)
and 5 % 2-mercaptoethanol (Sigma) for 5 min at 95  C. The
samples were then subjected to electrophoresis in a 12 %
polyacrylamide gel and transferred to a nitrocellulose membrane (Thermo Scientific). Blots were blocked with 2.5 %
(w/v) non-fat dry milk. EBI2 polyclonal goat IgG obtained
from Santa Cruz Biotechnology at a diluted 1 : 1000 was
used as the primary Ab. Rabbit anti-goat IgG-HRP obtained
from Santa Cruz Biotechnology was used as the secondary
Ab. ECL Plus (GE Healthcare) lumigen reagents and CDiGit blot scanner (LI-COR) were used to image the Western blot. For measuring protein loading, blots were stripped
using stripping buffer (100 mM b-mercaptoethanol, 2 %
SDS, 62.5 mM Tris/HCl, pH 6.7) and reprobed using goat
anti-actin (Abcam) as the primary antibody followed by secondary antibody and visualization as described for EBI2.
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